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Thesis Summary 
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive-aged 
women. The clinical and biochemical characteristics of PCOS typically include cystic ovaries, 
ovulatory dysfunction, and hyperandrogenaemia. PCOS is also associated with metabolic and 
psychological morbidity. Typically, management of PCOS focusses upon weight loss through 
positive lifestyle changes, namely caloric restriction and increasing physical activity (PA). Exercise 
is an effective treatment for a range of populations; despite its recommendation in PCOS, little is 
known about its effectiveness at improving health in this population. Accordingly, three studies were 
completed to investigate the effect of PA in the management of PCOS. 
Studies of women with PCOS that compared exercise (and diet) interventions to control conditions 
were meta-analysed in a systematic review. Exercise interventions improved insulin resistance, 
lipids, and cardiorespiratory fitness. However, the magnitude of these changes was small and the 
certainty of the evidence was graded as low or very low. A need for rigorously designed and 
sufficiently powered studies that address this question was highlighted. 
In study 2, despite no differences in PA, women with PCOS were found to be more overweight, and 
have poorer self-esteem and quality of life (QoL) than women without PCOS. Self-esteem, BMI and 
a PCOS diagnosis impaired QoL, whereas PA appeared to have no effect. 
Study 3 also reported less-favourable health, independent of BMI, in women with PCOS compared 
to controls. Cluster analysis was completed, and a larger proportion of women with PCOS were 
assigned to the poorer health cluster; this cluster was also less active. Furthermore, women who were 
more active, and spent less time sitting, had more favourable health. 
In conclusion, this PhD highlights a lack of high-quality studies to investigate the role of PA in 
women with PCOS; this should be a research priority. However, women with PCOS who are more 
active, and spend less time sitting have reduced cardiovascular risk, which supports current treatment 
recommendations. 
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1.1.  Introduction 
First described by Irving F. Stein and Michael L. Leventhal (Stein and Leventhal, 1935), polycystic 
ovary syndrome (PCOS) is regarded as the most common endocrinopathy in reproductive-aged 
women (Farquhar, 2007). Depending upon the diagnostic criteria used and the population studied 
(Teede, Deeks and Moran, 2010; Azziz et al. 2016), PCOS is thought to affect between 2% (Chen et 
al., 2008) and 21% (Lizneva et al. 2016) of reproductive-aged women in the general population. 
Despite its high prevalence, PCOS remains an under-studied endocrinopathy with a highly complex 
pathophysiology which has not yet been fully clarified.  
PCOS clinical and biochemical characteristics typically include reproductive complications 
(oligomenorrhea and amenorrhea); hyperandrogenaemia [either biochemical or/and clinical with 
manifestations such as hirsutism, acne and androgenic alopecia (Barber et al., 2006)]; and polycystic 
ovarian (PCO) morphology as identified via ultrasound (Adams et al., 1985). In addition to the 
aforementioned characteristics, PCOS is also associated with metabolic comorbidity, particularly 
overweightness and obesity (Lim et al., 2012), insulin resistance and type 2 diabetes (T2DM) (Stepto 
et al., 2013) and other cardio-metabolic risk factors (Cussons, Stuckey and Watts, 2007). These are 
so commonly linked with PCOS that there have been calls for them to be included in the diagnostic 
criteria/characterization of PCOS, whilst clinical guidelines recommend routine screening for such 
metabolic comorbidities (e.g., T2DM) in women with PCOS (Legro, Castracane and Kauffman, 
2004). Finally, it has been reported that women with PCOS are often also burdened with 
psychological morbidity; particularly, greater levels of anxiety and depression (Barry et al., 2011b), 
reduced self-esteem (Tay et al., 2019) and body dissatisfaction (Himelein and Thatcher, 2006), are 
all associated with PCOS. It is thought that this is caused, at least in part, by the clinical 
manifestations which are so often associated with PCOS (Barry, 2019). 
Of note, it is the widely reported success of lifestyle interventions, typically including increased 
exercise/physical activity (PA) and/or dietary restriction, at improving many of these health-related 
outcomes in a wide range of populations (Paffenbarger et al., 1986; Ekelund et al., 2015; Arem et 
17 
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al., 2015), which make lifestyle interventions a suitable candidate for improving the health of women 
with PCOS. Accordingly, the objective of this PhD is to investigate the role of exercise/PA in the 
management of women with PCOS. 
 
1.2.  PCOS Diagnostic Criteria 
Although originally described in the 1930s (Stein and Leventhal, 1935), PCOS was first 
defined/classified at a National Institute of Child Health and Human Development conference for the 
United States National Institute of Health (NIH) in 1990. The resulting diagnostic criteria (Zawadski 
and Dunaif, 1992) include the presence of clinical and/or biochemical signs of hyperandrogenism 
and oligo-anovulation, after the exclusion of other androgen excess or related disorders (Table 1.1); 
there was little consideration for the PCO morphology.  Polycystic ovaries are usually identified 
using ultrasound, and defined by the presence of at least 12 or more follicles (cysts) measuring 2-9 
mm in diameter on one ovary, or an ovarian volume >10 mL in the absence of a dominant (>10 mm) 
follicle (Jonard et al., 2007). However, the presence of ovarian cysts has also been identified in 
healthy women (Franks, 1995). In fact, the PCO morphology is a highly common ultrasonic feature 
that is present in ~20% of reproductive-aged females, many of whom exhibit no symptoms of the 
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Table 1.1. Diagnostic criteria/definitions for polycystic ovary syndrome (PCOS). 




 Must have both of the 
marked findings. 
Must have at least two 
of the marked findings. 
Must have the marked 
finding with either/or 
both of the other two. 
Hyperandrogenism  ✓ ✓ ✓ 
Oligo-anovulation ✓ ✓  
PCO morphology  ✓  
*In addition to the above criteria, PCOS diagnosis requires the exclusion of other androgen excess or related 
disorders, including: hyperprolactinaemia, thyroid dysfunction, adrenal hyperplasia, androgen secreting 
tumours, and Cushing’s syndrome. Key: PCO: polycystic ovarian; NIH: National Institute of Health; 
ESHRE: European Society for Human Reproduction and Embryology; ASRM: American Society for 
Reproductive Medicine; AE-PCOS: Androgen Excess and PCOS Society.  
 
Despite omission from the NIH PCOS definition, the PCO morphology was incorporated into an 
internationally accepted PCOS definition following a consensus conference in 2003. The European 
Society for Human Reproduction and Embryology (ESHRE) along with the American Society for 
Reproductive Medicine (ASRM) stated that women should be diagnosed with PCOS if they have 
two of the three cardinal characteristics; that is, oligo-anovulation, evidence of excess androgens and 
the PCO morphology (Table 1.1) (Rotterdam ESHRE/ASRM, 2004). This expanded Rotterdam 
definition also broadened the heterogeneity of PCOS phenotypes, since women with the PCO 
morphology and hyperandrogenism, and those with PCO and menstrual disruption were included for 
the first time. Notably, the additional phenotypic subgroups created by the introduction of the 
Rotterdam criteria meant that the number of women with PCOS was substantially increased, and that 
hyperandrogenism was no longer a prerequisite for diagnosis. Recent evidence-based guidelines 
(Teede et al. 2018) continue to support the Rotterdam criteria for use in adult women.  
However, there has been contention around the Rotterdam criteria; a growing body of literature 
implicates hyperandrogenism as the greatest determinant in the pathophysiology of PCOS 
(Georgopoulos et al., 2014), as well as being instrumental in the metabolism-related disorders 
(Carmina et al., 2005) which are frequently associated with this condition. This viewpoint was 
supported by the findings of an Androgen Excess and PCOS Society (AE-PCOS) task force (Azziz 
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et al., 2009) which reported that androgen excess is pivotal in PCOS and formed the AE-PCOS 
criteria. Thus, according to these criteria, a PCOS diagnosis must include the clinical or biochemical 
evidence of hyperandrogenism (Table 1.1). These findings effectively excluded the non-
hyperandrogenic phenotype (PCO morphology with oligo-anovulation) that was introduced by the 
Rotterdam guidelines.  
The heterogeneity of PCOS, alongside three internationally accepted diagnostic definitions brought 
about a lack of clarity in clinical practice. Therefore, a 2012 review of the guidelines (NIH, 2012) 
resulted in new diagnostic recommendations; a broadened version of the Rotterdam criteria was 
devised and this was accompanied by a detailed description of each PCOS phenotype as defined by 
the new criteria (Table 1.2). 
 
Table 1.2. Polycystic ovary syndrome (PCOS) phenotypic subgroups and inclusion within 
diagnostic criterion.  
Parameter Phenotype A Phenotype B Phenotype C Phenotype D 
Hyperandrogenism ✓ ✓ ✓ X 
Oligo-anovulation ✓ ✓ X ✓ 
PCO morphology ✓ X ✓ ✓ 
NIH (1990) ✓ ✓ X X 
ESHRE/ASRM (2004) ✓ ✓ ✓ ✓ 
AE-PCOS (2006) ✓ ✓ ✓ X 
Key: PCO: polycystic ovarian; NIH: National Institutes of Health; ESHRE/ASRM: Human Reproduction 
and Embryology/American Society for Reproductive Medicine; AE-PCOS: Androgen Excess and PCOS 
society (Lizneva et al., 2016). 
 
The global use of multiple diagnostic criteria has reportedly raised issues of compatibility for PCOS 
research worldwide, leading to delayed progress in gaining an understanding of the condition and 
confusion within clinical practice (NIH, 2012). The NIH consensus panel (2012) proposed the use 
of expanded Rotterdam (2003) criteria; as with these criteria, they recommend that diagnosis should 
be made when at least two of the three cardinal characteristics are present, but that they should also 
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be accompanied with a description of the phenotypic subgroup to which the patient has been 
diagnosed. Accordingly, the NIH consensus panel (2012) suggested the use of four phenotypic 
classifications (Table 1.2), which were previously outlined by Azziz et al. (2006), including: 
Phenotype A: clinical or biochemical hyperandrogenism + oligo-anovulation + PCO morphology; 
Phenotype B: hyperandrogenism + oligo-anovulation; Phenotype C: hyperandrogenism + PCO 
morphology; and Phenotype D: oligo-anovulation + PCO morphology. This phenotypic approach 
allows researchers and clinicians to characterise populations based upon the presence (or absence) 
of PCOS’s defining features (Lizneva et al., 2016).  
Furthermore, when making treatment recommendations in clinical practice, it is advantageous to 
identify the phenotype of a patient; for example, women who present with the “classic” PCOS 
phenotypes (A or B) often have more severe menstrual dysfunction and infertility (Kim et al., 2014), 
and are at a higher risk of metabolic dysfunction (Azziz et al., 2006). Indeed, women with these 
PCOS phenotypes are more hyperinsulinaemic (Welt et al., 2006) and more insulin resistant 
(Diamanti-Kandarakis and Panidis, 2007; Moran and Teede, 2009) than women presenting with 
phenotypes C or D. In addition, phenotypes A and B tend to have a higher body mass index (BMI) 
(Welt et al., 2006), increased body weight and central adiposity (Moran and Teede, 2009), as well a 
greater severity of dyslipidaemia (Carmina et al., 2005; Kim et al., 2014). The cumulative result is 
that those with “classic” PCOS have a greater risk for metabolic syndrome (MetS) than women with 
the non-classic (hyperandrogenism and PCO morphology) or non-hyperandrogenic phenotypes 
(Mehrabian et al., 2011). Moreover, Mehrabian et al. (2011) report differences in the prevalence of 
MetS between phenotypes A and B, with higher MetS prevalence in women with phenotype B (64% 
prevalence) than in those with the PCO morphology (23%). 
In contrast, women with hyperandrogenism and PCO (phenotype C), are reported to have 
intermediate levels of serum androgens and their associated clinical symptoms (i.e., hirsutism and/or 
acne), plasma insulin, and atherogenic lipids, when compared to those with the “classic” phenotypes 
(Lizneva et al., 2016). It is also often reported that women with non-hyperandrogenic PCOS have a 
lower degree of endocrine (Dewailly et al., 2006; Welt et al., 2006) and metabolic (Dewailly et al., 
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2006; Zhang et al., 2009) dysfunction, as well as a lower prevalence for MetS compared to 
hyperandrogenic PCOS (Mehrabian et al., 2011). 
 
1.3.  PCOS Global Prevalence 
One implication of the multiple definitions of PCOS is that it becomes difficult to precisely assess 
its global prevalence. Individual studies have reported PCOS prevalence rates between 2% (Chen et 
al., 2008) and 21% (Boyle et al. 2012), and this variation is likely attributed to the diagnostic criteria 
used, but also to ethnic variation and differences in clinical practice. A recent systematic review and 
meta-analysis (Bozdag et al., 2016) pooled data from studies that reported prevalence of PCOS 
according to at least one of the recognised diagnostic criteria. Based on data from 24 eligible trials, 
this analysis reported the PCOS prevalence and 95% confidence intervals (CIs) for each PCOS 
definition as follows: NIH = 6% (95% CIs: 5 to 8%; 18 trials), ESHRE/ASRM = 10% (95% CIs: 8 
to 13%; 15 trials), and AE-PCOS = 10% (95% CIs: 7 to 13%; 10 trials). Data for PCOS prevalence 
according to the geographical location of the included studies is presented in Figure 1.1. Based on 
the latter, there is evidence of significant geographical heterogeneity for individual diagnostic tools 
which may suggest a degree of regional inconsistency when identifying PCOS symptoms or 
interpreting phenotypic definitions (Bozdag et al., 2016).    
Overall, it is clear that PCOS prevalence varies greatly depending upon the criteria used. As such, 
due to their expansive definitions and inclusion of additional phenotypes, the Rotterdam (2003) and 
AE-PCOS (2006) criteria tend to produce greater estimates of PCOS prevalence than the original 
NIH (1990) criteria (Sirmans et al., 2014). In fact, the original use of the NIH (1990) criteria provided 
less variability when comparing countries/regions, but there are a few marked exceptions. For 
example, the study by Chen and colleagues (2008) assessed 915 women who were not presenting 
with a medical reason or complaint, and reported PCOS prevalence of only 2.2%. In contrast, studies 
in Australian Aboriginals (Boyle et al. 2012) and Mexican women (Goodarzi et al., 2005) report 
significantly higher prevalence rates (15.3% and 13.0%, respectively). However, these findings may 
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be partly explained by limitations in sampling, since in the two latter studies where prevalence is 
higher, participants were identified from individuals enrolled in trials studying diabetes (Boyle et al. 
2012) or coronary artery disease (CAD) (Goodarzi et al., 2005). Both these conditions are typically 
associated with poor metabolic health, and progression to these conditions is more common in PCOS 
than in the general population.  
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Figure 1.1. Worldwide prevalence of PCOS according to geographic location. Data are presented as percentage of population diagnosed and 95% 
confidence intervals (CIs). Data unavailable for geographic regions coloured in grey (Bozdag et al., 2016). 
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If the results of these epidemiologic studies may not be truly representative of the general population, 
then it is pertinent to consider studies with a more representative design. Li et al. (2013) randomly 
sampled nearly 17,000 women in a national Chinese study using the Rotterdam criteria and reported 
a PCOS prevalence of 5.6%. Utilising a smaller sample (n = 820), another study (Mehrabian et al., 
2011) randomly invited reproductive-aged women for PCOS screening and based on the Rotterdam 
criteria found the 15.2% of the screened women had a PCOS diagnosis. Of note, this was halved 
when NIH or AE-PCOS criteria were used. Another study of mainly Caucasian women assessed in 
adulthood (March et al., 2010) found that 17.8% were diagnosed with PCOS using the Rotterdam 
criteria. This was 8.7% and 10.2% when the NIH and AE-PCOS criteria were applied, respectively. 
It is evident that, there is still considerable variation in the reported data even when greater 
confidence can be assumed from the applied sampling methodology and the representativeness of 
the sampled population.  
Part of this variation may be explained by ethnic differences, whilst there are other factors to 
consider. One such factor is the complexity of PCOS assessments, since accurate diagnosis often 
requires multiple clinical and biochemical assessments, ultrasound, and likely multiple visits to 
specialist clinics (Lizneva et al., 2016). Interestingly, Mehrabian et al. (2011) acknowledge such a 
limitation in their data. Moreover, detection rates of PCO morphology (and therefore positive 
diagnoses) are greater when transvaginal ultrasound is used over transabdominal methods (Farquhar 
et al., 1994). The implication is that because of variations in routine clinical practice, or an inability 
to complete intensive assessments and appropriate follow-up in research projects, many studies may 
actually be underreporting PCOS prevalence (March et al., 2010). 
Notably, ethnicity may also constitute another contributing factor for geographical variations in 
reported PCOS prevalence. Indeed, it has been previously reported that the ethnic background of 
women with PCOS affects the severity of the clinical, hormonal, and metabolic characteristics 
associated with this syndrome (Ng et al., 2007), and large phenotypic variations have been reported 
in different populations. For example, Polson et al. (1988) report that the PCO morphology is a 
common feature of PCOS in Western women. Polycystic ovaries were reported in 26% and 87% of 
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women with amenorrhea and oligomenorrhea, respectively, and in 92% of those who were hirsute. 
In contrast, the PCO morphology was reported in ~6% of infertile Chinese women (Ng et al., 2004) 
and in only 1% of fertile Chinese women (Ng et al., 2001). When compared to an earlier study in 
South Asian women (Rodin et al., 1998), these numbers are much smaller, since Rodin and 
colleagues (1998) had previously reported a 52% prevalence of polycystic ovaries. The latter study 
also reported that 49% of these women had menstrual irregularity, whilst further documented that 
these South Asian women had comparable metabolic dysfunction (namely insulin resistance) 
compared to South Asian women with T2DM but no PCO morphology.   
 
1.4.  PCOS Diagnostic Components 
 Hyperandrogenism 
In healthy, reproductive-aged women the ovaries and the adrenal cortex share the bulk of the steroid 
biosynthesis pathways, with relatively equal contributions to the circulating levels of testosterone 
and androstenedione. The ovaries and the adrenal cortex both secrete more androstenedione than 
testosterone, but ~50% of circulating testosterone is derived from the peripheral metabolism of 
androstenedione (Ehrmann et al., 1995). Within the ovary, the theca interna layer within the ovarian 
follicle produces androgens, whilst within the adrenal cortex, it is the zona fasciculata responsible 
for synthesis (Nussdorfer, Mazzocchi and Meneghelli, 1978).  
Unlike protein- or peptide-producing cells, steroid-secreting cells do not store each hormone in a 
ready state, but synthesise them for secretion as they are required. Steroid hormone synthesising cells 
in the body (i.e. adrenal cortex, placenta and ovary) contain intracellular lipid droplets in the 
cytoplasm. Cholesterol (Figure 1.2), being the natural precursor to all steroid hormones, enters the 
cell and is stored as cholesterol esters within these lipid droplets until required (Brook and Marshall, 
1996). When required, the first step of steroid synthesis is the hydrolysis of cholesterol esters; 
cholesterol is then transported from the lipid droplet into the mitochondria of the cell where the 
primary reaction is the production of pregnenolone. 
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Figure 1.2. The ring-identification system of the steroid nucleus and the carbon numbering system 
used for steroids.  
 
Pregnenolone is then converted to dehydroepiandrosterone (DHEA) via another two-step process 
along the ∆5-pathway (Figure 1.3); in the adrenal gland, 17-hydroxyprogesterone is converted into 
either cortisol or sex hormones. Then 17β-hydroxysteroid dehydrogenase acts upon 17-ketosteroids 
to complete their conversion to testosterone, dihydrotestosterone and oestradiol (Balen et al., 2005). 
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Figure 1.3. Schematic representation of the female steroidogenic pathway (Balen et al. 2005). 
In healthy women, androgen secretion usually occurs in a two-fold episodic, diurnal manner that 
undergoes cyclic variation. A key event in the acute regulation of steroidogenesis occurs when 
cholesterol is delivered to the mitochondria and converted to pregnenolone (Clark et al., 1995). This 
process is governed by trophic hormones; luteinizing hormone (LH) in the ovary and 
adrenocorticotropic hormone (ACTH) in the adrenal cortex (Manna et al., 2009). The steroidogenic 
responses to LH and ACTH may also be further influenced by small peptides [i.e. insulin and/or 
insulin-like growth factors (IGFs)]. In in vitro models, insulin and IGF-1 and IGF-2 have been 
demonstrated to have a regulatory effect in ovarian theca and granulosa cells; insulin excess has been 
shown to increase androgen production (and promote follicular cyst development) in women with 
PCOS (Poretsky et al. 1999). Insulin action targets cytochrome P450c17α, increasing activity of 17α-
hydroxylase and 17,20-lyase (Figure 1.3), resulting in increased ovarian androgen production 
(Nestler, 2008). Elevated insulin levels directly stimulate ovarian androgen secretion but also inhibit 
synthesis of sex hormone binding globulin (SHBG), thus elevating circulating free androgens and 
further contributing to hyperandrogenism (Diamanti-Kandarakis and Dunaif, 2012).   
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Figure 1.4. Two-cell, two-gonadotropin mechanism of follicular steroidogenesis. 
 
Intra-ovarian androgens are an essential component of healthy follicular growth and oestradiol 
synthesis. However, when androgen synthesis is not fully co-ordinated (i.e., excessive levels) with 
the needs of the growing follicle, follicular atresia occurs (Harman, Louvet and Ross, 1975). Within 
a healthy ovary, LH acts upon the theca cells inducing androgen synthesis, whereas it is follicle-
stimulating hormone (FSH) that stimulates aromatase activity in the granulosa cells, facilitating the 
conversion of androstenedione and testosterone into oestrogens (Liu and Hsueh, 1986). This 
principle forms the basis of the two-cell, two-gonadotropin theory (Figure 1.4). 
The two-cell, two-gonadotropin mechanism of oestrogen biosynthesis theory states that the theca 
cells secrete androgens in response to LH levels. Any synthesised androstenedione is then converted, 
via aromatase, to oestrogens within the granulosa cells; this process in the granulosa, is regulated by 
FSH (Liu and Hsueh, 1986). During a normal menstrual cycle, a dominant follicle will emerge and 
oestrogen content dominates over androgens that is not mediated by long-loop negative feedback 
effects (i.e., oestrogen does not supress androgen production). These processes play an integral role 
in the regulation of these hormones and accordingly, overstimulation due to elevated LH results in a 
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downregulation of LH receptors which in turn, lowers activity of cholesterol side-chain cleavage, 
17,20-lyase and 17-hydroxylase. This downregulation alters the ratio of 17-hydroxprogesterone and 
androgens (White et al., 1995). Aromatase activity, in accordance with the development of granulosa 
cells, determine the rate of synthesis for androgens. A healthy follicle is able to convert 
androstenedione into oestrogen with efficiency but, in contrast, cystic follicles have an irregular ratio 
of androstenedione and oestrogen which desensitises them to the effects of FSH (via IGF-binding 
proteins) resulting in increased oestrogen production and decreased thecal androgen secretion (Balen 
et al., 2005).   
The increased ovarian androgen production that is often associated with PCOS is largely attributed 
to enhanced androgen synthesis by the follicular theca cells, which in women with PCOS often show 
increased expression of many genes that encode steroidogenic enzymes (McAllister et al., 2015). 
This supports the notion that ovarian androgen excess in PCOS may be determined by genetics, at 
least partially. In addition to the overexpression of certain genes, Nestler et al. (1998) also reported 
that theca cells in PCOS women are more responsive (in terms of androgen secretion) to insulin and 
LH than healthy controls. In addition to ovarian related hyperandrogenism, 20-30% of women with 
PCOS also report elevated adrenal androgens, which may be the result of adrenocortical 
hyperfunction (Yildiz and Azziz, 2007). 
Overall, biochemical hyperandrogenaemia in the context of PCOS relies on the measurement of 
circulating total or free testosterone levels. In clinical practice, using the free androgen index (FAI, 
calculated as the ratio of the circulating total testosterone levels divided by the circulating SHBG 
levels and then multiplied by a constant, typically 100) is also commonplace, since FAI is thought to 
be a sensitive method for assessing hyperandrogenaemia (Cibula et al., 2000). For clinical 
hyperandrogenaemia, the major clinical manifestations of hyperandrogenism include hirsutism, acne, 
androgenic alopecia, impaired follicular growth and ovulatory dysfunction (Barry, 2019). 
Hyperandrogenism can be an underlying cause of these symptoms alone, whilst in PCOS these are 
often further exacerbated by the concomitant presence of insulin resistance. 
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 Oligo/amenorrhea  
In healthy females, menstruation begins approximately three years after the onset of breast 
development (Swenson and Havens, 2010). A typical menstrual cycle lasts for 28 days (Figure 1.5a) 
and day one of the cycle is marked by the first day of menstrual bleeding (period). During the 
menstrual cycle 4-5 follicles will grow, but (usually) only one follicle will mature, and, whilst the 
dominant follicle matures (Figure 1.6a), the remaining follicles will degenerate (Elsheikh and 
Murphy, 2008). FSH stimulates follicular growth, but also promotes the synthesis of oestrogen in the 
granulosa cells surrounding the oocyte, whilst the increase in oestrogen further promotes follicular 
growth. Once the dominant follicle has grown to approximately 15 mm, oestrogen levels are 
sufficient to cause a surge in LH production by the pituitary gland, which in turn triggers ovulation 
(~day 14); concomitantly, oestrogen stimulates endometrial growth in preparation for pregnancy. 
The first phase of the menstrual cycle is defined as the follicular phase, whereas the following phase 
(between ovulation and menses) as the luteal phase (Wallach, McNeely and Soules., 1988). In the 
second phase, should the released egg not be fertilised, the endometrium is shed a further 14 days 
after ovulation and this cycle restarts. 
 
 
Figure 1.5. A. Hormonal responses during the menstrual cycle in healthy women; B. persistent 
ovulation in women with polycystic ovary syndrome. 
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Following ovulation, the empty follicle (corpus luteum) produces progesterone (Figure 1.5A) to 
cease the release of additional eggs and to prepare the womb for implantation with a fertilised egg 
and subsequent pregnancy. Should pregnancy not occur, the corpus luteum shrivels, reducing levels 
of oestrogen and progesterone; these falling levels allow for the shedding of the uterine lining during 
menstruation (Jabbour et al., 2006).  
The causes of menstrual disruption in PCOS are attributed to hormonal imbalances. Many women 
with PCOS have persistently elevated LH, and a constant level of FSH (Figure 1.5B). Persistently 
elevated LH stimulates the theca cells to produce an increased volume of androgens (namely 
androstenedione and testosterone). Alongside this, unwavering levels of FSH result in paused 
follicular development (Figure 1.6b), failure of follicular maturation and ultimately, no ovulation 
(Elsheikh and Murphy, 2008). Failure to reach the luteal phase, means that insufficient progesterone 
is produced to induce menstruation and periods become irregular (oligomenorrhea) or absent 
(amenorrhea). The immature follicles then remain within the ovary and form the ‘cysts’, as observed 
on ultrasound, that are synonymous with the condition (Couse et al., 2004).  
Figure 1.6. Follicular maturation, ovulation and luteal phase in a healthy ovary (a) and, paused 
follicular maturation and development of cysts within a polycystic ovary. 
32 
C S Kite, PhD Thesis, Aston University 2020 
Disturbance of the menstrual cycle is a cardinal characteristic of PCOS. As such, oligomenorrhea 
(menstruation occurs at intervals of between 35 days and 6 months) or amenorrhea (no menstrual 
bleeding for > 6 months) and anovulation (the ovaries do not release an oocyte during the menstrual 
cycle) are frequently associated with the condition (Balen et al., 2005). Indeed, in a sample of 1741 
women, Balen et al. (1995) reported that 47% experienced oligomenorrhea, ~19% amenorrhea, and 
~30% reported regular menses. Similarly, Robinson et al. (1993) reported that 73.6% of PCOS 
women in their study had either oligomenorrhea or amenorrhea and that the PCO morphology is 
detected in the majority of women with oligomenorrhea. 
The presence, and severity of menstrual disruption differs greatly between women with PCOS. These 
variations are often associated with comorbidities, such as obesity, insulin resistance, elevated 
androgens and concentrations of LH. When Balen et al. (1995) stratified PCOS women by BMI, a 
greater proportion (32%) of women had regular menstrual cycles when their BMI was < 30 kg/m2. 
In contrast, only 22% of those with a BMI > 30 kg/m2 experienced regular cycles. In addition, 
oligomenorrheic women with PCOS also had decreased insulin sensitivity when compared to healthy 
controls and, regularly menstruating PCOS women. This indicates that PCO morphology in 
combination with insulin resistance is associated with anovulation and menstrual irregularities 
(Robinson et al., 1993). 
 
  PCO Morphology 
There have been many descriptions and definitions of the PCO morphology, and, as imaging 
technology has progressed, these have been further refined. Based upon histological samples taken 
at wedge resection of the ovaries, Stein and Leventhal (1935) first characterised the ovarian features 
from seven hirsute, amenorrheic women which included a prominent theca, fibrotic thickening of the 
tunica albuginea and multiple cystic follicles. Goldzieher and Green (1962) have also reported an 
‘excessive’ number of antral follicles (2-6 mm in diameter) in a similar population. The introduction 
of transabdominal and transvaginal ultrasound scanning has altered the method in which the PCO 
morphology is identified.  
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The seminal work of Adams et al. (1985) used transabdominal ultrasound to define a PCO as 
containing at least 10 follicles, between 2-8 mm, in one plane, and either arranged peripherally 
around a dense core of ovarian stroma, or interspersed throughout an increased amount of stroma. 
This definition is commonly cited in subsequent studies that used ultrasound scanning to detect the 
PCO morphology. Transvaginal ultrasound scanning has largely superseded previous methods, as it 
offers a higher resolution and is more comfortable for the patient. Thus, this method may provide a 
more accurate view of the internal structures of the ovaries, avoiding apparently homogenous ovaries 
as described with transabdominal scans, which may be particularly beneficial in women with obesity 
(Balen et al., 2003). It is likely that three-dimensional ultrasound may further enhance the detection 
of the PCO morphology, and may be utilised more frequently in the coming years. 
The most comprehensive definition of the PCO morphology which is currently applied was 
introduced by a consensus meeting on PCOS held by the ESHRE/ASRM (2003). Based on this, PCO 
morphology should be characterised by either, 12 or more follicles measuring 2-9 mm in diameter, 
or ovarian volume >10 cm3. In the context of this consensus, it was further stated that the subjective 
appearance of the ovaries, follicular distribution and stromal echogenicity should not be utilised in 
defining the PCO morphology and that women who have the PCO morphology, but in the absence 
of ovulatory dysfunction or hyperandrogenism should not be diagnosed with PCOS.     
 
1.5.  PCOS and Metabolic complications 
 Insulin Resistance 
Hyperinsulinaemic insulin resistance is commonly associated with PCOS, and women with PCOS, 
either lean or obese, are more insulin resistant than BMI matched controls (Dunaif, et al., 1989; 
Norman, et al., 2001; DeUgarte, Bartolucci and Azziz, 2005). Iuorno (2007) defines insulin 
resistance as the reduced ability of insulin to stimulate glucose uptake. Insulin has a number of 
subcellular actions that are unrelated to glucose uptake, but there are two major pathways of insulin 
subcellular signalling: (1) the glucose transporter type 4 (GLUT-4), primarily located in adipose 
tissues and striated muscle, is stimulated by insulin to increase glucose uptake intracellularly (Sivitz 
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et al., 1989); and (2) the mitogen activated protein (MAP) kinase activation pathway, which is 
primarily involved in the regulation of mitogenesis. Whilst glucose uptake is downregulated in 
insulin resistance, the MAP kinase pathway may be upregulated, increasing lipogenesis in T2DM 
(Koistinen et al., 2003). Generally, the resistant pathway refers to the former; that is decreased insulin 
mediated intracellular uptake of glucose.    
Of note, insulin resistance is one of the two major contributing factors to the development of T2DM 
(Kahn, Hull and Utzschneider, 2006), which is extremely prevalent in women with PCOS (Teede et 
al., 2006). Higher rates/degrees of insulin resistance and the increased presence of concomitant 
obesity, β-cell dysfunction and dyslipidaemia increase the risk of T2DM in PCOS (Ovalle and Azziz, 
2002). Legro et al. (1999) suggested that up to 40% of women with PCOS may be insulin resistant, 
whilst Peppard et al. (2001) report that 25% of premenopausal women with T2DM may also have 
PCOS. 
Although not included in the PCOS diagnostic criteria, insulin resistance is clearly associated with 
the pathophysiology of PCOS, but the exact underlying mechanisms of these links remain not fully 
clarified. In contrast to eumennorhic women with insulin resistance, who have decreased cellular 
insulin receptors that are inversely proportional to the degree of hyperinsulinaemia (Olefsky and 
Kolterman, 1981), women with PCOS reportedly have normal insulin receptor numbers which have 
a normal affinity for insulin (Conway et al., 1994; Tarkun et al., 2005). Abnormalities in subcellular 
signalling pathways are considered as a likely mechanism for insulin resistance in PCOS. Indeed, in 
the initial steps of the insulin signalling pathway, downregulated insulin mediated glucose transport 
in adipocytes has been reported (Dunaif et al., 2001), as well as decreased insulin stimulated lipolysis 
(Rosenbaum, Haber and Dunaif, 1993). In addition, Dunaif (1995) reported that the fibroblasts of 
women with PCOS exhibited decreased serine autophosphorylation of the insulin receptor.  
Overall, the presence of insulin resistance in a substantial proportion of women with PCOS means 
that screening for metabolic irregularities in PCOS (e.g., for MetS and T2DM) should be 
commonplace, so that relevant prevention and treatment interventions should be promptly applied in 
the management of these patients. For a large proportion of women with PCOS, this aspect of the 
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management of PCOS requires equal attention to that of addressing menstruation and fertility 
problems.   
 
 Overweightness/Obesity in PCOS 
PCOS is also commonly associated with overweightness and obesity (Legro, 2012), whilst excess 
body weight may also worsen hyperandrogenism and menstrual disturbances in women with PCOS 
(Kiddy et al., 1990; Balen et al., 1995; Liou et al., 2009). Moreover, a number of studies have 
suggested that PCOS may also be more prevalent in women with overweightness or obesity; for 
example, a Spanish study (Alvarez-Blasco et al., 2006) reported that 28% of women with 
overweightness/obesity met PCOS diagnostic criteria. However, women with obesity and PCOS are 
more likely to develop worse reproductive clinical symptoms (Gambineri et al., 2002), and therefore 
contact a medical professional for support and so this increases the opportunity for a PCOS diagnosis 
to be made, which may partially exaggerate the association between PCOS and obesity (Lim et al., 
2012). 
In addition to increased risk of overweightness/obesity, it has also been reported that women with 
PCOS are more likely to have increased visceral adiposity when compared with BMI-matched 
controls without PCOS (Karabulut et al., 2012; Carmina et al., 2009). Indeed, in the general 
population, it is waist circumference as opposed to BMI, which better explains the obesity-related 
health-risks (Janssen, Katzmarzyk and Ross, 2004; Huxley et al., 2009). Similar effects are observed 
in women with PCOS, with women with PCOS and higher levels of central obesity exhibiting 
increased prevalence of insulin resistance (Lord et al., 2006; Karabulut et al., 2012), as well as higher 
severity of metabolic dysregulation (Pasquali et al., 1994; Lord et al., 2006), hyperandrogenism 
(Svendsen et al., 2008), and reproductive disruption (e.g., anovulation) (Carmina et al., 2009).  
Despite the apparent association between PCOS and obesity, determining the exact obesity 
prevalence in this population remains problematic. Within the general population, obesity prevalence 
is known to vary depending upon factors such as age, ethnicity, education status and geographical 
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location (Santos and Barros, 2003). In addition to these demographic characteristics, determining the 
precise prevalence of obesity in women with PCOS is further complicated by the use of multiple 
diagnostic criteria (Moran and Teede, 2009), and a potential lack of data that is representative of the 
general population.  
Lim and colleagues (2012) completed a systematic review and meta-analysis in order to provide an 
evidence-based evaluation of the prevalence rates of overweightness, obesity and central obesity in 
women with PCOS. Individual studies included in this analysis reported prevalence of overweight 
and obesity rates ranging from 6% (Ansarin et al., 2007) to 100% (Peppard et al., 2001; Glueck et 
al., 2003; Villaseca et al., 2004), whilst the performed meta-analysis identified a polled effect 
estimate of 61% (95% CI: 54-58%, 21 studies, 3132 participants). When Lim et al. (2012) separated 
data for obesity only, prevalence rates ranged from 12.5% (de Vries et al., 2007) to 100% (Peppard 
et al., 2001), and the pooled effect estimate was 49% (95% CI: 42-55%, 18 studies, 4160 
participants). In addition, the prevalence range for central obesity was 20% (Gul et al., 2008) to 86% 
(Glueck et al., 2003), with a pooled prevalence of 54% (95% CI: 43-62%, six studies, 1191 
participants). For all three analyses, women with PCOS demonstrated statistically higher values than 
control women without PCOS; all meta-analyses had statistically significant levels of heterogeneity 
(P <.001; I2 ≥ 84%) reducing confidence in effect estimates. It should also be noted that the majority 
of studies included in these analyses are drawn from medical settings that may introduce considerable 
selection bias. Indeed, studies utilising unselected populations have reported that BMI was markedly 
lower in unselected groups (i.e., not medically identified), and that prevalence of obesity was 
comparable to data from the general population (Ezeh, Yildiz and Azziz, 2013; Luque-Ramírez et 
al., 2016). This implies that at least a proportion of the observed higher obesity prevalence in PCOS 
may be due to self-referral to healthcare settings in response to exacerbated symptoms. 
Contrasting evidence also exists regarding whether increased BMI drives PCOS development; again, 
PCOS incidence was greater in women that had obesity when these women had been selected based 
upon referral for bariatric surgery (Gosman et al., 2010), dietary consultation (Alvarez-Blasco et al., 
2006) or in those self-reporting symptoms (Laitinen et al., 2003). In contrast, Yildiz el al. (2008) 
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found that increasing BMI had little influence upon PCOS prevalence in an unselected population. 
Whilst this methodology may help to reduce selection bias, a similarly designed study (Yildiz et al., 
2012) presented conflicting results, since it noted that as mean BMI increased, so too did instances 
of PCOS. This contrasting evidence makes it difficult to establish whether (and to what extend) 
obesity drives PCOS. Thus, based on the available evidence, it seems more likely that PCOS is 
present, but possibly undetected, and that increased adiposity exacerbates symptoms leading to 
clinical presentation (Lizneva et al., 2016). 
Irrespective of the order of exacerbated clinical manifestations, it is widely reported that women with 
PCOS and overweightness/obesity have poorer health than their lean counterparts, with the relevant 
impact of PCOS and obesity being both independent and additive (Dunaif et al., 1989). In fact, 
Dunaif et al. (1992) suggest that insulin action in women with obesity without PCOS is comparable 
to that of lean women with PCOS. Risk of impaired glucose tolerance (IGT) is also commonly 
associated with obesity; normal-weight women with PCOS seldom present with IGT, yet their 
counterparts with overweight/obesity are at a much higher risk (Ehrmann et al., 1999). Similarly, 
dyslipidaemia (Legro, Kunselman and Dunaif, 2010) and MetS (Ehrmann et al., 2006) are also 
associated with the degree of increased BMI in these women.  
When the severity of hormonal and reproductive PCOS symptoms are considered, their relationship 
with obesity is less certain. Previous evidence has not identified any clear relationship between 
obesity and menstrual regularity (Solomon et al., 2002), hyperandrogenaemia, hirsutism (Carmina 
et al., 1992) or the identification of PCO morphology using ultrasound (Legro et al., 2005). However, 
obesity is reportedly a predictor of how well women with PCOS respond to treatment, particularly 
treatments aimed at improving fertility outcomes (e.g., ovulation and likelihood of pregnancy) 
(Legro, 2012). Indeed, clomiphene resistance (Imani et al., 1999) and a failure to conceive via in 
vitro fertilisation (Rausch et al., 2009) are all negatively affected proportionate to the degree of 
obesity. In addition, a reduction in BMI can promote favourable effects upon other circulating 
factors, such as free androgen and IGF-1 levels, which are shown to predict ovulatory function (Imani 
et al., 2000).  
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1.6.  PCOS and Psychological wellbeing 
 PCOS and Depression - Anxiety 
Given the aforementioned disease burden, it is somewhat unsurprising that women with PCOS 
exhibit more often mental health complications (e.g., depression and anxiety) than their counterparts 
without PCOS (Farrell and Antoni, 2010). A previous systematic review used standardised mean 
difference (SMD, calculated using Hedges’ g with values of 0.2, 0.5 and >0.8 indicating, 
respectively, a small, moderate and large difference between groups) meta-analyses to assess the 
difference in depression and anxiety between women with PCOS and controls, showing that the 
former had higher levels of both depression (Hedges’ g: 0.82, 95% CI: 0.73 to 0.92; 13 studies, 2257 
participants) and anxiety (Hedges’ g: 0.54, 95% CI: 0.33 to 0.75; 6 studies, 375 participants) than 
the latter (Barry, Kuczmierczyk and Hardiman, 2011). Of note, Barry and colleagues (2011) state 
that there is some uncertainty around the clinical importance of these reported differences, since, 
although effect sizes were large, and women with PCOS had scored significantly higher, the real 
magnitude of the difference and average scores was representative of no depression in the controls 
and mild depression in the women with PCOS. Similarly, anxiety scores were only representative of 
modest clinical differences, with the average control group scores being slightly lower than the norm, 
and the scores for the women with PCOS being ‘mildly elevated’. Whilst this may seem as not 
significant, it is postulated that even a modest increase in a hyperandrogenic condition could further 
compound symptoms. Given that women produce ~25% of their testosterone from their adrenal 
glands (Burger, 2002), prolonged anxiety/stress may lead to elevated testosterone levels and a greater 
severity of symptoms by chronic activation of the adrenal glands via the hypothalamic-pituitary-
adrenal (HPA) axis (Reiche, Nunes and Morimoto, 2004). This effect may be further exaggerated 
due to an increased HPA response in women with PCOS (Benson et al., 2009). 
Moreover, the findings of a more recent systematic review and meta-analysis (Cooney et al., 2017) 
tended to agree with the findings of Barry, Kuczmierczyk and Hardiman (2011), since the prevalence 
of women with PCOS that had depression was 36.6% compared to only 14.2% in control women. 
Meta-analysis revealed that women with PCOS had increased odds of any depressive condition (odds 
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ratio, OR: 3.78, 95% CI: 3.03 to 4.72; 18 studies) and further increased odds of moderate/severe 
depressive symptoms (OR: 4.18, 95% CI: 2.68 to 6.52, 11 studies) compared to women without 
PCOS. When anxiety was analysed, the median prevalence was 41.9% in women with PCOS 
compared to 8.5% in a polled control. This also represents an increased likelihood of any anxiety 
(OR: 5.62, 95% CI: 3.22 to 9.80, 9 studies) or moderate/severe anxiety symptoms (OR: 6.55, 95% 
CI: 2.87 to14.93; 5 studies) in women with PCOS compared to controls. Of note, when women were 
matched for BMI, fewer studies were included in the analysis, but these odds were largely unaffected. 
As to the underlying cause of this increased psychological comorbidity, Barry (2019) states that there 
are differences between the causes of depression and anxiety in women with PCOS. Indeed, there is 
likely a host of factors which either directly or indirectly contribute to depression in PCOS, including 
increased body weight, acne, and hirsutism (Barry, Qu and Hardiman, 2018). Furthermore, it is likely 
that individuals who have been diagnosed with a chronic condition without definite treatment, such 
as PCOS, will experience an acute and chronic impact upon their quality of life, with subsequent 
mood disturbances as a result (Barry, 2019). In this context, it is postulated that, as opposed to 
elevated androgen levels directly causing depression, it is their influence upon the distressing 
symptoms of PCOS which promote a depressive state (Pastore et al., 2011; Borghi et al., 2018; 
Batool et al., 2016).  
Interestingly, anxiety in PCOS is also hypothesised to be associated with reactive hypoglycaemia (a 
state of lowered glucose which typically occurs after meals) which has previously been reported to 
be four times more frequent in women with PCOS than controls (Atluntas et al., 2005). A condition 
called ‘tense-tiredness’ often occurs in relation to hypoglycaemia, which results in the individual 
feeling depressed, anxious and fatigued (Thayer, 1989). Although increased fatigue is not widely 
reported in PCOS (Hollinrake et al., 2007), it has been suggested that women with PCOS 
demonstrate more of the psychological manifestations associated with tense-tiredness than their 
healthy counterparts (Barry et al., 2011a). Of note reactive hypoglycaemia could be controlled 
through dietary interventions (e.g., low-glycaemic index meals).  
 
40 
C S Kite, PhD Thesis, Aston University 2020 
1.7.  Treatment options for PCOS 
 International Guidelines for PCOS 
Due to the heterogeneous nature of PCOS, multiple diagnostic criteria and varying phenotypes, 
clinical practice for the management of PCOS is largely inconsistent (Teede et al., 2018).  Although 
a series of international guidelines have previously been developed (Balen et al., 2016; Goodman et 
al., 2015; Conway et al., 2014; Legro et al., 2013; Teede et al., 2011), many of these are now 
outdated. Furthermore, it is thought that there are gaps in the guidance provided due to a narrow 
scope, potential limitations of the methods used to develop them, and limited involvement from 
women with PCOS (Teede et al., 2018). Thus, clinical guidelines and recommendations for the 
management of women with PCOS remain relatively unclear. In 2018, Teede et al. developed 
comprehensive evidence-based guidelines that are intended to ‘serve as a single source of 
international evidence-based recommendations to guide clinical practice with the opportunity for 
adaptation in relevant health systems’. The following sections will briefly summarise treatment 
recommendations for the aforementioned symptoms of PCOS. 
 
 Hormonal contraceptives for PCOS 
For the management of irregular menstrual cycles and hyperandrogenism symptoms, treatment with 
combined oral contraceptives is recommended (Teede et al., 2018). The progestin contained within 
hormonal contraceptives has a supressing effect upon LH, which in turn reduces ovarian androgen 
production. Furthermore, the contained oestrogen increases circulating SHBG, thus reducing the 
amount of bioavailable androgens, which are responsible for hyperandrogenism-related PCOS 
symptoms (Legro et al., 2013). The effectiveness of hormonal contraceptives upon carbohydrate 
metabolism, lipid profiles and overweight/obesity are less clear and may be variable depending upon 
oestrogen dose and the progestin type that are prescribed (van der Vange, Kloosterboer, and Haspels, 
1987). Moreover, oral contraceptives may often be prescribed in combination with other 
pharmacological agents, such as insulin sensitizers and antiandrogens.   
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 Other pharmacological interventions for PCOS 
With regard to anovulation and improvements at conception and live birth rates, letrozole should be 
considered as first line pharmacological treatment when available, otherwise other ovulation 
induction agents, such as clomiphene citrate or gonadotropins, can be used (Teede et al., 2018). 
Women who are clomiphene citrate resistant may also be offered laparoscopic ovarian surgery as a 
second line treatment for anovulatory infertility (Seow et al., 2008); laparoscopic ovarian drilling 
has been shown to induce ovulation in 83% of clomiphene citrate resistant women with PCOS 
(Campo et al., 1993). Although not as effective as oral contraceptives (Morin-Papunen et al., 2003), 
the use of metformin has also been shown to improve menstrual cycle regularity (Nestler et al., 1998) 
and ovulation rates (Tang et al., 2012) in women with PCOS. Furthermore, metformin, alongside 
lifestyle changes are often recommended for women with PCOS and obesity, particularly when 
metabolic complications are present since this treatment appears to offer the greatest health benefit 
in those with T2DM risk factors or IGT (Teede et al., 2018). A previous systematic review in 
reproductive-aged women with PCOS and overweight/obesity has demonstrated that metformin was 
successful at promoting weight loss in women with PCOS (~2.9% decrease in body weight) when 
compared to a placebo (Nieuwenhuis-Ruifrok et al., 2009) which was equivalent to orlistat treatment 
for weigh loss (Padwal, Li and Lau, 2003). However, when women were adhering to a lifestyle 
weight loss intervention with increased PA and dietary control, there was additional benefit of adding 
metformin (Ladson et al., 2011; Nieuwenhuis-Ruifrok et al., 2009).  
 
 Lifestyle interventions for PCOS 
Overall, diet and exercise should form the principle treatment recommendation for women with 
PCOS and obesity (Legro et al., 2013). As such, in order to achieve/maintain a healthy weight, 
optimise hormone levels, metabolic profiles, and improve general health and quality of life, women 
with PCOS are advised to follow a healthy diet and engage in more and regular PA (Teede et al., 
2018). In women with PCOS and obesity, weight loss of 5-10% has been shown to induce clinically 
important changes across a range of outcomes and accordingly, lifestyle changes should be 
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recommended to all women with PCOS and increased BMI (Kiddy et al., 1992). In addition to diet 
and exercise, lifestyle interventions typically include behaviour change components that are designed 
to promote long-term adherence to an improved lifestyle.  
Given that PA has been proven to be effective at improving physical and psychological health in 
multiple populations and that it forms part of the primary treatment recommendation (lifestyle) in 
PCOS, further investigation as to its effectiveness is warranted. Indeed, there are no published large 
randomised controlled trials assessing the role of exercise in the management of PCOS, and the 
corresponding confidence – using the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) approach/system (Schünemann et al., 2013) – in international 
recommendations is low or very low (Teede et al., 2018). 
 
1.8.  Physical Activity and Exercise for PCOS 
 Defining physical activity (PA) 
PA has previously been defined as ‘any bodily movement produced by skeletal muscle that results in 
energy expenditure’ (Caspersen et al., 1985). On this basis, every human performs PA every minute 
of every day just to sustain life. However, the volume of PA completed varies from person to person, 
and for each individual over time, based upon their personal choices and circumstances. Caspersen 
et al. (1985) further state that exercise differs from PA, with the former being a subset of PA that is 
structured, planned and uses repetitive bodily movements with the aim of improvement or 
maintenance of physical fitness levels.  
This definition, along with others (Knuttgen, 1978; Rogers and Cavanagh, 1984; Faulkner, 2003) 
have proved to be slightly contentious. Winter and Fowler (2009) state that any definition of exercise 
(and terms associated with it) must adhere to universally adopted principles of science and satisfy 
the Système International d’Unités (SI), suggesting that these previous definitions of exercise fail to 
meet SI requirements. Winter and Fowler’s (2009) concern surrounds the wording of ‘repetitive 
bodily movement’, arguing that isometric muscular contraction (i.e. when there is no change in the 
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length of the contracting muscle and no corresponding movement) has been entirely overlooked. 
Accordingly, they suggest a potentially more suitable definition based on which exercise is a 
potential disruption to homeostasis by muscle activity that is either exclusively, or in combination, 
concentric, eccentric or isometric. Furthermore, they also cite that distinctions between PA and 
exercise must depend upon the context and circumstances. In the context of this thesis, the two terms 
(exercise and physical activity) are applied interchangeably.  
Following hypertension (responsible for 13% of global mortality), tobacco usage (9%) and elevated 
blood glucose levels (6%), physical inactivity represents the fourth leading risk factor for global 
mortality, accounting for 6% of global deaths (WHO, 2009). Additionally, physical inactivity is 
thought be pivotal in the development of non-communicable diseases and, particularly as a key 
determinant of energy expenditure, is considered a determinant of overweightness and obesity (the 
fifth leading risk factor for mortality; 5%). Accordingly, the World Health Organisation (WHO) 
implemented global PA guidelines, recommending that adults (aged 18-64) complete at least 150 
minutes of moderate-intensity aerobic exercise or 75 minutes of vigorous-intensity exercise per week 
(WHO, 2011). Alternatively, an equivalent amount using a combination of both intensities (moderate 
and vigorous) can be completed. Furthermore, aerobic activities should be completed in bouts lasting 
at least 10 minutes, whilst muscle strengthening exercises, involving the major muscle groups, should 
also be completed at least 2 days per week (WHO, 2011). Recommendations for adolescents (<18 
years) and the elderly (≥ 65 years) vary slightly to better suit each demographic. Within the UK, 
similar guidelines are outlined by the Department of Health (2011). 
When quantifying the intensity of PA, multiples of metabolic equivalents of task (MET) is the 
method that is commonly used. One MET is defined as the energy that an average individual expends 
when sitting quietly, and is based upon the relative rate of oxygen consumption (one MET is 3.5 
ml/kg/min of oxygen) (Ainsworth et al., 1993). This allows the intensity of PA to be categorised in 
absolute terms, as light (<3 METs), moderate (3-6 METs) or vigorous (>6 METs) (Saxton, 2011). 
Walking at ~5 km/h is an example of an activity that is roughly three METs, whereas brisk walking 
(~7 km/h) increases the METs to approximately five (Ainsworth, 2000). An activity that is five METs 
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would therefore expend five times more energy (~17.5ml/kg/min of oxygen) than when the body is 
at rest. In epidemiological studies, PA guidelines are often expressed as MET-minutes or MET hours 
per week (MET-h/wk), although this is often not appropriate for use by the general public. To 
complete 150 MET-minutes (or 2.5 MET-h) of PA, a five MET activity would need to be completed 
for 30 minutes. However, the same volume can be achieved by completing a 10-MET activity for 15 
minutes. Individuals following WHO PA guidelines should therefore achieve 8.3-16.7 MET-h/wk, 
which epidemiological studies suggest may be enough to elicit favourable changes (Liu et al., 2015; 
Li et al., 2015; Kelly et al., 2014). 
 
 Epidemiological evidence for physical activity 
Early studies by Morris and colleagues (1953) were arguably the first to investigate the effects of 
exercise and PA. Indeed, when comparing the relatively active double-decker bus conductors to the 
more sedentary drivers, they reported lower incidence and later onset of CAD, as well as lower CAD-
related mortality. Another landmark study with a 16-year follow up of >3000 dockworkers observed 
that those who were the most active had lower CAD mortality than their less active co-workers 
(Paffenbarger et al., 1970), independently of smoking status, BMI or blood pressure. A later study 
by the same authors, which analysed ~17,000 Harvard Alumni in a 16-year follow-up, reported an 
inverse dose-response association between PA levels and all-cause mortality rates (Paffenbarger et 
al., 1986).  
More recently, the European Prospective Investigation into Cancer and Nutrition Study (EPIC) 
completed a 12-year follow up of more than 300,000 individuals to assess whether associations 
between PA levels and all-cause mortality are influenced by body fat (Ekelund et al., 2015).  In this 
study, PA was associated with lower all-cause mortality irrespective of BMI or waist circumference, 
and it was concluded that if all the inactive study participants were at least moderately active, 
mortality rates would be substantially reduced. In addition, a number of systematic reviews, 
including meta-analyses, have collated and evaluated the evidence of PA at reducing all-cause 
mortality and morbidity. One such review pooled data from 661,137 participants, and found that 
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those who completed some moderate to vigorous leisure time PA, but less than national guidelines, 
had a 20% reduction in all-cause mortality. By contrast, those completing 3-5 times the 
recommended levels, saw a 39% reduction in all-cause premature mortality risk (Arem et al., 2015). 
Similar findings have been reported elsewhere, with Moore et al. (2012) identifying increases in life 
expectancy when leisure time PA was increased, and Hupin et al. (2015) reporting all-cause mortality 
risk reductions of up to 35% in older adults, whilst Samitz et al. (2011) found relative risk reductions 
of 9% and 4% for each 1-hour increment per week of vigorous- or moderate-intensity PA, 
respectively. 
Other reviews have also assessed the association between PA levels and the risk of chronic disease 
or disease-specific mortality. Kyu et al. (2016) reported that higher levels of PA were associated with 
a reduced risk of developing breast cancer, colon cancer, diabetes, CAD or ischemic stroke, and that 
the greatest risk reductions (14-28%) came from those who were in the highest PA group (5-6 times 
the current WHO recommendations). Similarly, Wahid et al. (2016) found that moving from being 
inactive to meeting recommended PA levels resulted in a 26% lower risk of T2DM, 20% lower risk 
of CAD and 18% lower risk of ischemic stroke. 
Overall, the available evidence strongly supports the notion that participation in moderate to vigorous 
PA is sufficient to reduce the risk of developing a host of conditions, and may prolong life. Despite 
this, there is an apparent lack of large scale randomised controlled trials (RCTs) that investigate 
exercise therapy in women with PCOS (Harrison et al., 2011). Despite this limited availability of 
existing evidence, Legro et al. (2013) still argue that the perceived benefits of exercise are strong 
enough to recommend it as a first line treatment in the management of PCOS. 
 
 Exercise and PCOS 
Given that PA has been shown to be effective in other insulin resistant populations, it is reasonable 
to assume that it would also be an effective treatment strategy for women with PCOS. Indeed, as 
aforementioned increased regular exercise is a first-line recommendation for the management of 
women with PCOS, along with wider lifestyle changes (Teede et al., 2018). Despite this current 
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recommendation, there is little consensus about the optimal frequency, intensity, duration, or type of 
PA that would be most beneficial within this female patient population. Therefore, women with 
PCOS and clinicians typically adopt a generic approach to exercise prescription (i.e. following PA 
guidelines), often alongside pharmacological intervention, with uncertainty of the effectiveness of 
PA (Stepto et al., 2019). 
Identifying this marked gap in the existing studies/evidence in this field was the primary motivation 
for the present PhD thesis. As such, the chapters hereafter will synthesise the existing evidence for 
exercise/PA in women with PCOS and present studies which aimed to offer better insight on its role 
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2.1. Methods for a systematic review and meta-analysis: Exercise, or exercise and diet for the 
management of polycystic ovary syndrome  
 
2.1.1. Systematic review protocol and registration  
This systematic review was prospectively registered on the Prospero International Prospective 
Register of Systematic Reviews (CRD42017062576) and is reported based on the guidelines of the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Moher 
et al., 2009). 
 
2.1.2. Search Methods for Identification of Studies 
The inclusion and exclusion criteria for eligible studies in this systematic review are presented in 
Table 2.1. In brief, 1) trials had to include women of a reproductive age who had received a PCOS 
diagnosis; 2) trials must have employed a randomised, or quasi-randomised experimental 
(intervention) design that 3) measured the chronic (i.e.  long-term) effects of exercise, or exercise 
and diet combined, in women with PCOS. Exercise was defined according to the definition set out 
by Winter and Fowler (2009): “a potential disruption to homeostasis by muscle activity that is either 
exclusively, or in combination, concentric, eccentric or isometric”. Accordingly, we included all 
methods of exercise training, including continuous aerobic exercise (e.g., walking, jogging, running, 
swimming or cycling); high-intensity interval training; resistance training (e.g., weight lifting); 
flexibility training; and yoga, Tai Chi, and Pilates. Trials were eligible if they compared a minimum 
of two conditions (e.g., exercise compared to control, or exercise compared to diet) and used either 
a within-subject crossover design, or a between-subject comparison to a control, or alternative 
treatment group, as long the effect of exercise could be isolated. Studies that included follow-up 
testing, at least one month after completion of the intervention, were also eligible for inclusion.  
 
The following databases were searched in June 2017: CENTRAL (in the Cochrane Library), 
PubMed, CINAHL, SCOPUS, EMBASE (via Web of Science), SportDiscus (via EBSCOhost), and 
PsycINFO (via OvidSP). There was no time limit specified for trial inclusion and only fully 
published, peer-reviewed papers were included; grey literature was not eligible for inclusion. In 
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addition, no language restrictions were placed on the search, meaning that foreign language papers 
could be included subject to translation. A search algorithm was developed for PubMed (Table 2.2), 
which was then modified for each additional database search.  
One reviewer completed (CK) the initial database searches and the titles and abstracts were exported 
into EndNote (EndNote X8.2, build 11343; Clarivate Analytics, Philadelphia, USA) and duplicate 
records were removed. The resulting database was transferred into Covidence (Covidence v1344; 
Melbourne, Australia) and an additional screen for duplicates was completed. Two reviewers (CK 
and IL) then independently screened each title and abstract excluding papers that were clearly 
ineligible. At the next stage, PDFs were retrieved, and the same two reviewers independently 
screened each full-text, ensuring that those which were eligible were retained in the Covidence 
software. At each stage of screening, all disagreements on paper eligibility were resolved by 
discussion between the two reviewers, whilst any unresolved disagreements were decided by 









Table 2.1. Eligibility criteria for including studies in this systematic review. 
Inclusion Criteria: 
1. Study Design: randomised controlled trials and quasi-randomised controlled trials. 
2. Types of Participants: reproductive-aged women with a diagnosis of polycystic ovary 
syndrome (PCOS) based on the National Institute of Health (NIH) diagnostic criteria 
(1990), or the Rotterdam ESHRE/ASRM (2003) diagnostic criteria, or the AE-PCOS 
Criteria (2006). Trials were also included where the PCOS diagnosis had been verified by 
a general practitioner or specialist clinician. 
3. Comparators: exercise vs usual care/control, exercise combined with diet vs usual 
care/control, exercise combined with diet vs diet only. Exercise combined with diet vs 
exercise only, exercise vs diet, exercise combined with pharmaceutical vs pharmaceutical. 
4. All outcomes: expected outcomes included: primary outcomes, such as blood pressure, 
fasting blood glucose, insulin and lipid concentrations; and secondary outcomes, such as 
body mass index, cardiorespiratory fitness, testosterone, free androgen index, and health-
related quality of life measures.  
 
Exclusion Criteria: 
1. Study Design: case studies, cross sectional and non-randomised controlled trials. 
2. Types of Participants: males, adolescent females, post-menopausal women, women 
without PCOS. 
3. Comparators: women with PCOS vs. healthy controls, pharmaceutical vs. exercise, 














Table 2.2. Search algorithm devised for advanced search in PubMed database. Algorithm adapted 
and implemented across additional databases. 
Search Query 
#1 Polycystic ovary syndrome [MeSH Terms] 
#2 Polycystic ovar* [Title/Abstract] 
#3 PCOS [Title/Abstract] 
#4 PCOD [Title/Abstract] 
#5 Stein levent* [Title/Abstract] 
#6 PCO [Title/Abstract] 
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 
#8 Exercise [MeSH Terms] 
#9 Exercise movement techniques [MeSH Terms] 
#10 Exercise Therapy [MeSH Terms] 
#11 Exercise [Title/Abstract] 
#12 Physical education and training [MeSH Terms] 
#13 Physical fitness [MeSH Terms] 
#14 Physical fitness [Title/Abstract] 
#15 Physical exertion [MeSH Terms] 
#16 Sports [MeSH Terms] 
#17 Physical Activity [MeSH Terms] 
#18 Sport* [Title/Abstract] 
#19 Physical activity [Title/Abstract] 
#20 Physical activities [Title/Abstract] 
#21 Walking [MeSH Terms] 
#22 Walk* [Title/Abstract] 
#23 Resistance Training [MeSH Terms] 
#24 Muscle training [Title/Abstract] 
#25 Strength training [Title/Abstract] 
#26 Endurance training [Title/Abstract] 
#27 Interval training [Title/Abstract] 
#28 Intermittent training [Title/Abstract] 
#29 Fitness [Title/Abstract]  
#30 Swimming [MeSH Terms] 
#31 Swim* [Title/Abstract] 
#32 Bicycling [MeSH Terms] 
#33 Bicycl* [Title/Abstract] 
#34 Cycling [Title/Abstract] 
#35 Cycle [Title/Abstract] 
#36 Strengthening [Title/Abstract] 
#37 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 
OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR 
#31 OR #32 OR #33 OR #34 OR #35 OR #36 
#38 #7 AND #37 
#39 Randomized controlled trial [Publication Type] 
#40 Controlled clinical trial [Publication Type] 
#41 Randomized [Title/Abstract] 
#42 Placebo [Title/Abstract] 
#43 Clinical trial as topic [MeSH Terms] 
#44 Randomly [Title/Abstract] 
#45 Trial [Title] 
#46 #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 
#47 #38 AND #46 
#48 Animals [MeSH Major Topic] NOT Humans [MeSH Major Topic] 




In some instances, there were multiple publications for the same trial; these papers were linked 
together, and the earliest paper of the trial was used as the primary reference. However, the earliest 
paper was only used as the reference and all data were extracted from these papers with the most 
comprehensive available data (i.e., largest available sample size) included for each outcome. Data 
were extracted from eligible studies and compiled in an Excel spreadsheet (Microsoft Excel 
v16.04849.1000; Microsoft Corporation, Washington, USA). Trial data for each individual outcome 
were then extracted and combined in meta-analyses using Review Manager (RevMan 5.3.5, 
Copenhagen, Denmark). 
All trial outcomes were eligible for inclusion following the search, but the primary outcomes were 
those linked to cardiovascular disease (CVD) risk (e.g., blood pressure, lipids, and glucose). 
Secondary outcomes were cardiorespiratory fitness, anthropometric measures, androgen levels, pro-
inflammatory markers, and psychosocial outcomes. 
 
2.1.3. Assessment of risk of bias in included studies 
The Cochrane Collaboration’s tool for assessing risk of bias was used; this tool allows assessment of 
seven specific domains (sequence generation, allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, 
and other bias). These domains are associated with five potential sources of bias (selection bias, 
performance bias, detection bias, attrition bias, and reporting bias). The risk of bias tool also allows 
reviewers to assess other sources of bias by adding fields they deem to be appropriate to the review. 
Accordingly, three additional domains were added: group similarity at baseline, adherence to 
intervention and contamination (i.e., control participants partaking in activities similar to the 
intervention). Two reviewers (CK and IA) assessed risk of bias, and a third reviewer (IL) arbitrated 
conflicts not due to assessor error. Recommendations from the Cochrane Handbook (Higgins and 




Studies with >20% of data missing were deemed to have a high risk of attrition bias. We also 
considered studies with between-group baseline differences that may have affected the outcome (e.g., 
age, BMI, or activity status), less than 75% adherence to the prescribed intervention, and those with 
contamination in the control group, as high risk of ‘other sources of bias’ (Furmaniak et al., 2016). 
It should also be noted that, in exercise trials it is difficult to blind participants and researchers 
(particularly when supervised) to the interventions. This resulted in a judgement of a high risk of 
performance bias being made; this does not infer that the methodological quality of the trial is poor, 
but rather that the inevitable bias related to lack of blinding has been acknowledged by the reviewers. 
A risk of bias table is presented in the appendices (Appendix 7.1) and risk of bias summarised in the 
results (Figure 3.2 and Figure 3.3). 
 
2.1.4. Strategy for data synthesis 
Where data from ≥2 trials were available, pooled intervention effect estimates and their 95% 
confidence intervals (CIs) are presented. A random effects model was adopted as it allows for 
differences in the treatment effect between studies (Riley, Higgins and Deeks, 2010). Meta-analytical 
methods for involving continuous outcomes assume that data are normally distributed; therefore, we 
excluded data from the meta-analysis if they were clearly skewed, or if study results were reported 
with median and range values, and/or non-parametric tests had been used in the subsequent analysis.  
All outcomes from each trial were presented as continuous data and, based on the Cochrane 
Handbook’s recommendations (Deeks et al., 2011), the random-effects method for meta-analysis 
was utilised to combine data (DerSimonian and Laird, 1986). Mean ± standard deviation (SD) data 
for both change from baseline to immediately post-intervention and immediately post-intervention 
values only were pooled in separate meta-analyses. Where data were missing, the RevMan calculator 
was used to convert standard errors, CIs or t-values to SD. A priori, the analysis was based on the 
change from baseline data as it removes a large component of between-person variability (Deeks et 
al., 2011). However, analysis of immediately post-intervention data was also included in order to 
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nullify the effect of selective reporting, and to better indicate whether there was a treatment effect 
regardless of baseline values.  
Where individual trials had reported the same outcome using the same scale, mean difference (MD) 
was used. Where outcomes were reported using various scales, the units of measurement were 
converted to the most common measure [e.g., fasting insulin (FI) converted from pmol/L to µIU/mL]. 
If this was not possible (e.g., relative and absolute values reported for cardiorespiratory fitness), then 
standardised mean difference (SMD) was used. Where a trial contained multiple intervention arms 
that were eligible for inclusion (e.g., Almenning et al., 2015; Thomson et al., 2008), the outcome 
data from both groups were combined using methods recommended in the Cochrane Handbook 
(Deeks et al., 2011). If a trial incorporated a crossover design (Roessler et al., 2013) then only data 
up to the point of crossover were included in the meta-analysis.   
To assess the quality of the evidence for the primary outcomes, the Grades of Recommendation, 
Assessment, Development, and Evaluation (GRADE) approach was utilised (Schünemann et al., 
2013). GRADE is a systematic framework for evaluating the quality and certainty of evidence for 
making recommendations in clinical practice (Guyatt et al., 2008). If a systematic review is able to 
provide a best estimate, from all the available evidence, of the effect size for each outcome, then 
GRADE allows a quality rating across a body of evidence (i.e. for each outcome). This is usually 
completed by taking the lowest quality of evidence from all of the outcomes that are most relevant 
to the research question and therefore, critical to the decision making process (Langer et al., 2012; 
Guyatt et al., 2013). GRADE utilises four levels of evidence: high, moderate, low and very low; 
evidence from RCTs starts out as high quality and is then downgraded based upon predetermined 
metrics. They are a risk of bias, imprecision around the effect estimate [i.e. wide 95% CIs around the 
effect estimate (Guyatt et al., 2011)], inconsistency, indirectness and publication bias. Accordingly, 
the findings for the most prevalent outcomes in the current review were graded against these criteria.  
Those primary outcomes in the review were: systolic blood pressure (SBP), diastolic blood pressure 
(DBP), blood glucose, FI, homeostatic model assessment of insulin resistance index (HOMA-IR), 
total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
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cholesterol (HDL-C), and triglycerides. To develop the ‘Summary of Findings’ tables, the 
GRADEpro GDT software was used; two review authors independently graded the quality of 
evidence for each primary outcome. Quality was not downgraded based upon lack of blinding alone; 
as stated in Section 2.1.3, this was due to the common difficulties associated with blinding 
participants (performance bias) and exercise supervising personnel. However, should the blinding of 
outcome assessors not be adequately reported, risk of detection bias was classified as high- or 
unclear-risk. However, the quality of evidence was downgraded based on risk of bias only if a lack 
of blinding was accompanied by high risks of bias in other domains (e.g., selection bias and 
incomplete outcome reporting). 
 
2.1.5. Investigation of heterogeneity 
To evaluate the heterogeneity of results for each outcome, the chi-square (χ²) test was used to quantify 
whether between study differences were due to chance alone. Where statistical heterogeneity was 
identified, the I2 statistic was used to quantify its magnitude. Although the I2 is not a measure of 
absolute heterogeneity, it describes the percentage of variability in the point estimates that is due to 
heterogeneity rather than sampling error (Deeks et al., 2011). As recommended by Deeks and 
colleagues (2011), the degree of between study heterogeneity was interpreted as: 0-40% ‘might not 
be important’, 30-60% ‘may represent moderate heterogeneity’, 50-90% ‘may represent substantial 
heterogeneity’, and 75-90% ‘considerable heterogeneity’. The importance of the observed I2 value 
depends on the magnitude and direction of effects, as well as the strength of evidence for 
heterogeneity. Accordingly, a visual inspection of each forest plot was completed, and there was an 
assumption of statistical heterogeneity if little or no overlap of the 95% CIs for the results of 
individual studies was observed. If there was evidence of at least substantial heterogeneity (≥ 50%), 
the potential cause was investigated by study population groups. In this instance, the largest outlier 
was identified, that trial was removed from the analysis and the I2 was re-assessed. If heterogeneity 
was not reduced to at least a moderate level (≤ 60%), it was also assessed in subgroup analyses and 




2.1.6. Assessment of reporting biases 
To investigate publication bias, if there were ten or more trials included in an individual analysis a 
funnel plot was used to explore the possibility of small study effects; this is because there is often a 
tendency for smaller studies to report larger beneficial effects (Sterne et al., 2000). Furthermore, 
when there is a small number of studies (< 10), the power of tests is too low to distinguish chance 
from real asymmetry (Deeks et al., 2011). In the current systematic review, only BMI had ≥ 10 
studies included within its analysis, so this was the only outcome where a funnel plot was completed. 
2.1.7. Subgroup analyses 
A subgroup analysis was conducted for each outcome where there were data from > 2 studies. The 
study characteristics that formed the subgroups for analysis were: BMI upon study entry (≤ 24.9 
kg/m2, 25.0-29.9 kg/m2 or ≥ 30.0 kg/m2), intervention type (aerobic exercise, resistance training, or 
interventions that combined both modalities), intervention duration (≤ 12 weeks or > 12 weeks), and 
the delivery format of the intervention (supervised, unsupervised, or mixed delivery). Outcome data 
were separated by subgroup and subtotal summary statistics were presented. The available data were 
insufficient to complete three of the sub-analyses from the original PROSPERO protocol; they are: 
exercise intensity, combined treatments, and behaviour change components. However, these findings 
have been reported qualitatively where available. 
 
2.1.8. Sensitivity analysis  
For all outcomes where a statistical effect was observed, sensitivity analyses were completed. This 
allowed an assessment of the effect of small sample size studies (n <30 total participants), and the 
effect of removing studies with high overall bias risk. Due to the nature of the interventions, 
performance bias was removed from the reviewer’s judgement. Because all studies exhibited at least 
one domain where risk of bias was unclear, only studies with at least one domain (excluding 






2.2. Methods for a case-control study: A comparison of self-reported energy expenditure, 
health-related quality of life, and attitudes towards physical activity in women with and 
without polycystic ovary syndrome. 
 
 
2.2.1. Study Design 
This protocol has been written following guidelines set out in the 22-item checklist (Appendix 7.4), 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement (von 
Elm et al., 2008). Favourable ethical opinion for this observational case-control trial was awarded 
from the School of Life and Health Sciences Ethics Committee at Aston University in January 2019 
(Ethics reference 1442).  
Recruitment of reproductive-aged women (aged 18-45) with and without PCOS took place between 
January 9th and May 9th 2019 via advertisements on social media, through PCOS support groups and 
in multiple online forums hosted by Verity, the UK-based PCOS charity. Inclusion/exclusion criteria 
are presented in Table 2.3. A range of questionnaires were used to collect the study data; 
questionnaires were completed online using the survey software, Qualtrics© XM (Qualtrics XM, 
Provo, Utah, USA); a URL link was either emailed directly to participants who expressed an interest 
in participation or participants could access the questionnaires directly via the same URL posted on 
social media channels.  
Table 2.3. Inclusion/exclusion criteria for participants in the current study 
Inclusion criteria: 
1. Reproductive aged women aged 18-45 years 
2. A self-reported diagnosis of PCOS, or a self-report of being healthy (i.e., free from any 




2. Females <18 years or >45 years 
3. Any chronic health condition other than PCOS 
4. Pregnancy 




2.2.2. Sample Size 
No single outcome was used to determine the required sample size. However, there was still a need 
to ensure that the sample size was adequate to detect meaningful between group differences, and to 
ensure that false positive/negative results were not reported. Therefore, a generic sample size 
calculation based on a minimally interesting effect size (δ) of 0.5, a power (1-β error probability) of 
0.80 and α error probability of 0.05 was used. Data was input into jpower (The Jamovi Project, 
v1.1.9.0) assuming a two-tailed hypothesis, indicating a sample size of 128 participants (64 per 
group) was required. The likelihood of reliably detecting various effect sizes is reported in Table 2.4 
and a power contour for the current design in Figure 2.1. 
Table 2.4. Statistical power by effect size based upon recruitment targets 
True effect size Power to detect Description 
0 < d = 0.349 ≤50% Likely miss 
0.349 < d = 0.499 50-80% Good chance of missing 
0.499 < d = 0.642 80-95% Probably detect 
d = 0.642 ≥95% Almost surely detect 




Figure 2.1. Power contour for current study design. The point represents the specified study 




2.2.3. Variables (Devising the theoretical model) 
To explore the relationships between participant’s circumstances, the role of PA, and their influence 
upon health-related quality of life (HRQoL), the constituent parts of Rosenstock and colleagues’ 
(1988) extended Health Belief Model (HBM) were utilised. The HBM is a widely used theoretical 
model associated with preventative health behaviours; it stipulates that the likelihood of an 
individual’s engagement in health protective behaviours (e.g., PA) depends on their perception of 
the severity of illness (e.g., PCOS, metabolic syndrome, T2DM) and also the perceived balance of 
cost versus benefit of taking action (Becker and Maiman, 1975). Those who believe that the severity 
of illness is great, and that there are more positives than negatives for engaging in PA, are more likely 
to adopt it as a behaviour. Whilst the HBM was originally designed to focus on disease, and not 
prediction of PA behaviours (Berger et al., 2015), it was felt that it represented an appropriate 
framework to guide the selection of outcomes for the path model that is included in this study (Figure 
2.2).  
The HBM incorporates three major components that may affect an individual’s readiness to engage 
in a specific health behaviour. Whilst it is suggested that the individual’s threat perception (i.e., how 
likely they are to get the disease, and how bad it would be if they did) and response effectiveness 
(i.e., what are the potential benefits/barriers of engaging?) may be the main determinants of 
behaviour (Abraham et al., 2016), there are also external variables which are also likely to contribute. 
Whilst the HBM has always included external variables (e.g., age, gender, socio-economic status, 
etc.), it wasn’t until 1988 that self-efficacy was introduced, which in certain studies, has proved to 
increase the predictive capabilities of this model (Hay et al., 2003). In order to capture variables that 
would constitute the external components, a sociodemographic questionnaire was devised, and a 
measure of self-efficacy for exercise and self-esteem was also implemented. To obtain the outcomes 
related to response effectiveness, a measure of participant perceptions of benefits and barriers to PA 
was used, and for threat perception, a disease specific (PCOS) questionnaire was incorporated. The 
primary outcome of interest is HRQoL; in both cases and controls, physical and mental health was 
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evaluated using the 12-item Short Form (SF-12) Health Survey and the differences between these 
populations reported. 
As stated above, it was anticipated that PA, as the target health behaviour would mediate the 
relationship between the constituent components of the HBM and HRQoL. PA-related outcomes are 
self-reported energy expenditure (MET-mins/wk), achieved through multiple domains of PA, sitting 




Figure 2.2. Adapted Health Belief Model. The behaviour of interest is physical activity. Red box denotes hypothesised outcome (HRQoL) affected by 






2.2.4. Outcome Measurements 
Health Related Quality of Life 
The 12-item Short Form (SF-12) Health Survey (Appendix 7.5) (Ware et al., 1996) was used to 
measure HRQoL from the patient’s perspective. The SF-12 is a shortened version of a longer generic 
survey; it presents a subset of 12 items from the SF-36 Health Survey (Ware and Sherbourne, 1992) 
and provides physical and mental component summary scores. Its shortened length was designed to 
reduce the burden upon respondents whilst achieving the required standards of precision needed to 
compare multiple health dimensions between groups. The SF-12 has been previously validated 
against the SF-36; product moment correlations between the physical (r = 0.94-0.96) and mental (r 
= 0.94-0.97) summary measures from each questionnaire are reportedly very high, suggesting that 
the SF-12 is a practical alternative to the SF-36 for use in a number of countries, including the UK 
(Gandek et al., 1998).  
For the path analysis, the individual mental and physical health scores were combined to give an 
overall composite score for quality of life (Ware, Kosinski, and Keller 1998). Whilst this practice is 
not commonplace, it was felt a reasonable approach due to a high degree of correlation between each 
domain score and the composite score and for simplification of the path analysis model. 
Participants in the PCOS patient group were also given a PCOS specific questionnaire called the 
PCOS-Q (Appendix 7.6). The PCOS-Q is a 26-item questionnaire that was developed to assess the 
impact of PCOS symptoms, and their associated treatments, across five domains, each related to a 
common symptom of PCOS (Cronin et al., 1998): emotions (eight items), body hair (five items), 
body weight (five items), infertility (four items) and menstrual problems (four items). Participants 
respond to each of the 26 items on the PCOS-Q by selecting an answer on a 1-7 scale; seven is 
representative of optimal function and one the poorest function. Each item is weighted equally when 




In lieu of another PCOS-specific questionnaire, Jones et al. (2004) found that the PCOS-Q 
demonstrated construct validity; statistically significant correlations were reported between the 
emotions domain from the PCOS-Q and the most relevant domains from the SF-36; that is the role 
emotional (r = 0.49; P <.01) and mental health (r = 0.62; P <.01) domains. Whilst both the PCOS-Q 
and SF-36 have previously been used in exercise intervention studies with women with PCOS 
(Stener-Victorin et al. 2013; Vizza et al. 2016), the PCOS-Q may allow a greater insight into the key 
dimensions of PCOS and their effect upon HRQoL (Teede et al., 2018).  
Physical Activity and Sedentary Behaviour  
Self-reported PA was measured using the International Physical Activity Questionnaire Long Last 7 
Days Self-administered Format (IPAQ-LF; Appendix 7.7). The IPAQ-LF is widely used in clinical 
settings and PA research and asks participants to recall their last seven days of PA, equating this into 
four comprehensive domains: leisure-time physical activity (LTPA), domestic and gardening 
activities, work-related physical activity, and transport-related physical activity. The structure then 
allows separate scoring for walking and either vigorous, or moderate-intensity activity within the 
other domains. Summation of self-reported PA duration, multiplied by weekly frequency and 
normative metabolic equivalent of task (MET) data (Ainsworth, et al., 2011) provides continuous 
data, reported as MET-minutes per week (MET-mins/wk). As sitting is an activity equivalent to 1-
MET, sitting time is reported as minutes per week (mins/wk).  
When data were analysed, data cleaning instructions from the Guidelines for Data Processing and 
Analysis of the IPAQ (IPAQ Research Committee, 2005) were followed. The main issues arising 
were: where minutes had been entered in the hour’s column they were manually corrected; where 
the sum total of all Walking, Moderate and Vigorous time variables exceeded 960 mins/day they 
were excluded from the analysis; responses of <10 minutes were recoded to zero; for each summed 
behaviour (i.e., total Walking, total Moderate- and total Vigorous-intensity) that was >180 minutes, 
the total value was truncated to exactly 180 minutes. These data processing rules mean that outliers 
are removed and also ensures that highly active people remain classified as highly active, whilst 
reducing the chance that those who are less active are incorrectly classified. 
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Criterion validity of the IPAQ-LF has previously shown fair to moderate agreement when compared 
with a Computer Science and Application’s Inc. accelerometer (CSA model 7164, Florida, USA); 
the pooled Spearman’s coefficient (p) = 0.33, and 95% CI were 0.26 to 0.39, although these values 
increased when categorical estimates of PA (i.e. sufficient or insufficient levels) were compared 
(Craig et al., 2003). 
Anthropometric and Sociodemographic information 
Participants completed a study-specific questionnaire (Appendix 7.8) to ascertain anthropometric 
and sociodemographic data for all participants. Questions about the participant’s physical 
characteristics were asked; these included self-reported age, height and weight (from which BMI was 
calculated as weight in kg divided by the height squared in metres) and waist circumference 
(centimetres). Furthermore, participants were asked if they had ever been diagnosed with PCOS; if 
they responded affirmatively, they were asked to specify the time (in years and months) since PCOS 
diagnosis and to identify the specific phenotype associated with their diagnosis. The four options 
available were: polycystic ovaries (PCO) menstrual disruption and excess androgens; PCO and 
menstrual disruption; PCO and excess androgens or; menstrual disruption and excess androgens. 
Participants could also answer as ‘do not know’. Questions about participant ethnicity, marital status, 
occupational status and education level, whether they have children and their approximate household 
income were also asked. 
Self-esteem 
Orth and Robins (2014) define the construct of self-esteem as an individual’s subjective evaluation 
of their own worth as a person; historically, self-esteem has also been viewed as an indication of 
mental and social life adjustment (Harter, 1989), as well as a mediator of behaviour (Marsh, 1993). 
In the general population, exercise and PA have often been related to an individual’s perceived self-
esteem levels (Fox, 1997); whilst a common belief is that improvements in self-esteem may stem 
from the positive bodily changes (e.g., reduced weight, improved muscle tone, smaller waist 
circumference) that result from participation in PA (Weinberg and Gould, 2019), there is a counter 
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argument that self-esteem may be increased from perceptions of improved performance, or additional 
biological/physical factors that may not be typically associated with physical fitness (Sonstroem, 
1997). Although self-esteem (Strauss, 2000; Strong et al., 2005) and PA/exercise (Fox, 1999) are 
acknowledged as important determinants of psychological wellbeing, less is known about the inter-
relationship between the three; increasing PA reportedly improves self-esteem, but it is unclear 
whether those with higher self-esteem are more likely to be physically active. 
Therefore, the Rosenberg Self-esteem (RSE) Scale (Appendix 7.9) was used to measure participant’s 
self-esteem. The scale utilises a four-point Likert scale allowing participants to respond to ten 
statements about themselves; a higher score indicates a greater level of self-esteem. The RSE Scale 
has been previously used in studies of women with PCOS (Açmaz et al., 2013), and in some instances 
(Bazarganipour et al., 2014; Bazarganipour et al., 2013) has been used to demonstrate that self-
esteem plays an important role, as a mediating factor, in the HRQoL of women with PCOS. The RSE 
Scale has received extensive psychometric analysis and empirical validation causing Gray-Little et 
al. (1997) to conclude that the RSE Scale provides a highly reliable, and internally consistent measure 
of self-esteem, thereby justifying its extensive use in psychosocial research. 
Self-efficacy for Exercise 
The Self-Efficacy for Exercise (SEE) Scale (Appendix 7.10) was administered to assess perceived 
motivational barriers to completion of PA. The SEE Scale is a revision of the unpublished work of 
McAuley (1990), a 13-item questionnaire that was intended to measure self-efficacy barriers to 
exercise. The revision of McAuley’s instrument was the result of an interdisciplinary study 
attempting to understand factors influencing adherence to a walking programme in older adults 
(Resnick and Spellbring, 2000). Based upon participant responses and feedback, the SEE Scale was 
devised; respondents are tasked with scoring from 0-10 (zero being not confident and ten being very 
confident) how confident they are that they could exercise for 20 minutes, three times per week given 
a variety of situations. The SEE Scale is a 9-item instrument and the total score is calculated by 
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summing the responses to each question; the scale has a possible scoring range of 0-90 and a higher 
score is indicative of higher self-efficacy for exercise.  
Resnick and Jenkins (2000) used structured equation modelling to test internal reliability and found 
that the SEE Scale demonstrated evidence of internal consistency (α-coefficient = 0.92). 
Furthermore, they assessed the construct validity of the scale using the mental and physical domains 
from the SF-12; when age and gender were controlled, the mental (F = 38.9, P <.05) and physical (F 
= 24.3, P <.05) domains from the SF-12 significantly predicted participant SEE. In addition, criterion 
validity was demonstrated as SEE Scale scores were able to significantly predict exercise activity 
(F = 78.8; P <.05), accounting for 30% of the variance in exercise activity. 
Perceived Benefits/Barriers  
The Exercise Benefits/Barriers Scale (EBBS) (Appendix 7.11) was used to measure participant’s 
perceived benefits and barriers to participation in exercise (Sechrist et al., 1987a). The EBBS 
requires respondents to rate their agreement with 43 statements (benefit items = 29; barrier items = 
14) using a four point Likert scale. Answers are scored from 1 to 4 (e.g. strongly agree = 4; strongly 
disagree =1), with the 14 barrier items being reverse scored; total scores can range between 43-172, 
with a lower score indicative of fewer perceived benefits and greater perceived barriers. During 
development (Sechrist et al., 1987b), the EBBS demonstrated extremely high internal consistency 
(Cronbach’s α = 0.953) and test-retest reliability (r = 0.89) for benefit barrier (Cronbach’s α = 0.886; 
r = 0.77) items, across a 2-week period.    
 
2.2.5. Risk of Bias 
This study was designed with a consideration of reducing potential risk of bias. In this context, the 
first consideration for this study design concerned the selection of participants. Thus, the included 
cases (i.e., women with PCOS) and controls in this study are clearly defined, and explicit 
inclusion/exclusion criteria were defined. However, this study relies upon self-reporting of either 
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having PCOS or being healthy, and whilst it would have been preferential to have the included cases 
and controls confirmed by a medical practitioner, this was not feasible in the context of this PhD 
work. Nevertheless, all study participants were recruited through the same methods (via social media 
channels) and during the same period, until recruitment targets had been met. The recruitment target 
was determined by a sample size calculation (Section 2.2.2), and recruitment was ceased once the 
required number of participants had completed a sufficient amount of the questionnaires. A case 
would be included in the study only if they had completed at least one questionnaire in addition the 
demographics information. 
Once the study recruitment had been completed, data analysis was completed using a Microsoft Excel 
spreadsheet. Each participant was assigned a participant identifier code and this was recorded against 
their membership to either the case or control group on a separate Excel workbook; this allowed the 
group membership identifier to be removed from the working file and to process each questionnaire 
response blinded to group allocation. The exception to this were the PCOS-Q responses, as they were 
only completed by the women with PCOS making blinding impossible. 
 
2.2.6. Statistical Methods 
Data analysis: All data analyses were performed on an encrypted laptop. Questionnaires were scored 
according to their individual criteria and data were collated in a password protected Excel 
spreadsheet (Microsoft Excel v16.04849.1000; Microsoft Corporation, Washington, USA). 
Statistical analysis was completed in IBM SPSS (SPSS, v.23.0.0, IBM Corporation, NY, USA) and 
in IBM SPSS Amos (IBM SPSS Amos, v.25.0.0, Amos Development Corporation, PA, USA).  
Due to the sample size (≥ 20), the Shapiro-Wilk test of normality was completed on each variable 
(Shapiro, Wilk and Chen, 1968); this was performed on the total data set and also split data according 
to the diagnosis of PCOS response. Non-parametric tests were used for data that are non-normally 
distributed. Whilst non-parametric tests may be less efficient at detecting genuine between group 
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differences than their parametric counterparts, they may be more robust as they are less influenced 
by extreme observations (Kirkwood and Stern, 2003). Non-parametric tests make no assumption 
about the shape of the distribution, but use the information about the rank of each data point. 
Furthermore, it is the median values that are compared when testing for differences and the 
probability of ranked order is tested (Field, 2014). Therefore, where data are non-normally 
distributed median and interquartile range were reported and independent samples Mann-Whitney U 
tests were completed to highlight between group differences. The Mann-Whitney U test compares 
the ranks of observations in two observed groups; data from the two groups are pooled and the ranks 
of each observation calculated. The rank of each group are separately summed and termed R1 and R2 
and then entered into the following calculations to give the tests statistics U1 and U2 (Ennos, 2007): 








In these formulae, the sample size of each group (i.e., Women with PCOS or Control) is represented 
by n1 and n2, respectively. The smaller U value is then compared to the critical values table for the 
relevant group sizes and the null hypothesis (i.e., there is no difference in the median between groups) 
is rejected if U is lower, or equal to a critical value. Between group median difference, effect size 
(Cohen’s d) and significance values (P) were reported for all non-parametric outcomes. 
Where data are normally distributed, mean ± standard deviation (SD) were reported, and if there was 
no violation of the assumption of equal variances, as tested by Levene’s test, a Student’s t-test was 
used to test for differences between women with PCOS and their healthy counterparts. Should the 
assumption of equality of variance be violated, then Welch’s t-test was used. Mean difference (MD), 
95% confidence intervals (95% CIs) of the MD, Cohen’s d and P were reported for all parametric 
variables. In these analyses, pairwise exclusion was used to deal with missing values.  
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A separate analysis was completed on the domain scores from the PCOS-Q. Because these data were 
non-parametric, a Durbin-Conover pairwise comparison was used to identify statistical differences 
between domains. Data for each comparison (median difference and P) are reported in Table 4.4. 
Correlations: Due to the prevalence of non-parametric variables, Kendall’s rank correlation (τb) was 
chosen to measure the strength of association between two variables. Kendall (1970) developed a 
rank correlation coefficient that offers an alternative to its counterpart, the Spearman’s rank 
correlation coefficient. Kendall’s τb is calculated in the following way: for each pair of subjects it is 
recorded whether the subjects are rank ordered in the same way for the two variables of interest, that 
is a concordant pair (P), ordered in opposite ways, a discordant pair (Q), or equal for one of the 
variables, a tied pair (X0 or Y0). Therefore, τb is the proportion of concordant pairs minus the 
proportion of discordant pairs; τb would be +1.00 if the rankings are identical, and -1.00 if they are 
exactly opposite (Bland, 2015): 
τ𝑏 =
𝑃 − 𝑄
√(𝑃 + 𝑄 + 𝑋0)(𝑃 + 𝑄 + 𝑌0)
 
Where variables were highly correlated and deemed to be reporting similar effects (e.g., body mass, 
BMI and waist circumference), the variable with the largest sample size was retained. Where these 
variables were domains from a questionnaire (e.g., mental and physical domains of the SF-12), the 
total score was used as the variable in the regression. 
Path Analysis: The SPSS data file was transferred to SPSS Amos. In order to generate a complete 
data set, full information maximum likelihood (FIML) regression imputation was used to account for 
missing data. Although pairwise or listwise deletion are commonly used by many applied 
researchers, it was felt that the use of FIML was favourable in order to preserve the sample size. 
Whilst other methods reportedly have no solid theoretical basis for their use, Enders and Bandalos 
(2001) found that when dealing with missing data, FIML provided data estimates that were unbiased 
and more efficient than other methods. FIML also yielded the lowest proportion of convergence 
failures and provided near optimal Type I error rates.  
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HRQoL, as measured by the SF-12, was used as the endogenous (dependent) variable; the remaining 
variables were arranged into a path model (Figure 4.3) to indicate causal relationships between the 
exogenous (diagnosis of PCOS, and BMI), mediating (self-efficacy for exercise, self-esteem, 
perceived benefits/barriers of exercise and MET-mins/wk) and endogenous variables (SF-12 total 
scores). A diagnosis of PCOS, and BMI were selected as exogenous variables because it is assumed 
that their variance is caused entirely by factors outside of the causal model (Wuensch, 2016). 
Because the causal model has two exogenous variables, the standardised path coefficients (β weights) 
are in fact partial regression coefficients which measure the direct effects that one variable has upon 
another, whilst controlling for a set of correlated exogenous variables (Sarwono, 2018). A diagnosis 
of PCOS serves as one of the exogenous variables in the path model; this is a binary variable (i.e., 
respondents could only answer either yes or no) which functions only as a predictor variable in the 
regression equations, and therefore does not affect the methods of the mediation analysis (Breisch 
and Rajagopal, 2010). Standardised path coefficients are calculated from the unstandardised 
regression coefficient using the following formula: 





In addition to the direct effects of variables upon the endogenous variable, indirect effects from both 
the exogenous and mediating variables partially account for some of the variability in the model. 
Indirect effects are calculated by multiplying the standardised β weights along each causal pathway; 
the indirect pathways, via all mediating variables are then summed to give the total indirect effect of 
the independent variable upon the dependent. To calculate the total effect, the direct effects are added 
to the indirect effects. Standardised regression coefficients, and their 95% CI’s for direct, indirect 
and total effects are presented in Table 4.7. In addition, a squared multiple correlation (R2) is 
calculated for each endogenous variable in the model; the R2 is indicative of the proportion of 
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variance in the dependent variable (i.e., HRQoL) explained by the other variables in the path model. 
This is calculated using the following formula: 






























2.3. Methods for a cluster analysis: Clustering of cardiometabolic risk factors and their 
association with physical activity and sedentary time in women with and without polycystic 
ovary syndrome. 
 
2.3.1. Study design 
The UK Biobank is a large open access national health resource with the aim of improving 
preventative measures, diagnostic processes and treatment of a wide range of serious diseases. 
Between 2006 and 2010, approximately 500,000 UK adults were enrolled following an invitation 
through population-based National Health Service (NHS) patient registers (Sudlow et al., 2015). 
Enrolled participants were aged 40-69 years and had to live within 25 miles of one of the 22 Biobank 
assessment centres located in England, Wales or Scotland (Littlejohns et al., 2019). All participants 
provided written informed consent before providing baseline measures; they answered questions 
(either electronically or verbally) on sociodemographic, lifestyle (including physical activity), and 
health-related characteristics. They also provided blood, urine, and saliva samples allowing for data 
on a range of biomarkers, many of which are associated with CVD development [e.g., blood levels 
of lipids, glucose, and C-reactive protein (CRP)] and/or manifestations of PCOS [e.g., testosterone, 
oestradiol, and SHBG] to be collected. 
The UK Biobank were granted ethical approval by the North West Multicentre Research Ethics 
Committee, and the National Information Governance Board for Health and Social Care in England 
and Wales, and the Community Health Index Advisory Group in Scotland. As the aims of the current 
study fall within the remit of the UK Biobank project objectives, no further ethical approval was 
required from Aston University, or any other local institution or organisation. However, to obtain the 
required data, an application was made to the UK Biobank (Application Reference Number 52771), 
in which the objectives and methods were reviewed and approved; furthermore, the host institution 
(Aston University) had to agree to a material transfer agreement (MTA) and pay an access charge. 
As per the application process, the outcomes that would be investigated had to be specified prior to 
the data release. The included outcomes were selected according to diagnostic features of metabolic 
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syndrome (waist circumference, blood pressure, blood glucose, and lipid profile). The physical 
(weight, BMI, cardiorespiratory fitness, inflammatory and androgenic biomarkers) and psychosocial 
(anxiety, depression, mood, self-esteem, and quality of life) characteristics that are often associated 
with PCOS were also included. It was also requested that outcomes related to self-reported PA, 
exercise and sedentary behaviour, in addition to objectively measured PA were included.  
 
2.3.2. Data Handling 
Once the UK Biobank had approved the study application, data were made available through their 
Application Management System (AMS). The main dataset was supplied in an encrypted format and 
required several steps in order to be accessed. The first step involved the downloading of a series of 
‘helper’ programmes in order to decrypt and convert to the main dataset. They are: ukbmd5 for 
ensuring the encrypted main dataset has downloaded correctly, ukbunpack for decrypting the main 
dataset, and ukbconv for converting the decrypted dataset into a suitable format [i.e. a Comma 
Separated Values (csv) file). Once these were installed, the main dataset was downloaded through 
the AMS; a 32-character authentication code (MD5 checksum) was supplied when access to the data 
was granted and it was used here to initiate the download. Once downloaded, the main data file 
needed to be validated; a Windows command prompt was opened and ukbmd5 was run to complete 
the validation. Next, the ukbunpack was run to decrypt and decompress the downloaded file into a 
custom UK Biobank format. Finally, the dataset was converted using ukbconv into a csv file suitable 
for use in Microsoft Excel, SPSS, and Jamovi. The converted file was immediately password 
protected and saved onto an encrypted, Aston University owned laptop. 
The final dataset included all female participants from the UK Biobank (~250,000 participants). 
From the full dataset, women with PCOS were identified; the inclusion for a ‘case’ participant was 
a diagnosis of PCOS as recorded by the UK Biobank. When selecting case-control participants from 
datasets such the UK Biobank, the case group should comprise all (or a high proportion) participants 
diagnosed with the outcome disease (i.e. PCOS), whereas the referent or control group(s) should be 
a random sample that are free from the disease at the specified sampling point (Läärä, 2011). It is 
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however important that within each group (i.e., case and each control) that no participant is sampled 
in more than one group. Although the comparator groups in the present study were age and/or BMI-
matched, they were randomly selected from the matched sample. 
In the present study, all participants with PCOS were identified in Microsoft Excel 
(v.16.0.4849.1000); this was done using the International Classification of Disease (ICD-10) codes 
that define participant characteristics in the UK Biobank. The ICD-10 for PCOS is E28.2, which 
appeared in the dataset as E282. Using the cut and paste function, each row of data for women with 
PCOS was transferred onto a separate tab on the same Excel workbook and the Sort function was 
used to organise them according to their age at assessment (i.e. from the youngest to the oldest). The 
next phase involved the selection of two comparator groups: 1) a non-PCOS age-matched cohort and 
2) a non-PCOS age- and BMI-matched cohort. These participants were selected concurrently as 
follows: 
Age-matched cohort: all eligible controls (i.e., all participants without PCOS) were also ordered in 
the dataset based upon their age at assessment (youngest to oldest). Participants were then matched 
on a two-to-one ratio for each age category (i.e., 40 years, 41 years, 42 years, etc.) of women with 
PCOS. For example, if there were 15 women with PCOS that were 40 years old, then the first 30 
women that were aged 40, were extracted from the control dataset and pasted into a separate tab of 
the same Excel workbook. 
Age- and BMI-matched cohort: similarly, the sort command was used to identify these participants. 
The participants with PCOS were sorted based upon their age (youngest to oldest) and then each age 
category was sorted based upon their BMI values. For example, if there were 15 women with PCOS 
that were 40 years of age, they were all selected as one age category. The sort command was used to 
arrange them with the lowest BMI value first, ascending to the highest. The same procedure was 
repeated in the dataset of non-PCOS women and once again, the non-PCOS group were allocated on 
a two-to-one ratio. To identify those participants who would be included, each BMI value from the 
cohort with PCOS was recorded and then within the control dataset, the two BMI values that were 
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closest, and within the corresponding age category determined which participants would be included. 
Once identified, these data were cut from the non-PCOS data and pasted onto a separate tab on the 
same Excel workbook. To allow statistical analyses, each cohort was labelled (either PCOS, Age, or 
BMI + Age) and the data were merged into one dataset. 
In addition to the above data, the ICD-10 was also used to capture non-PCOS morbidity incidence 
across all three study groups. 
 
2.3.3. Data Analysis 
Statistical analysis was completed in Jamovi (The Jamovi project: v1.2.16). Descriptive statistics 
were presented for each outcome according to individual cohort. Mean and SD were reported 
alongside median and interquartile range (IQR); the number of missing values (and corresponding 
cohort percentage) were also reported. Assumptions of normality were checked in Jamovi by 
completing Shapiro-Wilk tests of normality and analysis of skewness and kurtosis values. None of 
the included outcomes met the assumption of normality across all three groups; therefore, the 
following non-parametric analysis was adopted: a Kruskal-Wallis [one-way analysis of variance 
(ANOVA) on ranks] to compare outcomes in the three independent groups (PCOS vs Age vs BMI + 
Age). A statistically significant Kruskal-Wallis test is indicative that the outcome’s median value in 
at least one group is different to the median of at least one other group. In the current study, levels 
of significance were set at P <.05, and in order to gauge the magnitude of influence, an effect size 
was also reported for each comparison. When completing a Kruskal-Wallis test, there is no definitive 
effect size statistic that should be calculated to report magnitude of influence. Many statisticians use 
eta-squared (η²) or partial eta-squared (ηp²) but these have been cited as biased effect size estimators 
(Albers and Lakens, 2017) and their use as an effect size estimator in ANOVA is discouraged 
(Skidmore and Thompson, 2013). A less biased alternative to η² is the epsilon squared (ε²) effect size 
(Lakens, 2015); whilst a ε² of zero would indicate no effect, there is no formal way to determine the 
magnitude of an effect greater than zero. In this instance, recommendations from Rea and Parker 
(1992) have been used to report the strength of the observed effect. That is: <0.01 as negligible; 0.01 
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< 0.04 as weak; 0.04 < 0.16 as moderate; 0.16 < 0.36 as relatively strong; 0.36 < 0.64 as strong; and 
> 0.64 a very strong.  
What the Kruskal-Wallis test does not report is, if differences are present between groups, where do 
the differences occur, and for how many pairs of groups there is a difference. For the analysis of 
specific group pairings, a post-hoc test is required. The Dwass-Steel-Critchlow-Fligner (DSCF) post-
hoc test is often used when the null-hypothesis is rejected following a Kruskal-Wallis test. The DCSF 
test is a two-sided, non-parametric procedure that provides family-wise error (FWE) protection; FWE 
refers to the probability of making at least one type I error when completing a series of statistical 
tests (i.e., at least one false conclusion when multiple hypotheses are tested) (Hochberg and 
Tamhane, 1987). Following the one-way Kruskal-Wallis test, the DCSF test procedure is used to 
calculate a Wilcoxon (W) rank sum test statistic on each pair of groups with the “family” (Hollander, 
Wolfe, and Chicken, 2014). If data are tied, the average ranks are used in the individual rank sum 
statistics and statistical significance levels (p-value) are calculated using the distribution of the range 
of independent, standard-normal variables. It is this mechanism that differs from typical Mann-
Whitney U calculation and that provides the FWE protection. Therefore, the DCSF post-hoc test was 
completed on any Kruskal-Wallis analyses that were statistically significant; between pair 
significance are identified in bold text in Table 5.5. 
 
2.3.4. Categorical data 
Where data were categorical (e.g., IPAQ activity group, meeting PA guidelines, health ratings and 
satisfaction scores), Chi-square (χ²) and tests of frequencies were completed to determine whether 
there were any statistical difference (P <.05) between expected and observed frequencies based upon 




2.3.5. Cluster analysis for body composition and cardiometabolic outcomes 
Cluster analysis is a set of data reduction techniques that are used to identify natural groupings (or 
clusters) within a dataset. The objective of cluster analysis is to group cases (i.e. participants) together 
so that all observations within the same cluster are as similar to each other (homogenous) as possible, 
and conversely, cases in each cluster differ as much as possible to those in other clusters (Kaufman 
and Rousseeuw, 1990). Where cluster analysis varies from other data reduction techniques (e.g., 
factor analysis or principal component analysis) is that whereas they tend to group data by similarities 
across variables of a dataset (or columns), cluster analysis groups cases based upon similarities across 
rows (Columbia Public Health, 2020) 
A typical measure of similarity between variables is the correlation coefficient, which provides 
information about the degree of corresponding changes between variables. However, it is not the 
most suitable parameter to make a comparison of cases across variables. Although a simple 
correlation coefficient may provide information about whether the pattern of responses or measures 
are similar between cases, it does not provide any information about the distance between each case 
(Field, 2000). An alternative measure for comparing cases, particularly for continuous variables, is 
the Euclidean distance (Everitt et al., 2011). The Euclidean distance is the geometric distance 
between two objects (cases in this instance). If cases are labelled a and b then their Euclidean distance 
can be expressed in terms of the following equation: 





In essence, this formula reveals the difference between cases (a – b) by taking their scores on each 
variable (i) and calculating the difference. Because differences can be negative or positive, 
differences need to be squared before they are added together. Once the summed squared differences 
have been totalled, the square root is taken to give the measure of variance. The smaller the Euclidean 
distance, the greater the degree of similarity (Field, 2000). Before cluster analysis can be completed, 
several pre-analysis checks are needed to ensure the data is suitable for these analyses. These checks 
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are: 1) rows must be observations (participants) and columns should be variables, 2) Any missing 
data should be removed or imputed, and 3) all data must be standardised to make variables 
comparable (Kassambara, 2017).  
 
2.3.6. Outlier Identification 
All inferential statistics are generally sensitive to outliers and cluster analyses are no different. 
Indeed, values that are far from the mean can alter results considerably. Robust statistical analysis 
typically deals with the location of the large heterogeneous proportion of data alongside an unknown 
number of outliers (Hennig, 2003). When outliers are identified, a decision must be made about how 
to treat them. Typically, a researcher may return to the data collection instrumentation to determine 
whether the outlier is due to an equipment malfunction or a data entry error (Parke, 2013). However, 
because the current study utilises data from the UK Biobank, it is not possible to check the origin of 
the outlier, but in order to preserve as many cases as possible, it is also undesirable to simply delete 
the data. 
Descriptive statistics for each group (e.g., PCOS, Age-matched and Age + BMI-matched) were 
reported for the outcomes selected for the cluster analysis. In addition to median and IQR, the value 
of the 5th and 95th centiles were calculated (Appendix 7.13). The IQR indicates how spread out the 
middle values of the data are for each group, and can also identify outliers. If a data point was below 
1.5* IQR the 25th centile, or 1.5* IQR above the 75th centile it was marked as an outlier. Box plots 
were created for each outcome and data labels on each box plot identified those cases that lay beyond 
the pre-specified limits (i.e., Q1 - 1.5*IQR or Q3 + 1.5*IQR) for each outcome; these outliers were 
then transformed to a specified percentile of the data. In this instance, a 90th percentile Winsorization 
was performed that transformed all data below the 5th percentile to the 5th percentile and all data 
above the 95th percentile to match the 95th percentile (Aguinis, Gottfredson and Joo, 2013). 
Winsorization is not without drawbacks; systematic bias is introduced into results of analyses, 
although the degree of bias is less than if truncation (i.e. deletion of data point or case) had been 
performed. The alternative approach would have been to leave the outlier in place, but this may have 
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heavily influenced the manner in which clusters were formed (Garcia-Escudero and Gordaliza, 
1999). 
 
2.3.7. Cluster variable selection 
Variables used to determine clusters should be a thorough representation of the underlying construct 
of interest (Everitt et al. 2011). In this instance, the objective was to investigate whether outcomes 
associated with metabolic health cluster differently in each study population. Whilst variable choice 
is highly important, the consensus of many statisticians is that clustering should utilise all possible 
variables as long as they fit the model of interest (Steinbach, Kumar and Tan, 2005). Furthermore, 
variables that do not describe a great deal of the variance in Euclidean distances between observations 
should have a lower weighting when assigning cases to a cluster (Field, 2000).   
Whilst cluster analysis should include as many variables as are relevant, there is also a need to ensure 
that variables are not reporting similar phenomena, or that they are made up as a product of other 
variables. Therefore, Pearson’s correlation coefficient analysis was completed for all complete 
variable pairs that were deemed relevant to the study objective; that is outcomes associated with 
metabolic health, or those deemed to be important for PCOS. The analysis revealed that many 
outcomes were statistically significant so, where it was felt that variables were reporting similar 
effects (e.g., BMI, waist circumference and body fat percentage), the magnitude of correlation was 
considered, along with the completeness of data before outcomes were removed from subsequent 
analysis. 
The variables selected for subsequent analyses were: waist circumference (cm), Diastolic BP 
(mmHg), Systolic BP (mmHg), C-reactive protein (mg/L), HbA1c (mmol/mol), HDL-C (mmol/L), 





2.3.8. Missing value analysis 
With regard to the completeness of data, an analysis of missing values was completed in SPSS (SPSS, 
v.23.0.0, IBM Corporation, NY, USA). Missing data can be defined in two ways: user missing data 
or system missing data. User missing data may be coded by the user due to incompatibilities between 
case and variable (e.g., length of pregnancy in males), whereas system missing data are missing data 
that is not present in the dataset (Heymans and Eekhout, 2019). Further investigation of the 
complexity of missing data patterns (i.e. where values are systematically missing together) was 
investigated using the Missing Value Analysis and Multiple Imputation menu items in SPSS. 
Initially, missing data for each outcome was summarised, along with the number of participants with 
incomplete data. This confirmed that there is at least one missing value for each outcome to be 
included in the cluster analysis. Analysis of incomplete data also revealed the percentage of cases 
that have incomplete data; using listwise analysis, a substantial proportion of the sample would be 
absent from the statistical analysis. Initially, missing data were summarised (Appendix 7.14 and 7.15) 
and missing value patterns were identified from the output (Appendix 7.16). The ten most common 
missing value patterns were investigated and where recurring patterns were evident, these were 
summarised in the results. The volume of recurring patterns, (i.e., where values were often missing 
together) was indicative that data was missing not at random (MNAR) and this assumption was tested 
using Little’s (1988) MCAR test. Collectively, these recurring patterns are strong indicators that 
these data are not missing completely at random (non-MCAR); this notion is further supported by 
the result of Little’s MCAR test (χ² = 478.272, df = 354; P <.001) meaning that missing value 
multiple imputation can be completed.  
Jakobsen et al. (2017) outline criteria that would justify the use of multiple imputation. They state 
that complete case analysis can be completed if the proportion of missing data is below five percent; 
if the potential impact of missing data is deemed negligible, it can simply be ignored in the final 
analysis (Jakobsen et al., 2014). In contrast, if large proportions (> 40%) of data are missing from 
key variables then complete case analysis could also be used with the caveat that limitations of 
findings are clearly discussed. If imputation methods are used to replace missing data in these 
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circumstances, then study results should only be used to generate hypotheses (Clark and Altman, 
2003). Finally, if the missing completely at random and missing at random assumptions are not met 
based on the characteristics of missing data, results have an increased risk of incomplete outcome 
bias (Higgins and Green, 2011). Whilst no statistical methods are guaranteed to negate this bias 
(Sterne et al., 2009), multiple imputation can be used to estimate these missing values.  
 
2.3.9. Data Imputation 
Data imputation was completed in SPSS. All of the outcomes selected for inclusion in the model 
(based upon correlations and missing data) were selected for imputation; five iterations saved within 
a new dataset were requested. For the imputation methods, a custom approach was adopted and fully 
conditional specification (FCS) selected. FCS is the Bayesian approach to imputation and accounts 
for imputation uncertainty by both adding error variance to the predicted values and by accounting 
for the uncertainty in estimating the regression coefficients of the imputation model (Heymans and 
Eekhout, 2019). Bayesian theory states that there is not one “true” regression coefficient but that the 
coefficients themselves follow a distribution (Gelman et al., 2014). Following this, predictive mean 
matching (PMM) was selected as the model type; PMM is the default procedure when multivariate 
imputation by chained equations is used and is the method that predicts (and selects) data to replace 
missing values (Rubin, 1987).  
Pooled statistics were reported for each of the included outcomes and the dataset was combined (and 
original data removed) to allow clustering to be completed on the data. Prior to the cluster analysis, 
standardisation of the data was completed. Standardisation of variables is a necessary step to take 
because dissimilarity measures, such as Euclidean distance, are extremely sensitive to variability in 
the magnitude of scales (Milligan and Cooper, 1988). Standardisation of values not only equalises 
the magnitude and the variability of the variables within the model but also their relative weighting 
(Anderberg, 2014; Romesburg, 1984). Standardised values are derived from Z-scores; Z-scores are 
simply values that have been given a common standard, which is a mean of zero and a standard 
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deviation (SD) of one. Z-scores are calculated by first subtracting the mean score from each 
individual score and then dividing the remainder by the SD of the overall mean: 
𝑍𝑥 =  
𝑋𝑖 −  ?̅?
𝑆𝐷𝑥
 
Z-score standardisation is a type of linear transformation; transformed scores follow the same 
distribution as that of the original data and, if plotted against each other, data points would be linear.  
 
2.3.10. Cluster Analysis 
Once outcome scores had been standardised, a cluster analysis was completed using the non-
hierarchical K-means clustering in SPSS. K-means clustering divides observations into discrete 
groups based upon the Euclidean distance between the mean of included outcomes. The primary 
objective of the K-means algorithm is to minimise the sum of distances between the points and the 
cluster centroid to which they belong (Everitt et al. 2011). The K-means algorithm utilises iterative 
refinement in order to find the best solution; that is assigning points to a cluster based upon the size 
of the squared Euclidean distance, recalculation of the cluster centroid and then repeating until 
convergence is achieved. The algorithm has reached convergence when cases are no longer 
reassigned when the centroids are recalculated (Hartigan and Wong, 1979). 
K-means analysis should be completed when variables are quantitative and at either the interval or 
ratio level (as in the current study); hierarchical clustering would be used if data were binary or 
counts. To complete the analysis in SPSS, all standardised variables to be included in the model were 
selected and the number of clusters (k) were selected as two. The maximum number of iterations 
were set to 15 with a convergence criterion of zero, meaning that no new iterations would be 
generated when a complete iteration does not move any of the cluster centroids. Cluster membership 
was recorded for each case, which created a new categorical outcome within the dataset. It was also 
specified that initial cluster centres would be recorded and an ANOVA test between clusters for each 
outcome was generated. To assess the strongest solution (i.e. number of clusters) this process was 
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repeated using different numbers of clusters (up to five) and comparing results. The number of 
iterations before convergence was achieved, alongside the between cluster ANOVA results were 
used as confirmations that the strongest solution had been found. The optimal number of clusters 
identified was two and this was achieved after 12 iterations.  
Once cluster membership for each case had been determined, the categorical variable was used to 
generate descriptive statistics for each cluster. Furthermore, the number of cases (and relative 
percentages) from each study group and their cluster membership was reported; a graphical 
representation of each outcome, split by study group and cluster membership was also reported. 
Finally, the descriptive statistics for outcomes relating to PA, sedentary time, and co-morbidities 
were reported for each cluster and the appropriate independent samples t-test (Mann-Whitney) was 
completed for each outcome. 
 
2.3.11. Classification using physical activity and sedentary time  
For this analysis, participants were categorised according to their weekly physical activity level 
(MET-mins/week from IPAQ responses) and their time spent (h/day) in sedentary behaviour (SB) 
(summed screen time and driving time). The four categories are High PA + Low SB, High PA + 
High SB, Low PA + Low SB and Low PA + High SB. The groups were defined using quartiles from 
the respective outcome. Low PA included data from quartiles 1 and 2 of the MET-mins/wk outcome 
and High PA from quartiles 3 and 4. Similarly, Low SB used data from quartiles 1 and 2 of the 
summed sitting time variable, with high SB coming from quartiles 3 and 4 (Engelen et al., 2017). 
The visual binning function in SPSS was used to identify these quartiles and allocate participants 
into a new categorical variable.   
Once categories had been determined, a frequencies analysis was run to determine how participants 
had been allocated into groups based upon their cohort classification; these data were reported 
graphically and participants with missing data (i.e. missing MET-mins/week or missing sitting time) 
were removed from subsequent analyses. Shapiro-Wilk tests of normality were conducted, and a 
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non-parametric approach was then used. Descriptive statistics (median and IQR) were reported and 
a Kruskal-Wallis test completed to assess variability between groups for each outcome. Where 
statistically significant effects were reported, pairwise comparisons (Mann-Whitney U) were 
completed and results reported either graphically or in a tabular format.  
Finally, to calculate the probability of disease incidence between groups (i.e. low-risk vs high-risk 
behaviours), logistic regression analyses were used in SPSS. The disease of interest was set-up as a 
dichotomous variable (e.g., diagnosed or not diagnosed) and then input as the dependent variable in 
the model. The PA risk categories, High PA + Low SB and Low PA + High SB were selected as a 
categorical covariate in the model and the analysis run. The exponential of the coefficient [exp(β)] 
is called the odds ratio that describes, in this instance, the odds of disease incidence between the two 
groups. However, the odds ratio was transformed into a probability score using the formula: P = odds 
/ (1 + odds). This allows reporting of the increase in probability that a participant allocated in the 


















Chapter 3: Results 
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Exercise, or exercise and 
diet for the management of 
polycystic ovary syndrome: 








3.1. Introduction  
 
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive-aged 
women, that depending upon the studied population and the applied diagnostic criteria (Table 1.2), 
affects 6-21% of this female population worldwide (Boyle et al., 2012; Lizneva et al., 2016; Ma et 
al., 2010). PCOS is characterised by hyperandrogenism and/or chronic anovulation and typically 
manifests in a host of symptoms, including hirsutism, acne, menstrual disruption, and infertility 
(Costello et al., 2007). PCOS is also associated with an increased risk of cardiometabolic 
complications, such as hypertension, dyslipidaemia, insulin resistance (IR), and type 2 diabetes 
mellitus (T2DM; Azziz et al., 2016). Furthermore, PCOS is also associated with increased 
psychological morbidity [e.g., increased risk of stress, depression, low self-esteem, poor body image, 
and reduced health-related quality of life (HRQoL)] (Himelein et al., 2006; Weiner et al., 2004).  
The exact PCOS aetiology is yet to be fully defined, but increased body weight, particularly when 
associated with adiposity, is considered pivotal in its manifestation and severity of symptoms (Sam, 
2007). It has been reported that ~90% of women with PCOS also have a body mass index (BMI) > 
25 kg/m2, but encouragingly, even moderate weight loss (e.g. 5%) has been shown to elicit clinically 
meaningful reductions in hyperandrogenism and to improve menstrual regularity (Kiddy et al., 1992; 
Balen et al., 1995; Holte et al., 1995; Legro, 2000; Sir-Petermann et al., 2009). Of note, women with 
PCOS are also reported to have a greater severity of IR than weight-matched women without PCOS 
(Dunaif et al., 1989; Norman et al., 2001). Additionally, the increased susceptibility to obesity that 
is associated with PCOS (Glueck et al., 2005) further exacerbates IR and the accompanying 
metabolic (Legro et al., 2001; Ehrmann et al., 2006) and reproductive (Balen et al., 1995; Kiddy et 
al., 1990) dysfunctions. Therefore, women with PCOS exhibit increased risk of impaired glucose 
tolerance (IGT) and T2DM regardless of weight and age (Legro et al., 1999).  
Because no curative treatment for PCOS is currently known, management of women with PCOS and 
overweight/obesity focuses on weight loss through lifestyle changes, namely increased 
exercise/physical activity and caloric restriction through improved diet. The ultimate aim of these 
lifestyle changes is to alleviate PCOS’s clinical manifestations and lower the related risk of T2DM 
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and cardiovascular disease (CVD; National Institute for Health and Care Excellence, 2013). Exercise 
interventions have been shown to be beneficial to the health of different IR populations, independent 
of weight loss (Boulé et al., 2001; Thomas et al., 2006; Yang et al., 2014), therefore, the 
incorporation of moderate-intensity exercise in the treatment of PCOS may be favourable. The 
current evidence tends to support this notion; although most studies incorporating exercise 
interventions in women with PCOS report little or no weight loss (Azziz et al., 2016), exercise has 
been shown to have favourable effects on IR, body fat levels and distribution (i.e. central or 
peripheral adiposity), and CVD risk in these patients (Harrison et al., 2011).  
 
3.1.1 Rationale for a systematic review 
In contrast to available published systematic reviews at the time of protocol registration (Harrison et 
al., 2011; Moran et al., 2011; Domecq et al., 2013; Haqq et al., 2015), the current systematic review 
proposed to make a greater number of comparisons (Section 3.2) and include more outcomes than 
similar previous reviews. Although some components of the current systematic review may draw 
parallels with previous lifestyle reviews, it is notable that the most recent prior searches were 
completed in 2009; it is therefore reasonable to assume that there is a substantial body of new 
literature that has not been subjected to analysis. Furthermore, no previous review has made all of 
the comparisons that are being made in the current review (Table 3.1). 
From the PROSPERO website, at the time of protocol registration four additional systematic reviews 
were identified, and their working status was classified as ongoing. Two of these were considerably 
over their anticipated completion date (Mani et al., 2013; Lundgren, Moholdt and Riphagen, 2015), 
whilst the literature searching for the current review did not locate any related evidence of publication 
or dissemination of findings from these authors. A third study (Santos et al., 2017) stipulated that 
their ongoing review is an update of previous work, but again, a final published manuscript, or indeed 
the original work was not located in this literature search. The fourth study Benham et al. (2018) has 
since been published and an overview of this study is presented in Appendix 7.2. Whilst there may 
be some overlap between the outcomes assessed in the current review and those of Santos et al. 
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(2017) and Benham et al. (2018), the focus of the review and the primary aims are different. The 
primary aim of Santos et al. (2017) and Benham et al. (2018) was to investigate the effect that 
exercise may specifically have upon reproductive health when compared to usual care or a no-
exercise control group. 
The current review presented here aimed to directly measure the effect of exercise in PCOS women 
and this was done in part by comparing intervention groups to a control or no treatment group. Where 
this differs to Santos et al. (2017) and Benham et al. (2017) is that studies including a third arm or 
combined treatment arms were included providing that the effect of exercise can be isolated. This 
provided an opportunity to complete a sub-analysis of treatment variations, where feasible; for 
example, interventions that contain dietary elements compared to those that do not, home-based or 
unsupervised programmes compared to those that are supervised. Also, studies that include 
behavioural components, versus those that have none, can be contrasted and have their varying 
effectiveness assessed. It is assumed that varying methodologies will influence participant adherence 
and attrition rates and this was also investigated. 
In addition, the current systematic review also completed subgroup analyses where data were 
available. Sub-analyses to assess the effects of exercise mode (e.g., aerobic exercise versus resistance 
training), duration, frequency, and intensity, method of intervention delivery (e.g., supervised versus 
unsupervised), and participant BMI upon study entry (e.g., ≤ 24.9 kg/m2 versus ≥ 25.0 kg/m2) were 
completed. There were insufficient data to complete sub-analysis on the use of pharmacological 
treatments, or the effects of adding a behaviour change component. However, intervention adherence 
and attrition rates were reported.   
Where previous systematic reviews have only completed risk of bias over a score-based assessment, 
there may be methodological concerns. Risk of bias tools typically give equal weighting to each 
limitation they measure; in reality, different limitations may affect validity to varying degrees. The 
Cochrane Collaboration recommends using an approach that defines the quality of a body of evidence 
as the extent to which a reviewer can be confident that an estimate of effect or association is close to 
the quantity of specific interest (Schünemann et al., 2011). This is not completely apparent in 
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previous reviews, so the current review addressed this by offering a quality assessment of included 
studies using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) 
assessment tool (Guyatt et al., 2008). Furthermore, assessment of heterogeneity was completed using 
the I2 statistic, as is also recommended by the Cochrane collaboration (Deeks, Higgins and Altman, 
2011). 
Despite some similarities, the current review differs significantly from existing works, including a 
wide range of outcomes and analyses that have not been included in previous published work or 
proposed reviews from PROSPERO. Furthermore, by following recommendations from the 
Cochrane Handbook for Systematic Reviews of Interventions, it set the highest standard in terms of 
process and statistical analysis. 
Therefore, the principal objective of the present review is to identify the optimal exercise, or 
combination of diet and exercise, prescription to elicit maximum benefit in women with PCOS.  
 
 
3.2. Aims and Hypothesis 
 
This systematic review aimed to analyse the evidence on the effectiveness of exercise compared to: 
i. control or usual care;  
ii. diet alone; and  
iii. exercise combined with diet;  
 
In addition, it also evaluated the effectiveness of exercise combined with diet compared to: 
iv. control or usual care; and  












3.4.1. Search Results  
The database searches returned 2,390 articles for assessment; one additional article was also sent 
after requesting further information from one of the study authors (Costa et al., 2018). After the 
removal of duplicate papers, 1,908 articles remained and were screened for eligibility based upon 
their title and abstract. Following removal of ineligible papers, 87 full-text articles were retrieved for 
detailed evaluation, and an additional 60 of these were excluded with detailed reason (Figure 3.1 and 
Appendix 7.3)  
This left 27 articles meeting the inclusion criteria (Table 2.1). They are: Almenning, et al., 2015; 
Brown et al., 2009; Bruner et al., 2006; Costa et al., 2018; Guzick et al., 1994; Hoeger et al., 2004; 
Jedel et al., 2011; Konopka et al., 2015; Leonhardt et al., 2015; Nasrekani et al., 2016; Nybacka et 
al., 2011; Nybacka et al., 2013; Petrányi and Zaoura-Petrányi, 2011; Sá et al., 2015; Roessler et al., 
2013; Saremi et al., 2013; Saremi and Yaghoubi, 2016; Stener-Victorin et al., 2009; Stener-Victorin 
et al., 2012; Stener-Victorin et al., 2013; Thomson et al., 2008; Thomson et al., 2010; Thomson et 
al., 2012; Thomson et al., 2016; Turan et al., 2015; Vigorito et al., 2007; and Vizza et al., 2016. 
However, these publications were based on the findings of only 18 trials, because four trials had 
multiple publications; these are: Stener-Victorin et al. (2009) which had four additional papers (Jedel 
et al., 2011; Leonhardt et al., 2015; Stener-Victorin  et al., 2012; Stener-Victorin et al., 2013); 
Thomson et al. (2008) that had three additional publications (Thomson et al., 2010; Thomson et al., 
2012; Thomson et al., 2016); Nybacka et al. (2011) who had one additional publication (Nybacka et 
al., 2013); and Sá et al., (2015) who also had one additional publication (Costa et al., 2018). 
Although included within the qualitative synthesis, one study was excluded from the meta-analysis 
(Brown et al., 2009) because data were reported as median and range values (attempts to contact the 




Figure 3.1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow 
diagram. 
 
3.4.2 Design and attrition of eligible studies  
Of the 18 included studies, 16 of them were classified as randomised controlled clinical trials (RCTs), 
one trial was a quasi-RCT (Petrányi and Zaoura-Petrányi, 2011) and the final study employed a 
randomised crossover design (Roessler et al., 2013). Study characteristics are presented in Table 3.1. 
Twelve trials made the comparison of exercise with usual care, minimal intervention, or control 
(Almenning, et al., 2015; Brown et al., 2009; Konopka et al., 2015; Nasrekani et al., 2016; Roessler 
et al., 2013; Sá et al., 2015; Saremi et al., 2013; Saremi and Yaghoubi, 2016; Stener-Victorin et al., 
2009; Turan et al., 2015; Vigorito et al., 2007; Vizza et al., 2016). Three trials compared a combined 
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exercise and diet intervention to diet alone (Thomson et al., 2008; Bruner et al., 2006; Nybacka et 
al., 2011) and a further three, exercise and diet combined with usual care/minimal 
intervention/control (Guzick et al., 1994; Hoeger et al., 2004; Petrányi and Zaoura-Petrányi, 2011). 
Only one trial made the comparison of exercise versus diet, and also of exercise versus exercise and 
diet combined (Nybacka et al., 2011). The total number of participants included within all trials 
combined were 758 (exercise/intervention, n = 230; control, n = 257; combined treatment arms, n = 
174; and diet alone, n = 54). In addition, a total of 43 additional participants were present in ineligible 
arms (i.e. pharmacological or low-frequency electroacupuncture) from four of the included studies 
(Hoeger et al., 2004; Petrányi and Zaoura-Petrányi, 2011; Saremi and Yaghoubi, 2016; Stener-
Victorin et al., 2009). 
Where reported, study attrition ranged from 6% (Turan et al., 2015) up to 50% (Thomson et al., 
2008) with a median value of 19.5%; five trials (28%) reported attrition over 20% (Almenning, et 
al., 2015; Brown et al., 2009; Hoeger et al., 2004; Nybacka et al., 2011; Thomson et al., 2008). 
Reasons for exercise dropouts included non-exercise related injury (Almenning, et al., 2015; Brown 
et al., 2009; Roessler et al., 2013; Thomson et al., 2008; Vizza et al., 2016), pregnancy (Almenning, 
et al., 2015; Hoeger et al., 2004; Roessler et al., 2013; Thomson et al., 2008; Vizza et al., 2016), 
time (Brown et al., 2009; Roessler et al., 2013; Thomson et al., 2008), work/family commitments 
(Almenning, et al., 2015; Thomson et al., 2008; Vizza et al., 2016), personal reasons (Nybacka et 
al., 2011; Sá et al., 2015; Stener-Victorin et al., 2009; Thomson et al., 2008), medical grounds 
(Brown et al., 2009; Nybacka et al., 2011; Stener-Victorin et al., 2009), and relocation (Thomson et 
al., 2008). Two trials excluded participants because adherence to intervention was <75% (Turan et 
al., 2015) or due to a failure to comply with study requirements (Thomson et al., 2008). Eight trials 
(44%) did not report any attrition (Bruner et al., 2006; Guzick et al., 1994; Konopka et al., 2015; 
Nasrekani et al., 2016; Petrányi and Zaoura-Petrányi, 2011; Saremi et al., 2013; Saremi and 
Yaghoubi, 2016; Vigorito et al., 2007).
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Intervention Outcome measures 
Almenning et 








age: 27.2±5.5 y 
BMI: 26.7±6.0 kg/m2 
(Rotterdam) 
HIIT frequency: 3 times/wk 
HIIT intensity: 2 d/wk, 4 x 4 mins 90-95% 
HRmax /3 x 3 mins ~70% HRmax. 1 d/wk, 10 x 
1 min ‘all-out’/10 x 1 min rest. 
RT frequency: 3 times/wk 
RT sets x reps: 3 x 10 
RT load: 75% 1-RM 
HOMA-IR, FBG, FI, 
TG, TC, LDL-C, HDL-
C VO2 max, RHR, 
BW, BMI, WC, BF%, 
FM, FFM, T, SHBG, 
FAI, hsCRP 





20-24 wks due 
to varying 





age: 32.3 ± ns y  
BMI: 33.0 kg/m2 
(NIH) 
Exercise: 12 wk moderate-intensity 
intervention preceded by 8-12 wk ramp-up. 
Aerobic duration: ~228 mins/wk (≤ 60 bouts) 
Aerobic intensity: 40-60% VO2 max 
FBG, FI, HOMA-IR, 
TG, LDL-C, HDL-C, 
VO2 max, BW, BMI, 
WC, FT, SBP, DBP 
Bruner et al., 
2006  
(RCT) 





age: 30.7±4.6 y    
BMI: 36.6±6.0 kg/m2 
(Rotterdam) 
Exercise frequency: 3 times/wk 
Aerobic intensity: 70-85% HRmax 
Aerobic duration: 30 mins (+10-min warm-
up) 
RT sets x reps: 2-3 x 10-15 
RT load: not specified 
Diet: 1 hour/wk of nutritional counselling 
FI, QUICKI, VO2 max, 
BW, BMI, WC, T, 
SHBG, FAI 
Guzick et al., 
1994 
(RCT) 
EX + DIET: 6/6 
CON: 6/6 
12 wks  
(baseline, 12 
weeks) 
age: 31.7±10.0 y 
BMI: ns 
(NIH) 
Exercise frequency: 5 times/wk 
Exercise intensity: 1050-4200 kJ/wk 
 
Diet: VLCD (8 wks) with calories increased 
over final 4 wks (4200-5040 kJ/d).  
‘Optifast’ used to supplement diet. 
FBG, FI, BW, WHR, 
















Intervention Outcome measures 
Hoeger et al., 
2004 
(RCT) 
LS + PLA: 11/6 
PLA: 9/7 




wks, 48 wks) 
Age: 28.5±5.2 y 
BMI: 39.0±6.1 kg/m2   
(NIH) 
Exercise programme: Individualised to 
achieve 150 minutes per wk 
 
Diet: Individualised healthy balanced meal 
plan to achieve 500-1000 kcal deficit per day 
 
Metformin: 850 mg 2 times/day 
BW, T, SHBG, FAI 








Age: 35±5.0 y 
BMI: 33.0±5.0 kg/m2 
(Rotterdam) 
Exercise frequency: 5 times/wk 
Exercise intensity: 65% VO2 peak 
Exercise duration: 60 mins 
FBG, FI, HOMA-IR, 
BMI, BW, FM, FFM, 
E2 








Age: 30.4±5.9 y 
BMI: 28.3±6.2 kg/m2 
(Rotterdam) 
Exercise frequency: 3 times/wk 
Exercise intensity: 40-65% HRmax 
Exercise duration: 25-30 mins 
VO2 max, BW, BMI, 
FSH, LH 









Age: 30.8±5.2 y  
BMI: 36.0±6.2 kg/m2  
(Rotterdam) 
 
Exercise programme: Individualised to meet 
individuals’ capacity, goals and interest 
 
Diet: ≥ 600 kcal/day reduction maintaining 
55-60% CHO, 25-30% fat and 10-15% 
protein  
FBG, FI, HOMA-IR, 
BW, BMI, WHR, 
BF%, FFM, T, SHBG, 
FT, E2, FSH, LH 








Age: 29 ± ns y 
BMI: 27.2±6.9 kg/m2 
(Rotterdam) 
Exercise programme: recommendation to 
increase physical activity levels (specifics 
unclear) 
Diet: low glycaemic index diet with caloric 
restriction for those who are obese. 
















Intervention Outcome measures 








wks, 16 wks) 
Age: 31.7±7.9 y 
BMI: 36.3±7.2 kg/m2 
(Rotterdam) 
Exercise frequency: 3 times/wk (2 x cycle, 1 
x walk) 
Exercise intensity: following 2-week ramp, 
cycling 20-180 secs 80-100% HRmax / rest 
25-180 secs 45-65% HRmax. Walking 3-5 
mins 80-90% HRmax / 1 min 50-60% HRmax. 
Exercise duration: 45 mins (+10 min warm-
up) 
Control: Group counselling sessions (2 
hours, 1 time/wk) focussing on barriers and 
motivation  
VO2 max, BW, BMI, 
WC 







Age: 26.0±5.0 y  
BMI: 32.8±4.6 kg/m2  
(Rotterdam) 
Exercise frequency: 3 times/wk 
Exercise intensity: 60-85% HRmax 
Exercise duration: 40 mins (+5 mins) 
SBP, DBP, FI, BMI, 
RHR, VO2 max, T, 
FSH, LH 








Age: 35.2±4.4 y  
BMI: 28.3±4.3 kg/m2 
(Rotterdam) 
Exercise frequency: 3 times/wk 
Exercise intensity: 40-65% HRmax 
Exercise duration: 30 mins 
 
FBG, FI, HOMA-IR, 
TG, TC, LDL-C, HDL-
C, VO2 peak, BW, 
BMI, BF%, WC, WHR  
Saremi et al., 
2016 
(RCT) 
EX + PLA: 10/10 
CON : 10/10 




Age: 27.1±5.1 y 
BMI: 25.5±2.7 kg/m2  
(Rotterdam) 
Exercise frequency: 3 times/wk 
RT sets x reps: 1-2 x 15-20 
RT load: 40-60% 1-RM 
FBG, FI, HOMA-IR, 
TG, TC, LDL-C, HDL-
C, BW, BMI 
Stener-Victorin 
et al., 2009 
(RCT) 
EX: 34/22 





wks, 32 wks) 
Age: 30±4.4 y 
BMI: 28.1±7.3 kg/m2 
(Rotterdam) 
Exercise frequency: 3 times/wk 
Exercise intensity: HR ≥ 120 BPM 
Exercise duration: 30-45 mins 
 
Low-frequency electroacupuncture: 14 x 30 
min treatments over 16 wks 
SBP, DBP, FBG, FI, 
HOMA-IR, TG, TC, 
LDL-C, HDL-C, BMI, 
WHR, T, FT, SHBG, 
FAI, LH, FSH, 















Intervention Outcome measures 
Thomson et al., 
2008 
(RCT) 
AET + DIET: 
31/18 
AET + RT + 
DIET: 33/20 
DIET: 30/14  
20 wks 
(baseline, 10 
wks, 20 wks) 
Age: 29.3±6.8 y 
BMI: 36.1±4.8 kg/m2 
(Rotterdam) 
Exercise frequency: 5 times/wk (3 x aerobic, 
2 x RT in combined exercise group)  
Aerobic intensity: 60-65% HRmax progressed 
to 75-80% HRmax by study end 
Aerobic duration: 25-30 mins progressed to 
45 mins by study end 
RT sets x reps: 3 x 12 
RT load: 50-60% 1-RM progressed to 65-
75% 1-RM after 2 weeks 
Diet: energy restricted high protein diet 
(5000-6000 kJ/day) 
SBP, DBP, FBG, FI, 
HOMA-IR, TG, TC, 
LDL-C, HDL-C, BW, 
BF%, FM, FFM, WC, 
T, SHBG, FAI, PCOS-
Q 








Age: 24.5 ± 2.8 y 
BMI: 21.9±3.5 kg/m2 
(Rotterdam) 
Exercise frequency: 3 times/wk 
Exercise duration: 50-60 mins 
Aerobic intensity: 65-70% HRmax 
RT sets x reps: 1 x 15 
RT load: 5-6 on RPE for RT scale 
SBP, DBP, FBG, 
HOMA-IR, FI, TG, 
TC, HDL-C, LDL-C, 
BMI, WC, RHR, VO2 
max, T, FT, E2, LH, 
FSH 








Age: 21.8±2.1 y 
BMI: 29.4±3.2 kg/m2  
(Rotterdam) 
Exercise frequency: 3 times/wk 
Exercise intensity: 60-70% VO2 max 
Exercise duration: 30 mins 
SBP, DBP, FBG, FI, 
TG, TC, LDL-C, HDL-
C, VO2 max, RHR, 
BMI, WC, E2, T, FT, 
SHBG, FAI, LH, FSH, 
CRP 




12 wks  
(baseline, 12 
wks) 
Age: 27±5.0 y 
BMI: 37.8±11.4 
kg/m2 
Exercise frequency: 4 times/wk (2 x RT, 2 
home-based) 
RT sets x reps: 2-3 x 8-12 
RT load: Progressed with strength gains 
Home-based: Callisthenics, 3 sets of 10 reps 
FBG, FI, HOMA-IR, 
BW, BMI, WC, FM, 
FFM, BF%, hsCRP, T, 




Key: Design; RCT: randomised controlled trial, QRCT: quasi-randomised controlled trial. N randomised: the number of participants randomised into each study arm at the 
study initiation; analysed is the number of participants included within the analysis; HIIT: high-intensity interval training; RT: resistance training; CON: control group; EX: 
exercise group; DIET: dietary intervention; LS: lifestyle; PLA: placebo; MF: metformin; ACU: acupuncture; AET: aerobic exercise training; CAL: calcium supplementation. 
Intervention duration: length of the duration; assessment points: the time-points at which researchers have assessed outcome measures. Participant characteristics presented 
as mean ± standard deviation (SD) or median in one study [96] for age (in years; y) and BMI (kg/m2) at study entry; ns: not specified. Diagnostic criteria: the specific criteria 
used to confirm a PCOS diagnosis; NIH: National Institute of Health (1990) diagnostic criteria; Rotterdam: European Society for Human Reproductive and 
Embryology/American Society for Reproductive Medicine (2003) diagnostic criteria. Outcome measures refers to the outcomes from each study that are relevant to this 
systematic review. VO2 max: maximum oxygen uptake; RHR: resting heart rate; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; 
TC: total cholesterol; TG: triglycerides; FBG: fasting blood glucose; FI: fasting insulin; HOMA-IR: homeostatic assessment of insulin resistance; QUICKI: quantitative 
insulin sensitivity check index; FM: fat mass; FFM: fat free mass; BF%: body fat percentage; BW: body weight; BMI: body mass index; WC: waist circumference; WHR: 
waist to hip ratio; SHBG: sex hormone binding globulin; FAI: free androgen index; T: testosterone; FT: free testosterone; E2: oestradiol; LH: luteinising hormone; FSH: 
follicle stimulating hormone; SBP: systolic blood pressure; DBP: diastolic blood pressure; hsCRP: high-sensitivity C-reactive protein; d: day; mins: minutes; wk: week; reps: 
repetitions; RM: maximum number of repetitions; HRmax: maximum heart rate; PCOSQ: PCOS health-related questionnaire; SF-36: Optum36-item Short Form Survey; 











3.4.3. Participant characteristics of included studies 
Participant characteristics are presented in Table 3.1. Included trials used a range of criteria to 
diagnose PCOS (Table 1.1). Only three trials (Brown et al., 2009; Guzick et al., 1994; Hoeger et al., 
2004) used the NIH diagnostic criteria (Zawadski and Dunaif, 1992), whereas 14 studies 
(Almenning, et al., 2015; Bruner et al., 2006; Konopka et al., 2015; Nasrekani et al., 2016; Nybacka 
et al., 2011; Petrányi and Zaoura-Petrányi, 2011; Roessler et al., 2013; Sá et al., 2015; Saremi et al., 
2013; Saremi and Yaghoubi, 2016; Stener-Victorin et al., 2009; Thomson et al., 2008; Turan et al., 
2015; Vigorito et al., 2007) utilised the Rotterdam consensus criteria (ESHRE/ASRM, 2004). One 
trial confirmed the PCOS diagnosis via participants’ general practitioner/specialist (Vizza et al., 
2016), but the criteria used were not explicitly stated. None of these trials specified use of the AE-
PCOS definition (Azziz et al., 2008). 
Many of the included studies stated clear inclusion/exclusion eligibility criteria for participation. 
Participants with T2DM, fasting hyperglycaemia, or glucose intolerance were explicitly excluded in 
nine trials (Brown et al., 2009; Bruner et al., 2006; Konopka et al., 2015; Roessler et al., 2013; 
Saremi et al., 2013; Stener-Victorin et al., 2009; Thomson et al., 2008; Turan et al., 2015; Vigorito 
et al., 2007), and nine trials additionally excluded participants with any diagnosed CVD (Bruner et 
al., 2006; Guzick et al., 1994; Roessler et al., 2013; Saremi et al., 2013; Stener-Victorin et al., 2009; 
Thomson et al., 2008; Turan et al., 2015; Vigorito et al., 2007; Vizza et al., 2016). Another 
prerequisite in seven trials (39%) was the activity status of participants upon enrolment; participants 
had to have a sedentary lifestyle without any recent involvement in any other exercise intervention 
(Almenning, et al., 2015; Brown et al., 2009; Konopka et al., 2015; Nasrekani et al., 2016; Saremi 
et al., 2013; Thomson et al., 2008; Vizza et al., 2016).  
 
3.4.4 Intervention and comparison details 
Fourteen trials (74%) assessed the effectiveness of an exercise only intervention and six trials (32%) 
assessed the effectiveness of combined exercise and dietary interventions. Of the included trials, 14 
(74%) included intervention arms which consisted of aerobic exercise only, whereas a further three 
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(16%) combined aerobic exercise with resistance training (Bruner et al., 2006; Thomson et al., 2008; 
Turan et al., 2015). Of those studies which incorporated some form of aerobic exercise (n = 17, 94%), 
11 trials (61%) specified either walking, brisk walking or jogging (Almenning et al., 2015; Brown et 
al., 2009; Bruner et al., 2006; Guzick et al., 1994; Nasrekani et al., 2016; Nybacka et al., 2011; 
Roessler et al., 2013; Sá et al., 2015; Saremi et al., 2013; Stener-Victorin et al., 2009; Thomson et 
al., 2008); and seven (39%) incorporated static cycling either on its own or as part of a wider 
intervention (Almenning et al., 2015; Brown et al., 2009; Bruner et al., 2006; Konopka et al., 2015; 
Roessler et al., 2013; Stener-Victorin et al., 2009; Vigorito et al., 2007). There were also three single 
trials which each incorporated either elliptical training (Brown et al., 2009), step training (Turan et 
al., 2015), or swimming (Nybacka et al., 2011). Five trials (28%) specified that they had allowed 
participants to self-select training modality from those listed above (Almenning et al., 2015; Brown 
et al., 2009; Bruner et al., 2006; Nybacka et al., 2011; Stener-Victorin et al., 2009), whereas two 
trials (Hoeger et al., 2004; Petrányi and Zaoura-Petrányi, 2011) state that they allowed participants 
to self-select a modality but do not list the exercise choices. Three trials (16%) had intervention arms 
that were resistance training only (Almenning et al., 2015; Saremi and Yaghoubi, 2016; Vizza et al., 
2016). However, one of the trials did not specify the type of exercise undertaken by participants 
(Petrányi and Zaoura-Petrányi, 2011). 
In 10 trials (56%) the modal training session frequency was three times per week (Almenning et al., 
2015; Bruner et al., 2006; Nasrekani et al., 2016; Sá et al., 2015; Saremi et al., 2013; Saremi and 
Yaghoubi, 2016; Stener-Victorin et al., 2009; Thomson et al., 2008; Turan et al., 2015; Vigorito et 
al., 2007). In contrast, five sessions per week were prescribed in three trials (17%) (Guzick et al., 
1994; Konopka et al., 2015; Thomson et al., 2008). In a single trial (Vizza et al., 2016) four training 
sessions per week were set. Of the remaining four trials, one trial specified a weekly physical activity 
(PA) time target of 150 minutes per week (Hoeger et al., 2004), another set an exercise dose of 14 
kcal/kg/week (Brown et al., 2009), and the final two did not specify any information on the training 
frequency or volume (Nybacka et al., 2011; Petrányi and Zaoura-Petrányi, 2011).  
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Eight included trials (44%) set the aerobic exercise intensity based upon a percentage of the 
participants’ maximum heart rate (HRmax; Almenning et al., 2015; Bruner et al., 2006; Nasrekani et 
al., 2016; Roessler et al., 2013; Sá et al., 2015; Saremi et al., 2013; Thomson et al., 2008; Turan et 
al., 2015), whereas three trials set intensity based upon a percentage of maximal oxygen uptake (VO2 
max; Brown et al., 2009; Konopka et al., 2015; Vigorito et al., 2007). One trial specified that heart 
rate (HR) during exercise was set at ≥120 beats/min (Stener-Victorin et al., 2009). Three of the trials 
that used resistance training prescribed the intensity of each exercise based upon a percentage of a 
pre-determined one-repetition maximum [either 40-60% (Saremi and Yaghoubi, 2016) or 50-75% 
(Almenning et al., 2015; Thomson et al., 2008)]. One resistance training intervention set the exercise 
intensity using a rate of perceived exertion (RPE) of 5-6 out of 10 (Turan et al., 2015). Four trials 
increased the exercise intensity as the intervention progressed (Nasrekani et al., 2016; Saremi et al., 
2013; Saremi and Yaghoubi, 2016; Thomson et al., 2008) and a further six trials did not specify any 
intensity information for their interventions (Bruner et al., 2006; Guzick et al., 1994; Hoeger et al., 
2004; Nybacka et al., 2011; Petrányi and Zaoura-Petrányi, 2011; Vizza et al., 2016). 
Eleven trials (61%) prescribed session durations lasting for one hour or less; the individual session 
durations were ≤30 minutes (Almenning et al., 2015; Nasrekani et al., 2016; Roessler et al., 2013; 
Saremi et al., 2013; Vigorito et al., 2007), >30-60 minutes (Brown et al., 2009; Konopka et al., 2015; 
Sá et al., 2015; Stener-Victorin et al., 2009; Vizza et al., 2016), or 20-30 to 45 minutes (Thomson et 
al., 2008). Only one trial incorporated training sessions of >60 minutes (Bruner et al., 2006). Hoeger 
and colleagues (2004) specified 150 minutes as a weekly target, whereas another trial used a target 
distance of 10 miles per week (Guzick et al., 1994). Four trials did not specify any timings, or 
equivalent information, for their individual session duration (Nybacka et al., 2011; Petrányi and 
Zaoura-Petrányi, 2011; Saremi and Yaghoubi, 2016; Vizza et al., 2016). 
In ten of the included trials (56%), participants were fully supervised at every exercise session 
(Bruner et al., 2006; Konopka et al., 2015; Nasrekani et al., 2016; Nybacka et al., 2011; Roessler et 
al., 2013; Sá et al., 2015; Saremi et al., 2013; Saremi and Yaghoubi, 2016; Turan et al., 2015; 
Vigorito et al., 2007), whereas two trials (11%) utilised a mixed approach with some sessions being 
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supervised and others classified as home-based with participants exercising independently 
(Almenning et al., 2015; Vizza et al., 2016). Exercise sessions were completely unsupervised in one 
(6%) additional trial (Stener-Victorin et al., 2009) with support provided by weekly telephone calls. 
The remaining five trials (26%) did not report supervision arrangements (Brown et al., 2009; Guzick 
et al., 1994; Hoeger et al., 2004; Petrányi and Zaoura-Petrányi, 2011; Thomson et al., 2008). 
Of the six trials (33%) that incorporated a dietary component, five specified either a daily caloric 
target (Guzick et al., 1994; Thomson et al., 2008), a reduced caloric intake (Nybacka et al., 2011; 
Petrányi and Zaoura-Petrányi, 2011), or an individualised caloric deficit (Hoeger et al., 2004). One 
of these six trials (Bruner et al., 2006) incorporated weekly nutritional counselling sessions in order 
to educate participants on a range of nutritional topics. 
Thirteen of the included trials (72%) had a control arm (Table 3.2; Almenning et al., 2015; Brown et 
al., 2009; Guzick et al., 1994; Konopka et al., 2015; Nasrekani et al., 2016; Roessler et al., 2013; Sá 
et al., 2015; Saremi et al., 2013; Saremi and Yaghoubi, 2016; Stener-Victorin et al., 2009; Turan et 
al., 2015; Vigorito et al., 2007; Vizza et al., 2016). Three of these 13 trials used a wait-list control 
and either offered participants the same intervention (Roessler et al., 2013; Guzick et al., 1994) or a 
one-month gym membership (Almenning et al., 2015) upon trial completion. Three of the remaining 
trials (17%) had a diet only intervention arm as their comparison group (Bruner et al., 2006; Nybacka 
et al., 2011; Thomson et al., 2008), one trial used a placebo (Hoeger et al., 2004), and another trial 
used metformin treatment only (Petrányi and Zaoura-Petrányi, 2011). 
 
3.4.5. Characteristics of the outcome measures 
All studies incorporated participant assessment at baseline and immediately following completion of 
the intervention; two other trials incorporated an additional midway assessment (Hoeger et al., 2004; 
Thomson et al., 2008), one trial added a follow-up assessment 16 weeks post-intervention (Stener-
Victorin et al., 2009), and another trial assessed at baseline, crossover and immediately post-
103 
 
intervention (Roessler et al., 2013). No post-intervention follow-up analysis was possible due to lack 
of studies. 
Seven trials (39%) specified the methods which were used to calculate sample size (Almenning et 
al., 2015; Brown et al., 2009; Sá et al., 2015; Saremi et al., 2013; Saremi and Yaghoubi, 2016; 
Stener-Victorin et al., 2009; Vigorito et al., 2007), although only five (28%) of those reported the 
outcome upon which their calculations were based. The primary outcomes that were used in the 
sample size calculations were: HOMA-IR (Almenning et al., 2015), VO2 peak (Sá et al., 2015), total 
testosterone (Stener-Victorin et al., 2009), insulin sensitivity (Brown et al., 2009), and BMI 
(Nybacka et al., 2011). Only three of the trials stated specific recruitment targets (Almenning et al., 
2015; Sá et al., 2015; Stener-Victorin et al., 2009) and all of those trials achieved their calculated 
sample size target. The additional outcomes included in each trial are provided in Table 3.1.  
 
3.4.6. Assessment of risk of bias in included studies 
The assessment of risk of bias in included studies is presented in the Risk of Bias Graph (Figure 3.2), 
and detailed study information is provided in Figure 3.3 and Appendix 7.1. 
 
 
Figure 3.2. Risk of bias judgement for each methodological quality item from the Cochrane Risk of 




Figure 3.3. Risk of bias items for each included study. 
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Four of the included trials (22%) were judged to have a low risk of selection bias; that is, they were 
deemed to have used appropriate methods to generate their sequence for participant randomisation 
and group allocation concealment (Almenning et al., 2015; Brown et al., 2009; Turan et al., 2015; 
Vizza et al., 2016). Only one trial was judged to have a high risk of selection bias (Sá et al., 2015) 
because five participants were allocated to the control group based upon their geographical location. 
The remaining trials were deemed to have an unclear risk of selection bias due to insufficient 
reporting of sequence generation or allocation concealment methods. As discussed previously 
(Section 2.1.3), all trials were judged to be at a high risk of performance bias because of the way 
exercise interventions are typically structured. Only one trial had a low risk for detection bias 
(Vigorito et al., 2007) with all remaining trials judged to be at a high risk as it was not stated whether 
outcome assessors were blinded to participant allocation. One trial (Almenning et al., 2015) used an 
independent, and blinded, assessor for evaluation of only one outcome (flow mediated dilation). 
Eight trials (44%) were judged to be high risk for attrition bias. This was because participant 
withdrawal rates were >20% (Brown et al., 2009; Hoeger et al., 2004; Nybacka et al., 2011; Stener-
Victorin et al., 2009; Thomson et al., 2008), incomplete data due to lab error (Bruner et al., 2006), 
inappropriate handling of missing data (i.e., last observation carried forward; Vizza et al., 2016), or 
only a subset of participants completing components of assessment (i.e., hyperinsulinaemic-
euglycemic clamp testing; Konopka et al., 2015). A prospective protocol document, or evidence of 
trial registration was only identified for three trials (Almenning et al., 2015; Konopka et al., 2015; 
Stener-Victorin et al., 2009), thus making it difficult to judge whether all intended outcomes had 
been fully reported. Fourteen of the remaining trials (78%) were judged to have an unclear risk of 
reporting bias, and the final trial (Sá et al., 2015) was judged to be high risk due to incomplete 
reporting of results.  
Eleven trials (61%) were judged to have a low risk of bias based upon similarities between 
comparative groups at baseline (Almenning, et al., 2015; Bruner et al., 2006; Guzick et al., 1994; 
Hoeger et al., 2004; Konopka et al., 2015; Nybacka et al., 2011; Roessler et al., 2013; Sá et al., 2015; 
Stener-Victorin et al., 2009; Thomson et al., 2008; Turan et al., 2015). Of the trials deemed to be 
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high-risk, one (Vizza et al., 2016) had participants in the intervention group with greater adiposity 
and less favourable body composition compared to the control group. Another trial (Brown et al., 
2009) had an older intervention group that was less hyperandrogenic, hirsute and had lower levels of 
cardiorespiratory fitness, as well as higher mean BMI, plasma lipids, and IR levels than the control 
study arm. 
Adherence was only reported in seven trials (39%; Almenning, et al., 2015; Brown et al., 2009; 
Roessler et al., 2013; Stener-Victorin et al., 2009; Turan et al., 2015; Vigorito et al., 2007; Vizza et 
al., 2016); where reported, the median adherence was 90% with a range from 67% (Roessler et al., 
2013) to 103% (Stener-Victorin et al., 2009); participants in the latter study completed more of the 
intervention than was prescribed. Two included trials (11%) reported intervention adherence below 
the high-risk threshold of <75% that was outlined in Section 2.1.3 (Roessler et al., 2013; Vizza et 
al., 2016). Five trials (28%) were judged to have a low risk of adherence bias because intervention 
adherence was ≥75% (Almenning, et al., 2015; Brown et al., 2009; Stener-Victorin et al., 2009; 
Turan et al., 2015; Vigorito et al., 2007). Finally, due to an absence of reporting, 14 trials (78%) 
were judged to have an unclear risk of contamination bias. Only one trial (Vigorito et al., 2007) had 
a low risk of contamination bias as it was clearly stated that during the intervention period, the control 
group did not increase PA levels by >4 MET/hr/wk (Waters et al., 2012). In contrast, three trials 
(17%) had a high risk of contamination bias because comparison groups had either engaged in 
treatment (Roessler et al., 2013; Stener-Victorin et al., 2009), or control groups had not received 
their allocated intervention (Sá et al., 2015). 
 
3.5. Effects of interventions 
Due to data availability, a meta-analysis was possible only for three comparisons: 1) exercise 
compared to control; 2) exercise combined with diet compared to a control; and 3) exercise combined 
with diet compared with diet only. 
107 
 
3.5.1. Exercise versus Control: Primary Outcomes 
Eleven trials were included in the exercise versus control meta-analysis (Almenning, et al., 2015; 
Konopka et al., 2015; Nasrekani et al., 2016; Roessler et al., 2013; Sá et al., 2015; Saremi et al., 
2013; Saremi and Yaghoubi, 2016; Stener-Victorin et al., 2009; Turan et al., 2015; Vigorito et al., 
2007; Vizza et al., 2016). A summary of key change from baseline findings for the primary outcomes 
(SBP, DBP, FBG, FI, HOMA-IR, cholesterol, LDL-C, HDL-C and triglycerides), and an overview 
of the quality of evidence are presented in Table 3.2. 
Effect estimates for all included outcomes are presented in Table 3.3. Data are presented for changes 
from baseline to immediately post-intervention and also for comparisons of values immediately post-





Table 3.2. Summary of findings for primary outcomes: exercise versus control. 
Intervention: exercise; Comparison: usual care  
Outcomes Anticipated absolute effects* (95% CI)  № of participants  
(№ of studies)  
Certainty of the evidence 
(GRADE)  
Comments 
Risk with usual care Risk with exercise 
Systolic blood pressure (change 
from baseline) 
follow up: range 8 weeks to 16 
weeks  
The mean systolic blood pressure 
(change from baseline) ranged from -2.5 
to 1.1 mmHg  
The mean systolic blood pressure (change 
from baseline) in the intervention group 
was 2.93 mmHg lower (7.06 lower to 1.2 
higher)  
158 
(4 RCTs)  
⨁⨁◯◯ 
LOW a,b 
Exercise may result in little to no 
difference in systolic blood pressure 
(change from baseline)  
Diastolic blood pressure (change 
from baseline) 
follow up: range 8 weeks to 16 
weeks  
The mean diastolic blood pressure 
(change from baseline) ranged from -3.1 
to 2.9 mmHg  
The mean diastolic blood pressure 
(change from baseline) in the intervention 
group was 2.19 mmHg lower (5.23 lower to 
0.85 higher)  
158 
(4 RCTs)  
⨁⨁◯◯ 
LOW a,b 
Exercise may result in little to no 
difference in diastolic blood pressure 
(change from baseline)  
Fasting blood glucose (change from 
baseline) 
follow up: range 8 weeks to 16 
weeks  
The mean fasting blood glucose (change 
from baseline) ranged from -1.3 to 2.6 
mg/dL  
The mean fasting blood glucose (change 
from baseline) in the intervention group 
was 1.08 mg/dL lower (2.47 lower to 0.3 
higher)  
263 
(9 RCTs)  
⨁⨁◯◯ 
LOW c,d 
Exercise may result in little to no 
difference in fasting blood glucose 
(change from baseline)  
Fasting insulin (change from 
baseline) 
follow up: range 8 weeks to 16 
weeks  
The mean fasting insulin (change from 
baseline) ranged from -4.1 to 2.5 μU/ml  
The mean fasting insulin (change from 
baseline) in the intervention group was 
2.44 μU/ml lower (4.42 lower to 0.64 lower)  
263 
(9 RCTs)  
⨁◯◯◯ 
VERY LOW e,f,g 
Exercise may reduce fasting insulin 
(change from baseline), but we are 
very uncertain  
HOMA-IR (change from baseline) 
follow up: range 8 weeks to 16 
weeks  
The mean HOMA-IR (change from 
baseline) ranged from -0.4 to 0.7  
The mean HOMA-IR (change from 
baseline) in the intervention group was 
0.57 lower (0.99 lower to 0.14 lower)  
173 
(8 RCTs)  
⨁◯◯◯ 
VERY LOW d,e,h 
Exercise may reduce HOMA-IR 
(change from baseline), but we are 
very uncertain  
Total cholesterol (change from 
baseline) 
follow up: range 8 weeks to 16 
weeks  
The mean total cholesterol (change from 
baseline) ranged from -8.85 to 6.85 
mg/dL  
The mean total cholesterol (change from 
baseline) in the intervention group was 
6.48 mg/dL lower (10.5 lower to 2.45 
lower)  
225 
(7 RCTs)  
⨁⨁◯◯ 
LOW g,i 
Exercise may reduce total 




Intervention: exercise; Comparison: usual care  
Outcomes Anticipated absolute effects* (95% CI)  № of participants  
(№ of studies)  
Certainty of the evidence 
(GRADE)  
Comments 
Risk with usual care Risk with exercise 
LDL-C (change from baseline) 
follow up: range 8 weeks to 16 
weeks  
The mean LDL-C (change from baseline) 
ranged from -17.7 to 7.03 mg/dL  
The mean LDL-C (change from baseline) 
in the intervention group was 7.51 mg/dL 
lower (10.01 lower to 5.02 lower)  
225 
(7 RCTs)  
⨁⨁◯◯ 
LOW g,i 
Exercise may reduce LDL-C 
(change from baseline) slightly  
HDL-C (change from baseline) 
follow up: range 8 weeks to 16 
weeks  
The mean HDL-C (change from 
baseline) ranged from -17.7 to 3.5 
mg/dL  
The mean HDL-C (change from baseline) 
in the intervention group was 0.01 mg/dL 
lower (1.91 lower to 1.89 higher)  
225 
(7 RCTs)  
⨁⨁◯◯ 
LOW d,i 
Exercise may result in little to no 
difference in HDL-C (change from 
baseline)  
Triglycerides (change from baseline) 
follow up: range 8 weeks to 16 
weeks  
The mean triglycerides (change from 
baseline) ranged from -1.0 to 8.9 mg/dL  
The mean triglycerides (change from 
baseline) in the intervention group was 
4.78 mg/dL lower (7.52 lower to 2.05 
lower)  
225 
(7 RCTs)  
⨁⨁◯◯ 
LOW g,i 
Exercise likely results in a small 
effect that may not be an important 
(or unimportant) reduction in 
triglycerides (change from baseline)  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; MD: Mean difference  
GRADE Working Group grades of evidence 
➢ High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
➢ Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
➢ Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
➢ Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a) Three of the four trials had a high or unclear risk of selection bias, detection bias, and reporting bias; all were at high risk of performance bias; two were at high or unclear risk of attrition bias; and all were at a high or unclear 
risk of contamination. Therefore, we downgraded by one level.  
b) Small number of participants, wide confidence intervals for three of the four trials, and null/negligible effect and appreciable benefit included in the confidence interval for the mean difference. Therefore, we downgraded by one 
level.  
c) Most trials were at an unclear or high risk of selection bias, detection bias, and reporting bias; and all trials were at a high or unclear risk of contamination and low adherence. Therefore, we downgraded by one level.  
d) Small number of participants and null/negligible effect and appreciable benefit included in the confidence interval for the mean difference. Therefore, we downgraded by one level.  
e) Most trials were at an unclear or high risk of selection bias, detection bias, attrition bias, and reporting bias; and most trials were at a high or unclear risk of contamination and low adherence. Therefore, we downgraded by one 
level.  
f) Considerable heterogeneity was observed. Therefore, we downgraded by one level.  
g) Small number of participants and wide confidence intervals in the included trials. Therefore, we downgraded by one level.  
h) Considerable heterogeneity was observed and there was minimal or no overlap of confidence intervals. Therefore, we downgraded by one level.  
i) Most trials were at an unclear or high risk of selection bias, detection bias, and reporting bias; and all trials were at a high or unclear risk of contamination. Therefore, we downgraded by one level. 
110 
 
Table 3.3. Effect estimates and heterogeneity for change from baseline to post-intervention scores and immediately post-intervention values, for all outcomes 
analysed in the exercise versus control comparison. 
  Change from baseline  Immediately post-intervention values 










SBP (mmHg) 5,8,10-11  158 -2.93 -7.06 1.20 50 158 2.02 -6.82 10.86 87 
DBP (mmHg) 5,8,10-11 158 -2.19 -5.23 0.85 46 158 -0.82 -3.49 1.84 31 
FBG (mg/dL) 1,2⚫,5-8,10-12 263 -1.08 -2.47 0.30 16 238 -1.69 -4.35 0.97 37 
FI (µIU/mL) 1,2⚫,5-8,10-12 263 -2.44** -4.24 -0.64 91 238 -2.11** -3.49 -0.73 40 
HOMA-IR 1, 2⚫,5-8,10,12 173 -0.57** -0.99 -0.14 87 148 -0.22 -0.80 0.36 69 
TC (mg/dL) 1,5-8,10-11 225 -5.88** -9.92 -1.83 35 225 -6.35** -10.76 -1.95 0 
LDL-C (mg/dL) 1,5-8,10-11 225 -7.39*** -9.83 -4.95 0 225 -6.68** -11.66 -1.70 0 
HDL-C (mg/dL)▲ 1,5-8,10-11 225 0.29 -1.46 2.04 52 225 1.87 -1.59 5.33 65 
TG (mg/dL) 1,5-8,10-11 225 -4.78*** -7.52 -2.05 3 225 -1.97 -7.36 3.42 18 
VO2 max (ml/kg/min) 1,3,5-6,8⚫,11  229 3.84*** 2.87 4.81 17 184 5.01*** 3.48 6.54 42 
RHR (bpm) 1,8,10-11 156 -2.65 -5.55 0.25 51 156 -3.26*** -4.93 -1.59 0 
BMI (kg/m2) 1,2⚫,3,4-8,10-12 331 -0.49 -1.04 0.06 66 272 -1.02** -1.81 -0.23 0 
Body Mass (kg) 1,2⚫,3,4,6-7,12 139 -1.25 -3.27 0.76 33 128 -0.48 -4.86 3.91 0 
WC (cm) 1,4-6,10-12 221 -2.62*** -4.13 -1.11 53 221 -2.33 -5.23 0.58 15 
WHR 8,11 101 -0.03 -0.08 0.02 0 101 -0.04 -0.08 0.01 19 
Body Fat (%) 1,6,12 60 -1.39* -2.61 -0.18 30 60 -3.28 -7.39 0.83 22 
Fat Mass (kg) 1,2⚫,12 63 -1.70 -3.93 0.53 70 38 5.14 -14.39 24.68 65 
FFM (kg) 1,2⚫,12 63 0.46 -0.89 1.81 58 38 4.99 -7.31 17.28 75 
Testosterone (nmol/L) 1,8,10-12 203 -0.09 -0.24 0.06 0 169 -0.08 -0.35 0.19 37 
SHBG (nmol/L) 1,8,11-12 173 7.51 -8.01 23.04 89 139 4.03 -18.57 26.63 66 
Free T (pg/mL) 8,10 74 -0.43 -1.74 0.88 76 41 0.33 -0.10 0.77 0 
FAI 1,8,11-12 139 0.24 -0.55 1.04 0 139 0.68 -1.09 2.44 46 
FG 8,11 135 -0.63 -2.08 0.81 0 101 -0.75 -2.03 0.54 0 
Oestradiol (pmol/L) 2⚫,8⚫,10-11 190 -13.94 -54.53 26.64 65 120 0.27 -11.27 11.80 0 
DHEA-S (µmol/L) 1,8 70 -0.60 -1.58 0.39 0 36 -0.20 -1.87 1.46 0 
LH (IU/L) 3,8,10-11 185 -0.30 -2.54 1.95 72 151 -0.66 -2.39 1.06 43 
FSH (IU/L) 3,8,10-11 185 0.23 -0.08 0.53 0 151 -0.01 -0.40 0.37 0 
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  Change from baseline  Immediately post-intervention values 










LH/FSH ratio 8,10 41 -0.02 -0.38 0.33 0 41 0.1 -0.22 0.86 37 
PG (nmol/L) 2,11 115 -0.72 -2.53 1.09 74 - - - - - 
Prolactin (ng/mL) 3,11 13 -0.05 -0.71 0.61 0 13 0.20 -0.27 0.68 0 
hsCRP (mg/L) 1,12 38 -0.41 -1.19 0.37 0 38 0.67 -1.31 2.65 0 
AMH (ng/mL) 1,6-7 67 -0.67 -1.65 0.1 0 67 0.48 -1.89 2.84 0 
Adiponectin (µg/mL) 1,8 70 -0.20 -1.04 0.64 0 - - - - - 
Studies: 1: Almenning et al., 2015; 2: Konopka et al., 2015; 3: Nasrekani et al., 2016; 4: Roessler et al., 2013; 5: Sa et al., 2015; 6: Saremi et al., 2013; 7: Saremi and Yaghoubi, 
2016; 8: Stener-Victorin et al., 2009; 9: Thomson et al., 2008; 10: Turan et al., 2015; 11: Vigorito et al., 2007; 12: Vizza et al., 2016. Key: 95% CI: 95% confidence intervals; 
SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; FI: fasting insulin; HOMA-IR: homeostatic model of assessment - insulin resistance; 
TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; RHR: resting heart rate; BMI: body mass 
index; WC: waist circumference; WHR: waist to hip ratio; FFM: fat free mass; SHBG: sex hormone binding globulin; Free T: free testosterone; FAI: free androgen index; FG: 
Ferriman-Gallwey score; DHEA-S: dehydroepiandrosterone sulfate; LH: luteinising hormone; FSH: follicle stimulating hormone; PG: progesterone; hsCRP: high-sensitivity 
C-reactive protein; AMH: anti-Müllerian hormone. ▲: positive values favour exercise over control. ⚫: Study only included in the change from baseline analysis; statistically 
significant effects denoted by: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; N: number or participants included within analysis. Effect estimates are reported as mean differences 






3.5.2. Blood Pressure 
Four eligible trials (158 participants) assessed changes in blood pressure (Sá et al., 2015; Stener-
Victorin et al., 2009; Turan et al., 2015; Vigorito et al., 2007). There was no significant effect of 
exercise on systolic blood pressure (SBP) or diastolic blood pressure (DBP) for either change scores 
or post-intervention values compared with control (Table 3.3). When assessing the quality of the 
evidence, the result of both SBP and DBP was low-quality evidence due to imprecision (small 
number of participants, and a null and appreciable effect were included in the 95% CI for the MD), 
and high or unclear risk of selection bias, detection bias, reporting bias, attrition bias, and 
contamination (Table 3.2). 
In subgroup analyses (Table 3.4), there was evidence of effects for supervised interventions (MD: -
4.42 mmHg, 95% CI: -8.32 to -0.51; 3 trials, 147 participants, I2 = 31%) for SBP change scores 
compared with control. No effects were found in subgroup analysis of SBP post-intervention values 
or in any DBP subgroup analysis. 
 
3.5.3. Fasting Blood Glucose  
Based on data from nine trials (263 participants), there was no effect of exercise on fasting blood 
glucose (FBG) change from baseline values compared with control (Table 3.3: Almenning, et al., 
2015; Konopka et al., 2015; Sá et al., 2015; Saremi et al., 2013; Saremi and Yaghoubi, 2016; Stener-
Victorin et al., 2009; Turan et al., 2015; Vigorito et al., 2007; Vizza et al., 2016). Due to unreported 
data, one trial was removed (Konopka et al., 2015) for the comparison of absolute post-intervention 
values (leaving 238 participants in this analysis); there was still no observed effect. There was also 
no effect of exercise for any of the subgroup analyses (Table 3.4). These findings were judged to be 
low-quality evidence due to an unclear or high-risk of selection, detection, and reporting bias, 
contamination, low adherence, small number of participants, and the incorporation of a null or 




3.5.4. Fasting Insulin 
Meta-analysis of data from 263 participants in nine trials (Almenning, et al., 2015; Konopka et al., 
2015; Sá et al., 2015; Saremi et al., 2013; Saremi and Yaghoubi, 2016; Stener-Victorin et al., 2009; 
Turan et al., 2015; Vigorito et al., 2007; Vizza et al., 2016) revealed a favourable effect of exercise 
on the change from baseline values of FI compared with control (MD: -2.44 µIU/mL, 95% CI: -4.24 
to -0.64; Figure 3.3), but there was evidence of considerable heterogeneity (I2 = 91%). Similarly, 
statistically significant lowering effects of exercise versus control were found for FI post-intervention 
values (MD: -2.11 µIU/mL, 95% CI: -3.49 to -0.73; 8 trials, 238 participants, I2 = 40%). Applying 
GRADE guidelines, the quality of the evidence was deemed as very low-quality evidence (Table 3.2) 
due to unclear or high risk judgements of randomisation or allocation procedures, lack of (assessor) 
blinding, high rate of incomplete outcome data, unclear reporting of outcomes and contamination, 
low adherence, considerable heterogeneity in the effects of individual studies, small numbers of 
participants, and wide confidence interval for the mean difference.   
In sensitivity analyses, when only trials with larger sample sizes (n ≥ 30 total participants) were 
included, although slightly reduced, the observed effect on change from baseline FI remained (MD: 
-1.09 µIU/mL, 95% CI: -1.64 to -0.53; 2 trials, 120 participants, I2 = 7%). Similarly, when analysis 
included only studies with a low risk of bias, an effect of exercise was also found (MD: -3.18 
µIU/mL, 95% CI: -5.63 to -0.74; 187 participants, 5 trials, I2 = 95%). Likewise, post-intervention FI 
effects remained when small trials (MD: -1.73 µIU/mL, 95% CI: -3.00 to -0.47; 2 trials, 160 
participants, I2 = 5%) and trials with a high risk of bias (MD: -2.10 µIU/mL, 95% CI: -3.04 to -1.17; 
5 trials, 187 participants, I2 = 0%) were removed. 
To identify the potential source of heterogeneity in the FI change from baseline analysis, the study 
by Saremi and Yaghoubi (2016) was removed because it was the greatest outlier. This reduced the I2 
statistic to a level that may not be important (18%) and the effect was maintained (MD: -1.54 
µIU/mL, 95% CI: -2.36 to -0.71). The results of the removed trial may have varied due to the mode 
of exercise used (resistance training) or the use of a placebo.  
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A statistical effect of exercise versus control on FI was shown in multiple subgroups (Table 3.4). A 
change in FI from baseline to immediately post-intervention was observed in studies with participants 
who had a BMI that was 25-29.9 kg/m2 (MD: -3.25 µIU/mL, 95% CI: -5.27 to -1.22; 5 trials, 168 
participants, I2 = 75%); in interventions that utilised aerobic based exercise (MD: -2.22 µIU/mL, 95% 
CI: -3.57 to -0.86; 6 trials, 192 participants, I2 = 10%); also in interventions that were ≤ 12 weeks in 
duration (MD: -2.92 µIU/mL, 95% CI: -4.91 to -0.93; 7 trials, 225 participants, I2 = 93%); and where 
participants were either fully supervised or had a combination of supervised and unsupervised 
exercise sessions (MD: -2.54 µIU/mL, 95% CI: -4.82 to -0.26; 6 trials, 214 participants, I2 = 94%, 
and MD: -3.08 µIU/mL, 95% CI: -5.63 to -0.53; 2 trials, 38 participants, I2 = 17%, respectively). 
Compared with control, there were favourable effects of exercise on post-intervention FI values for 
participants with a BMI that was 25-29.9 kg/m2 (MD: -2.27 µIU/mL, 95% CI: -3.24 to -1.31; 5 trials, 
168 participants, I2 = 0%); in interventions that were aerobic exercise-based (MD: -2.48 µIU/mL, 
95% CI: -3.92 to -1.04; 5 trials, 167 participants, I2 = 10%); ≤ 12 weeks duration (MD: -1.80 µIU/mL, 
95% CI: -3.18 to -0.42; 6 trials, 200 participants, I2 = 32%); and supervised (MD: -2.39 µIU/mL, 




Figure 3.4. Forest plot of comparison: Exercise vs. Control, outcome: fasting insulin plasma levels (µIU/mL). 
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3.5.5. HOMA-IR  
For the eight studies that were included (Almenning, et al., 2015; Konopka et al., 2015; Sá et al., 
2015; Saremi et al., 2013; Saremi and Yaghoubi, 2016; Stener-Victorin et al., 2009; Turan et al., 
2015; Vizza et al., 2016), there was evidence of greater reductions in HOMA-IR change scores for 
exercise when compared to control (MD: -0.57, 95% CI: -0.99 to -0.14; 173 participants, I2 = 87%; 
Table 3.3; Figure 3.5), but this was not the case and no effect of exercise was evident when the 
comparison of post-intervention HOMA-IR was completed (Konopka et al., 2015 removed due to 
lack of data). In a sensitivity analysis that included only trials judged to have a low risk of bias, the 
effect of exercise was maintained (MD: -0.81, 95% CI: -1.40 to -0.21; 97 participants, 4 trials, I2 = 
77%). Only one trial had a sample size of ≥ 30 participants (Turan et al., 2015), so a corresponding 
sensitivity analysis was not completed. The quality of the evidence was rated as very low-quality; 
this was due to unclear or high risk of selection, detection, attrition, and reporting bias, 
contamination, low adherence, considerable heterogeneity with minimal or no overlap of confidence 
intervals, a small number of participants, and a null or negligible effect and appreciable benefit 
included in the confidence interval for the mean difference (Table 3.2).  
In the investigation of heterogeneity, the most extreme value was removed (Almenning, et al., 2015); 
this had a negligible effect on the degree of heterogeneity (I2 = 89%), but a small effect was still 
evident (MD: -0.50, 95% CI: -0.96 to -0.05). Similarly, the I2 statistic remained representative of at 
least substantial heterogeneity in sub-analyses; the lowest reported value was 60% which was 
observed in the aerobic exercise intervention subgroup (Table 3.4).  
In subgroup analyses statistical effects on HOMA-IR were revealed for change from baseline to 
immediately post-intervention values for aerobic exercise interventions (MD: -0.73, 95% CI: -1.24 
to -0.21; 5 trials, 102 participants, I2 = 60%); interventions which were ≤ 12 weeks in duration (MD: 
-0.69, 95% CI: -1.13 to -0.26; 6 trials, 135 participants, I2 = 89%); for interventions that had a 
supervised delivery (MD: -0.80, 95% CI: -1.19 to -0.42; 5 trials, 124 participants, I2 = 76%); and also 
for participants in the BMI 25-29.9 kg/m2 subgroup (MD: -0.83, 95% CI: -1.39 to -0.26; 4 trials, 78 
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participants, I2 = 75%). There were no statistical effects observed in the post-intervention subgroup 









Figure 3.5. Forest plot of comparison: Exercise vs. Control, outcome: Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). 
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Table 3.4. Summary of effect estimates and heterogeneity from sub-group analyses in blood pressure and glucose homeostasis related outcomes.  
 Change from baseline Post-intervention 
Outcome Sub-analysis Sub-group Trials 
(N) 
Effect Estimate MD 
(95% CI) 
I2 (%) Trials 
(N) 





BMI at entry 25-29.9 kg/m2 2 (101) -1.80 (-8.53 to 4.93) 65 2 (101) 0.19 (-12.94 to 13.31) 82 
Intervention Aerobic exercise 3 (128) -3.71 (-8.88 to 1.47) 60 3 (128) -1.41 (-8.65 to 5.82) 65 
Duration ≤12 weeks 2 (120) -3.03 (-7.54 to 1.47) 27 2 (120) 1.90 (-13.19 to 16.99) 95 
>12 weeks 2 (38) -2.91 (-12.41 to 6.60) 79 2 (38) 2.06 (-8.29 to 12.41) 59 




BMI at entry 25-29.9 kg/m2 2 (101) -1.19 (-3.11 to 0.73) 0 2 (101) -1.31 (-3.09 to 0.47) 0 
Intervention Aerobic exercise 3 (128) -2.67 (-6.50 to 1.17) 62 3 (128) -1.41 (-3.12 to 0.29) 0 
Duration ≤12 weeks 2 (120) -1.30 (-3.31 to 0.71) 0 2 (120) 0.96 (-4.33 to 6.26) 68 
>12 weeks 2 (38) -3.95 (-11.78 to 3.89) 77 2 (38) -3.16 (-7.54 to 1.22) 0 
Format Supervised 3 (147) -3.03 (-7.36 to 1.30) 60 3 (147) -0.22 (-3.50 to 3.07) 43 
FBG 
(mg/dL) 
BMI at entry 25-29.9 kg/m2 5 (168) -0.79 (-2.08 to 0.50) 0 5 (168) -1.59 (-5.29 to 2.11) 62 
≥ 30 kg/m2 3 (65) -0.87 (-8.95 to 7.22) 58 2 (40) -1.21 (-8.83 to 6.41) 0 
Intervention Aerobic exercise 6 (192) -0.70 (-2.46 to 1.05) 21 5 (167) -0.83 (-2.80 to 1.13) 0 
Resistance exercise 3 (50) -1.01 (-3.37 to 1.34) 11 3 (50) -3.81 (-13.74 to 6.11) 76 
Duration ≤12 weeks 7 (225) -1.47 (-3.03 to 0.10) 18 6 (200) -2.18 (-5.82 to 1.46) 53 
>12 weeks 2 (38) 0.38 (-2.42 to 3.19) 0 2 (38) -0.33 (-4.29 to 3.64) 0 
Format Supervised 6 (214) -1.75 (-4.06 to 0.56) 40 5 (189) -3.04 (-7.59 to 1.52) 60 
Mixed Delivery 2 (38) -0.73 (-3.05 to 1.58) 0 2 (38) 0.00 (-4.91 to 4.91) 0 
FI (µIU/mL) BMI at entry 25-29.9 kg/m2 5 (168) -3.25 (-5.27 to -1.22) ** 75 5 (168) -2.27 (-3.24 to -1.31) *** 0 
≥ 30 kg/m2 3 (65) -1.94 (-3.94 to 0.06) 0 2 (40) 1.30 (-14.29 to 16.89) 88 
Intervention Aerobic exercise 6 (192) -2.22 (-3.57 to -0.86) *** 10 5 (167) -2.48 (-3.92 to -1.04) *** 10 
Resistance exercise 3 (50) -3.99 (-5.97 to -2.00) *** 54 3 (50) -0.24 (-6.99 to 6.51) 68 
Duration ≤12 weeks 7 (225) -2.92 (-4.91 to -0.93) ** 93 6 (200) -1.80 (-3.18 to -0.42) ** 32 
>12 weeks 2 (38) 0.06 (-2.87 to 2.99) 0 2 (38) -3.63 (-8.11 to 0.85) 67 
Format Supervised 6 (214) -2.54 (-4.82 to -0.26) * 94 5 (189) -2.39 (-3.62 to -1.17) *** 30 
Mixed Delivery 2 (38) -3.08 (-5.63 to -0.53) * 17 2 (38) 3.54 (-8.29 to 15.37) 71 
HOMA-IR BMI at entry 25-29.9 kg/m2 4 (78) -0.83 (-1.39 to -0.26) ** 75 4 (78) -0.51 (-1.10 to 0.07) 55 
≥ 30 kg/m2 3 (65) -0.43 (-1.19 to 0.32) 87 2 (40) 0.71 (-1.47 to 2.88) 55 
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 Change from baseline Post-intervention 
Outcome Sub-analysis Sub-group Trials 
(N) 
Effect Estimate MD 
(95% CI) 
I2 (%) Trials 
(N) 
Effect Estimate MD 
(95% CI) 
I2 (%) 
Intervention Aerobic exercise 5 (102) -0.73 (-1.24 to -0.21) ** 60 4 (77) -0.15 (-0.70 to 0.40) 0 
Resistance exercise 3 (50) -0.74 (-1.58 to 0.10) 94 3 (50) -0.24 (-1.89 to 1.41) 85 
Duration ≤12 weeks 6 (135) -0.69 (-1.13 to -0.26) ** 89 5 (110) -0.14 (-0.88 to 0.59) 78 
Format Supervised 5 (124) -0.80 (-1.19 to -0.42) *** 76 4 (99) -0.46 (-1.09 to 0.17) 66 
Mixed Delivery 2 (38) -0.55 (-1.60 to 0.50) 77 2 (38) 0.47 (-1.49 to 2.42) 66 
Key: Outcome: outcome where sub-analysis was completed. Sub-analysis: how the studies were categorised for analysis; BMI at entry: mean baseline BMI of participants; 
Intervention: type of intervention; Duration: length of exercise intervention; Format: delivery mode of intervention. Sub-group: groups each study was classified into. Trials: 
number of studies included within sub-analysis, N: number or participants included within sub-analysis. Effect estimates are reported as mean difference (MD), and 95% 
confidence intervals, between exercise and control groups. Significant evidence of effect denoted by: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001. Heterogeneity reported using I2 
statistic: 0-40% might not be important; 30-60% may represent moderate heterogeneity; 50-90% may represent substantial heterogeneity; 75-100% may represent considerable 
heterogeneity. SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; FI: fasting insulin; BMI: body mass index. 
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3.5.6. Circulating lipids 
Seven trials (225 participants) were included in the analysis of all outcomes related to participants’ 
lipid profile (Almenning, et al., 2015; Sá et al., 2015; Saremi et al., 2013; Saremi and Yaghoubi, 
2016; Stener-Victorin et al., 2009; Turan et al., 2015; Vigorito et al., 2007). A statistical effect of 
exercise compared to control change scores was observed for total cholesterol (MD: -5.88 mg/dL, 
95% CI: -9.92 to -1.83; I2 = 35%), LDL-C (MD: -7.39 mg/dL, 95% CI: -9.83 to -4.95; I2 = 0%), and 
triglycerides (MD: -4.78 mg/dL, 95% CI: -7.52 to -2.05; I2 = 3%), but not for HDL-C (Figure 3.6). 
Analysis of post-intervention values for lipid-related outcomes revealed an effect on total cholesterol 
(MD: -6.35 mg/dL, 95% CI: -10.76 to -1.95; I2 = 0%) and LDL-C (MD: -6.68 mg/dL, 95% CI: -11.66 
to -1.70; I2 = 0%) only (Table 3.3). These results were rated as low-quality evidence (Table 3.2) due 
to high or unclear risk of selection bias, detection bias, reporting bias, contamination, imprecision 
due to small number of participants and also wide confidence intervals in the included trials. 
In sensitivity analyses, the favourable effects of exercise versus control on change scores for total 
cholesterol (MD: -5.94 md/dL, 95% CI: -10.32 to -1.55; 5 trials, 187 participants, I2 = 40%), LDL-C 
(MD: -6.60 mg/dL, 95% CI: -9.88 to -3.32; 5 trials, 187 participants, I2 = 14%), and triglycerides 
(MD: -5.97 mg/dL, 95% CI: -10.91 to -1.03; 5 trials, 187 participants, I2 = 33%), were maintained in 
studies with a low risk of bias, and also in larger trials (MD: -3.74 mg/dL, 95% CI: -6.13 to -1.35; 
120 participants, 2 trials, I2 = 0%; MD: -8.58, 95% CI: -11.44 to -5.71; 120 participants, 2 trials, I2 = 
0%; and MD: -3.62 mg/dL, 95% CI: -6.22 to -1.02; 120 participants, 2 trials, I2 = 0%, respectively). 
Sensitivity analyses for LDL-C post-intervention values showed a retained effect when trials with a 
high risk of bias were excluded (MD: -8.64 mg/dL, 95% CI: -16.30 to -0.98; 5 trials, 187 participants, 
I2 = 22%), but not when smaller trials were removed.
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Figure 3.6. Forest plot of comparison: Exercise vs. Control, change from baseline to immediately post-intervention analysis of outcomes related to lipid 
profile [circulating triglycerides, total cholesterol, and low-density lipoprotein cholesterol (LDL-C) levels; all in mg/dL]. 
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Subgroup analyses of total cholesterol change (Table 3.5) revealed statistical effects for interventions 
that were ≤ 12 weeks duration (MD: -5.94 mg/dL, 95% CI: -10.32 to -1.55; 5 trials, 187 participants, 
I2 = 37%) or where participants were supervised (MD: -7.25 mg/dL, 95% CI: -11.92 to -2.58; 5 trials, 
189 participants, I2 = 48%). There was also evidence of an effect in subgroup analysis for change 
from baseline (MD: -6.68 mg/dL, 95% CI: -13.00 to -0.35; 5 trials, 167 participants, I2 = 39%) and 
post-intervention total cholesterol values (MD: -6.90 mg/dL, 95% CI: -11.90 to -1.90; 5 trials, 167 
participants, I2 = 0%) when interventions were aerobic in nature. Subgroup analysis of post-
intervention total cholesterol also revealed a statistical effect when interventions were > 12 weeks in 
length (MD: -9.92 mg/dL, 95% CI: -17.81 to -2.04; 2 trials, 38 participants, I2 = 0%) or when 
participants were supervised (MD: -6.76 mg/dL, 95% CI: -11.27 to -2.26; 5 trials, 189 participants, 
I2 = 0%).  
In subgroup analyses for change from baseline LDL-C, a statistically favourable exercise effect was 
found when interventions were ≤ 12 weeks duration (MD: -6.60 mg/dL, 95% CI: -9.88 to -3.32; 5 
trials, 187 participants, I2 = 13%), or interventions were supervised (MD: -6.70 mg/dL, 95% CI: -
10.29 to -3.12; 5 trials, 189 participants, I2 = 23%). Subgroup analysis for post-intervention LDL-C 
circulating levels revealed favourable exercise effects in participants with BMI of 25-29.9 kg/m2 
(MD: -9.54 mg/dL, 95% CI: -18.71 to -0.36; 5 trials, 168 participants, I2 = 22%), and interventions 
of ≤ 12 weeks duration (MD: -8.64 mg/dL, 95% CI: -16.30 to -0.98; 5 trials, 187 participants, I2 = 
22%), that were supervised (MD: -7.58 mg/dL, 95% CI: -13.73 to -1.43; 5 trials, 187 participants, I2 
= 24%) or aerobic in nature (MD: -5.87 mg/dL, 95% CI: -11.68 to -0.07; 5 trials, 167 participants, I2 
= 0%; Table 3.5).  
For HDL-C, only subgroup analyses of resistance training interventions showed statistically 
significant effects; resistance training had a negative effect on change from baseline levels (MD: -
2.19 mg/dL, 95% CI: -4.21 to -0.18; 2 trials, 37 participants, I2 = 0%), but a positive effect on post-
intervention values (MD: 7.29 mg/dL, 95% CI: 1.11 to 13.46; 2 trials, 37 participants, I2 = 17%; 
Table 3.5). No effects of exercise were found in other HDL-C subgroup analyses. 
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Compared with control, exercise had a statistically favourable effect on circulating triglyceride 
values in the following subgroups: BMI: 25-29.9 kg/m2 (MD: -8.17 mg/dL, 95% CI: -14.44 to -1.89; 
5 trials, 167 participants, I2 = 13%); aerobic exercise interventions (MD: -6.80 mg/dL, 95% CI: -
13.12 to -0.48; 5 trials, 167 participants, I2 = 5%); ≤12 weeks duration (MD: -6.06 mg/dL, 95% CI: 
-10.82 to -1.31; 5 trials, 187 participants, I2 = 30%); and when interventions were supervised (MD: -
5.91 mg/dL, 95% CI: -10.75 to -1.06; 5 trials, 189 participants, I2 = 29%; Table 3.5). Analysis of 
triglyceride post-intervention values only revealed an effect of exercise in trials that were > 12 weeks 









Table 3.5. Summary of effect estimates and heterogeneity from sub-group analyses in lipidemic related outcomes. 
 Change from baseline Post-intervention 
Outcome Sub-analysis Sub-group Trials 
(N) 












BMI at entry 25-29.9 kg/m2 5 (168) -8.17 (-14.44 to -1.89) ** 13 5 (168) 3.04 (-4.97 to 11.05) 0 
Intervention Aerobic exercise 5 (167) -6.80 (-13.12 to -0.48) * 5 5 (167) -2.89 (-14.44 to 8.65) 41 
Resistance exercise 2 (37) -9.91 (-22.32 to 2.49) 0 2 (37) 6.05 (-12.08 to 24.19) 0 
Duration ≤12 weeks 5 (187) -6.06 (-10.82 to -1.31) ** 30 5 (187) -1.10 (-4.73 to 2.54) 0 
>12 weeks 2 (38) -6.18 (-15.44 to 3.09) 0 2 (38) -13.85 (-26.33 to -1.36) * 0 
Format Supervised 5 (189) -5.91 (-10.75 to -1.06) * 29 5 (189) -2.49 (-6.77 to 1.79) 7 
TC (mg/dL) BMI at entry 25-29.9 kg/m2 5 (168) -6.30 (-12.81 to 0.21) 41 5 (168) -4.16 (-10.31 to 2.00) 0 
Intervention Aerobic exercise 5 (167) -6.68 (-13.00 to -0.35) * 39 5 (167) -6.90 (-11.90 to -1.90) ** 0 
Resistance exercise 2 (37) -9.72 (-21.67 to 2.22) 0 2 (37) 6.47 (-16.70 to 29.63) 0 
Duration ≤12 weeks 5 (187) -5.94 (-10.32 to -1.55) ** 37 5 (187) -4.74 (-10.05 to 0.57) 0 
>12 weeks 2 (38) -4.78 (-20.35 to 10.80) 61 2 (38) -9.92 (-17.81 to -2.04) ** 0 
Format Supervised 5 (189) -7.25 (-11.92 to -2.58) ** 48 5 (189) -6.76 (-11.27 to -2.26) ** 0 
LDL-C 
(mg/dL) 
BMI at entry 25-29.9 kg/m2 5 (168) -3.41 (-8.05 to 1.24) 0 5 (168) -9.54 (-18.71 to -0.36) * 22 
Intervention Aerobic exercise 5 (167) -4.17 (-9.23 to 0.90) 0 5 (167) -5.87 (-11.68 to -0.07) * 0 
Resistance exercise 2 (37) -6.50 (-16.32 to 3.32) 22 2 (37) -13.57 (-38.44 to 11.29)  45 
Duration ≤12 weeks 5 (187) -6.60 (-9.88 to -3.32) *** 13 5 (187) -8.64 (-16.30 to -0.98) * 22 
>12 weeks 2 (38) -8.62 (-17.37 to 0.14) 0 2 (38) -5.05 (-12.97 to 2.86) 0 
Format Supervised 5 (187) -6.70 (-10.29 to -3.12) *** 23 5 (187) -7.58 (-13.73 to -1.43) * 24 
HDL-C▲ 
(mg/dL) 
BMI at entry 25-29.9 kg/m2 5 (168) 0.99 (-2.89 to 4.88) 61 5 (168) 3.36 (-3.33 to 10.05) 62 
Intervention Aerobic exercise 5 (167) 2.69 (-1.47 to 6.86) 59 5 (167) 1.04 (-3.06 to 5.15) 29 
Resistance exercise 2 (37) -2.19 (-4.21 to -0.18) * 0 2 (37) 7.29 (1.11 to 13.46) * 17 
Duration ≤12 weeks 5 (187) -0.10 (-2.27 to 2.08) 57 5 (187) 2.83 (-2.73 to 8.40) 76 
>12 weeks 2 (38) 2.93 (-3.96 to 9.82) 64 2 (38) 1.25 (-1.42 to 3.92) 0 
Format Supervised 5 (189) -0.32 (-1.87 to 1.23) 45 5 (189) 1.93 (-1.86 to 5.72) 75 
Key: Outcome: outcome where sub-analysis was completed. Sub-analysis: how the studies were categorised for analysis; BMI at entry: mean baseline BMI of participants; 
Intervention: type of intervention; Duration: length of exercise intervention; Format: delivery mode of intervention. Sub-group: groups each study was classified into. Trials: 
number of studies included within sub-analysis, N: number or participants included within sub-analysis. Effect estimates are reported as mean difference (MD), and 95% 
confidence intervals, between exercise and control groups. Significant evidence of effect denoted by: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001. Heterogeneity reported using I2 
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statistic: 0-40% might not be important; 30-60% may represent moderate heterogeneity; 50-90% may represent substantial heterogeneity; 75-100% may represent considerable 
heterogeneity. ▲: positive values favour exercise over control. TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol. 
127 
 
3.5.7. Exercise versus Control: Secondary outcomes 
In addition to the primary outcomes, effect estimates were calculated for all outcomes that were 
reported within the included studies. Where more than one study reported an outcome, meta-analyses 
have been completed (Table 3.3); single study outcomes have also been reported qualitatively within 
the results. 
 
3.5.8. Maximal or peak oxygen uptake 
Seven trials were included in the meta-analysis of maximal (VO2 max) or peak (VO2 peak) values 
(Almenning, et al., 2015; Nasrekani et al., 2016; Sá et al., 2015; Saremi et al., 2013; Stener-Victorin 
et al., 2009; Turan et al., 2015; Vigorito et al., 2007). A large statistical effect of exercise versus 
control was reported for both change scores (SMD: 1.43, 95% CI: 0.84 to 2.03; 259 participants, 7 
trials, I2 = 74%) and comparison of post-intervention (SMD: 1.19, 95% CI: 0.40 to 1.99; I2 = 83%) 
VO2 max/peak values (Figure 3.7). When studies that only reported relative VO2 max/peak values 
(i.e. expressed as ml/kg/min) were included (Figure 3.8), the effect of exercise was maintained in 
both change from baseline values (MD: 3.84 ml/kg/min, 95% CI: 2.87 to 4.81; 6 trials, 229 
participants, I2 = 17%) and post-intervention values and (MD: 5.01 ml/kg/min, 95% CI: 3.48 to 6.54; 
5 trials, 184 participants, I2 = 42%).  
Sensitivity analyses were completed for the SMD VO2 max/peak change from baseline values. An 
effect was maintained when small trials (SMD: 1.21, 95% CI: 0.29 to 2.12; 3 trials, 165 participants, 
I2 = 83%) and those with a high risk of bias (SMD: 1.63, 95% CI: 0.78 to 2.48; 5 trials, 187 
participants, I2 = 80%) were removed. SMD was also used to complete sensitivity analysis for sample 
size in the comparison of post-intervention values; 2 trials (Turan et al., 2015; Vigorito et al., 2007), 
involving 120 participants were included, but the effect was lost. However, an effect remained when 
the trials with a high risk of bias were removed (SMD: 1.16, 95% CI: 0.21 to 2.12; 5 trials, 187 
participants, I2 = 87%). 
128 
 
When only studies incorporating relative VO2 max/peak change scores were considered, small 
studies were removed in sensitivity analysis and the effect of exercise was maintained (MD: 1.21 
ml/kg/min, 95% CI: 0.29 to 2.12, 165 participants, 3 trials, I2 = 83%). An effect also remained when 
studies with a high risk of bias were removed (MD: 3.35 ml/kg/min, 95% CI: 2.59 to 4.10; 157 
participants, 4 trials, I2 = 0%). All trials in the post-intervention relative VO2 max/peak analysis were 







Figure 3.7. Forest plot of comparison: exercise vs. control, standardised mean difference; outcome: VO2 max/peak. 
 




For ease of interpretation, we performed subgroup analyses only on the relative VO2 max/peak (i.e. 
ml/kg/min) data (Table 3.6). Subgroup analysis of the change from baseline relative VO2 max/peak 
values revealed statistical improvements with aerobic exercise (MD: 4.11 ml/kg/min, 95% CI: 3.07 
to 5.14; 221 participants, 6 trials; I2 = 21%), for interventions that were short (MD: 3.35 ml/kg/min, 
95% CI: 2.59 to 4.10; 157 participants, 4 trials; I2 = 0%) or long (MD: 5.17 ml/kg/min, 95% CI: 3.11 
to 7.23; 72 participants, 2 trials; I2 = 0%) in duration and also for participants that had a BMI of 25-
29.9 kg/m2 (MD: 3.39 ml/kg/min, 95% CI: 2.66 to 4.13; 202 participants, 5 trials; I2 = 0%). The post-
intervention pooled analysis showed an effect of exercise on relative VO2 max/peak in four 
subgroups: participants with a BMI of 25-29.9 kg/m2 or ≤ 12 weeks in duration (both subgroups: 
MD: 4.70 ml/kg/min, 95% CI: 2.90 to 6.49; 157 participants, 4 trials; I2 = 51%), and for aerobic 
exercise (MD: 5.05 ml/kg/min, 95% CI: 3.53 to 6.56; 176 participants, 5 trials; I2 = 41%), and 
supervised (MD: 5.04 ml/kg/min, 95% CI: 3.25 to 6.82; 159 participants, 4 trials; I2 = 56%) 
interventions.  
Only one trial reported data from a 16-week post-intervention follow-up (Stener-Victorin et al., 
2009). They reported that a 12% increase in VO2 max (4.11 ± 5.20 ml/kg/min), that was statistically 
different (P = .001) from baseline was still evident in the exercise group at follow-up. The 
corresponding change for control (+7%) was not statistically significant, and there were no 
significant differences between groups.  
 
3.5.9. Resting heart rate  
A meta-analysis of four included trials (Almenning, et al., 2015; Stener-Victorin et al., 2009; Turan 
et al., 2015; Vigorito et al., 2007) showed no effect of exercise on the change from baseline for 
resting heart rate (RHR) values (Table 3.3). However, in these trials, RHR post-intervention values 
were statistically lower in the exercise interventions when compared to control (MD: -3.26 beats/min, 
95% CI: -4.93 to -1.59; 156 participants, I2 = 0%). When the post-intervention sensitivity analyses 
were completed, this effect remained when only larger trials were considered (MD: -3.18 beats/min, 
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95% CI: -5.59 to -0.77, 3 trials, 145 participants, I2 = 16%), and also in those with a low risk of bias 
(MD: -3.53 beats/min, 95% CI: -5.28 to -1.78; 2 trials, 120 participants, I2 = 0%). 
When subgroup analyses were completed, there was a statistical effect of exercise compared with 
control on both RHR change from baseline and post-intervention values in interventions that were 
aerobic exercise-based (MD: -3.32 beats/min, 95% CI: -5.50 to -1.15; 118 participants, 3 trials; I2 = 
0%; and, MD: -3.00 beats/min, 95% CI: -4.72 to -1.28; 118 participants, 3 trials; I2 = 0% 
respectively), and in those that were supervised (MD: -4.06 beats/min, 95% CI: -7.42 to -0.70; 120 
participants, 2 trials; I2 = 26%; and, MD: -3.53 beats/min, 95% CI: -5.28 to -1.78; 120 participants, 
2 trials; I2 = 0% respectively). Post-intervention subgroup analysis also revealed effects in 
interventions of ≤ 12 weeks (MD: -3.18 beats/min, 95% CI: -5.59 to -0.77; 145 participants, 3 trials; 
I2 = 16%) and when participants had a BMI 25-29.9 kg/m2 at study entry (MD: -3.04 beats/min, 95% 
CI: -4.76 to -1.32; 126 participants, 3 trials; I2 = 10%); these effects were not observed in the change 
form baseline data (Table 3.6). 
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Table 3.6. Summary of effect estimates and heterogeneity from sub-group analyses in cardiorespiratory, anthropometric and body composition related 
outcomes. 
 Change from baseline Post-intervention 
Outcome Sub-analysis Sub-group Trials 
(N) 













BMI at entry 25-29.9 kg/m2 5 (202) 3.39 (2.66 to 4.13) *** 0 4 (157) 4.70 (2.90 to 6.49) *** 51 
Intervention Aerobic exercise 6 (221) 4.11 (3.07 to 5.14) *** 21 5 (176) 5.05 (3.53 to 6.56) *** 41 
Duration ≤12 weeks 4 (157) 3.35 (2.59 to 4.10) *** 0 4 (157) 4.70 (2.90 to 6.49) *** 51 




BMI at entry 25-29.9 kg/m2 3 (126) -1.76 (-4.41 to 0.89) 58 3 (126) -3.04 (-4.76 to -1.32) *** 10 
Intervention Aerobic exercise 3 (118) -3.32 (-5.50 to -1.15) ** 0 3 (118) -3.00 (-4.72 to -1.28) *** 0 
Duration ≤12 weeks 3 (145) -2.54 (-5.90 to 0.81) 66 3 (145) -3.18 (-5.59 to -0.77) ** 16 
Format Supervised 2 (120) -4.06 (-7.42 to -0.70) * 26 2 (120) -3.53 (-5.28 to -1.78) *** 0 
BMI (kg/m2) BMI at entry ≤ 24.9 kg/m2 1 (30) -0.14 (-1.23 to 0.95) NA 1 (30) 0.00 (-3.05 to 3.05) 0 
25-29.9 kg/m2 6 (222) -0.01 (-0.47 to 0.45) 30 6 (188) -1.04 (-1.89 to -0.19) * 0 
 ≥ 30 kg/m2 4 (79) -1.34 (-1.86 to -0.82) *** 0 3 (54) -0.70 (-5.55 to 4.15) 38 
Intervention Aerobic exercise 8 (260) -0.78 (-1.38 to -0.18) ** 57 7 (201) -1.45 (-2.59 to -0.32) ** 0 
Resistance exercise 3 (50) 0.50 (0.00 to 1.00) * 0 3 (50) -0.10 (-2.76 to 2.55) 23 
Duration ≤12 weeks 8 (245) -0.43 (-1.22 to 0.35) 64 7 (220) -0.91 (-1.73 to -0.08) * 0 
>12 weeks 3 (86) -0.61 (-1.61 to 0.38) 77 3 (52) -2.42 (-5.28 to 0.45) 0 
Format Supervised 8 (248) -0.65 (-1.42 to 0.12) 74 7 (223) -1.06 (-1.87 to -0.25) ** 0 
 Mixed Delivery 2 (38) 0.19 (-1.56 to 1.93) 0 2 (38) 1.82 (-5.85 to 9.50) 45 
Body Mass 
(kg) 
BMI at entry 25-29.9 kg/m2 3 (67) -0.40 (-3.02 to 2.21) 0 3 (67) -0.55 (-7.88 to 6.78) 0 
 ≥ 30 kg/m2 3 (52) -4.07 (-6.46 to -1.67) *** 0 2 (27) 13.88 (-16.21 to 43.97) 61 
Intervention Aerobic exercise 5 (98) -1.88 (-4.08 to 0.32) 38 4 (73) -1.54 (-8.26 to 5.17) 0 
Resistance exercise 3 (50) 0.62 (-1.27 to 2.51) 0 3 (50) 3.99 (-9.39 to 17.36) 50 
Duration ≤12 weeks 6 (125) -1.23 (-3.45 to 0.98) 44 5 (100) -0.59 (-5.10 to 3.92) 0 
Format Supervised 5 (101) -1.61 (-4.21 to 0.99) 49 4 (76) -1.00 (-5.72 to 3.72) 0 




BMI at entry 25-29.9 kg/m2 3 (137) -2.21 (-4.25 to -0.16) * 0 3 (137) -2.02 (-3.39 to -0.65) ** 0 
 ≥ 30 kg/m2 3 (54) -4.18 (-7.86 to -0.50) * 62 3 (54) 1.38 (-14.27 to 17.04) 69 
Intervention Aerobic exercise 5 (170) -3.30 (-6.10 to -0.51) * 50 5 (170) -2.22 (-3.56 to -0.87) *** 0 
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 Change from baseline Post-intervention 
Outcome Sub-analysis Sub-group Trials 
(N) 










Resistance exercise 2 (30) -2.40 (-4.04 to -0.75) ** 0 2 (30) 10.31 (-13.73 to 34.35) 62 
Duration ≤12 weeks 5 (180) -1.69 (-2.38 to -0.99) *** 0 5 (180) -1.73 (-4.25 to 0.78) 8 
>12 weeks 2 (41) -5.19 (-11.43 to 1.05) 52 2 (41) -6.86 (-14.02 to 0.30) 0 
Format Supervised 5 (183) -3.21 (-5.56 to -0.85) ** 64 5 (183) -2.16 (-3.50 to -0.82) ** 0 
 Mixed Delivery 2 (38) -2.09 (-4.36 to 0.19) 28 2 (38) 8.80 (-17.70 to 35.29) 72 
Body Fat (%) BMI at entry 25-29.9 kg/m2 2 (47) -1.60 (-3.68 to 0.47) 59 2 (47) -4.51 (-8.10 to -0.92) ** 0 
Intervention Aerobic exercise 2 (39) -1.36 (-3.73 to 1.01) 76 2 (39) -4.99 (-8.73 to -1.25) ** 0 
 Resistance exercise 2 (30) -0.95 (-2.02 to 0.13) 0 2 (30) 0.47 (-5.95 to 6.88) 0 
Format Mixed Delivery 2 (38) -0.81 (-2.03 to 0.42) 0 2 (38) -0.88 (-6.32 to 4.56) 0 
Key: Outcome: outcome where sub-analysis was completed. Sub-analysis: how the studies were categorised for analysis; BMI at entry: mean baseline BMI of participants; 
Intervention: type of intervention; Duration: length of exercise intervention; Format: delivery mode of intervention. Sub-group: groups each study was classified into. Trials: 
number of studies included within sub-analysis, N: number or participants included within sub-analysis. Effect estimates are reported as mean difference (MD), and 95% 
confidence intervals, between exercise and control groups. Significant evidence of effect denoted by: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001. Heterogeneity reported using I2 
statistic: 0-40% might not be important; 30-60% may represent moderate heterogeneity; 50-90% may represent substantial heterogeneity; 75-100% may represent considerable 
heterogeneity. ▲: positive values favour exercise over control. VO2 max/peak: relative maximal/peak oxygen uptake; BMI: body mass index.  
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3.5.10. Body Mass Index and Body Mass  
Ten trials were included in the meta-analysis of BMI (Almenning et al., 2015; Nasrekani et al., 2016; 
Roessler et al., 2013; Sá et al., 2015; Saremi et al., 2013; Saremi and Yaghoubi, 2016; Stener-
Victorin et al., 2009; Turan et al., 2015; Vigorito et al., 2007; Vizza et al., 2016). When compared 
with control, there was a statistical effect of exercise on BMI post-intervention (MD: -1.02 kg/m2, 
95% CI: -1.81 to -0.23; 10 trials, 272 participants, I2 = 0%), but not change from baseline values 
(Table 3.3). When sensitivity analyses were completed, trials with a high risk of bias were removed 
and a post-intervention effect remained (MD: -0.95 kg/m2, 95% CI: -1.78 to -0.12; 6 trials, 207 
participants, I2 = 0%), but there was no longer an effect when trials with a small number of 
participants were removed.  
Subgroup analysis (Table 3.6) revealed a statistical reduction in BMI change scores with exercise in 
studies that involved participants with BMI ≥30 kg/m2 (MD: -1.34 kg/m2, 95% CI: -1.86 to -0.82; 79 
participants, 4 trials; I2 = 0%). Change from baseline analysis also revealed a statistical decrease in 
participant BMI when aerobic exercise interventions were used (MD: -0.78 kg/m2, 95% CI: -1.38 to 
-0.18; 260 participants, 8 trials; I2 = 57%). In contrast, a statistical increase was observed when 
studies incorporated resistance training interventions (MD: 0.50 kg/m2, 95% CI: 0.00 to 1.00; 50 
participants, 3 trials; I2 = 0%). Furthermore, post-intervention subgroup analyses revealed reductions 
in BMI for aerobic exercise-based (MD: -1.45 kg/m2, 95% CI: -2.59 to -0.32; 201 participants, 7 
trials; I2 = 0%), and supervised interventions (MD: -1.06 kg/m2, 95% CI: -1.87 to -0.25; 223 
participants, 7 trials; I2 = 0%), as well as those that were ≤12 weeks in duration (MD: -0.91 kg/m2, 
95% CI: -1.73 to -0.08; 220 participants, 7 trials; I2 = 0%), and also in trials where participants had 
a BMI of 25-29.9 kg/m2 at study entry (MD: -1.04 kg/m2, 95% CI: -1.89 to -0.19; 188 participants, 
6 trials; I2 = 0%). 
Follow-up reporting (16 weeks post-intervention) of BMI from one trial (Stener-Victorin et al., 2009) 
showed no statistically significant within-group changes or between-group differences in either 




When comparisons of body mass change from baseline to immediately post-intervention, and post-
intervention only values were made, the meta-analysis revealed no statistical effects of exercise 
versus control (Table 3.3). However, when body mass subgroup analysis was completed, statistical 
effects of exercise versus control for change from baseline values were observed for studies involving 
participants with BMI ≥30 kg/m2 (MD: -4.07 kg, 95% CI: -6.46 to -1.67; 52 participants, 3 trials; I2 
= 0%). Further body mass analyses revealed no additional statistical effects in any other subgroup 
(Table 3.6). 
 
3.5.11. Waist and hip circumference and waist-to-hip ratio 
Seven trials reported waist circumference (WC) change values (Almenning et al., 2015; Roessler et 
al., 2013; Sá et al., 2015; Saremi et al., 2013; Turan et al., 2015; Vigorito et al., 2007; Vizza et al., 
2016), and when their findings were pooled (Table 3.3), a statistically significant beneficial effect of 
exercise compared with controls was revealed (MD: -2.62 cm, 95% CI: -4.13 to -1.11; 7 trials, 221 
participants, I2 = 53%). In contrast, there were no observed effects in the analysis for post-
intervention WC values. The favourable effect of exercise on WC change values remained when 
trials with a low risk of bias (MD: -1.51 cm, 95% CI: -2.26 to -0.76; 167 participants, 4 trials, I2 = 
0%), or with larger sample sizes (MD: -1.48 cm, 95% CI: -2.26 to -0.71; 120 participants, 2 trials, I2 
= 0%) were analysed separately in the sensitivity analysis. Furthermore, in the investigation of 
heterogeneity, when the largest study outlier (Sá et al., 2015) was removed from this analysis, the I2 
was reduced to 0%, whilst an effect remained (MD: -1.68 cm, 95% CI: -2.38 to -0.99). 
In subgroup analyses for WC change (Table 3.6), exercise had a statistically beneficial effect in 
studies involving participants with a BMI of 25-29.9 kg/m2 and ≥30 kg/m2 (MD: -2.21 cm, 95% CI: 
-4.25 to -0.16; 137 participants, 3 trials, I2 = 0%; and MD: -4.18 cm, 95% CI: -7.86 to -0.50; 54 
participants, 3 trials, I2 = 62%, respectively). Beneficial effects were also observed when 
interventions had a duration of ≤ 12 weeks (MD: -1.69 cm, 95% CI: -2.38 to -0.99; 180 participants, 
5 trials, I2 = 0%), were aerobic or resistance-based (MD: -3.30 cm, 95% CI: -6.10 to -0.51; 170 
participants, 5 trials, I2 = 50%; and MD: -2.40 cm, 95% CI: -4.04 to -0.75; 30 participants, 2 trials, I2 
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= 0%, respectively), and were supervised (MD: -3.21 cm, 95% CI: -5.56 to -0.85; 183 participants, 
5 trials, I2 = 64%). Subgroup analysis of post-intervention WC revealed statistically lower values in 
exercise interventions that involved aerobic exercise (MD: -2.22 cm, 95% CI: -3.56 to -0.87; 170 
participants, 5 trials, I2 = 0%), or were supervised (MD: -2.16 cm, 95% CI: -3.50 to -0.82; 183 
participants, 5 trials, I2 = 0%), and for those where participants had a BMI of 25-29.9 kg/m2 at study 
entry (MD: -2.02 cm, 95% CI: -3.39 to -0.65; 137 participants, 3 trials, I2 = 0%). 
Data from two trials (Stener-Victorin et al., 2009; Vigorito et al., 2007) were pooled in the analysis 
of waist-to-hip ratio (WHR); there was no effect in either change from baseline or post-intervention 
values analyses (Table 3.3).  
 
3.5.12. Body composition 
The pooled MD for change from baseline of body fat percentage (Table 3.3) showed a favourable 
statistical effect (MD: -1.39%, 95% CI: -2.61 to -0.18; 3 trials, 60 participants, I2 = 30%), but this 
was not apparent for comparison of post-intervention values (Almenning et al., 2015; Saremi et al., 
2013; Vizza et al., 2016). Trials that were judged to have a high risk of bias were removed, resulting 
in a disappearance of any statistical effect. There was an insufficient number of large studies for this 
sensitivity analysis to be performed. Moreover, no effect of exercise versus control for change from 
baseline, or post-intervention analysis was found for fat mass or fat-free mass outcomes (Table 3.3). 
A statistical effect of exercise was observed for body fat percentage change only in interventions 
lasting ≤ 12 weeks; the main analysis included only trials ≤ 12 weeks in duration (Table 3.3), meaning 
results of this sub analysis were identical. No other statistical effects were found across any of the 
other subgroup analyses on body fat percentage change (Table 3.6). However, body fat percentage 
was statistically lower post-intervention in exercise interventions that included participants with BMI 
of 25-29.9 kg/m2 (MD: -4.51%, 95% CI: -8.10 to -0.92; 47 participants, 2 trials, I2 = 0%), or that 
utilised aerobic exercise (MD: -4.99%, 95% CI: -8.73 to -1.25; 39 participants, 2 trials, I2 = 0%). 
There was no evidence of effect in the subgroup analyses for fat mass or fat-free mass. 
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3.5.13. Androgenic, hormonal, and inflammatory markers 
In pooled analyses of change from baseline and post-intervention values, no statistical effects (either 
beneficial or harmful) of exercise were found for any of the androgenic/hormonal and 
biomarkers/variables that are associated with inflammation [i.e., testosterone, free testosterone, FAI, 
SHBG, Ferriman-Gallwey scores, oestradiol, LH, FSH, LH/FSH ratio, progesterone, prolactin, high-
sensitivity C-reactive protein (hsCRP), anti-Mullerian hormone (AMH), or adiponectin] when 
compared with control (Table 3.3). Similarly, no statistical effects were observed for any subgroup 





Table 3.7. Summary of effect estimates and heterogeneity from sub-group analyses in androgenic and inflammatory related outcomes. 
 Change from baseline Post-intervention 
Outcome Sub-analysis Sub-group Trials 
(N) 













BMI at entry 25-29.9 kg/m2 3 (160) -0.11 (-0.27 to 0.05) 0 3 (126) -0.03 (-0.46 to 0.41) 68 
Intervention Aerobic exercise 3 (152) -0.10 (-0.27 to 0.06) 0 3 (118) -0.03 (-0.48 to 0.43) 60 
Resistance exercise 2 (30) 0.00 (-0.30 to 0.30) 0 2 (30) 0.04 (-0.29 to 0.36) 0 
Duration ≤12 weeks 4 (158) -0.02 (-0.23 to 0.19) 0 4 (158) -0.08 (-0.40 to 0.25) 50 
Format Supervised 2 (120) -0.10 (-0.41 to 0.21) 0 2 (120) -0.30 (-0.51 to -0.09) 0 






BMI at entry 25-29.9 kg/m2 3 (160) 11.16 (-8.39 to 30.71) 92 3 (126) 14.99 (-18.49 to 48.47) 0 
Intervention Aerobic exercise 3 (152) 9.49 (-13.77 to 32.76) 92 3 (118) 18.97 (-23.25 to 61.19) 69 
Resistance exercise 2 (30) 4.98 (-14.52 to 24.49) 68 2 (30) -0.79 (-45.26 to 43.67) 67 
Duration ≤12 weeks 3 (128) 2.45 (-1.04 to 5.93) 0 3 (128) -0.81 (-8.06 to 6.45) 22 
Format Mixed Delivery 2 (38) -3.23 (-14.91 to 8.46) 0 2 (38) 4.51 (-56.46 to 85.47) 89 
Free Androgen 
Index 
BMI at entry 25-29.9 kg/m2 3 (126) 0.09 (-0.78 to 0.96) 0 3 (126) 0.06 (-1.13 to 1.26) 10 
Intervention Aerobic exercise 3 (118) 0.51 (-0.52 to 1.53) 0 3 (118) 0.10 (-1.17 to 1.36) 10 
Resistance exercise 2 (30) -0.04 (-1.67 to 1.58) 57 2 (30) 1.71 (-3.65 to 7.08) 74 
Duration ≤12 weeks 3 (128) 0.11 (-0.71 to 0.93) 0 3 (128) 0.34 (-1.45 to 2.13) 50 
Format Mixed Delivery 2 (38) 1.79 (-3.18 to 6.76) 72 2 (38) 1.67 (-3.80 to 7.14) 75 
Oestradiol 
(pmol/L) 
BMI at entry 25-29.9 kg/m2 2 (135) -41.14 (-141.68 to 59.40) 70 - - - 
Intervention Aerobic exercise 3 (160) -47.22 (-117.52 to 23.08) 65 - - - 
Duration ≤12 weeks 3 (145) -1.14 (-36.61 to 34.33) 61 2 (120) 0.27 (-11.27 to 11.80) 0 




BMI at entry 25-29.9 kg/m2 3 (155) -1.12 (-3.63 to 1.39) 61 3 (121) 0.15 (-0.92 to 1.22) 0 
Intervention Aerobic exercise 3 (155) -1.12 (-3.63 to 1.39) 61 3 (121) 0.15 (-0.92 to 1.22) 0 
Duration ≤12 weeks 3 (140) -0.59 (-3.24 to 2.06) 81 3 (140) -1.60 (-4.73 to 1.54) 62 





BMI at entry 25-29.9 kg/m2 3 (155) 0.09 (-0.35 to 0.52) 0 3 (121) 0.11 (-0.35 to 0.56) 0 
Intervention Aerobic exercise 3 (155) 0.09 (-0.35 to 0.52) 0 3 (121) 0.11 (-0.35 to 0.56) 0 
Duration ≤12 weeks 3 (140) 0.19 (-0.13 to 0.51) 0 3 (140) -0.03 (-0.42 to 0.37) 0 
Format Supervised 3 (140) 0.19 (-0.13 to 0.51) 0 3 (140) -0.03 (-0.42 to 0.37) 0 
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Key: Outcome: outcome where sub-analysis was completed. Sub-analysis: how the studies were categorised for analysis; BMI at entry: mean baseline BMI of participants; 
Intervention: type of intervention; Duration: length of exercise intervention; Format: delivery mode of intervention. Sub-group: groups each study was classified into. Trials: 
number of studies included within sub-analysis, N: number or participants included within sub-analysis. Effect estimates are reported as mean difference (MD), and 95% 
confidence intervals, between exercise and control groups. Significant evidence of effect denoted by: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001. Heterogeneity reported using I2 
statistic: 0-40% might not be important; 30-60% may represent moderate heterogeneity; 50-90% may represent substantial heterogeneity; 75-100% may represent considerable 
heterogeneity. ▲: positive values favour exercise over control.; SHBG: sex hormone-binding globulin.   
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3.5.14. Psychosocial Outcomes 
In two trials (57 participants) that assessed psychosocial outcomes using the PCOS-Q, we found no 
effect of exercise on any PCOS-Q domain compared with control. Three trials (84 participants) used 
the SF-36 (Sá et al., 2015; Stener-Victorin et al., 2009; Vizza et al., 2016). Data only allowed for 
change from baseline analysis and no sub-analysis was possible. For SF-36 domains, a favourable 
effect of exercise versus control was found for physical functioning (MD: 11.81, 95% CI: 2.36 to 
21.25; I2 = 74%), general health (MD: 10.05, 95% CI: 3.89 to 16.20; I2 = 0%), social functioning 
(MD: 11.75, 95% CI: 2.56 to 20.95; I2 = 6%), and mental health (MD: 11.70, 95% CI: 1.27 to 22.13; 
I2 = 47%) domains (Figure 3.9). When the change values for SF-36 total score (i.e. all domain scores 
combined) were analysed, a statistical effect was evident (MD: 7.78, 95% CI: 4.41 to 11.14; I2 = 
50%). 
There were insufficient data to complete sensitivity analyses; however, all three trials were judged 
to have a high risk of bias in at least one domain (Figure 3.9), and only one trial had a sample size ≥ 
30 (Vizza et al., 2016). Heterogeneity was investigated in the physical functioning domain; the 
largest outlier was removed (Sá et al., 2015) and the I2 was reduced to 33%, whilst an effect was 
maintained (MD: 7.23, 95% CI: 1.66 to 12.80). The same trial was removed in the general health 
analysis, resulting in a reduction in I2 to 0%, and a preserved effect (MD: 7.97, 95% CI: 1.07 to 4.88). 
When the greatest outliers were removed from the social functioning (Vizza et al., 2016) and mental 
health (Stener-Victorin et al., 2009) domains, both I2 values were reduced to 0%, but the effect only 
remained in the mental health domain (MD: 17.84, 95% CI: 7.33 to 28.36).  
 
3.5.15. Additional Outcomes  
Six trials (Almenning et al., 2015; Sá et al., 2015; Stener-Victorin et al., 2009; Turan et al., 2015; 
Vigorito et al., 2007; Vizza et al., 2016) also reported a range of additional outcomes; these outcomes 
were unique to these studies and so they could not be included in the meta-analysis. Key findings 










Table 3.8. Exercise versus control: summary of findings regarding study outcomes that were reported only by a corresponding single trial. 
Trial Statistical significance Outcomes 
Almenning et al., 2015 No statistically significant 
findings 
HR recovery; Leptin 
Statistically significant 
findings 
➢ Nitric oxide bio-availability [as measured by FMD %] - reported a statistically significant improvement 
in FMD following a HIIT intervention, but not resistance training 
➢ Homocysteine – significant change from baseline concentrations (MD: -0.6 µmol/L, 95% CI: -1.0 to -
0.1) following a HIIT intervention, but no between group differences 
Sá et al., 2015 No statistically significant 
findings 




➢ Mean arterial blood pressure; a statistical reduction in the exercise group (MD: -6.8 mmHg, 95% CI: -
10.6 to -3.0; 14 participants) and a significant time by group interaction, representative of a moderate 
effect size (d) was also reported (d: -1.0; 95% CI: -1.7 to -0.3) 
Stener-Victorin et al., 
2009 
No statistically significant 
findings 
➢ Number of participants with acne; menstrual frequency; 5α-dihydrotestosterone; estrone; DHEA; 
androstenedione; 5-androstene-3β, 17β-diol, androsterone glucuronide; androstane-3α, 17β-diol-3 
glucuronide; 17β-diol-17 glucuronide; insulin growth factor-1; thyroid stimulating hormone; free 
thyroxin 4; fibrinogen; fibrin ᴅ-dimer; von Willebrand factor; factor VIII; tissue plasminogen activator 
and plasminogen activator inhibitor; ovarian volume; Montgomery Asberg Depression Rating Scale 
and the Brief Scale for Anxiety 
Statistically significant 
findings 
➢ Estrone sulfate (E1-S) was significantly lower (P <.05) in the exercise group versus control when 
measured immediately post-intervention; this effect disappeared during follow-up assessment 
➢ Median antral follicle counts were significantly lower (-11.7%; P = .010) from baseline to follow-up in 
the exercise group 
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Trial Statistical significance Outcomes 
Turan et al., 2015 Statistically significant 
findings 
➢ Respiratory rate: significant within group changes in respiratory rate (-1.0±0.4 breaths/minute) 
following exercise, but no between group differences. 
➢ Hip circumference: a statistically significant (P <.05) reduction following exercise training, and a 
statistical difference (P <.05) between change values in each arm 
Vigorito et al., 2007 No statistically significant 
findings 
➢ Respiratory exchange ratio; Peak HR 
Statistically significant 
findings 
➢ AUC-insulin and AUC-glucose to AUC-insulin ratio: a statistically significant change from baseline 
for AUC-insulin and the ratio with AUC-glucose in the exercise group but not in the control. AUC-
insulin significantly improved (P <.001) compared to the control group 
➢ VO2 at anaerobic threshold: within and between group statistical changes for VO2 at anaerobic threshold 
(MD: 4.4 ml/kg/min; P <.001) 
➢ Maximum workload: within and between group statistical changes (MD: 32.3 Watts; P <.001) 
➢ Ventilatory equivalent for carbon dioxide production: only within group changes were reported 
(VE/VCO2: MD: -0.6; P = .01) 
➢ Participant leisure time physical activity (MET-hrs/wk): significantly higher (P <.001) following an 
exercise intervention 
Vizza et al., 2016 Statistically significant 
findings 
➢ Glycated haemoglobin (HbA1c): Resistance training statistically reduced (P = .037) within group 
HbA1c, and when compared with control (P = .03, d= 0.39). 
➢ Lower, but not upper, body strength was significantly increased (P = .04) following a resistance training 
intervention; it was also significantly improved compared to a control (ES: 0.45; P = .03) 
➢ Depression, Anxiety and Stress Scale 21 (DASS-21): the depression domain showed within group (P = 
.05) and between group (ES: 0.50; P = .01) reductions following resistance training 
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Trial Statistical significance Outcomes 
➢ Exercise Self Efficacy Scale: a statistically significant reduction (P = .04) of self-efficacy within the 
control group, but no changes in the exercise groups or differences between groups 
Key: HR: heart rate; FMD: flow mediated dilation; HIIT: high-intensity interval training; MD: mean difference; DHEA: dehydroepiandrosterone; AUC: area under the curve; 
VO2: volume of oxygen; VE/VCO2: minute ventilation/carbon dioxide production; MET: metabolic equivalent of task  
146 
 
3.6. Effects of interventions: exercise and diet vs. control 
Three included trials made the comparison of exercise and diet combined against a control/usual care 
group. Only one of these trials used a control group that was described as no treatment (Guzick et 
al., 1994), whereas the other two (Hoeger et al., 2004; Petrányi and Zaoura-Petrányi, 2011) compared 
exercise, diet and metformin (or placebo) to metformin only groups. As the pharmacological 
component of the intervention was present in each treatment arm, the assumption was made that any 
between group variations were attributable to the exercise and dietary components.  
Due to insufficient data, only two outcomes (WHR and SHBG) were eligible to be included in the 
meta-analysis. Meta-analysis of the two trials (68 participants) reporting change from baseline to 
post-intervention WHR values (Guzick et al., 1994; Petrányi and Zaoura-Petrányi, 2011) revealed a 
small statistical favourable effect of exercise and diet (MD: -0.02, 95% CI: -0.03 to -0.01; I2 = 0%) 
compared to control (Figure 3.10). The effect was not replicated in the comparison of post-
intervention values. 
Furthermore, no effect of exercise and diet combined versus control was found for the change from 
baseline to post-intervention circulating SHBG levels. There were insufficient data to complete 
analysis of post-intervention values or subgroups. A range of individual outcomes were also reported 














Table 3.9.  Combined exercise and diet versus control: summary of findings from investigative outcomes that were reported only in single trials. 
Trial Statistical significance Outcomes 
Guzick et al., 1994 No statistically significant 
findings 
➢ Fasting insulin; luteinising hormone; follicle stimulating hormone. 
Statistically significant 
findings 
➢ Body weight: statistical interaction effect (P <.0001) reflecting an improvement following combined 
exercise and diet intervention, but not control 
➢ Free testosterone: statistical interaction effect (P =.02) following a combined exercise and diet 
intervention, but not control 
Hoeger et al., 2004 No statistically significant 
findings 
➢ Free androgen index; AUC-glucose; AUC-insulin; fasting blood glucose; ovulatory status 
Statistically significant 
findings 
➢ Body weight: statistically significant (P <.05) within-group body weight reductions for lifestyle and 
placebo, but no statistical differences versus placebo alone 
➢ When lifestyle was combined with Metformin, statistical differences (P <.05) compared to placebo only 
were reported for body weight, SHBG and FAI 
Petrányi et al., 2011 Statistically significant 
findings 
➢ Statistically significant (P <.001) reductions in levels of acne, FG scores and BMI following lifestyle 
and Metformin therapy; changes in the Metformin only arm were comparable apart for that for BMI, 
which was statistically higher in the combined treatment (P = .03) 
Key: AUC: area under the curve; SHBG: sex hormone binding globulin; FAI: free androgen index; FG: Ferriman-Gallwey; BMI: body mass index 
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3.7. Effects of interventions: exercise and diet vs. diet 
Three trials had intervention arms that compared the combination of exercise and diet to diet only 
(Bruner et al., 2006; Nybacka et al., 2011; Thomson et al., 2008). For any assessed primary outcome 
(Table 3.10: FBG, FI, and HOMA-IR; all very low-quality evidence) or secondary outcome (body 
weight, BMI, WC, body fat, fat-free mass, testosterone, SHBG and FAI) of these studies, analyses 
of change from baseline and post-intervention values (Table 3.11) revealed no statistical difference 
between the two interventions (combined exercise and diet vs diet only). Furthermore, there were 
insufficient data to complete subgroup analyses within this comparison. 
All these three included trials reported a range of other outcomes which were not eligible to be 













Table 3.10. Summary of findings for primary outcomes: exercise and diet versus diet only. 
Intervention: Exercise and diet; Comparison: Diet  
Outcomes Anticipated absolute effects* (95% CI)  № of participants  
(№ of studies)  
Certainty of the evidence 
(GRADE)  
Comments 
Risk with Diet Risk with exercise and diet 
Fasting blood glucose (change from 
baseline) 
follow up: range 16 weeks to 20 
weeks  
The mean fasting blood glucose 
(change from baseline) ranged from -
7.0 to -3.2 mg/dL  
The mean fasting blood glucose (change 
from baseline) in the intervention group 
was 2.92 mg/dL higher (0.4 lower to 6.23 
higher)  
78 
(2 RCTs)  
⨁◯◯◯ 
VERY LOW a,b 
We are uncertain about the effect of 
exercise and diet on fasting blood 
glucose (change from baseline).  
Fasting insulin (change from 
baseline) 
follow up: range 12 weeks to 20 
weeks  
The mean fasting insulin (change 
from baseline) ranged from -2.9 to -
18.54 μU/ml  
The mean fasting insulin (change from 
baseline) in the intervention group was 
2.22 μU/ml higher (3.7 lower to 8.14 
higher)  
90 
(3 RCTs)  
⨁◯◯◯ 
VERY LOW a,c,d 
We are uncertain about the effect of 
exercise and diet on fasting insulin 
(change from baseline).  
HOMA-IR (change from baseline) 
follow up: range 16 weeks to 20 
weeks  
The mean HOMA-IR (change from 
baseline) ranged from -0.74 to -0.56  
The mean HOMA-IR (change from 
baseline) in the intervention group was 
0.01 lower (0.45 lower to 0.43 higher)  
78 
(2 RCTs)  
⨁◯◯◯ 
VERY LOW a,b 
We are uncertain about the effect of 
exercise and diet on HOMA-IR 
(change from baseline).  
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; MD: Mean difference  
GRADE Working Group grades of evidence 
➢ High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
➢ Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
➢ Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
➢ Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a) All trials were at an unclear risk of selection bias, reporting bias, contamination, and adherence issues. All trials were at a high risk of detection bias and attrition bias. Therefore, we downgraded by one level.  
b) Small number of participants, only two trials, and wide confidence intervals in the included trials. Therefore, we downgraded by two levels.  
c) Substantial heterogeneity was observed. Therefore, we downgraded by one level.  





Table 3.11. Effect estimates and heterogeneity for change from baseline to immediately post-intervention, and immediately post-intervention values only, for 
all outcomes analysed in the comparison between combined exercise and diet versus diet only. 
 Change from baseline Immediately post-intervention 
Outcome Trials N MD 95% CI I2 (%) Trials N MD 95% CI I2 (%) 
Lower Upper     Lower Upper  
FBG (mg/dL) 2 78 2.92 -0.40 6.23 42 2 78 2.86 -1.56 7.29 0 
FI (µIU/mL) 3 90 2.22 -3.70 8.14 62 2 64 -2.72 -7.70 2.27 0 
HOMA-IR 2 78 -0.01 -0.45 0.43 0 - - - - - - 
Body Weight (kg) 2 64 -0.40 -3.64 2.83 0 2 64 1.49 -8.05 11.03 0 
BMI (kg/m2) 2 38 -0.09 -1.27 1.09 0 2 38 2.56 -1.77 6.88 0 
WC (cm) 2 64 -0.47 -3.95 3.01 0 2 64 -1.51 -8.69 5.67 0 
Body Fat (%) 2 78 -1.05 -4.61 2.50 85 2 78 -0.93 -3.63 1.77 10 
FFM (kg) ▲ 2 78 0.40 -3.24 4.03 85 2 78 2.07 -1.72 5.86 0 
Testosterone (nmol/L) 3 90 0.29 -0.49 1.08 78 3 90 0.08 -0.38 0.54 0 
SHBG (nmol/L) ▲ 3 90 2.18 -3.15 7.51 51 3 90 6.45 -5.52 18.42 61 
FAI 2 64 0.11 -2.28 2.50 0 2 64 -2.88 -6.58 0.81 0 
Key: Negative values favour exercise and diet combined except where stated otherwise. ▲: positive values favour exercise and diet combined over diet only. Trials: number of 
studies included within analysis, N: number or participants included within analysis. Effect estimates are reported as mean differences (MD), and 95% confidence intervals 
(CI), between exercise and diet combined vs diet only groups. Heterogeneity reported using I2 statistic. FBG: fasting blood glucose; FI: fasting insulin; HOMA-IR: homeostatic 









Table 3.12. Combined exercise and diet versus diet: summary of findings from study outcomes that were reported only in single trials. 
Trial Statistical significance Outcomes 
Bruner et al., 2006  No statistically significant 
findings 
➢ Resting energy expenditure; LH/FSH ratio; number of ovarian follicles (left and right) 
Statistically significant 
findings 
➢ Sum of two skinfolds (subscapular and iliac crest): statistically lower than at baseline and a group x 
time interaction (P= .002) immediately post-intervention with a greater decrease in the combined 
exercise and diet group compared with the diet only group 
Nybacka et al., 2011  No statistically significant 
findings 
➢ No significant changes seen in any intervention arm for ratio of upper/lower body fat. No effect seen in 
upper body fat (kg) for diet only or diet and exercise combined; no reduction in lower body fat for the 
exercise only arm 
➢ Exercise and diet combined did not significantly reduce IGF-I or IGFBP-1 
Statistically significant 
findings 
➢ In the diet only arm statistical changes in free testosterone (-3.66 pg/mL, 95% CI: -6.12 to -1.20; P 
<.001), AMH (P <.01), IGF-1 (17.1 µg/L, 95% CI: 0.3 to 33.9; P <.05), and IGFBP-1 (0.32 µg/L, 95% 
CI: 0.01 to 0.64; P <.05) were reported that were not present in the combined diet and exercise arm 
➢ There were statistically significant reductions in: lower body fat for the diet only arm (-1055g, 95% CI: 
-1787 to -322; P <.01) and the combined diet and exercise arm (1616g, 95% CI: -2407 to -825; P <.001); 
lean body mass only in the combined diet and exercise arm (-2.66kg, 95% CI: -4.14 to -1.18; P <.001); 
mean ovarian follicle number in both diet only (P <.05) and the combined arm (P <.05); as well as 
improvements to ovulatory function in both intervention arms (diet: P <.001; combined: P <.05) 
➢ Mean ovarian volume was reduced only in the combined diet and exercise arm (P <.05) 
Thomson et al., 2008  No statistically significant 
findings 
The Centre of Epidemiologic Studies Depression Scale was also used, but there were no differences in 
post-intervention scores compared to baseline 
Statistically significant 
findings 
➢ Statistically significant reductions (P ≤.03) to fat mass and abdominal fat mass in all groups; both 
exercise arms were also statistically different (P ≤.03) to the diet only arm. 
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Trial Statistical significance Outcomes 
➢ Levels of endothelial function were also measured; vascular cell adhesion molecule-I (P= .01), 
plasminogen activator inhibitor-I (P <.001) and intra-cellular adhesion molecule-I (P <.001) were 
reduced in all treatment arms with no statistical differences between treatments  
➢ PCOS-Q was used to assess quality of life, showing statistical improvements (P ≤.001) across all 
treatment arms in each domain apart from body hair scores, while no differences were found between 
treatment arms 
Key: LH/FSH: luteinising hormone/follicle stimulating hormone; IGF-1: insulin-like growth factor-1; IGFBP-1; insulin-like growth factor binding protein-1; AMH: anti-
Müllerian hormone; PCOS-Q; polycystic ovary syndrome questionnaire. 
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3.8. Effects of interventions: Exercise vs. diet, and exercise and diet vs exercise.  
A relevant meta-analysis was not possible as only one trial (Nybacka et al., 2011) compared exercise 
with diet, and exercise combined with diet to exercise alone. Effects from this study for the diet only 
and combined diet and exercise groups have been reported in Section 3.6 and in Table 3.12. In 
addition to these findings, the exercise only intervention reduced BMI (-0.85 kg/m2, 95% CI: -1.69 
to -0.02; P <.05), but the magnitude of these changes was smaller than those seen in the other 
treatment arms (i.e. diet only, or combined diet and exercise). Upper body fat was statistically 
reduced only in the exercise group (-1.57 kg, 95% CI: -2.86 to -0.28; P <.05) and also, mean follicle 
number exhibited the greatest improvement in the exercise only group (P <.01). There were no 
within-group effects reported for body fat (%), lower body fat (kg), lean body mass, free testosterone, 
insulin-like growth factor-1, insulin-like growth factor binding protein-1, FBG, FI, HOMA-IR, LH, 


















3.9.1. Summary of Main Results 
The current systematic review and meta-analysis provides up-to-date analyses of the existing 
published evidence regarding the impact of exercise interventions in the management of PCOS. The 
present analyses identified a marked paucity of well-designed, long-term and large studies in this 
field, whilst the existing evidence, albeit of low quality, suggests that incorporation of exercise 
interventions in the management of PCOS may result in relatively small benefits in certain PCOS 
patient groups and with certain interventions. Indeed, when exercise interventions were compared to 
a no-intervention/usual care control group, there were statistically beneficial effects observed for 
both change from baseline to immediately post-intervention and comparison of immediately post-
intervention values, for fasting insulin, total cholesterol, LDL-C, and VO2 max. The clinical 
relevance of these changes is unclear. Furthermore, there were statistically favourable changes from 
baseline (but not post-intervention comparison) for HOMA-IR, triglycerides, waist circumference, 
and body fat percentage, as well as statistically lower post-intervention values for BMI and resting 
heart rate. Whether such changes translate to clinically meaningful benefit for the long-term cardio-
metabolic risk of women with PCOS (particularly for different PCOS phenotypes) remains to be 
studied in long-term prospective trials. Moreover, although the analysis comparing exercise and diet 
to a control incorporated few outcomes and a limited number of studies, there was a small statistical 
effect in favour of exercise and diet for waist-hip-ratio. In the combined exercise and diet versus diet 
only comparison, there was no evidence of intervention effect for any included outcome, but again 
there were strikingly scant data available. Indeed, only one study made the remaining comparisons 
(i.e. exercise versus diet, and exercise combined with diet versus exercise only) and, whilst there are 
some beneficial effects reported, it is difficult to draw meaningful conclusions from a single trial. 
3.9.2. Primary Outcomes     
A small beneficial change in SBP from baseline to post-intervention was observed with supervised 
exercise interventions versus control. Searches of existing literature suggest that this is the first 
systematic review to report on the effects of exercise on blood pressure in women with PCOS. A 
156 
 
previous study in the general population provides evidence suggesting that it is aerobic exercise 
interventions which induce the greatest improvements to blood pressure (both SBP and DBP) in 
hypertensive participants (Cornelissen and Smart, 2013), and that there are less marked effects in 
normotensive participants (i.e., small decreases in DBP and no effect on SBP). The mean SBP (116 
mmHg) and DBP (73 mmHg) values in the current systematic review indicate that most enrolled 
women with PCOS in the included studies were normotensive at baseline, which explain, at least 
partly, why a larger beneficial effect was not observed.   
When surrogate markers of insulin resistance (FI and HOMA-IR) were considered, statistically 
beneficial changes from baseline (FI and HOMA-IR), and more favourable post-intervention values 
(FI) for exercise compared with control were observed. Subgroup analyses were also indicative that 
the greatest improvements appeared in women with PCOS and BMI ≥ 25.0 kg/m2, and from 
interventions which were supervised, aerobic-based and shorter in duration. These findings are 
partially supported by two previous systematic reviews (Domecq et al., 2013; Moran et al., 2011); 
however, these reviews did not make the distinction between exercise, diet or a combination of the 
two, but instead indiscriminately combined these three terms under the heading ‘lifestyle 
interventions’ which was compared to a control group. The more recent of these systematic reviews 
(Domecq et al., 2013) reported a small, but statistically significant effect on FI change from baseline 
(MD: -2.1 µIU/mL, 95% CI: -3.3 to -1.0; 5 trials, I2 = 0%). The other review (Moran et al., 2011) 
compared post-intervention FI values and reported that lifestyle interventions induced decreased FI 
values compared to control (MD: -2.02 µIU/mL, 95% CI: -3.28 to -0.77; 144 participants, 5 trials, I2 
= 0%). These previous findings have been expanded upon in the current meta-analysis because a 
greater number of trials and participants have been included and also by separating exercise only 
trials. What this has shown is that, based on the best available data, exercise alone has a comparable 
effect to that of lifestyle interventions, but the degree of benefit is likely trivial. 
Although IR is not currently included within the PCOS diagnostic criteria, it is widely acknowledged 
to have a key role in the pathophysiology of PCOS (Iuorno, 2007). It has been reported that 
approximately 50-70% of women with PCOS have been diagnosed with IR and hyperinsulinaemia 
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(Marin et al., 2003), whereas many also present evidence of glucose intolerance (Ng et al., 2019). 
Alongside the potential metabolic implications, hyperinsulinaemia in PCOS also promotes further 
secretion of androgens from the ovarian theca cells, whilst also supressing hepatic SHBG secretion, 
which causes an increase in free androgens and further exacerbates the associated symptoms (Zhang 
et al., 2018). Despite the integral role of IR in PCOS, there is scant information for FI reference 
values in the literature (Chevenne et al., 1999). One historic study (Boyns et al., 1969) reported FI 
levels ranging from 2-60 µIU/mL in a sample of 111 healthy women, and a mean value of 17.6 ± 5.7 
µIU/mL in a subset of those women aged 25-34 years (n = 22). For women with PCOS, a large-scale 
case-control study of 1404 women with PCOS reported mean FI levels of 14.3 ± 1.6 µIU/mL, which 
was significantly higher than healthy controls (Zhang et al., 2013). The mean baseline FI level of all 
intervention participants in the current systematic review was 16.21 µIU/mL, and a reduction of 
~13% was reported following exercise interventions. Although statistical effects are reported in the 
current review, it is unclear whether these exercise-induced reductions are clinically meaningful 
because there is marked variability of normative FI values in PCOS. 
Although FI correlates with IR, especially in normoglycemic populations (Olefsky et al., 1973; 
Philips et al., 1994) it has been shown that HOMA-IR [fasting glucose (nmol/L) * fasting insulin 
(µU/mL) / 22.5]; Matthews et al., 1985) may be a better estimate of insulin sensitivity (Emoto et al., 
1999). In the current review, the mean baseline HOMA-IR values for intervention-group participants 
was 2.99, which dropped to 2.43 (MD: -0.57) following exercise, with no corresponding reduction 
in control groups. A generally adopted HOMA-IR cut-off value for the identification of IR is 2.6 
(Ascaso et al., 2003). This implies that exercise may have a significant effect on IR compared with 
usual care, which may result in less required insulin levels to maintain normoglycemia. Conversely, 
no statistical or clinical effect of exercise was observed for FBG; however, participants were within 
normal FBG at baseline.  
In contrast to previous reviews (Moran et al., 2011; Haqq et al., 2015), an effect of exercise on 
lipidemic profiles was observed in the current systematic review. When compared to control, there 
were improvements in exercise-induced changes for circulating levels of total cholesterol, LDL-C 
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and triglycerides. Based on data included in this systematic review, the mean baseline values for total 
cholesterol (233 mg/dL) and LDL-C (142 mg/dL) are classified as borderline high or elevated in the 
presence of concomitant CVD risk factors (National Cholesterol Education Program, 1993). Post-
intervention values for LDL-C were lower for exercise compared to control, but total cholesterol 
levels were comparable (approximately 229 mg/dL in both).  LDL-C plays a key role in 
atherogenesis; the risk of coronary heart disease (CHD) progressively increases as LDL plasma levels 
increase (Sniderman et al., 1997). Conversely, there is an inverse association between HDL-C and 
both atherosclerosis severity and CHD risk, with HDL-C levels ≥60 mg/dL having a potentially 
protective effect against CHD (National Institutes of Health Consensus Development Panel, 1993). 
Within this systematic review, baseline and post-intervention HDL-C values were >60 mg/dL, which 
may partially explain why there was no observed effect of exercise. However, in the current 
systematic review, total cholesterol and LDL-C levels were elevated at baseline, and there is evidence 
of a statistical effect following exercise, but the magnitude of the observed changes may not be 
clinically important (Puska, 2010; Wadhera et al., 2016).  
For the present analysis on the effect on circulating triglyceride levels, mean baseline concentrations 
were higher in the exercise group (+11 mg/dL) compared with control, although both groups were 
within a range that would be considered as normal (<150 mg/dL). That said, exercise statistically 
reduced triglyceride levels, but the comparison of post-intervention values revealed that 
concentrations were still lower in the control group. Triglycerides are independent predictors of CVD 
mortality in women (Bass et al., 1993); however, in the present systematic review the magnitude of 
exercise-induced triglyceride reduction within the reported range is unlikely to be clinically 
important. Future research should aim to investigate the independent effect of exercise in women 
(with and without PCOS) with hypertriglyceridaemia. 
 
3.9.3. Secondary Outcomes 
A statistically significant and potentially clinically important effect was observed for VO2 max (>3.5 
ml/kg/min) when exercise was compared to control (Lakoski et al., 2015) but this may be in part due 
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to weight loss. Subgroup analyses revealed that aerobic exercise, regardless of other all other 
assessed variables, improved VO2 max in women with PCOS.  
Low cardiorespiratory fitness, as measured by VO2 max, is often associated with an increased risk 
of chronic disease and all-cause mortality (Blair et al., 1989; Kodama et al., 2009). Whilst reductions 
in cardiorespiratory fitness occur physiologically with age, being physically inactive may also 
contribute to a lower VO2 max. The consequences of reduced cardiorespiratory fitness include 
impaired capability to exercise, reduced ability to perform activities of daily living, as well as lower 
overall quality of life (Donà et al., 2017). Because of this, cardiorespiratory fitness improvement is 
a goal of many lifestyle interventions, although this is often overlooked in PCOS. Studies assessing 
patient VO2 max in this female patient population are limited; one study in overweight (Orio et al., 
2006), and another in lean (Bacchi et al., 2015) women with PCOS reveal markedly lower 
cardiorespiratory fitness than healthy controls. Only one previous systematic review of 
exercise/lifestyle and women with PCOS report on VO2 max/peak (Haqq et al., 2015), reporting 
improvements for both lifestyle (i.e. exercise and diet combined; MD: 5.09 ml/kg/min, 95% CI: 3.13 
to 7.05, 3 trials, 137 participants) and exercise only (MD: 4.86 ml/kg/min, 95% CI: 2.83 to 6.88, 2 
trials, 125 participants) interventions when compared with usual care. Although we noted a 
marginally smaller effect, the agreement between these results and the findings of the analysis of 
relative VO2 max changes in the current systematic review, which combined data from 92 more 
participants than the review by Haqq et al. (2015), suggests that exercise has the potential to improve 
cardiorespiratory fitness in women with PCOS.   
In addition, the current systematic review found slight reductions in WC and body fat percentage in 
the exercise groups, suggesting that exercise may stimulate small favourable changes to body 
composition in women with PCOS. As a measure of central/abdominal obesity, WC is reportedly a 
better independent predictor of obesity-related disorders than BMI (Lean et al., 1995). This is 
potentially attributed, at least in part, to the pivotal role that central adiposity plays in the 
development of IR and T2DM, even in those with normal BMI (Gómez‐Ambrosi et al., 2011). 
However, despite statistical significance, the exercise-induced WC changes observed in this 
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systematic review may have questionable clinical relevance because the observed average reduction 
from baseline was 2.8% (95% CI: 1.31 to 4.24), which is less than the suggested 3-5% reduction 
considered as clinically significant (Verweij et al., 2013). Findings for body fat (%) are similar; 
despite modest change from baseline improvements, there were no difference between those 
completing exercise interventions or controls. 
A previous systematic review reported improvements to anthropometric outcomes (Haqq et al., 
2015), but the basis of these compared lifestyle modification, as opposed to exercise, with a control 
group. In addition to this, when comparing lifestyle interventions to control, another review (Moran 
et al., 2011) reported statistical improvements in body mass and abdominal adiposity. In the current 
systematic review, exercise and diet interventions were compared to diet alone and both groups 
demonstrated favourable changes; however, there was no evidence of an effect in favour of either 
intervention for any of these outcomes. 
There was no evidence of a statistical effect of exercise on the androgenic profile of included 
participants when compared with control. Similarly, where such analyses were possible, there was 
no evidence of effect favouring either diet and exercise combined or diet only. This was further 
supported by subgroup analyses where the evidence of relevant effects was minimal. To investigate 
these findings, the baseline values of women with PCOS included in this current review were 
considered; typically, hormonal concentrations were below recommended cut-offs for diagnosing 
hyperandrogenism [testosterone >2.5 nmol/L and SHBG <30 nmol/L (Vanky et al., 2004)], which 
suggests that the included participants were not markedly hyperandrogenic. In contrast to the present 
study, Moran et al. (2011) did observe a testosterone reduction following lifestyle interventions, but 
no effects upon FAI (100 x total testosterone/SHBG), which is often considered a more valid marker 
of hyperandrogenism (ESHRE/ASRM, 2004). Previous studies have investigated the effects of 
exercise on androgens in the general population, Indeed, a review of exercise-induced changes on 
the androgenic profile of premenopausal healthy women reporting that exercise invoked an acute 
increase to circulating androgens (Enea et al., 2011), but the longer-term effects are less clear. 
Another meta-analysis investigated the chronic androgenic responses which were attributable to 
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exercise and reported a statistical reduction in concentrations of bioavailable testosterone (MD: -0.18 
pg/mL, 95% CI: -0.29 to -0.07; 1369 participants, 9 trials, I2 = 0%), as well as increased SHBG (MD: 
3.93 nmol/L, 95% CI: 0.98 to 6.87; 1643 participants, 14 trials, I2 = 75%) following participation in 
an exercise regime in healthy women (Ennour-Idrissi et al., 2015). Collectively, these data suggest 
that exercise interventions may play a role in the regulation of androgenic profiles. However, the 
optimal dose is unclear and, potentially, there could be an unquantifiable variation to responses in 
women with menstrual disruption (Tworoger et al., 2007). 
Finally, although there appears to be an increasing recognition of the deleterious effects of PCOS on 
HRQoL and other psychosocial components, only three of the included trials measured these 
outcomes in the comparison of exercise versus control. Although there was no evidence of effect in 
any of the PCOS-Q domains, scores in four domains of the SF-36, namely physical functioning, 
general health, social functioning and mental health, were all statistically improved following 
exercise compared to control. The meta-analysis revealed improvements of ≥10% in these four 
domains for exercise, supporting the notion that exercise in these patients may improve their 
perception of physical and mental wellbeing. 
 
3.9.4. Overall completeness and applicability of evidence 
A comprehensive and systematic search of relevant electronic databases, and the reference lists from 
included publications and relevant reviews was completed. From this search,16 RCTs, one quasi-
RCT, and one randomised crossover trial were identified. The applied review process located and 
combined data from more trials, made a greater number of comparisons and included a wider range 
of outcomes when compared to previous systematic reviews (Harrison et al., 2011; Domecq et al., 
2013; Moran et al., 2011; Haqq et al., 2015). At the time of writing, this was the first time data from 
10 of the trials included in this systematic review have been meta-analysed (Almenning, et al., 2015; 
Konopka et al., 2015; Nasrekani et al., 2016; Petrányi and Zaoura-Petrányi, 2011; Roessler et al., 
2013; Sá et al., 2015; Saremi et al., 2013; Saremi and Yaghoubi, 2016; Turan et al., 2015; Vizza et 
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al., 2016), which suggests that this may be the most comprehensive and up-to-date systematic review 
on the topic of exercise in the management of women with PCOS.  
Despite this, it must be noted that there are certain limitations to the studies included in this 
systematic review, which reflect the overall low quality of the relevant existing data. As such, it is 
likely that many of the included trials did not have sufficient statistical power to detect meaningful 
differences between study groups. In fact, only seven of the included trials stated the methods 
employed to calculate their target sample size. Due to small participant numbers (e.g., median: 
exercise n = 11; control n = 12) in these studies, it is unlikely that sufficient statistical power was 
achieved to make findings applicable to the general population, or to ensure that false 
positive/negative results were not reported. Therefore, it is important that future trials are sufficiently 
powered to detect changes in (at least) their primary outcomes. 
Moreover, PCOS is a heterogeneous condition that is categorised by a range of phenotypes; the 
respective phenotypic subgroups may present varying levels of hyperandrogenism, menstrual 
disruption and polycystic ovarian morphology (Kyrou et al., 2014). Because of this, it can be 
assumed that each phenotype will respond differently to exercise and/or dietary interventions. Of the 
included trials, most did not target a specific PCOS phenotype, and in addition, the pre-defined 
review protocol specified that studies were eligible for inclusion as long as they defined their 
participants based on any of the existing PCOS definitions and/or diagnostic criteria. It would be 
beneficial for future studies to specify PCOS subgroups/phenotypes of their participants and 
investigate the phenotypic exercise-induced effects accordingly. Another concern surrounds the 
representativeness of the cohorts included in the studies which were included in this systematic 
review; it is unclear whether the ethnicity, socio-economic or educational status of included 
participants is a true representation of typical patients with PCOS, or whether these variables have 
influenced the observed (or unobserved) effects.   
Finally, all included trials reported baseline and immediately post-intervention data, but only one 
trial (Stener-Victorin et al., 2009) completed follow-up beyond the end of the intervention. 
Therefore, based on the existing data, it is difficult to assess the lasting, long-term effects of exercise 
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(or exercise and diet) for women with PCOS. Hence, future research should attempt to determine 
whether behaviours relating to PA are changed (i.e., are patients able to maintain PA levels beyond 
study end) in this patient population, and whether the observed physical and physiological effects 
remain beyond the short-term.  
 
3.9.5. Quality of the evidence 
As outlined in the methods (Section 2.1.3), due to the general nature of exercise interventions, all 
included trials were deemed to have a high risk of performance bias, but the quality of the evidence 
was not downgraded based on this alone. All included trials, but one (Vigorito et al., 2007), was 
judged to have a high risk of detection bias due to lack of blinding outcome assessors. Although the 
logistics of assessor blinding can be more difficult and additional resources may be required, 
reasonable steps could have been taken to reduce detection bias risk in each of these trials. Both 
selection and reporting bias were inadequately reported in >50% of trials, resulting in judgements of 
unclear risk being made. Furthermore, nearly 45% (n = 8) of the included trials were judged to be at 
a high risk of attrition bias. There were six trials with an unclear or high risk of imbalances between 
study groups at baseline, whilst, in most instances, contamination was also unreported resulting in 
an unclear judgement. Again, few studies reported data on intervention adherence (33%, n = 6); 
however, from the trials that did report these data, adherence rates were generally good (median: 
90%). Similarly, in the 10 trials that did report on attrition, the median value was 19.5%, with five 
of these trials reporting drop-out values that were under the 20% attrition threshold outlined in the 
protocol (Section 2.1.3). 
Statistical effects were observed in 13 of the main analyses, but in three of those evidence of at least 
substantial heterogeneity (I2 ≥50%) was reported. However, this was largely explained by 
investigation of subgroups and/or the removal of trials with the most extreme values. For all primary 
outcomes, the quality of evidence was rated as very low to low due to a combination of unclear or 
high risk for randomisation or allocation procedures, lack of blinding, unclear or improper handling 
of missing data, high attrition rates, unclear risk of selective reporting bias, contamination, low 
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adherence, or evidence of considerable heterogeneity. The quality of evidence for all outcomes was 
downgraded due to imprecision resulting from a small number of participants and either wide 
confidence intervals surrounding the effect estimate, or the inclusion of a null or negligible effect, as 
well as an appreciable benefit, within the confidence interval for the mean difference.  
 
3.9.6. Limitations and potential biases in the review process 
In addition to the limitations of the included studies mentioned in Section 3.9.4, there are potentially 
further limitations to the current systematic review. As such, despite a thorough and comprehensive 
search of relevant databases, it is possible that searches may have missed trials that were eligible for 
inclusion. Furthermore, no additional studies were identified from the reference lists of the included 
publications; whilst this may support the comprehensiveness of completed searches, it may also 
represent a potential methodological flaw. Also, no language restriction was placed upon the searches 
resulting in the return of several foreign language papers; three trials were written in Persian (Farsi) 
(Nasrekani et al., 2016; Saremi et al., 2013; Saremi and Yaghoubi, 2016), and another was in 
Hungarian (Petrányi and Zaoura-Petrányi, 2011). To assess these trials, translation services and 
software were utilised; whilst interpretation of results tables was reasonably straightforward, 
evaluating the quality of these studies was a considerable challenge. Consequently, in most instances, 
when assessment for risk of bias in these trials was completed, judgements of ‘unclear risk’ had to 
be made. 
Finally, only full publications were eligible for inclusion in the review and this may have contributed 
to publication bias. Whilst the inclusion of grey literature may have influenced the findings of this 
review, its inclusion may also have increased the risk of associated bias. However, due to a lack of 




3.9.7. Future Directions 
Based upon the findings of this review, it is evident that there is a dearth of trials comparing exercise 
and diet in combination with other comparators (e.g., diet only, exercise only, and usual care control). 
Considering that lifestyle changes (i.e. both diet and exercise) are recommended in the management 
of PCOS, there is a scarcity of studies assessing the effectiveness of these interventions and the 
available data are not sufficient to draw definitive conclusions/recommendations for use by clinical 
practitioners. Therefore, future trials should aim to make comprehensive comparisons involving 
interventions that incorporate both exercise and diet.  
Furthermore, the majority of studies included in the current systematic review have small sample 
sizes, and even where studies have reported power calculations, it is likely that they are still 
insufficiently powered to detect meaningful changes in all reported outcomes. Therefore, it is 
important that future studies are robustly designed and sufficiently powered to more reliably inform 
future clinical practice, and support relevant evidence-based guidelines and recommendations. 
Considering the high prevalence of PCOS in reproductive-aged women, large RCTs studying the 
effectiveness of lifestyle interventions in this young patient population are still clearly needed. 
There was also a striking lack of follow-up testing, beyond that which was done immediately post-
intervention, to assess the longer-term effects of such interventions. Without follow-up 
reassessments, it is impossible to determine whether any intervention-induced improvements are 
maintained, and to ascertain whether the studied intervention has resulted in sustained changes to the 
lifestyle behaviours of participants, an aspect which is vital for the long-term management of these 
patients. 
The final consideration for future works surrounds the internal validity within each study. The 
majority of included studies in this review had an unclear or high risk of bias across multiple risk of 
bias domains. The risk of bias could be addressed in the following ways; to address selection bias, 
participants must be randomised appropriately (i.e., computer generated randomisation, allocation 
concealed from researchers, opaque envelopes, etc.) and importantly, these methods should be 
explicitly described within publications. Due to the nature of exercise interventions, it is difficult to 
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reduce performance bias but this should not necessarily reduce the quality of the evidence. In 
pharmaceutical trials, performance bias can be avoided through the use of placebos, but creating 
sham exercise intervention arms is challenging (El-Kotob and Giangregorio, 2018). One potential 
solution could be through the use of multiple comparisons; this review highlights a paucity of trials 
that incorporate diet and exercise in their intervention arms. Future studies could compare lifestyle 
intervention A (i.e. diet and education) to lifestyle intervention B (i.e. diet and exercise), effectively 
masking participants to which is the true intervention.   
Detection bias was also high across studies, within the current systematic review. Detection bias can 
quite easily be negated by blinding those who will assess outcomes, to the allocation of the 
participant, which logistically can be achieved quite simply. The methods adopted for this process 
should also be clearly reported within methodologies. Attrition from study groups is another way in 
which bias can be introduced to RCTs, thus reducing statistical power and affecting generalisability 
of findings (Fewtrell et al., 2008). Attrition can be managed in many ways; regular communication 
with all participants, reduced burden upon participants (e.g., shorter questionnaires, reduced follow-
up, etc.), provision of incentives for continued engagement, and behavioural strategies (Brueton et 
al., 2011) could all be used to reduce attrition bias in future studies. Another bias that can be reduced 
in a straightforward manner is reporting bias; by pre-registering a trial, explicitly stating which 
outcomes will be analysed, and the methods used for analysis, reporting bias can be nullified. Pre-
registration of trials has also been shown to substantially reduce publication bias (Warren, 2018). 
Finally, studies should also record and report adherence to an intervention and any potential 
contamination in comparator groups (El-Kotob and Giangregorio, 2018). Providing these data can 
provide important information about whether the intervention group actually received what they were 
prescribed and whether, inadvertently or not, the control group received a dose of the intervention. 
If researchers are able to address these issues, there will undoubtedly be a reduced risk of bias within 





When data were combined in meta-analyses, only FI, total cholesterol, LDL-C and VO2 max had 
statistically favourable changes for both change from baseline and comparison of post-intervention 
values. In addition to this, HOMA-IR, triglycerides and waist circumference were statistically 
improved from baseline after exercise, but were not different to post-intervention control values. 
Finally, RHR and BMI following exercise were statistically lower than post-intervention values of 
control groups. Compared with control, exercise also improved multiple domains of the SF-36; the 
physical functioning, general health, social functioning, and mental health domains all improved 
following exercise.  
Subgroup analyses revealed that the greatest favourable changes when exercise was compared to 
control were seen in participants with overweight (FI, HOMA-IR, triglycerides, VO2 max and waist 
circumference) or obesity (BMI, body mass and waist circumference); post-intervention value 
analyses also showed beneficial effects in those who were overweight (LDL-C, VO2 max, RHR, 
BMI, waist circumference and body fat percentage). Aerobic exercise interventions improved FI, 
HOMA-IR, total cholesterol, triglycerides, VO2 max, BMI, waist circumference and body fat 
percentage. Conversely, resistance training lowered HDL-C concentrations and increased BMI, but 
reduced waist circumference, whilst post-intervention improvements in HDL-C were also evident 
following resistance training interventions. Compared to control, supervised exercise interventions 
improved outcomes more than those that were unsupervised. Shorter duration interventions 
performed better than longer interventions; improved change from baseline FI, HOMA-IR, total 
cholesterol, LDL-C, triglycerides, VO2 max and waist circumference was found in shorter duration 
trials, compared with only improved VO2 max in those >12 weeks. Based on limited available data, 
there were no notable differences between the effects of exercise and diet combined, and diet alone. 
Due to lack of available trials, it was not possible to compare the effectiveness of exercise versus diet 
or exercise and diet combined versus diet. 
Although the evidence presented within this systematic review is largely drawn from RCTs, a 
cautious approach should be adopted when interpreting the present findings. Many of the outcomes 
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presented statistically significant, yet modest, effects and generally had wide confidence intervals 
around the effect estimate (indicating greater uncertainty). Furthermore, the observed statistical 
effects in many of the analyses were sensitive to the addition/removal of individual trials regardless 
of their weighting within the analysis. Using the GRADE approach, the quality of evidence was rated 
as very low or low for all primary outcomes. It is recommended that future trials should be rigorously 
designed and sufficiently powered so that they are more generalizable to the wider PCOS population. 
In order to be more closely aligned with current treatment recommendations, future studies should 




















Chapter 4: Results  
Study 2. 
A comparison of self-
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Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects up to 21% of 
reproductive-aged women (Yildiz et al., 2012). Diagnosis is usually made when women are 
hyperandrogenic with the presence of oligomenorrhea and/or polycystic ovaries and this often 
manifests in a range of undesirable symptoms such as acne, hirsutism and infertility. Alongside these 
defining characteristics, many women with PCOS experience metabolic complications; some 
estimated 40-60% are either overweight or obese (Moran et al., 2009), and when compared to women 
without PCOS, up to 70% have increased insulin resistance (IR) (Hutchison et al., 2011), 
independent of obesity (Teede, Hutchison and Zoungas, 2007; Dunaif et al., 1989).  
In addition to these hyperandrogenic and metabolic symptoms, PCOS is also recognised as a chronic 
disorder that adversely affects patient health-related quality of life (HRQoL; Jedel et al., 2010). 
HRQoL is a widely reported outcome which is deemed an important consideration in the treatment 
and management of chronic disease (Dokras et al., 2018). This is because it relates to the patient-
reported physical, social and emotional effects of an underlying condition and the treatments that are 
associated with it (Colwell et al., 1998). The assessment of HRQoL is usually completed via generic 
self-report questionnaires, such as the Short Form 36-item (SF-36) Health Survey, or disease specific 
questionnaires, such as the PCOS-Questionnaire (PCOS-Q).   
Previous studies have consistently reported lower HRQoL in women with PCOS when compared 
with either normative data from the general population (Jones et al., 2010; Ching, Burke and Stuckey, 
2007), or control groups (Li et al., 2011; Barnard et al., 2007; Coffey, Bano and Mason, 2006; Hahn 
et al., 2005). Furthermore, women with PCOS are more likely to experience greater levels of 
psychological morbidity (i.e. anxiety and/or depression) than women without PCOS (Deeks et al., 
2011). The psychological components of HRQoL for women with PCOS are also reportedly poorer 
than in women with other physical conditions, such as asthma, epilepsy, coronary heart disease or 
arthritis (Coffey, Bano and Mason, 2006).  
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Previous studies have compared physical activity (PA) levels of women with PCOS against controls, 
with the majority of such findings reporting no statistical differences in energy expenditure (MET-
mins/wk) between these groups (Mario et al., 2012; Rodino et al., 2016), despite poorer physical and 
mental health in women with PCOS. It can therefore be assumed that PA, or lack thereof, is not 
implicated in the health differences between women with PCOS and healthy women. However, there 
is less evidence about the effectiveness of increasing PA to manage PCOS symptoms. Indeed, the 
physical benefits of increasing PA levels (e.g. improvements to fitness, body composition or 
metabolic health) have been widely reported across a range of populations. However, it has also been 
stated that increased PA may improve HRQoL; following exercise interventions, beneficial effects 
have been reported in both cancer patients receiving treatment and in cancer survivors (Mishra et al., 
2012), in patients with chronic respiratory conditions (Eichenberger, et al., 2013) and in patients with 
rheumatoid arthritis or osteoarthritis (Kelley, et al., 2015).  
Despite the high global prevalence of PCOS, less is known about the effectiveness of PA at 
improving HRQoL within this patient population. The author’s recent systematic review (Chapter 3) 
reported statistical improvements in a range of outcomes (i.e. fasting insulin, lipids, and 
cardiorespiratory fitness), including components of HRQoL. Moreover, whilst no benefit was 
observed in any domain of the PCOS-Q, statistical improvements were also found in multiple 
domains of the SF-36. When exercise was compared to usual care, physical functioning [mean 
difference (MD): 11.81, 95% confidence interval (CI): 2.36 to 21.25; I2 = 74%], general health (MD: 
10.05, 95% CI: 3.89 to 16.20; I2 = 0%), social functioning (MD: 11.75, 95% CI: 2.56 to 
20.95; I2 = 6%) and mental health (MD: 11.70, 95% CI: 1.27 to 22.13; I2 = 47%) domains were all 
statistically improved from baseline. Another recent systematic review (Lim, et al., 2019) assessed 
the effectiveness of lifestyle interventions (i.e. exercise and diet) upon HRQoL (as measured by the 
PCOS-Q) in women with PCOS. This systematic review reported statistical improvements for the 
Emotions (MD: 0.77, 95% CI: 0.30 to 1.23; I2 = 92%) and Infertility (MD: 0.68, 95% CI: 0.21 to 
1.14; I2 = 87%) domains of the PCOS-Q. Whilst these findings appear promising, there are some 
limitations, namely small sample sizes (n = 84 and n = 95, respectively), evidence of considerable 
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heterogeneity and also the lack of a current consensus as to what constitutes a clinically meaningful 
difference for these metrics within this patient population (Teede, et al., 2018).  
Although there is limited evidence supporting the effectiveness of exercise interventions, there 
appears to be a paucity of research on the role of habitual PA in the management of PCOS. In contrast 
to structured exercise interventions, habitual activity accounts for activities of daily living (e.g. 
walking for transport, shopping or household chores) and, when undertaken in combination with 
aerobic exercise, may potentiate the cardio-metabolic health benefits of exercise alone (Swift et al., 
2012). Independently, higher habitual PA levels have been linked with improved health outcomes in 
a range of patient populations (Dwyer et al., 2007; Jennersjö et al., 2012; Manjoo et al., 2012). More 
specifically, in women with type 2 diabetes, a 1000 steps per day increment has been associated with 
clinically important reductions in systolic (-2.6 mmHg, 95% CI: -4.1 to -1.1) and diastolic (-1.4 
mmHg, 95% CI: -2.2 to -0.6) blood pressure. Furthermore, another study reported that women who 
demonstrated moderate levels of ambulatory activity (≥7500 steps/day) had ~50% lower levels of 
depression (assessed via the computerised Composite International Diagnostic Interview) when 
compared to their sedentary (<5000 steps/day) counterparts (McKercher et al., 2008); these 
associations were not evident when males were analysed. 
In women with PCOS, studies that have used objective measurements of habitual PA are sparse. One 
such cross-sectional study used pedometers to measure habitual PA, comparing health outcomes of 
those who were active (≥7500 steps/day) against those who were inactive (Mario et al., 2017), and 
reported lower BMI, waist circumference, serum androgens and an improved lipid profile in the 
former more active group. A more recent study also reported a modest reduction in BMI (-0.20 kg/m2, 
95% CI: -0.38 to -0.01) alongside clinically important differences in inflammatory biomarkers 
(interleukin-6: -0.81 ng/L, 95% CI: -1.37 to -0.25; and C-reactive protein: -0.68 mg/L, 95% CI: -1.30 
to -0.06) for each additional 1000 steps per day (Webb et al., 2018).  
In other studies, participants with PCOS have self-reported their PA levels, often using the 
International PA Questionnaire (IPAQ). One such study (Lamb et al., 2011) categorised participants 
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as either meeting (active), or not meeting (inactive) the US Department of Health and Human 
Services (DHHS) PA guidelines (i.e. 150 mins per/week of moderate-intensity PA, or 75 mins per/wk 
of vigorous-intensity PA, or an equivalent combination of both). This study reported that ~59% of 
women with PCOS in this study sample (n = 88) met the DHHS PA guidelines and that, when 
compared to active women, the inactive group had a higher BMI, waist circumference and increased 
weight fluctuations. Furthermore, inactive participants also had higher fasting blood glucose (94.0 ± 
21.3 mg/dL versus 87.8 ± 12.1 mg/dL) and lower sex hormone binding globulin (SHBG) 
concentrations (40.4 ± 5.9 nmol/L versus 68.4 ± 7.3 nmol/L) than their physically active counterparts. 
One additional finding was that inactive participants had higher depression scores on the Beck 
Depression Inventory-Fast Screen (BDI-FS) questionnaire. 
A more recent study (Greenwood et al., 2016) sampled 326 women with PCOS and found that 56% 
met the Department of Health and Human Services (DHHS) PA guidelines, with 83% of these 
women meeting the guidelines primarily through vigorous-intensity exercise (defined as: ‘activities 
that take hard physical effort and make you breathe much harder than normal’) as opposed to 
moderate intensity. In this study, women classified as vigorous exercisers had a lower median BMI, 
smaller waist circumference and greater concentrations of high-density lipoprotein cholesterol 
(HDL-C) when compared to those who were inactive or moderately active. Moreover, despite no 
statistical between-group differences in fasting blood glucose and insulin concentrations, the 
vigorous group demonstrated an improved metabolic profile [i.e. significant decrease in oral glucose 
tolerance test (OGTT) and homeostasis model assessment-insulin resistance (HOMA-IR) values], 
and fewer diagnoses of metabolic syndrome when compared to those who were inactive. 
In summary, women with PCOS reportedly have poorer HRQoL than their healthy counterparts 
regardless of PA levels. However, whilst the evidence of exercise’s potential to improve HRQoL is 
limited, there appears to be some evidence that if women with PCOS increase their activities of daily 




4.2. Objectives and hypotheses 
Based on the aforementioned background, the hypotheses explored in the present study can be 
summarized in the following points: 
1. Women with PCOS have a poorer quality of life than women without PCOS, irrespective of 
PA levels. 
2. The higher the PA level of women with PCOS, the less severe their symptoms and higher 
their HRQoL. 
3. Greater perceived benefits, and fewer perceived barriers to PA leads to increased self-
efficacy for exercise, which in turn improves PA levels. 
4. A diagnosis of PCOS decreases participant self-esteem, which also reduces HRQoL. 
 
Accordingly, the objectives of the current study were to identify whether there are significant 
differences in HRQoL (including physical and psychological components) between women with 
PCOS and a healthy control group, and to explore whether higher levels of PA facilitate improved 
PCOS-related symptoms (as measured by PCOS-Q). Furthermore, this study aimed to estimate any 
potential simultaneous impact of not only a PCOS diagnosis, but also of other predictive factors (i.e., 

































4.4.1. Study cohort - Participants characteristics  
Following the recruitment period, 194 participants accessed the online surveys and agreed to 
participate (Figure 4.1). Based upon the exclusion criteria, 40 participants were deemed ineligible 
for participation and their involvement in the study ceased. Reasons for exclusion were: asthma (n = 
19), depression (n = 4), endometriosis (n =3), inflammatory arthritis (n = 3), hypothyroidism (n = 2), 
osteoporosis, osteoarthritis, irritable bowel syndrome, Sjorgen’s syndrome, chronic migraines, 
bipolar disorder, type 2 diabetes mellitus, hypermobility syndrome, Ehlers-Danlos syndrome, 
multiple sclerosis, Raynaud’s phenomenon, spinal cord injury and pregnancy (all n = 1). Three 
participants cited two conditions. 
 
 




Of the remaining 154 participants, 24 failed to complete any data beyond the demographic 
questionnaire and, thus, were deemed to have provided insufficient data to warrant inclusion in the 
analysis. Descriptive statistics for women with PCOS (n = 64) and the control group (n = 66) are 
presented in Table 4.1. 
 
Table 4.1. Demographics of participants.  
Variable Total Women with 
PCOS 
(n = 64) 
Control 
 
(n = 66) 
Age Range (years) 19-45 21-45 19-45 
Ethnicity 
White 
Asian or Asian British 
Black or Black British 
Chinese 
Gypsy or Traveller 
Other Mixed background 










































































































































The majority of participants were of White ethnicity (83.1%) and were either single (40%) or married 
(40%), in full-time employment (48.5%), educated to degree level (38.5%), had a household income 
≤ £39,999 (59.2%), and did not have children (70.8%). There were some demographical differences 
between the groups; ~63% of women with children came from the control group. Women in the 
control group also tended to be educated to a higher level and have a greater household income than 
their counterparts. A larger number of women in the control group also self-reported that they were 
currently a student; this trend may be associated with the location that the recruitment took place 
(i.e., Aston University). 
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Table 4.2. Comparison of self-reported variables between women with PCOS and control group.  
 Total 
(n = 130) 
PCOS 
(n = 64) 
Control 
(n = 66) 
Missing 
PCOS / CON 
Median or 
mean diff 
95% CI for MD Cohen’s 
d 
P value 
 Lower Upper  
Age (years) 31 (11.25) 30 (9.75) 32 (13.5) 0 / 0 -2.00 - - -0.192 .297 
Height (cm) 165.1 (10.00) 165.1 (8.06) 164.5 (9.25) 0 / 0 0.60 - - 0.107 .349 
Weight (kg) 65.16 (38.27) 91.3 (45.31) 63.0 (18.3) 0 / 0 28.30 - - 1.121 <.001 
BMI (kg/m2) 24.51 (13.29) 32.91 (16.6) 23.28 (5.25) 0 / 0 9.63 - - 1.129 <.001 
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SEE⚫ 42.40 (17.77) 40.44 (21.35) 43.64 (15.95) 2 / 0 -3.20 -9.83 3.43 -0.171 .341 
Key: Unless otherwise indicated, data presented as median (IQR) and Mann-Witney U tests performed; ▲ Parametric data reported as mean (SD) and Student’s t-test performed; 
⚫ Parametric data reported as mean (SD) and Welch’s test performed; CON: Control group; CI: confidence interval; MD: Mean difference; BMI: Body Mass Index; WC: waist 
circumference; HRQoL: Health-related Quality of Life; IPAQ: International Physical Activity Questionnaire; SES: self-esteem scale; EBBS: Exercise Benefits/Barriers Scale; 






There were no statistically significant differences between the age and height of the two groups but, 
women with PCOS had higher body weight, BMI and waist circumference than the control group 
(Table 4.2). In addition to this, women with PCOS reported lower scores in the physical and mental 
domains of the SF-12, and overall poorer HRQoL as assessed by the total SF-12 score. They also 
had significantly lower self-esteem than control women did. In addition to this, women with PCOS 
also perceived fewer benefits and greater barriers to exercise.  
When individual perceived benefits of exercise were identified, the top three with the highest mean 
(± SD) scores (out of 4) in sequence were: ‘exercising increases my level of physical fitness’ (3.45 ± 
0.55), ‘exercising improves functioning of my cardiovascular system’ (3.38 ± 0.56), and ‘exercise 
gives me a sense of personal accomplishment’ (3.33 ± 0.65). In contrast, the three perceived benefits 
with the lowest scores were: ‘exercising increases my acceptance by others’ (2.14 ± 0.78), 
‘exercising lets me have contact with friends and persons I enjoy’ (2.23 ± 0.90), and ‘exercising is a 
good way for me to meet new people’ (2.29 ± 0.85). When each group’s benefits were assessed 
separately, the top three perceived benefits for the control group were identical to the whole cohort. 
Women with PCOS perceived ‘exercise improves my flexibility’ (3.52 ± 0.75) as their second benefit, 
just behind ‘exercising increases my level of physical fitness’ and ahead of ‘exercising improves 
functioning of my cardiovascular system’. The least cited perceived benefits for each group were 
different to the whole cohort. In women with PCOS, ‘exercising lets me have contact with friends 
and persons I enjoy’ scored lowest, followed by ‘exercise is good entertainment for me’ and 
‘exercising is a good way for me to meet new people’. The least scored benefits in the control were 
the same as the whole cohort, but with ‘exercising lets me have contact with friends and persons I 
enjoy’ and ‘exercising is a good way for me to meet new people’ reversed. 
When the perceived barriers were scored, the ranking for the highest scores were virtually identical 
for the whole cohort and each population, respectively. These are: 1) ‘exercise tires me’; 2) ‘exercise 
is hard work for me’, and; 3) ‘I am fatigued by exercise’. The mean score for the barrier ‘exercising 
takes too much of my time’ was also equal 3rd in the control group. Similarly, the lowest scoring 
barrier across both groups and the whole cohort was ‘I think people in exercise clothes look funny’. 
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This was followed by ‘places for me to exercise are too far away’ and ‘there are too few places for 
me to exercise’ in the PCOS group and whole cohort. The control group barriers with the 2nd and 3rd 
lowest scores were ‘I am too embarrassed to exercise’ and ‘my spouse (or significant other) does not 
encourage exercising’, respectively. 
In contrast to EBBS, there were no statistical differences in self-efficacy for exercise, and when data 
from the IPAQ was analysed, there were also no between-group statistical differences in either MET-
min/wk or sitting time. 
Women with PCOS were asked to stipulate to which phenotypic subgroup they belonged. The 
majority (51.6%) self-reported as having excess androgens, menstrual dysfunction and polycystic 
ovaries as identified by ultrasound (Figure 4.2). A further 11 (17.1%) of the women with PCOS in 
this study were unsure of the characteristics of which their diagnosis had been made.  
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Table 4.3. PCOS-Q domain specific scores from women with PCOS.  
PCOS-Q Domain Median Score Interquartile Range 
Emotions 3.05 1.57 
Body Hair 2.60 3.30 
Weight 1.90 2.75 
Infertility 2.50 3.81 
Menstrual Problems 3.00 2.25 
Key: Emotions: Emotion domain scores from the PCOS-Q; Body Hair: Body hair domain scores 
from the PCOS-Q; Weight: Weight domain scores from the PCOS-Q; Infertility: Infertility domain 
scores from the PCOS-Q; Menstrual Problems: Menstrual Problems domain scores from the PCOS-
Q. A lower score indicates a greater severity of problem. 
 
 
Results from the PCOS-Q are presented in Table 4.3; it is evident that concerns about body weight 
and infertility are the most prevalent in this sample. When domain scores were compared, there were 
statistical differences between five domains (Table 4.4); the Weight domain was significantly lower 
than the other four domains and Infertility domain scores were significantly lower than the Emotions 
domain.  
There were no statistically significant differences in PCOS-Q domain scores between the self-
reported phenotypic subgroups. 
 
Table 4.4. Pairwise comparison (Durbin-Conover) of PCOS-Q domains. 
Pairwise Comparison Median Diff Statistic P value 
Emotions Body Hair -0.45 1.389 .166 
Emotions Weight -1.15 4.291 <.001 
Emotions Infertility -0.55 2.037 .043 
Emotions Menstrual Problems -0.05 0.772 .441 
Body Hair Weight -0.70 2.902 .004 
Body Hair Infertility -0.10 0.648 .517 
Body Hair Menstrual Problems 0.40 0.617 .538 
Weight Infertility 0.60 2.253 .025 
Weight Menstrual Problems 1.10 3.519 <.001 
Infertility Menstrual Problems 0.50 1.266 .207 
Key: Emotions: Emotion domain scores from the PCOS-Q; Body Hair: Body hair domain scores from the 
PCOS-Q; Weight: Weight domain scores from the PCOS-Q; Infertility: Infertility domain scores from the 
PCOS-Q; Menstrual Problems: Menstrual Problems domain scores from the PCOS-Q; P value: significant 





Waist circumference was strongly (P <.001) correlated with BMI (τb = .652). Whilst waist 
circumference is an important clinical measure of central obesity, it was felt that because it had a 
number of missing values in both groups (11 and 8 in the women with PCOS and control group, 
respectively), and a strong correlation with BMI, that BMI was the most suitable weight-related 
variable for subsequent analysis. Similarly, the Benefit (τb = .819) and Barrier (τb = .611) scores were 
strongly associated with the total score from the EBBS; so too were the Physical (τb = .737) and 
Mental (τb = .844) domain scores with the total score from the SF-12. Accordingly, only the total 
scores from the EBBS and SF-12 were used in subsequent analyses. 
BMI had a statistically significant negative correlation with the SF-12 total score (τb = -.297), RSE 
Scale (τb = -.271), and EBBS total score (τb = -.188). The implication here is that the higher the BMI 
of a participant, then the lower the score in these metrics. Conversely, there was a smaller, but 
statistically significant positive correlation between BMI and MET-mins/wk (τb = .139). 
Furthermore, there was a significant positive correlation between SEE Scale scores and EBBS (τb = 
.340) and MET-mins/wk (τb = .212). Moreover, those who reported higher SEE had lower weekly 
sitting (τb = -.167). The EBBS total scores were positively correlated with RSE Scale scores (τb = 
.234), HRQoL (τb = .339) and with MET-mins/wk (τb = .175). Higher self-esteem had a significant 
association with improved HRQoL (τb = .463) and a higher volume of MET-mins/wk was negatively 
associated with sitting time (τb = -.161). These results are summarized in Table 4.5. 
Further Kendall’s τb were completed only for women with PCOS and included their responses to the 
PCOS-Q domains. There were statistically significant negative correlations between BMI and the 
Weight (τb = -.638), Emotions (τb = -.415), Body Hair (τb = -.213), and Infertility (τb = -.193) domains, 
whilst there was no statistical correlation between the Menstrual domain and BMI. The Emotions 
domain was positively correlated with SEE (τb = .199), EBBS (τb = .338), RSE Scale (τb = .436), and 
SF-12 (τb = .506). Although to a lesser extent, the Body Hair (τb = .202), Weight (τb = .333) and 
Menstrual (τb = .450) domains were positively correlated with SF-12 Total Scores. Three PCOS-Q 
domains were positively correlated with RSES scores, namely the Weight (τb = .319), Infertility (τb 
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= .226) and Menstrual (τb = .241) domains. The Body Hair domain also had a statistically significant 
positive association with the EBBS (τb = .204). Of the PCOS-Q domains, only the Emotions domain 
was associated with Weekly Sitting Time, with a negative correlation (τb = -.209) between these two 
variables. Many of the PCOS-Q domain scores also demonstrated correlation with other domain 
scores; the Emotions domain showed statistical association with all other domains (Table 4.6), with 
the strongest association being with the Weight domain (τb = .525). The Weight domain was also 
correlated with both the Infertility (τb = .288) and Menstrual (τb = .274) domains. The Menstrual and 
Infertility domains also showed significant correlation (τb = .300). 
Aside from the PCOS-Q domain scores, a number of other outcomes correlated with each other. 
Similarly, to the whole cohort analysis, negative correlations remained for BMI with RSE Scale (τb 
= -.253), and BMI with SF-12 scores (τb = -.296). SEE was still correlated with EBBS (τb = .483), 
MET-min/wk (τb = .373) and Weekly Sitting Time (τb = -.217). SEE also showed a moderate 
correlation with RSES (τb = .207), which was not present when the whole cohort was included in the 
analysis. EBBS remained correlated with RSE Scale (τb = .291), MET-min/wk (τb = .278) and SF-12 
(τb = .407). SF-12 total scores also remained correlated with RSE Scale (τb = .393). Finally, a 





Table 4.5. Correlation matrix (Kendall’s τb) for self-reported variables for all study participants. 











































































































      




















     






















    

















































































Key: BMI: Body mass index; WC; waist circumference; SEE: self-efficacy for exercise; Benefit: Exercise Benefits Barriers Scale perceived benefits score; Barrier: Exercise Benefits Barriers 
Scale perceived barriers score; EBBS: Exercise Benefits Barriers Scale total score; SES: self-esteem scale; SF12 Phys: Physical domain scores from the SF-12; SF Mental: Mental domain scores 
from the SF-12; SF12 Total: Total scores from the SF-12; MET-min/wk: Metabolic equivalent of task minutes per week as measured by the IPAQ-LF; Sitting: minutes per week of self-reported 





Table 4.6. Correlation matrix (Kendall’s τb) for self-reported variables for women with PCOS. 









































         



























       




































































































































Key: BMI: Body mass index; SEE: self-efficacy for exercise; EBBS: Exercise Benefits Barriers Scale total score; SES: self-esteem scale; SF12 Total: Total scores from the SF-12; Emotions: 
Emotion domain scores from the PCOS-Q; Body Hair: Body hair domain scores from the PCOS-Q; Weight: Weight domain scores from the PCOS-Q; Infertility: Infertility domain scores from 
the PCOS-Q; Menstrual: Menstrual Problems domain scores from the PCOS-Q; MET-min/wk: Metabolic equivalent of task minutes per week as measured by the IPAQ-LF; Sitting: minutes per 
week of self-reported sitting as measured by the IPAQ-LF; τ: Kendall’s Tau B; P: significance value. 
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4.4.3 Path Analysis 
The causal path model of this study is presented in Figure 4.3. Both a diagnosis of PCOS and BMI 
have direct effects on HRQoL (standardised β = .230, and β = .234, respectively) and self-esteem (β 
= .364 and β = -.213, respectively). Furthermore, PCOS also has the largest indirect (β = .177) and 
total effect (β =.407) upon HRQoL, although it is closely followed by BMI (indirect β = -.116; total 
β = -.351, respectively). BMI also had a direct effect on EBBS (β = -.180). Self-esteem (β = .326) 
and EBBS (β = .254) also demonstrate a direct effect upon HRQoL and although they have no 
significant indirect effects (via weekly PA as a mediator), both demonstrate a total effect upon 
HRQoL in this model (β = .324 and β = .265, respectively). EBBS also had a significant total effect 
on weekly PA (β = .376). Self-efficacy for exercise and weekly PA had no effect (either direct or 





Figure 4.3. Path analysis model based on the findings of this study. Bi-directional arrows indicative of correlation between exogenous variables. Single 
directional arrows indicate significant standardised path coefficients and bias corrected 95% confidence intervals for direct effects. A dashed arrow indicates 






Table 4.9. Direct, indirect and total effects of variables in the HRQoL causal model. 
 Standardised 
Coefficient 
95% CI for β 2-tailed 
Significance Lower Upper 
Direct Effects     
PCOS → HRQoL .230 .099 .420 .004 
PCOS → Self-esteem† .364 .163 .517 .021 
PCOS → SEE† -.039 -.220 .116 .517 
PCOS → EBBS† .225 -.022 .426 .068 
BMI → HRQoL -.234 -.368 -.076 .007 
BMI → Self-esteem† -.213 -.478 .000 .050 
BMI → SEE† .082 -.134 .233 .460 
BMI → EBBS† -.180 -.415 -.009 .038 
Self-esteem → HRQoL .326 .185 .445 .018 
Self-esteem → MET-min/wk† -.069 -.252 .162 .612 
SEE → MET-min/wk† .224 -.078 .419 .118 
EBBS → MET-min/wk .260 -.055 .542 .119 
EBBS → HRQoL .254 .124 .391 .010 
EBBS → SEE† .520 .368 .654 .006 
MET-min/wk → HRQoL† .029 -.113 .164 .740 
Indirect Effects     
PCOS → HRQoL .177 .072 .283 .018 
PCOS → MET-min/wk† .051 -.057 .177 .305 
BMI → HRQoL -.116 -.266 -.018 .023 
BMI → MET-min/wk† -.035 -.154 .059 .519 
Self-esteem → HRQoL -.002 -.035 .008 .626 
SEE → HRQoL† -.006 -.026 .038 .411 
EBBS → MET-min/wk .117 -.006 .285 .066 
EBBS → HRQoL .011 -.038 .093 .684 
Total Effects     
PCOS → HRQoL .407 .255 .571 .011 
BMI → HRQoL -.351 -.507 -.194 .005 
Self-esteem → HRQoL .324 .196 .446 .012 
EBBS → HRQoL .265 .127 .407 .012 
EBBS → MET-min/wk .376 .130 .586 .015 
Key: PCOS: Diagnosed with PCOS; HRQoL: Health-related Quality of Life as measured by total SF-12 score; 
SEE: self-efficacy for exercise; EBBS: Exercise Benefits/Barriers Scale; MET-min/wk: Metabolic equivalent 
of task minutes per week as measured by the IPAQ-LF; 95% CI: Bias corrected 95% confidence interval; → 








4.5.1. Key Findings within the study cohort and the PCOS study group 
The present findings show that despite no statistical differences in self-reported PA or sitting time, 
women with PCOS had greater body weight, BMI and waist circumference than women without 
PCOS. Moreover, women with PCOS also demonstrated lower physical, mental and total domain 
scores for HRQoL than their non-PCOS counterparts, whilst also reporting lower self-esteem. When 
determinants of PA were considered, women with PCOS perceived fewer benefits and more barriers 
to exercise than women without PCOS, but there were no statistical between group differences for 
self-efficacy for exercise. In addition, for the whole cohort higher PA was, unsurprisingly, associated 
with greater self-efficacy for exercise and higher EBBS scores. In this context, what was less 
expected was the positive association between body mass and anthropometric outcomes (i.e., body 
weight, BMI and waist circumference) and MET-mins performed each week. However, PA-levels 
were not associated with SF-12 results or self-esteem. In contrast, BMI had a statistical negative 
association with HRQoL, self-esteem and total EBBS scores (i.e., more perceived barriers and fewer 
perceived benefits). Increased self-esteem was positively associated with HRQoL and this effect was 
greater in the mental health domain. When determinants of PA were considered, EBBS scores were 
associated with self-efficacy for exercise, HRQoL and self-esteem. Apart from its association with 
EBBS, self-efficacy for exercise was only associated with one other variable, exhibiting a negative 
association with sitting time. 
Overall, the path analysis in this study indicated that both PCOS diagnosis and participant’s BMI 
had statistical direct, indirect and total effects upon HRQoL, with the former having the largest total 
effect. Interestingly, self-esteem levels had the largest direct effect upon HRQoL, and also 
constituted an important mediator between PCOS/BMI and HRQoL. 
In the analyses only for the group of participants with PCOS, there were no statistical differences 
between the subgroups for each self-reported PCOS phenotype. It was perhaps surprising to note that 
~17% of these women were unsure regarding the PCOS phenotype which characterized their PCOS 
diagnosis. Regarding the PCOS-Q domains, the weight domain was scored statistically lower than 
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all other domains, indicating that this represents the largest concern for women with PCOS in this 
study cohort. Of note, the Weight, Emotions, Body Hair and Infertility PCOS-Q domains were all 
negatively associated with BMI. Furthermore, HRQoL (total SF-12 score) was correlated with all 
PCOS-Q domains apart from Infertility. Interestingly, self-esteem was correlated with the Weight, 
Infertility and Menstrual domains. The Emotions domain was also positively correlated with self-
efficacy for exercise, EBBS and self-esteem, but showed a negative association with sitting time, 
whilst EBBS scores correlated with the body hair domain. In addition to PCOS-Q domain scores, the 
associations between PA-levels and both self-efficacy for exercise and EBBS scores remained, and 
were in fact stronger for the former, in the PCOS study group, whilst a negative association between 
PA and sitting time also remained. Similarly, BMI still exhibited a negative association with both 
self-esteem and HRQoL, and self-efficacy for exercise with EBBS score and sitting time. The results 
within the PCOS study group varied from the whole cohort analysis by demonstrating a moderate 
correlation between self-esteem and self-efficacy for exercise.  
 
4.5.2. Between group differences 
Regardless of PCOS phenotype, it is clear that the symptomatic manifestations of PCOS may impact 
upon the HRQoL of a woman with PCOS. Indeed, it has been widely reported that women with 
PCOS demonstrate reduced HRQoL compared to healthy control groups or normative population 
data (Barnard et al., 2007; Ching, Burke and Stuckey, 2007; Coffey, Bano and Mason, 2006; Hahn 
et al., 2005; Jones et al., 2010; Li et al., 2011). The findings reported here tend to agree with these 
previous studies, with statistically significant differences noted for the Physical, Mental and Total 
scores from the SF-12. Despite statistical differences, the degree of clinical importance associated 
with this is less straightforward to determine. To the author’s knowledge, this is the first study that 
has used the SF-12 to assess HRQoL in women with PCOS, so there are no normative data with 
which to compare. However, Costa et al. (2018) reported change in the scores for each domain of 
the SF-36 before and after an aerobic exercise intervention. Whilst it is not possible to compare these 
scores directly, the effect size (d) of the most relevant domains can be compared. In the present study, 
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the effect size for between group differences for the SF-12 Physical Domain (d = -0.999) is 
comparable to the SF-36 Physical Functioning (d = 1.2, 95% CI: 0.5 to 1.9) and Role Physical (d = 
1.0, 95% CI: 0.1 to 1.8) change from baseline effect sizes reported in Costa et al. (2018). Using 
magnitude-based inference (Hopkins et al., 2009) they state that the magnitude of effect sizes for 
Role Physical ‘Very Likely’, and Physical Functioning ‘Almost Certainly’ represent clinically 
significant changes. Similarly, they report a ‘Likely’ chance that the Role Emotional (d = 0.8, 95% 
CI: 0.0 to 1.6) and Mental Health (d = 1.0, 95% CI: 0.1 to 1.8) domain scores are clinically important; 
the magnitude of the effect size they report is smaller than that reported in the present study (d = -
1.346), suggesting that the observed differences in perceived mental health between women with 
PCOS and controls may have clinical relevance. 
However, there is some contrasting evidence presented in a study of non-PCOS participants (those 
who had received anterior cervical discectomy and fusion) that did use the SF-12 to evaluate HRQoL 
(Parker et al., 2013). Using the minimum detectable change (MDC) method, they do quantify 
minimal clinically important differences for domain scores of the SF-12; MDC defines clinically 
important differences as the smallest change which can be observed above the measurement error 
with a given level of confidence (e.g., 95% CI). Therefore, the minimal clinically important 
difference is equal to the upper value of the 95% CI (Copay et al., 2007). Parker et al. (2013) identify 
the threshold for clinically important change as ±8.1 points for the SF-12 Physical domain and ± 4.7 
points for the mental domain scores. Although caution should be adopted because of the variation in 
different populations, the implication in the current study is that women with PCOS have statistically 
and potentially clinically lower levels of perceived mental health than women without PCOS. 
Furthermore, whilst statistically lower physical wellbeing scores were observed in women with 
PCOS, the corresponding degree of clinical importance is unclear. For greater confidence in these 
findings, future work should focus upon identifying the HRQoL thresholds for clinically important 
changes in women with PCOS. 
The present findings also document that the SF-12 mental health domain was the most severely 
impacted domain by a diagnosis of PCOS. Notably, there was a statistically significant difference 
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between mental and physical domain scores (mean difference = 2.67, 95% CI: 1.74 to 3.60; P <.001) 
in women with PCOS that was not present in the control group (mean difference = 0.60, 95% CI: -
0.25 to 1.45). This suggests that, according to the SF-12, PCOS has a greater psychological than 
physical effect. Indeed, these findings agree with those reported by Bazarganipour et al. (2013), 
although the SF-36 domain scores were utilised in this study. This underlines the importance of 
incorporating assessments of psychological wellbeing, and the appropriate treatment strategies 
during the management of PCOS. When differences between phenotypic subgroups were evaluated, 
there were no statistical differences for either SF-12 domain. 
Aside from the SF-12, there were also additional differences between women with PCOS and the 
control group, with women with PCOS reporting higher body mass, BMI and waist circumference 
than the control group. Across the UK general population, obesity levels have increased from 15% 
in 1993, to 27% in 2015 (Moody et al., 2016). Specifically among UK women, a 31% obesity 
prevalence has been reported, with the highest rates in the 55-64 years age group (~34%), and 
considerably lower rates (~22%) in younger age groups (i.e., 16-44) (Moody et al., 2016). The 
association between obesity and PCOS has been widely reported, with older data indicating that the 
obesity prevalence in UK women with PCOS was at 35-38% (Kiddy et al., 1990; Balen et al., 1995). 
Given the increasing obesity prevalence rates in general population over the past few decades, it is a 
reasonable assumption that a similar growth may have been observed in women with PCOS. Indeed, 
in the current study ~63% of women with PCOS had a BMI ≥30 kg/m2 (compared to ~17% in the 
control group). This finding is further supported by a North American review (Yildiz et al., 2008) 
which found that the temporal trends of obesity prevalence in women with PCOS appear to reflect 
the increases in obesity prevalence in the general American population (obesity prevalence in women 
with PCOS increased from 51% in 1987 to 74% in 2002).  
BMI may provide a standardized index to evaluate an individual’s weight status, but it does not 
distinguish between fat, muscle or bone mass, whilst it also makes no inference about body 
composition, or the distribution of adipose tissue. Although the current study did not assess body 
composition, data on self-reported waist circumference were captured as an index of central 
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adiposity. As expected, median waist circumference was statistically higher in women with PCOS. 
Of note, based on the waist circumference cut-off points outlined in clinical guidelines (NICE, 2014) 
to identify women at a high risk of developing health problems (waist circumference ≥80 cm, and 
further increased risk for waist circumference 88 cm), most of the control study group self-reported 
as being under this threshold (mean: 77.2 cm; median: 74 cm), but most study participants with PCOS 
far exceeded these waist circumference cut-off points (mean: 101 cm; median: 101.6 cm). This 
indicates that there are both statistical and clinically meaningful differences regarding waist 
circumference - and so central adiposity - between the two study groups. Interestingly, it has also 
been reported that the distribution of adipose tissue in PCOS tends to be more central (Talbott et al., 
1995; Taponen et al., 2003), thus further promoting metabolic disturbances (Pasquali, 2006) and 
increasing the risk of metabolic syndrome and type 2 diabetes (Kousta and Franks, 2007). Whilst 
instances of metabolic disturbances are beyond the scope of the current study, the degree of 
difference in waist circumference certainly tends to agree with previous findings, suggesting that 
these women with PCOS are at an increased risk of cardio-metabolic disease. 
There were no statistical differences in the amount of self-reported PA (MET-mins/wk) or sitting 
time between women with PCOS and the control group. This result partially agrees with previous 
findings. Moran and colleagues (2013) analysed data from a large cohort study and found that there 
were no differences in total PA levels between women with PCOS and controls, whilst this tends to 
agree with the findings of others too (Douglas et al., 2006; Wright et al., 2004; Alvarez-Blasco et 
al., 2011; Cutler, Pride and Cheung, 2018). Similarly, a more recent study (Lin et al., 2019) also 
reported no statistical differences of PA levels between women with PCOS and a control group. In 
fact, in this study there were no differences (P ≥ 0.14) in the duration, type or intensity of PA 
regardless of the measurement methods used (i.e., accelerometry or self-report). This implies that 
PA-levels may not be a key contributing factor to the widely reported increased body weight and 
metabolic complications associated with PCOS. Indeed, both Moran et al. (2013) and Lin et al. 
(2019) reported less favourable values in women with PCOS for body weight and BMI, despite no 
differences in PA. Considering this, it is possible that these disparities may be due to differences in 
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dietary intake. Although a dietary analysis was beyond the scope of the present study, it has been 
investigated in numerous previous studies, with Moran et al. (2013) reporting higher daily energy 
intake (but better dietary quality) in women with PCOS (P = .02). Contrastingly, Lin et al. (2019) 
cite no difference in daily kcal consumption (P = .64) or key macronutrients between these 
populations, which also agrees with previous studies (Douglas et al., 2006; Wright et al., 2004; 
Alvarez-Blasco et al., 2011; Cutler, Pride and Cheung, 2018). In fact, a systematic search of the 
relevant literature identified only two additional studies in which energy intake was reportedly higher 
in women with PCOS, with Zhang et al. (2015) reporting that Southwest Chinese women with PCOS 
(n = 169) had a higher energy (KJ) and fat intake, but consumed fewer carbohydrates than their age-
matched non-PCOS counterparts (n = 338), whilst Ahmadi et al. (2013) have also reported similar 
findings with women with PCOS consuming more calories (P = .001) and fat (P = .019) than women 
without PCOS.    
As stated earlier, the present study observed no differences in weekly sitting time between women 
with PCOS and women without. To the best of the author’s knowledge, only one study has reported 
findings that contradict this result. Moran et al. (2013) report increased sitting time in women with 
PCOS compared to a control group (6.3 ± 2.8 vs 5.8 ± 2.9 hr/day; P = .008). Conversely, there is a 
significant body of literature that agrees with the present findings and reports no statistical 
differences in sitting time (Ahmadi et al., 2013; Wright et al., 2004; Alvarez-Blasco et al., 2011; Lin 
et al., 2019). Variation in these factors (PA-levels, diet and sitting time) which are established 
contributors to energy balance may well have a role in weight and anthropometric differences 
between women with and women without PCOS. However, given the contrasting findings of the 
evidence to date (including the present study) it is difficult to draw definitive conclusions.  
The current study also revealed that self-esteem, as measured by the Rosenberg Self-esteem Scale, 
was statistically lower in women with PCOS than in the control group. This is in contrast to a 
previous study (Annagür, Tazegül, & Akbaba, 2014) which reported no statistical difference in self-
esteem between women with PCOS and a control group. This may be attributed, at least partly, to 
the group characteristics in this study, since the mean BMI of both study groups was <24 kg/m2. In 
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contrast, the women with PCOS in the present study were mostly overweight or obese. Indeed, 
another study (Acmaz et al., 2013) reported significantly lower (P <.001) self-esteem across subsets 
of women with PCOS (i.e., subgroups with hirsutism, infertility and obesity) compared to healthy 
controls, but it was those with obesity (BMI ≥ 30 kg/m2) and PCOS who were far more likely to have 
the lowest self-esteem. This also tends to reflect what has been widely reported in the general 
population, with Strauss (2000) reporting that Caucasian females with obesity demonstrated lower 
levels of self-esteem than their non-obese counterparts. Another longitudinal study (n ~2400) 
followed girls from adolescence to 22 years and found that BMI was an important predictor of self-
esteem (Biro et al. 2006), whilst an Australian study also found that overweight/obesity preceded 
poor self-esteem in a mixed-gender cohort of >1100 participants (Hesketh, Wake and Waters, 2004). 
Despite the apparent relationship between excess body weight and self-esteem, there is a dearth of 
literature on this topic in women with PCOS. Many women with PCOS reportedly have poorer self-
esteem compared to their healthy counterparts, but it is unclear whether the sequelae of PCOS is 
responsible for poorer self-esteem in these women, and also whether the excess weight gain can be 
attributed to an effect that low self-esteem and depression may have upon diet (e.g., emotional eating) 
and a reluctance to exercise (Elsheik and Murphy, 2008). Alternatively, it is also likely that the 
genetic predisposition to obesity in PCOS, and the subsequent weight gain, are contributing factors 
to poorer self-esteem and that the clinical manifestations of PCOS, which are seemingly worsened 
by obesity, further exacerbate this problem. A key question to address then surrounds the impact of 
weight loss upon self-esteem and whether a concomitant improvement in physical manifestations of 
PCOS is also a driving factor in improved self-esteem. 
A recent study in a predominantly female population (Borbón-Castro et al., 2019) has reported the 
effectiveness of exercise, compared to control, at improving self-esteem (post-intervention mean 
difference: P = .005). Within PCOS cohorts, previous studies have also evaluated the effect of 
exercise/lifestyle interventions on self-esteem, with reported findings suggesting a similar effect. 
Indeed, a study in women with PCOS who completed a 6-month lifestyle intervention (incorporating 
aerobic exercise and gradual dietary changes) reported improved self-esteem (Clark et al., 1995). 
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What is less clear is whether these observed improvements were attributable to the undertaking of an 
exercise intervention or the resultant weight loss (mean change from baseline: -6.3 ± 4.2 kg; P <.001). 
Two additional studies also report similar findings (Clark et al., 1998; Galletly et al., 1996). As such, 
a larger cohort of women with obesity and fertility problems (including women with PCOS) 
demonstrated statistical improvements in self-esteem following a 6-month exercise intervention 
(Clark et al., 1998). Concomitantly, the women completing this intervention also reduced their BMI 
(-3.7 ± 1.6 kg/m2; P <.001). Galletly et al. (1996) also documented improvements in self-esteem 
alongside weight loss in a cohort of infertile women following an exercise and dietary advice group 
intervention. Given the scarcity of literature exploring the role of exercise upon self-esteem in PCOS, 
and the uncertainty surrounding the role of adiposity, future studies should further explore the 
relationship between self-esteem and body weight. 
Despite there being no statistical differences in self-reported PA between the women with PCOS and 
the control group, it is evident that women with PCOS perceive both fewer benefits (d = -0.595; P = 
.001), and a greater number of barriers (d = -0.482; P = .003) to participation in exercise. 
Contradictory to the findings of the current study, but rather unsurprisingly, it has been reported in 
non-PCOS individuals that those who perceive greater benefits and fewer barriers to exercise 
participation exercise more regularly (Grubbs and Carter, 2002) and tend to be more physically active 
in comparison to those who perceive less benefit and more barriers (Bonheur and Young, 1991; Jones 
and Nies, 1996). Indeed, it has been previously reported that perceived barriers are the most powerful 
predictor of a health behaviour (Janz and Becker, 1984). Although there is mixed evidence as to 
whether women with PCOS are less active than their non-PCOS counterparts, few studies have 
investigated the relationship between barrier/benefit perception and PCOS. One such study compared 
women with PCOS to controls and found many similarities between groups (Banting et al., 2014); 
both groups cited ‘lack of time’, ‘fatigue’ and ‘not confident can maintain’ as the top three barriers 
to participation in exercise. However, following Chi-squared goodness of fit analyses, they found 
that a statistically significant greater proportion of women with PCOS cited a lack of confidence to 
maintain (χ2 = 3.97; P = .046), fear of injury (χ2 = 4.08; P = .043) and physical limitations (χ2 = 
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11.92; P = .001) when compared to women without PCOS. A more recent study (Thomson, Buckley 
and Brinkworth, 2016) reported that the most common perceived barriers to PA were those related 
to physical exertion (i.e., exercise is tiring, hard work and fatiguing) and these findings exactly match 
the top cited barriers identified in this study. However, Thomson and colleagues (2016) further stated 
that exposure to a lifestyle intervention may improve these perceptions; total EBBS and barriers only 
scores improved 10-weeks into a lifestyle intervention (either diet only, diet and aerobic exercise, or 
diet combined with resistance and aerobic exercise), with no further statistical improvements over 
the final 10-weeks. Commencement of a new exercise regime is often perceived as fatiguing, 
particularly to those leading a previously sedentary lifestyle, and this may explain why the perceived 
barriers were reduced in the initial 10-weeks (P ≤ .001), but not during the subsequent 10-20 week 
period (P = 1.0). 
When perceived benefits were considered, slight differences between the top three cited benefits 
were reported between women with PCOS and controls; all three in PCOS focussed on improving 
fitness (i.e., exercise improves physical fitness, flexibility and cardiovascular fitness), whereas the 
control group did not mention flexibility, but cited that ‘exercise gives me a sense of personal 
accomplishment’ instead of flexibility. Despite using different methods, Banting et al. (2014) found 
no differences between women with PCOS and controls for the top five exercise motivators (1: 
weight control; 2: health improvements; 3: increased energy; 4: stress reduction; and 5: health 
maintenance), or the number of motivating factors reported by each cohort (PCOS: 8.51 ± 3.27; 
Control: 8.27 ± 2.68). In fact, it was only ‘controlling a medical condition’ that was more commonly 
cited as an exercise motivator by women with PCOS (40% vs 19%, P = .006) which is unsurprising 
as women with PCOS were compared to healthy controls. When Thomson and colleagues (2016) 
measured changes to the perceived benefits in response to a lifestyle intervention, they report findings 
that contrasted those of perceived barriers. Whereas perceived barriers were reduced in the first 10-
weeks of an intervention, there was no corresponding improvement in perceived benefits (P = .90). 
However, there were statistical improvements from weeks 10-20 (P = .003) for perceived benefits; 
it is suggested that there may be a phase, during the early stages of a lifestyle regime where the 
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individual is becoming accustomed to the changes, and a period of adaptation before the benefits 
become apparent to the individual (Thomson et al., 2016). The implication of this is that in order to 
improve PA levels in PCOS, an initial focus should be placed upon removing barriers to 
participation; PA and exercise do not influence the existence of barriers, but those who are physically 
active appear to be more capable of overcoming them (Van Zanten et al., 2015). As the intervention 
progresses, there should be a change of focus to targeting the perceived benefits in order to promote 
long-term exercise adherence (Pentecost and Taket, 2011). 
Whilst poor self-efficacy itself is not a barrier to behaviours, it reportedly influences the chosen 
activity (i.e., PA), the effort expended within those activities and the degree of persistence when 
faced with adverse events or barriers (Bandura, 1977; Bandura, 1986). Accordingly, self-efficacy for 
exercise has been shown to be a significant predictor of both exercise adoption and exercise regime 
adherence (Sallis et al., 1986). Furthermore, there is a reciprocal relationship between self-efficacy 
and the activity. For example, increased self-efficacy may contribute to the uptake of an exercise 
programme, but a negative experience may serve to lower self-efficacy, which in turn may cause 
early attrition and resistance to future participation (McAuley and Jacobson, 1991). The current study 
found no statistically significant differences in SEE between PCOS and control groups, but also no 
difference in self-reported PA or sedentary activities. Although this does suggest that there are no 
differences between the two groups in this study, it does not mean that SEE does not contribute to 
PA behaviours. Whilst not direct measures of SEE, Banting et al. (2014) report that women with 
PCOS cited a lack of confidence to maintain an exercise programme, a greater fear of injury, and 
their own physical limitations as barriers to participation, more frequently than their healthy 
counterparts. SEE was not measured in the study by Banting et al. (2014), but it could be argued that 
these traits are strong examples of low confidence in their own ability to perform PA.  
 
4.5.3. PCOS-Q domains 
Based on the data on the five PCOS-Q domains, the largest HRQoL concern of the women with 
PCOS in this study relates to weight, with the weight domain score being significantly lower than all 
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other domain scores. This is further supported by a strong negative correlation between Weight 
domain scores and self-reported BMI, indicating that the higher the BMI the greater weight-related 
concerns (i.e., lower scores) were for this cohort. This finding has also been documented in previous 
studies (McCook, Reame and Thatcher, 2004; Coffey, Bano and Mason, 2006). However, other 
studies have shown various domain scores as having the greatest impact upon HRQoL. For example, 
baseline data from a randomised controlled trial (RCT) reported that either the Weight or Infertility 
domains had the lowest mean score depending upon treatment arm (Dokras et al., 2016), whilst 
another study found the Infertility domain score to be the lowest (followed by weight) in two 
treatment arms (Vizza et al., 2016). Another RCT reported the lowest baseline data for the Body Hair 
domain in two out of three treatment arms (Stener-Victorin et al., 2013), with the Weight domain 
being the lowest in the third study arm.   
Although studies utilising the PCOS-Q are limited, a number of studies in non-PCOS populations 
that have used the SF-36 to assess HRQoL in patients with obesity. In this context, individuals with 
obesity undertaking a weight loss programme in the United States scored significantly lower across 
all domains of the SF-36 when compared to normative population data (Fontaine, Chesky and 
Barofsky, 1996). A similar study in Australia also reported that subjects with obesity scored 
significantly lower on the SF-36 Physical and Emotional domain scores when compared to age-
matched normative data (Anandacoomarasamy et al., 2009), whilst they also reported significantly 
lower Assessment of Quality of Life (AQoL) scores and significantly higher fatigue (as measured by 
the Multidimensional Assessment of Fatigue). Of note, it has also been previously reported that 
HRQoL is improved following a small to moderate weight loss (via non-surgical methods) (Rippe et 
al., 1998).   
A landmark study in women with PCOS (Balen et al., 1995) reported that an increased BMI was 
associated with increased rates of infertility and menstrual disruption, as well as with elevated serum 
testosterone levels and hirsutism prevalence. Furthermore, whilst women with PCOS are at a greater 
risk of metabolic abnormalities (Azziz et al., 2016), it has also been reported that obesity further 
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exacerbates metabolic complications (Sam, 2007). Although these symptoms are not direct measures 
of HRQoL, it is reasonable to suggest that these may also have a detrimental effect on both the 
physical and emotional components of HRQoL. The reduced self-esteem of women with PCOS in 
the current study, alongside significantly elevated BMI, also suggests that there may be a causal 
relationship between these two outcomes. 
 
4.5.4. Correlations 
The current study revealed no statistical relationship between total SF-12 scores and PA for women 
with PCOS, or the combined cohort. Similarly, there were also no significant relationships between 
the Mental and Physical domains from the SF-12 and PA performed. Furthermore, when the domain 
scores from the PCOS-Q were considered, there was no evidence of a relationship between PA and 
any of the domains; the author’s recent systematic review (Kite et al., 2019) also reported no 
statistical benefit, following exercise interventions, upon any domain of the PCOS-Q. The current 
study also found no relationship between HRQoL and weekly sitting time. Although no studies have 
assessed the role habitual PA has upon the HRQoL of women with PCOS directly, Banting et al. 
(2014) reported on PA status for some relevant outcomes, which tend to contradict the findings of 
the current study. Indeed, Banting and colleagues (2014) have found that both anxiety and depression 
(as measured by the Hospital Anxiety and Depression Scale) were significantly lower in physically 
active women with PCOS compared to inactive women with PCOS. Similarly, Lamb et al. (2011) 
found that inactive women with PCOS presented with mild depression, whereas their active 
counterparts did not (BDI: 5.5 ± 4.4 vs 3.6 ± 3.6; P = .005). This study also reported data on numerous 
cardio-metabolic outcomes (BMI, waist circumference, weight fluctuations, and fasting glucose) 
which all statistically favoured those who were active.  
It is not possible from the current results to state that women with PCOS (or in fact healthy women) 
have reduced symptoms and improved quality of life if they are more physically active. To date, 
there is some evidence that exercise interventions can contribute to perceived improvements in 
HRQoL; however, the quality of this evidence is limited and the clinical importance of these changes 
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uncertain (Kite et al., 2019). What is more widely known is that increasing PA levels in the general 
population lowers the risk of morbidity. For example, Kyu et al. (2016) meta-analysed data from 174 
studies (149.2 million total person years of follow-up) and reported that higher levels of PA are 
associated with lower risk for five common chronic diseases, including type 2 diabetes, ischaemic 
heart disease and stroke. Although reporting incidence of disease is not a direct measure of HRQoL, 
it is previously reported that those with symptoms deemed as risk factors for chronic disease 
(Fontaine, Chesky and Barofsky, 1996; Anandacoomarasamy et al., 2009), or those living with 
chronic disease (Safita et al., 2016; Westin et al., 1998) have markedly lower HRQoL than their 
healthy counterparts. The present study also indicates that women with PCOS have poorer HRQoL 
than controls, but the relationship with PA is less clear. This represents an under-researched area, 
with existing studies utilizing mostly self-report measures of PA and no direct measure of HRQoL. 
Future work should therefore employ objective measures of PA alongside well-established and 
validated measures of HRQoL. 
When correlation analyses were completed using all study participants, there were some statistically 
significant positive associations between the self-reported PA (MET-mins/wk) and Weight (τ = 
.163), BMI (τ = .139), waist circumference (τ = .137), SEE (τ = .212) and EBBS (τ = .175), albeit 
with a small magnitude (Cohen, 1988). The anthropometric findings are somewhat surprising, since, 
typically, it would be expected that those performing more PA would have lower body weight and 
waist circumference (Hu et al., 2004; Mario et al., 2016), and, if the PA type completed was mainly 
aerobic in nature, also lower BMI (Kite et al., 2019). When the study groups are split, associations 
between PA with weight and BMI only remain in the control group (τ = .262 and τ = .178, 
respectively) and the effect is slightly increased. Waist circumference ceases to have statistical 
association in either group. These findings make the data difficult to interpret and presents a potential 
limitation of this study, since it is possible that waist circumference could have been incorrectly 
measured and also that participants may have over reported their weight or height. It is also likely 
that participants have overstated their PA levels. Indeed, Prince et al. (2008) compared self-report 
measures with objective measures of PA in large meta-analyses (173 studies), showing that, whilst 
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there were no clear trends in the over- or under-reporting of PA, females self-reported higher levels 
of PA compared to accelerometers (mean percent difference = 138%). Of note, these meta-analyses 
also revealed that self-report measures that categorise PA by level of exertion (such as the IPAQ-LF) 
led to the largest total over-report, largely due to over-reporting in the higher intensity categories 
(i.e., vigorous PA). Another study (Ferrari, Friedenreich and Matthews, 2007) also found that self-
report data from females was less accurate when compared to accelerometry, but, in addition, the 
greater an individual’s BMI, then the less accurate their responses were. This may partially explain 
the surprising effects of increased weight and BMI being associated with increased PA that were 
observed in the current study. Furthermore, the self-reported MET-mins/wk in the current study 
appear to be considerably higher than both the current WHO (2010) PA guidelines (600 MET-
mins/wk) and the corresponding female normative data from the UK (Love-Koh and Taylor, 2018). 
Thus, it is likely that in the current study a response bias, potentially due to social desirability, has 
influenced the degree of over-reporting, particularly in those women with increased BMI (Prince et 
al., 2008). 
Further highlighting the importance of SEE in the uptake and maintenance of exercise/PA, there was 
a small (τ < .3), but statistically significant, positive correlation between SEE and MET-mins/wk (τ 
= .212; P <.001), and a negative correlation between SEE and weekly sitting time (τ = -.167; P = 
.006) when all participants were included in the analysis. Furthermore, the magnitude of each 
relationship was greater in only the PCOS group (MET-mins/wk τ = .404; P <.001, and sitting time 
τ = -.269; P =.002) than in the whole group. Neither of these associations were present when the 
control group was analysed independently. Although participation in PA can be attributed to a 
number of environmental, physical, social and psychological factors, an individual’s belief (e.g., self-
efficacy for exercise) in his/hers capabilities to perform physical activity is consistently cited as a 
predictor of exercise adherence and compliance (McAuley and Blissmer, 2000). Notably, previous 
research indicates that it may be only in the early stages of an exercise programme (i.e., the adoption 
phase) where self-efficacy levels successfully predict the behaviour (Oman and King, 1998). Another 
study reported that SEE was an effective predictor of long-term adherence to home-based exercise 
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programmes, suggesting that self-efficacy could be targeted in interventions, alongside barrier 
removal, to improve adherence (King et al., 1995). The contrasting viewpoint is that engagement in 
PA itself promotes improved SEE; acute bouts of exercise typically improve efficacy, but prolonged 
exposure to PA is where the greatest improvements are seen (McAuley, Lox and Duncan, 1993). The 
implication here is that, without knowing how participants in the current study were engaging in PA, 
and at what stage they were at in their PA lives, it is difficult to determine the effect of improved 
self-efficacy on PA levels. Equally, it is difficult to hypothesise whether the causal relationship is 
reversed, and that it is engagement in PA which is promoting self-efficacy levels, especially since 
there were no statistical differences between either outcome in the PCOS or control groups. 
A statistical correlation was also observed between MET-mins/wk and EBBS when all participants 
were included in the analysis, with the magnitude being smallest (τ = 0.175; P = .006) with small 
increases when only women with PCOS (τ = 0.278) or the control (τ = 0.290) were considered. When 
Benefits and Barriers were considered separately, there were statistically significant correlations of 
small magnitude for PCOS, control and all participants for each domain. This indicates that more PA 
is performed (and so self-reported for the last seven days) if participants perceive greater benefits 
and fewer barriers to exercise. Theoretical models, such as the Health Belief Model (Rosenstock et 
al., 1988), purport that an individual simultaneously evaluates the perceived exercise benefits and 
barriers associated in engaging with PA before making what they consider to be an informed decision 
whether or not to engage. This theory appears to be supported by the findings of the current study. 
Whilst the current study reports that women with PCOS perceive statistically fewer benefits and 
greater barriers to PA, the benefits and barriers with the highest mean score are similar across groups, 
with the top three barriers relating to fatigue and the top three benefits mainly related to improving 
fitness. These findings tend to be consistent with previous findings both in women with PCOS 
(Thomson, Buckley and Brinkworth, 2016) and in healthy participants (Chung-Yan Chan, 2014). As 
such, Chung-Yan Chan (2014) reports that both perceived benefits and perceived barriers to exercise 
were independent predictors of exercise behaviour, and that self-efficacy for exercise is a predictor 
of physical activity in healthy participants. Whilst the current study revealed a statistical association 
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between SEE and MET-mins/wk, there was a statistical correlation of greater magnitude between 
SEE and EBBS (τ = .340; P <.001) and this relationship was further enhanced when only women 
with PCOS (τ = .483) were included in the analysis. Indeed, SEE is widely reported to improve PA 
behaviours (Higgins et al., 2014; Schwarzer, et al., 2008) and the observed relationship between SEE 
and EBBS may play a pivotal role in contributing to PA. Bandura (1997) states that if an individual 
interprets physiological and psychological feedback positively, self-efficacy can be enhanced. If this 
is true, it can be assumed that the inverse may also be true; therefore, the three highest scored barriers 
which all relate to exercise being hard work, fatiguing and tiring, all likely contribute to decreased 
SEE and hence reduce PA levels. 
Finally, a notable correlation between self-esteem and the total and domain scores from the SF-12 
was also noted in the present study. In the whole study cohort, the magnitude of association between 
the total SF-12 and self-esteem (τ = .463) suggests that self-esteem may have an important role in 
HRQoL. Indeed, it is possible that that the causal effect may be reversed (i.e., improved HRQoL 
promotes higher self-esteem), but this effect can be further explored. When domain scores from the 
SF-12 are correlated with self-esteem, a large (τ = .535) magnitude is evident with the Mental domain 
which is far less pronounced in the Physical domain (τ = .299). Self-esteem has previously been 
identified as a major factor that impacts upon HRQoL, with Bazarganipour et al. (2014) stating that 
self-esteem, alongside body image and sexual function, significantly impaired HRQoL. However, 
using structured equation modelling, it was suggested that it was a greater severity of PCOS 
symptoms that promoted decreased self-esteem leading to poorer HRQoL. Although physical 
measurements in the current study were not taken, when PCOS-Q domain scores were correlated 
with self-esteem, it was found in all domains that the more severe participants perceived their 
symptoms (i.e., lower domain scores), the lower their self-esteem. This was observed with increased 
body weight and BMI also having statistically negative associations. Whilst increased body 
weight/BMI may be a driver of self-esteem, it is unlikely that it explains all of the variance. Miller 
and Downey (1999) meta-analysed data on this topic, revealing only a modest relationship between 
the two (d = -0.36, 95% CI: -0.33 to -0.40), although this did increase as individuals aged. Due to the 
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nature of PCOS symptoms, it is likely that the severity of individual’s physical manifestations 
directly contributes to decreased self-esteem which in turn indirectly reduces HRQoL. 
 
4.5.5. Path Analysis 
To the best of the author’s knowledge, this is the first study that has attempted to quantify the role of 
PA on HRQoL within PCOS, whilst simultaneously examining the relationship between exogenous 
variables, determinants of PA and their direct/indirect effects upon each other within a causal model. 
The use of path analysis in the study of chronic disease (including PCOS) is rare. Path analysis is a 
multivariate technique that is both exploratory and confirmatory, allowing relationship testing 
between multiple constructs within a theoretical framework. As such, it has been cited as a suitable 
statistical approach for examining associations within complex, heterogeneous diseases, such as 
PCOS (Bazarganipour et al., 2013).  
Here, the path analysis model showed little evidence that PA had any influence upon HRQoL. Indeed, 
no single outcome had any direct effect upon the amount of self-reported PA, and similarly PA did 
not have a direct effect on SF-12 scores. A statistical total effect of perceived exercise 
benefits/barriers upon MET-mins/week is reported, but this is likely due to the strength of the direct 
effect (standardised β = .52, 95% CI: .37 to .65) of EBBS upon self-efficacy for exercise (as a 
mediating variable). This relationship was the only instance where an outcome was deemed to have 
any effect upon PA levels. There may be no legitimate relationship between PA and HRQoL, but 
having previously noted some of the limitations with self-reported data, particularly that associated 
with PA, it is difficult to definitively state this. In this context, it is of note that the MET-mins/wk 
data generated from participant’s responses to the IPAQ in this study is certainly higher than UK 
population normative data. For example, using participant data from the Health Survey England 
(2014), Love-Koh and Taylor (2018) report gender specific MET-mins/wk data for different age 
groups (i.e., 16-24, 25-34, 35-44, etc.). Utilising MET calculations derived from the same source as 
the IPAQ (Ainsworth et al., 2011), the normative data they report for the most active female group 
(16-24 years) is considerably lower than that observed in the present study (mean: 2854 versus 3953 
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MET-mins/wk). It is of course possible that the participants within the current study are indeed very 
active. However, there are also a number of well documented limitations with self-reported PA data 
which may have influenced the results in the present study. Recalling PA is a highly complex 
cognitive task (Baranowski, 1988) and the instruments available may also vary in their cognitive 
demands (Sallis and Saelens, 2000). Whilst the wording of the IPAQ-LF is reasonably unambiguous, 
it is possible that the respondents have misread the question or failed to fully understand what they 
were being asked, leading to errors in the answer provided. Also, responses may have been influenced 
by social-desirability bias leading to the over reporting of weekly PA (Warnecke et al., 1997). The 
validity of PA levels may have been improved if the IPAQ-LF had been administered by a member 
of the research team either as a face-to-face (Van Dyck et al., 2015) or telephone (Hallal et al., 2010) 
interview, but this was beyond the scope of the present study. 
When direct and indirect effects were summed, the causal model identified a diagnosis of PCOS as 
having the largest total effect (standardised β = .407, 95% CI: .255 to .571) on participant’s HRQoL. 
When only direct effects were considered, the effect of PCOS upon HRQoL was comparable to the 
effect of BMI. A diagnosis of PCOS had a greater direct effect on participant self-esteem than did 
BMI, but both were statistically significant. In-turn, self-esteem had the largest direct effect upon 
HRQoL. In fact, self-esteem emerged as a key mediator between the exogenous variables and 
HRQoL (Total effect: standardised β = .324, 95% CI: .196 to .446). It is therefore likely that women 
with PCOS have a two-fold effect upon their self-esteem; that is, managing a chronic disease and its 
associated symptoms promoting lower self-esteem (Reitzes and Mutran, 2006), but also increased 
BMI (a frequent component of PCOS) contributing to poor self-esteem (Tiggemann, 2005). Another 
key consideration is the bi-directional effects of self-esteem, where chronic disease reduces an 
individual’s self-esteem, but the reverse is also true. Previous studies have identified that low self-
esteem is associated with physical dysregulation (in the context of stress) and physical health 
complications (Liu et al., 2014; Cott et al., 1999).  
In this study, women with PCOS had statistically lower self-esteem than women without. These 
findings agree with a large community-based cohort study that also reported lower self-esteem in 
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women with PCOS compared to healthy controls (Tay et al., 2019). This cohort study also found, 
that as BMI increased, self-esteem was further reduced and levels of psychological distress (as 
measured by the Kessler Psychological Distress Scale) were increased. Within the general 
population, it has been previously reported that individuals with a higher body weight/BMI 
(Tiggemann, 2005) or self-perception of being overweight (Kim and Kim, 2001) are more prone to 
impaired self-esteem. Furthermore, this effect is greater in females than males (Becerra et al., 2015). 
In the current study, when the whole cohort was included in analyses, this notion is supported, with 
the noted statistically significant negative correlation (τ = -.211; P <.001) indicating that as BMI 
increases, self-esteem decreases. However, when the data are split into case (PCOS) or control, the 
result changes. The relationship between self-esteem and BMI is still evident in women with PCOS 
(τ = -.250; P = .006), but disappears in the control group (P = .222). A potential reason for this is that 
the median BMI in the latter group is indicative that most of these women are of a weight/BMI within 
the healthy range.  
However, there are well-documented limitations with BMI, particularly regarding characterizing 
body fat distribution (Nuttall, 2015) which is an important variable in the assessment of metabolic 
health and mortality risk. As a measure of central adiposity, participants in the current study were 
asked to provide their waist circumference measurement, which again had statistical and clinical 
differences between groups. Whilst waist circumference was not included in the path analysis due a 
number of missing values in both groups, there was a high degree of correlation between the two 
variables (τ = .652). Self-esteem was negatively correlated with waist circumference in whole group 
analyses (τ = -.326) and in PCOS (τ = -.394; P <.001), whist this effect again disappeared when only 
the healthy women were included. Therefore, it is difficult to conclude from the present study 
whether it is BMI or central adiposity alone that are influencing self-esteem, or whether it is the 
sequelae associated with PCOS. A previous study (Bazarganipour et al., 2013) investigated self-
esteem in 300 women with PCOS, showing that there was no relationship with BMI, although poorer 
self-esteem was reported for women who were hirsute and/or infertile. This tends to suggest that it 
is the other manifestations of PCOS driving the impairment of self-esteem in these women. However, 
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delineating these effects was beyond the scope of this study and so to add clarity to this point, future 
research should utilise age- and BMI-matched control groups to further investigate the role of BMI 
upon self-esteem and other outcomes in women with PCOS.    
Similarly, future work may also wish to manipulate the causal flow of the model. Previously, Joseph 
et al. (2014) utilised path analysis in a healthy student population to assess the role of PA on HRQoL. 
This analysis incorporated PA as the exogenous variable, and found that individuals with higher total 
PA had increased self-esteem (β = .10; P <.001), which in turn promoted improved QoL (β = 0.30; 
P < .001). Regardless of the theoretical model’s structure, it appears that self-esteem has an important 
role in the perception of HRQoL. Therefore, interventions designed to improve HRQoL in women 
with PCOS (and potentially in other populations) should also focus at improving self-esteem and 
may wish to incorporate components utilising PA interventions (Ekeland, Heian and Hagen, 2005). 
 
4.6. Limitations 
Despite the present study achieving the recruitment target, there are some potential limitations, 
mostly associated with the manner in which study participants were recruited. Firstly, it could be 
argued that the case and control groups were recruited from different populations; or more precisely, 
that a proportion of the control group was recruited through advertisements within the local 
university. Communications were sent via internal university systems calling out for volunteers with 
or without PCOS. The control group has a higher number of participants who were students, and 
those who have a doctorate level qualification at the time of survey. Whilst not explicitly stated, this 
data tends to suggest that they may have come from the university population. The degree to which 
this may have influenced the results or introduced bias into the study is difficult to assess. When the 
recruitment methods are measured against the National Institute of Health (NIH) Quality Assessment 
tool (NIH, 2014), then it could be argued that participants were drawn from the same population. 
The eligibility criteria stipulated that women had to be UK-based, either with or without PCOS and 
recruitment for both case and control was conducted at the same time. Indeed, this could be indicative 
that women were drawn from the same population. However, if a significant proportion of one group 
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were drawn from a Birmingham-based university, the outcomes of interest may have been influenced 
by environmental factors associated with university attendance or education status. 
It was also stipulated that participants had to have PCOS or be healthy; that is free from any other 
condition that may affect their ability to perform PA. Whilst the objective behind this decision was 
an attempt to isolate the impact of a PCOS diagnosis, rather than any other comorbidity, this decision 
meant that 40 study respondents were deemed as ineligible from participating, with the majority of 
these being women with PCOS. It is widely stated that women with PCOS are more susceptible to a 
range of physical (e.g., CVD, diabetes and insulin resistance, metabolic syndrome, endometrial 
cancer) and psychological (e.g., anxiety and depression) conditions (Gilbert et al., 2018). By 
excluding these women, some key aspects of living with PCOS, and important data about the 
prevalence of comorbidities may have been overlooked.  
The fact that study data was also entirely self-reported is a methodological concern. Given the time 
constraints and the pilot nature of this study, this approach was necessary, but it may have led to 
inaccuracies in the captured data. The issues around the self-report of physical activity data are 
discussed earlier in the chapter, with the main concern being the over reporting of PA and under 
reporting of sedentary behaviours. In fact, a large systematic review has reported that there was a 
44% mean difference (favouring over-reporting) when self-report was compared to objective 
measures of PA, whilst the mean percentage difference increased to 138% when only females were 
analysed, (Prince et al., 2008). Similarly, another large meta-analysis reports that sedentary 
behaviours are under-reported by ~105 minutes per day when compared to objective measures. 
Single-item questionnaires (such as the IPAQ-LF used in this study) further increased the level of 
disagreement with sedentary time being under-reported by ~160 minutes per day (Prince et al., 2020). 
The implication for the current study is likely that participants have either consciously or 
unconsciously over-reported PA or under-reported sedentary time, which may be a contributing 
factor to these outcomes not contributing to variance in HRQoL.  
There may also be inconsistencies with the reporting of a PCOS diagnosis in this study, since formal 
diagnoses from a medical professional were not obtained for the participants. Whilst the majority of 
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participants undoubtedly will have received a formal diagnosis, it is not certain that all would have 
been through this process. The majority of women with PCOS indicated the phenotype with which 
they had been diagnosed, but ~17% were unable to provide this information. This may be due to a 
poor diagnosis experience or lack of information provision about the condition (Sills et al., 2001; 
Gibson-Helm et al., 2016). However, it is also possible that participants have self-diagnosed, without 
medical intervention, based upon their own experiences and research.  
Participants were also asked to provide their own anthropometric measurements. Previous research 
has shown that people tend to over-report their height and under-report their weight (Gorber et al. 
2006). In fact, one study in individuals with overweight or obesity has shown under reporting of 
weight by up to 6 kg (Nawaz et al., 2001). In the current study, participants were asked to also self-
report their waist circumference measurement, but ~15% of respondents did not provide that 
information. Waist circumference is an important (and practical) measure of central obesity that is 
often self-reported in population-level studies of obesity. However, it has previously been reported 
that self-reported waist circumference measurements are under-reported by participants, and that the 
degree of inaccuracy tends to be greater in women and in those with a higher BMI (Bigaard et al., 
2005), much like the women with PCOS in this study. The survey used in the current study provided 
some basic instructions about how to measure waist circumference, but in retrospect these 
instructions may have been insufficient, meaning that the size of error may have been greater, and 
uncertainty about how to measure waist circumference may also have contributed to the high rate of 
the relevant missing data. 
 
4.7. Conclusions 
The current study has highlighted less favourable values for women with PCOS, across most included 
outcomes, suggesting that women with PCOS have worse physical and mental health than their age-
matched counterparts without PCOS. In fact, women with PCOS in this study had higher body weight 
(median difference: 28.3 kg) and BMI (median difference: 9.63 kg/m2). Whilst there was no direct 
measure of body fat, the magnitude of difference reported for waist circumference (+27.60 cm) in 
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women with PCOS demonstrates that central adiposity is also statistically and clinically worse, 
increasing their risk of type 2 diabetes, cardiovascular disease and all-cause mortality. In addition, 
women with PCOS had poorer self-esteem and HRQoL, with the size of these effects suggesting that 
these between group differences may be clinically important and should be a target for improvement 
in future treatment strategies. There were no between group differences observed for weekly PA 
levels or sitting time, and nor were there any differences in perceived self-efficacy for exercise. 
Despite this, observations revealed that women with PCOS perceived fewer benefits and greater 
barriers to PA participation. What is pertinent is that despite no observed differences in the current 
study, and the fact that PA and sedentary time are integral variables in the energy balance equation, 
there are still large differences in weight between cohorts.  
Another key study finding was that a PCOS diagnosis has a more severe impact upon perceived 
mental health than it does upon physical health. Whilst both HRQoL domains were impaired in 
women with PCOS, the mental health domain was more affected. Contrary to our initial hypothesis, 
reduced HRQoL was evident irrespective of PA levels and sitting time. There was no evidence in the 
current study to suggest that those women who performed more PA and spent less time sitting had 
improved HRQoL, and this was true in both PCOS and control groups. Whilst there are the 
aforementioned limitations with self-report data, particularly self-reporting of PA and sedentary time, 
previous studies indicate that there may be some precedent for further research on the role of PA 
(and sitting time) on HRQoL in women with PCOS. Future studies may wish to utilise measurement 
methods with greater validity; objective measurement of these metrics alongside HRQoL outcomes 
should be a research priority, with the inclusion of biochemical analyses where possible. 
Whereas PA had no effect upon HRQoL in either study group, self-esteem emerged as an important 
outcome in individuals’ perceived HRQoL. For the whole cohort, there were highly significant 
positive correlations between self-esteem and the mental, physical and total domain scores of the SF-
12. However, when data were separated, the magnitude of this effect increased in women with PCOS; 
any relationship between self-esteem and the physical domain ceased in the control group. The 
importance of self-esteem was further augmented during the path analysis, where self-esteem 
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demonstrated the single largest direct effect upon HRQoL, more so than a diagnosis of PCOS or 
BMI. Self-esteem is also a key mediator between PCOS and BMI, with both outcomes having a 
direct effect upon self-esteem, which in turn influences HRQoL. What is less clear is how self-esteem 
can be improved in these women. BMI may be influenced by lifestyle and pharmaceutical 
interventions, which may in turn improve self-esteem, but PCOS cannot be prevented and there is no 
cure. Perhaps increasing PA can improve self-esteem (Spence, McGannon and Poon, 2005), but there 
is little evidence to support this notion in the current study, since the correlation coefficients between 
PA and self-esteem were close to zero regardless of the group being analysed. However, the role of 
PA in the promotion of self-esteem also warrants further investigation. The MET-mins/wk reported 
in the current study far exceed population norms causing a null relationship. Thus, it should be 
reiterated that objective measures of PA in women with PCOS should be a research priority. The 
importance of self-esteem in the promotion of HRQoL is paramount and the impaired self-esteem of 
women with PCOS is alarming. Investigation of this phenomena should be a priority for medical 
professionals and researchers alike. 
Despite the lack of evidence supporting the notion here, there is a consensus that participation in 
exercise and PA is beneficial for the participant’s mental and physical health. Prior evidence 
(although not particularly strong) suggests that exercise interventions have the potential to improve 
a range of outcomes in PCOS (Kite et al., 2019). Therefore, it is important that women with PCOS 
are achieving at least the current PA recommendations. In this context, the current study revealed 
that women with PCOS perceive more barriers and fewer benefits to PA participation than the women 
in the control group. Despite this, the top cited barriers and benefits between groups are similar with 
an emphasis upon the physical components as opposed to mental; it is largely the degree to which 
these are perceived that differs. What is also apparent in the present data is that it is those women 
who perceive fewer barriers and greater benefits that have greater self-efficacy for exercise, and, in-
turn, higher levels of PA. Correlation analyses revealed that this effect is greater in women with 
PCOS than in the control. In fact, the control group had no statistical relationship between self-
efficacy for exercise and PA performed. Despite this, the path analysis model revealed exercise 
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benefits and barriers as the only variable that had any influence upon PA, and this was achieved 
through self-efficacy as a mediator. The significance of this is that education may have an important 
role in improving both individual perceptions of PA and confidence to perform exercise. 
Furthermore, support should be offered to facilitate barrier removal and to design programmes of 
exercise that are suitable for the needs and abilities of these women. However, the methods in which 
this could be delivered are uncertain and certainly warrant further investigation. 
In summary, the present study highlights that poorer HRQoL is reported by women with PCOS 
compared to those without PCOS, and highlights self-esteem as a key factor in the promotion of 
health in this female population. Whilst previous studies suggest that PA has a key role at improving 
health in a range of populations, the link here is not apparent. This demonstrates a need for future 
studies, preferably using objective measures to better understand the impact of PA on the health of 
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Polycystic ovary syndrome (PCOS) is a common endocrine disorder, affecting up to 21% of 
reproductive-aged women (Lizneva et al. 2016). PCOS is characterised by hyperandrogenism and 
ovulatory disruption, and typically manifests in a range of undesirable symptoms such as acne, 
hirsutism and infertility (Barber et al., 2006). Women with PCOS are also at an increased risk of 
cardiometabolic disturbances, such as obesity (particularly central obesity with increased waist 
circumference), and elevated circulating cholesterol levels (Lim et al., 2012; Stepto et al., 2013; 
Cussons, Stuckey and Watts, 2007). Typically, management of PCOS focuses on lifestyle changes 
(Legro et al., 2013), incorporating increased physical activity (PA), aiming to alleviate symptoms, 
and lower the associated risk of type 2 diabetes and cardiovascular disease (CVD).  
Although increasing PA is a well-established method for improving CVD risk factors (Ekelund et 
al., 2015; Samitz et al., 2011), the effect of reducing sedentary behaviours has become a more recent 
focus. The proportion of sedentary time an individual engages in has been strongly linked to 
cardiometabolic risk, independent of PA (Tremblay et al., 2010). If a diagnosis of PCOS increases 
cardiometabolic risk, then those who are not physically active and also spend more time sitting are 
further increasing the risk of disease.  
As such, better understanding of the characteristics of women with PCOS (and their counterparts 
without PCOS), including risk factors that are modifiable (e.g., PA levels), may lead to more effective 
and targeted interventions for these risk factors, improving health-related outcomes in these women. 
Furthermore, this may allow earlier identification of individuals at risk of metabolic syndrome as a 
co-morbidity, and thus enable intervention that may reduce risk, decrease morbidity, improve patient 
quality of life, and lower subsequent health care cost. 
Consistent with the results of previous studies (Barnard et al., 2007; Ching, Burke and Stuckey, 2007; 
Coffey, Bano and Mason, 2006; Hahn et al., 2005; Jones et al., 2010; Li et al., 2011), the previous 
results chapter identified that women with PCOS have poorer health related quality of life (HRQoL) 
than women without PCOS. It was also revealed that women with PCOS have lower self-esteem than 
healthy controls and this was a key mediator in the promotion of HRQoL (Chapter 4). There is 
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contrasting evidence about the relationship between PCOS and self-esteem, but one theory relates to 
the prevalence of overweightness and obesity in PCOS, and how this influences self-esteem. Indeed, 
the previous chapter identifies that women with PCOS were statistically and clinically more 
overweight than their healthy counterparts, placing them at an increased risk of cardiovascular 
disease.  
Despite the aforementioned indicators of poorer health in women with PCOS, there appears to be no 
difference in the volume of PA performed (Douglas et al., 2006; Wright et al., 2004; Alvarez-Blasco 
et al., 2011; Cutler, Pride and Cheung, 2018) when compared to women without PCOS. Similarly, 
there are no observed differences for time engaged in sedentary behaviour when compared to a 
control group (Ahmadi et al., 2013; Wright et al., 2004; Alvarez-Blasco et al., 2011; Lin et al., 2019). 
Although contrasting the findings of a previous population-based study (Legro et al.,2013), this may 
be indicative that these outcomes have no role in the maintenance and promotion of health in women 
with PCOS. 
Previous studies have investigated the effectiveness of exercise interventions for improvement in a 
range of physiological and psychological outcomes in these women. When the results of these studies 
are meta-analysed (as in Chapter 3), some beneficial effects of exercise are observed but confidence 
in these findings are uncertain. Effect estimates generally have wide 95% confidence intervals (CIs) 
that often include negligible change and furthermore, included studies often have poorly reported 
methodologies and results. One such area that is poorly reported is the degree of compliance to 
prescribed exercise programmes; indeed, of the studies included in Chapter 3, 61% (n = 11) did not 
report any information on adherence. Without appropriate reporting, it is difficult to evaluate 
intervention integrity (Higgins and Deeks, 2008); for instance, negligible effects may be observed 
due to non-participation, and conversely, if participants receive a higher dose than that prescribed, 
results may be inflated. Whilst objective measures of PA may be preferential, self-report methods 
remain the most practical means for population-based measurement (Prince et al., 2019). One such 
example of this is the UK Biobank project; 502,617 UK-based adults were recruited into the project 
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between 2006-2010, with the vast majority completing self-report measures of PA and sedentary 
behaviour (Guo et al., 2020).  
The beneficial health-effects of PA are widely reported in previous literature; whilst these effects 
may be ambiguous in women with PCOS, it is fair to say that information about the health-effect of 
excessive sitting/sedentary behaviours as part of daily living in these women is even less clear. 
Analysis of data from the UK Biobank will provide self-report activity data for nearly all participants 
and where available, objective data for a subset too. 
 
5.2. Objectives and Hypotheses 
The objective of the present study is to address some of the research gaps identified in Chapter 4. 
The UK Biobank provides objective data on a range of physical/physiological outcomes (e.g., weight, 
glucose, testosterone, etc.) that are often associated with a greater severity of symptoms in PCOS. 
These objective measures allow a direct comparison between women with PCOS and their age-, and 
age + BMI-matched counterparts, providing an indication of the degree to which a PCOS diagnosis 
increases cardiometabolic risk. Therefore, cluster analysis was used to identify whether 
cardiometabolic risk factors cluster together in women with PCOS, and if they do, assess whether 
the clustering pattern is different compared to those without PCOS.  
Furthermore, measures of PA and sedentary behaviour also permit an evaluation of their importance 
as independent risk factors in the development of cardiometabolic conditions. Using objective and 
self-report measures, the impact of low PA levels and high sedentary time can be measured and the 
existence of differences between women with PCOS, and those without, assessed. In addition, the 
characteristics of participants included in the study can be classified according to their PA and 
sedentary behaviour profiles. Those classifications are: high PA + low sedentary behaviour (low 
cardiometabolic risk, reference group); high PA + high sedentary behaviour, and low PA + low 
sedentary behaviour (intermediate risk); or low PA + high sedentary behaviour (high cardiometabolic 
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risk), and the associations between groups and prevalence of PCOS, CVD, type 2 diabetes, and 
metabolic syndrome. 
 
The exploratory hypotheses for the current study are therefore: 
1. Women with PCOS have less favourable physical and psychological health than their 
counterparts without PCOS. Outcomes will differ between women with PCOS and the age 
+ BMI matched group but the greatest differences will occur between women with PCOS 
and the age-matched only cohort. 
2. Women with PCOS will generally have poorer metabolic health and will demonstrate a 
greater clustering of risk factors. The age + BMI-matched cohort will share many similar 
traits, but this will differ considerably from the age-matched group.  
3. There will be no between group statistical differences for PA and sedentary behaviour, but, 
those who are more physically active with the lowest time spent in sedentary behaviour will 






















5.4.1. Descriptive Characteristics 
The descriptive characteristics of the three groups are presented in Table 5.1. Assumption checks 
(distribution, skewness and kurtosis) were completed for each outcome and are reported in Appendix 
7.17. No single outcome met the assumptions for all criteria across each group. In the PCOS group, 
SBP, DBP, total cholesterol, LDL-C and IGF-1 did meet the assumptions of normality. However, 
none of these outcomes met the same requirements in the other groups; indeed, stature (age-matched 
and BMI + age-matched) and body fat % (age-matched) were the only other outcomes to meet these 
assumptions. Therefore, non-parametric statistics were used for further analyses. Kruskal-Wallis 
tests were therefore completed and between group differences were observed for all outcomes apart 








Table 5.1. Descriptive characteristics (median and IQR) of study participants and between group comparisons (Kruskal-Wallis) including outcomes relating to 
sedentary behaviour and physical activity. 
Outcome PCOS 
 





Stature (cm) 164.0 (159-167) 164 (160-168) 164 (160-168) 3.603 .165 0.00228 
Body weight (kg) 80.0 (66.8-97.8) 68.5 (61.1-80.6) 81.5 (68.5-97.3) 139.010 < .001 0.08793 
BMI (kg/m2) 30.1 (25.5-36.8) 25.4 (22.6-29.7) 30.1 (25.5-36.8) 152.935 < .001 0.09673 
Waist circumference (cm) 92.0 (80.8-106) 81.0 (73.0-91.0) 92.0 (79.0-105.0) 136.841 < .001 0.08650 
Hip circumference (cm) 108 (100-120) 101 (95.0-109) 109 (101-121) 138.988 < .001 0.08786 
WHR 0.835 (0.780-0.890) 0.80 (0.76-0.85) 0.82 (0.77-0.88) 48.442 < .001 0.03062 
WHtR 0.570 (0.490-0.650) 0.49 (0.45-0.56) 0.56 (0.48-0.64) 138.832 < .001 0.08776 
Body fat (%) 40.8 (34.3-46.0) 35.4 (29.5-40.6) 41.0 (34.2-46.0) 120.922 < .001 0.07817 
Systolic BP (mmHg) 129 (119-140) 126 (116-137) 128 (118-140) 7.864 .020 0.00527 
Diastolic BP (mmHg) 83.0 (74.0-89.0) 79.0 (72-86) 82.0 (73-88) 19.159 < .001 0.01283 
Total cholesterol (mmol/L) 5.35 (4.70-6.05) 5.41 (4.76-6.05) 5.42 (4.75-6.17) 0.502 .778 3.39e-4 
HDL-C (mmol/L) 1.30 (1.11-1.56) 1.49 (1.28-1.80) 1.38 (1.17-1.66) 59.311 < .001 0.04433 
LDL-C (mmol/L) 3.37 (2.87-3.91) 3.28 (2.78-3.81) 3.30 (2.88-3.96) 2.980 .225 0.00202 
Triglycerides (mmol/L) 1.48 (0.96-2.14) 1.09 (0.81-1.64) 1.29 (0.93-1.81) 37.323 < .001 0.02523 
HbA1c (mmol/mol) 35.2 (32.0-38.2) 33.5 (31.1-35.9) 33.9 (31.4-36.6) 27.836 < .001 0.01897 
Glucose (mmol/L) 4.81 (4.49-5.24) 4.80 (4.50-5.13) 4.84 (4.50-5.21) 0.341 .843 2.55e-4 
IGF-1 (nmol/L) 22.2 (16.9-26.3) 23.1 (19.7-27.1) 21.8 (17.9-26.4) 16.338 < .001 0.01108 
Testosterone (nmol/L) 1.19 (0.91-1.62) 1.14 (0.82-1.49) 1.18 (0.84-1.56) 6.532 .038 0.00491 
SHBG (nmol/L) 43.0 (28.9-68.2) 57.7 (39.8-80.3) 49.6 (33.8-72.3) 32.383 < .001 0.02463 
Oestradiol (pmol/L) 357 (255-619) 443 (304-637) 421 (300-660) 5.248 .072 0.00621 
CRP (mg/L) 2.00 (0.74-4.81) 1.18 (0.50-2.45) 1.93 (0.79-5.24) 53.979  < .001 0.03650 
MET-mins/wk 1386 (516-2880) 1646 (733-3230) 1493 (688-3282) 4.32 .115 0.00311 
Summed PA (mins/wk) 80 (40-150) 90 (50-155) 90 (45-160) 3.08 .214 0.00222 
MET-mins/wk VPA 0 (0-480) 240 (0-960) 240 (0-800) 16.18 < .001 0.01165 
MET-mins/wk MPA 360 (40-900) 360 (120-960) 360 (75-840) 2.18 .336 0.00157 
Screen time (hrs/day) 3.9 (2.9-5.0) 3.0 (2.0-4.0) 3.0 (2.0-5.0) 11.63 .003 0.00729 
Sedentary time (hrs/day) 4.9 (3.0-6.0) 4.0 (3.0-5.8) 4.0 (3.0-5.9) 7.64 .022 0.00479 
Key: BMI: body mass index; WHR: waist-to-hip-ratio; WHtR: waist-height-ratio; BP: blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density 
lipoprotein cholesterol; HbA1c: glycated haemoglobin; IGF-1: Insulin-like growth factor-1; SHBG: sex hormone-binding globulin; CRP: C-reactive protein; SD: standard 
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deviation; IQR: interquartile range; %: percentage of data missing form sample; P: significance level from Kruskal-Wallis test of difference; χ²: chi-square statistic; df: degrees 
of freedom (equals 2 for all outcomes); P: significance level; ε²: epsilon square effect size; reported outcomes are based upon fasted data; MET: metabolic equivalent of task; 
mins/wk: minutes per week; hrs/day: hours per day; PA: physical activity; Screen time: summed values of computer usage and TV viewing; Sedentary time: screen time and 




















Table 5.2. Dwass-Steel-Critchlow-Fligner pairwise comparisons of between group characteristics.   
Outcome Group One Group Two Median diff  
(95% CIs) 
W P 
Weight (kg) PCOS Age 11.50 (8.40, 16.20) -11.601 < .001 
PCOS BMI + Age -1.50 (-5.70, 2.90) 0.789 .843 
Age BMI + Age -13.00 (-17.00, -10.70) 15.682 < .001 
BMI (kg/m2) 
 
PCOS Age 4.70 (3.19, 6.13) -13.0269 < .001 
PCOS BMI + Age 0.00 (-1.78, 1.35) 0.0212 1.000 
Age BMI + Age -4.70 (-6.03, -3.84) 15.9619 < .001 
Waist circumference (cm) 
 
PCOS Age 11.0 (8.0, 12.5) -12.92 <.001 
PCOS BMI + Age 0.00 (-4.00, 4.00) -1.18 .684 
Age BMI + Age -11.00 (-14.00, -9.00) 14.69 <.001 
Hip circumference (cm) PCOS Age 7.00 (5.00, 11.00) -11.15 < .001 
PCOS BMI + Age -1.00 (-5.00, 1.00) 1.47 .553 
Age BMI + Age -8.00 (-12.00, -7.00) 15.89 < .001 
WHR PCOS Age 0.04 (0.02, 0.05) -8.99 < .001 
PCOS BMI + Age 0.02 (-0.01, 0.03) -3.08 .075 
Age BMI + Age -0.02 (-0.04, -0.01) 7.30 < .001 
WHtR PCOS Age 0.08 (0.05, 0.09) -13.44 < .001 
PCOS BMI + Age 0.01 (-0.02, 0.03) -1.62 .488 
Age BMI + Age -0.07 (-0.08, -0.05) 14.47 < .001 
Body fat (%) 
 
PCOS Age 5.40 (3.80, 7.40) -11.467 < .001 
PCOS BMI + Age -0.20 (-2.20, 1.30) 0.328 .971 
Age BMI + Age -5.60 (-7.60, -4.70) 14.255 < .001 
Systolic BP (mmHg) PCOS Age 3.00 (1.00, 6.99) -3.294 .052 
PCOS BMI + Age 1.00 (-4.00, 3.00) -0.570 .915 
Age BMI + Age -2.00 (-7.00, -1.00) 3.361 .046 
Diastolic BP (mmHg) PCOS Age 4.00 (1.00, 5.00) -5.22 < .001 
PCOS BMI + Age 1.00 (-2.00, 3.00) -1.09 .720 
Age BMI + Age -3.00 (-5.00, -1.00) 5.16 < .001 
HDL-C (mmol/L) 
 
PCOS Age -0.19 (-0.2, -0.12) 10.31 < .001 
PCOS BMI + Age -0.08 (-0.13, -0.03) 4.53 .004 
Age BMI + Age 0.09 (0.01, 0.22) -7.31 < .001 
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Outcome Group One Group Two Median diff  
(95% CIs) 
W P 
Triglycerides (mmol/L) PCOS Age 0.39 (0.17, 0.47) -7.95 < .001 
PCOS BMI + Age 0.19 (0.04, 0.25) -3.74 .022 
Age BMI + Age -0.20 (-0.33, -0.14) 5.97 < .001 
HbA1c 
 
PCOS Age 1.70 (0.50, 2.10) -7.48 < .001 
PCOS BMI + Age 1.30 (0.50, 2.10) -4.93 .001 
Age BMI + Age -0.40 (-0.70, 0.70) 3.11 .072 
IGF-1 (nmol/L) PCOS Age -0.90 (-3.78, -1.10) 4.286 .007 
PCOS BMI + Age 0.40 (-2.29, 0.45) 0.351 .967 
Age BMI + Age 1.3 (0.47, 2.63) -5.202 < .001 
Testosterone (nmol/L) PCOS Age 0.05 (-0.05, 0.17) -3.57 .300 
PCOS BMI + Age 0.01 (-0.06, 0.18) -2.15 .281 
Age BMI + Age -0.04 (-0.09, 0.09) 1.84 .394 
SHBG (nmol/L) PCOS Age -14.70 (-22.74, -10.92) 7.62 < .001 
PCOS BMI + Age -6.60 (-12.03, -0.92) 3.80 .020 
Age BMI + Age 8.10 (5.26, 15.58) -5.19 < .001 
CRP (mg/L) PCOS Age 0.82 (0.34, 1.05) -8.099 < .001 
PCOS BMI + Age 0.07 (-0.29, 0.38) -0.235 .985 
Age Age and BMI -0.75 (-0.83, -0.29) 9.277 < .001 
MET-mins/wk VPA PCOS Age -240 (-336, 36) 5.59 <.001 
 PCOS BMI + Age -240 (-244, 34.0) 4.47 .005 
 Age BMI + Age 0 (-31.1, 193) -1.81 .406 
Screen time (hrs/day) PCOS Age 0.90 (0.32, 1.30) -4.87 .002 
 PCOS BMI + Age 0.00 (-0.09, 0.61) -3.05 .078 
 Age BMI + Age 0.00 (-0.60, 0.09) 2.07 .307 
Sedentary time (hrs/day) PCOS Age 0.90 (0.20, 1.35) -3.881 .017 
 PCOS BMI + Age 0.00 (-0.07, 0.65) -3.058 .078 
 Age Age and BMI 0.00 (-0.48, 0.05) 0.885 .806 
Key: BMI: body mass index; WHR: waist-hip-ratio; WSR: waist-stature-ratio; BP: blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density 
lipoprotein cholesterol; HbA1c: glycated haemoglobin; IGF-1: Insulin-like growth factor-1; SHBG: sex hormone-binding globulin; CRP: C-reactive protein; W: test statistic; 




When post-hoc DSCF pairwise comparisons were made to identify where the differences lie, it was 
revealed that the majority of differences were found when the PCOS cohort were compared to the 
age-matched control group (Table 5.2). Of the 15 statistical differences that were identified, seven 
related to body composition: weight, BMI, waist circumference, hip circumference, waist-to-hip-
ratio, waist-stature ratio, and body fat percentage. Given that these groups were not BMI-matched, 
this is to be expected. Indeed, for these seven outcomes, there were no significant differences between 
the PCOS and the age + BMI-matched group, and furthermore, these differences were still apparent 
when the BMI + age-matched was compared to the age-matched only. 
Aside from body weight/composition associated outcomes, eight additional outcomes differed 
between the PCOS and age-matched cohort: DBP, HDL-C, triglycerides, HbA1c, IGF-1, 
testosterone, SHBG and CRP, with all these exhibiting less favourable values in the PCOS group. 
The age + BMI-matched group compared to the age-matched group exhibited similar differences; all 
outcomes were similar with the exception of no differences between HbA1c, and testosterone, whilst 
there was also a significant difference in SBP, with the age + BMI-matched group having higher 
values. There were also four outcomes that were significantly different when PCOS was compared 
to the age + BMI-matched group; HDL-C, triglycerides, HbA1c and SHBG all had less favourable 
values in the PCOS cohort. 
 
5.4.2. Physical Activity and Sedentary Behaviour 
For these analyses, outcomes related to either self-reported PA levels or sedentary behaviours (i.e., 
screen time, passive transport), with the least missing data were identified. None of these outcomes 
met the assumptions of a normal distribution (Appendix 7.17), so non-parametric analyses were 
completed. 
There were no statistically significant between group differences for summed MET-mins/week, 
summed weekly minutes of activity or MET-mins/week completed through moderate intensity PA 
(Table 5.1). The Kruskal-Wallis test identified a statistical difference (P <.001; ε² = 0.01165) in the 
weekly amount of MET-mins/wk achieved through vigorous intensity PA. DSCF pairwise 
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comparisons (Table 5.2) identified that these differences lay between the women with PCOS and the 
age-matched cohort (W = 5.59; P <.001), and between the women with PCOS and the BMI + age-
matched cohort (W = 4.47; P = .005). There were no differences when the two non-PCOS cohorts 
were compared. Despite statistical significance, it should be noted that, where differences exist, the 
volume of VPA is relatively small, so too is the effect size, and the 95% CIs include negligible 
differences. 
The screen time outcome, derived from the summation of TV viewing time and computer usage 
(hrs/day), and the sedentary time outcome, derived from screen time summed with driving time, both 
reported statistical significance (P = .003 and P = .022) when Kruskal-Wallis analyses was 
completed. For both outcomes, post-hoc DSCF tests (Table 5.2) revealed that between groups 
differences lay between the PCOS group and the age-matched group only (screen time: W = -4.87; 
P = .002, and sedentary behaviours: W = -3.881; P = .017). As with VPA, caution should be adopted 
in translating these findings; when comparing women with PCOS to the age-matched control, the 
actual difference represents only a small difference in minutes per day. The lower CIs represent < 20 
minutes per day for screen time and 12 minutes per day for summed sedentary behaviours. 
 
When activity levels were assessed via IPAQ categorical score, a statistical effect was found (χ² = 
10.7; P = .031) indicating that there is a significant difference between the expected and the observed 
frequencies in one or more categories (Table 5.3). The frequencies reported suggest that a greater 
percentage of women with PCOS are in the lowest level activity group when compared to the other 
groups. Furthermore, a smaller percentage of women with PCOS are categorised as achieving the 













Table 5.3. Frequencies of IPAQ activity categorisation. 




n = 253 
Age-matched 
n = 525 
BMI + Age -matched 
n = 612 
Low 77 (30.4) 109 (20.7) 134 (21.9) 
Moderate 98 (38.7) 215 (40.9) 247 (40.4) 
High 78 (30.8) 201 (38.2) 231 (37.7) 
Key: IPAQ: International Physical Activity Questionnaire; PCOS: polycystic ovary syndrome; age-matched: 
control group age-matched only to case; BMI: body mass index; BMI + age-matched: control group both BMI 
+ age-matched to case; n: total participants in analysis; Data are presented as number of participants in each 
IPAQ activity group (percentage of study group). 
  
 
Similarly, using the IPAQ results to assess whether participants met national PA recommendations 
(Appendix 7.18), a chi-squared test revealed a statistical effect (χ² = 6.06; P = .048). Despite 
statistical significance, confidence can be reduced in these findings due to significance being so close 
to the threshold (P <.05) for statistical significance (likely false positive) and from looking at the 
walking data. When walking was not included, fewer women (~9%) with PCOS met PA 
recommendations than the age-matched group; compared to the age-matched group, BMI + age-
matched women also reported 5.5% less that were meeting PA recommendations. When walking was 
included, there were no statistical differences. 
 
 
5.4.3. Health ratings and satisfaction scores 
 
All UK Biobank participants were asked to self-rate their perceived health. A chi-squared analysis 
revealed a statistically significant effect (χ² = 80.1; P <.001) indicating a difference from the expected 
frequencies (Table 5.4). Compared to the age-matched group and the BMI + age-matched group, a 
lower percentage of women with PCOS rated their health as either “Excellent” or “Good”. 
Furthermore, a higher percentage also self-rated their health as “Poor”. There are differences between 
the age- and BMI + age-matched groups, but scores tend to be less favourable in the PCOS cohort. 
The relatively high proportion of participants who have rated their health as “Excellent” or “Good” 




 Table 5.4. Frequencies for Health Rating. 
 Study Group 
 PCOS 
n = 319 
Age-matched 
n = 637 
Age and BMI-matched 
n = 638 
Excellent 32 (10.0) 103 (16.2) 95 (14.9) 
Good 133 (41.7) 382 (60.0) 327 (51.3) 
Fair 95 (29.8) 122 (19.2) 162 (25.4) 
Poor 58 (18.2) 29 (4.6) 50 (7.8) 
Do not know 1 (0.3) 1 (0.2) 3 (1.3) 
Prefer not to answer 0 (0) 0 (0) 1 (0.2) 
Key: IPAQ: International Physical Activity Questionnaire; PCOS: polycystic ovary syndrome; age-matched: 
control group age-matched only to case; BMI: body mass index; BMI + age-matched: control group both BMI 
+ age-matched to case; n: total participants in analysis; Data are presented as number of participants in each 
IPAQ activity group (percentage of study group). 
 
A smaller number of participants (PCOS: n = 134; age-matched: n = 217; age + BMI-matched: n = 
223) responded to the questions about their satisfaction with a range of outcomes related to 
psychosocial components of their life. When their health satisfaction was assessed (Figure 5.1A), 
chi-squared analysis found a statistical effect (χ² = 44.6; P <.001). A higher proportion of women 
with PCOS stated that they were either “extremely unhappy”, or “very unhappy” with their health 
compared to the other cohorts. Conversely, a lower percentage stated that they were “Very Happy” 







Figure 5.1. A. Frequencies for health satisfaction; B. Frequencies for happiness; C. Frequencies for 




Similarly, when participants were asked to rate their happiness (Figure 5.1B), it was the age-matched 
cohort who were the happiest, with ~38% having stated that they were “Very Happy” compared to 
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31.4% and 21.6% in the Age + BMI-matched and the PCOS group, respectively. A higher proportion 
of women with PCOS were “Moderately Happy” compared to their non-PCOS counterparts. Women 
with PCOS and the Age + BMI group had similar levels of moderate unhappiness, but a greater 
number with PCOS were either “Very Unhappy”, or “Extremely Unhappy”.  
Analysis of frequencies for Family Satisfaction (Figure 5.1C) revealed a statistically significant 
effect (χ² = 27.0; P = .019). A greater proportion of women with PCOS were either “Moderately 
Unhappy”, “Very Unhappy” or “Extremely Unhappy” with their familial situation. In contrast, the 
largest proportion of those who were “Very Happy” (49.3%) came from the Age-matched group.  
When responses on Financial Satisfaction were analysed (Figure 5.1D), a significant effect was 
observed (χ² = 33.6; P = .002); a greater number of women with PCOS reported greater 
dissatisfaction with their financial situation than the number of women in the other groups. In 
contrast, the large majority of the Age-matched group (81%) responded positively to this question. 
Analysis of Friendship Satisfaction (Figure 5.1E) revealed no statistical significance between groups 






Table 5.5. Frequencies and χ² tests of frequencies for comorbidities (interpreted from ICD10). 
 PCOS (n = 318) Age (n = 638) Age + BMI (n = 638) χ² P 
 Frequency % Frequency % Frequency % 
Type 2 diabetes 49 15.4 17 2.7 30 4.7 63.90 <.001 
Type 1 diabetes 7 2.2 4 0.6 6 0.9 5.11 .078 
Hypertension 97 30.4 61 9.6 91 14.3 71.60 <.001 
Hypercholesterolaemia 35 11.0 18 2.8 29 4.5 29.70 <.001 
Hyperlipidaemia 2 0.6 4 0.6 7 1.1 1.05 .592 
Heart Disease 10 3.1 8 1.3 11 1.7 4.27 .118 
Obesity 59 18.5 27 4.2 58 9.1 52.7 <.001 
Liver Disease 2 0.6 1 0.2 0 0 4.51 .105 
Kidney Disease 10 3.1 4 0.6 7 1.1 10.70 .005 
Chronic Lung Disease 57 17.9 58 9.1 69 10.8 16.6 <.001 
Anxiety/Depression 15 4.7 13 2.0 19 3.0 5.28 .071 
Benign Cancer 40 12.5 32 5.0 32 5.0 23.70 <.001 
Malignant Cancer 20 6.2 37 5.8 28 4.4 1.96 .376 
Key: n: number from each study group; %: percentage with or without comorbidity from each cohort; Yes: positive diagnosis for comorbidity; No: no diagnosis 
for comorbidity; χ²: chi-square statistic; P: significance value from χ²; PCOS: women with PCOS group; Age: age-matched control group; Age + BMI: age and 




When tests of frequencies were analysed for comorbidities (Table 5.5), statistically significant chi-
squared tests were returned for type 2 diabetes, hypertension, hypercholesterolaemia, obesity, kidney 
disease, chronic lung disease, and benign cancers. Without exception, prevalence was higher for 
women with PCOS than the other two cohorts. In fact, prevalence of type 2 diabetes was ~6 times 
greater in women with PCOS than in the age-matched group, and ~3 times that of the BMI + age-
matched group. Similar trends were observed for hypertension (approximately twice more prevalent 
than the BMI + age-matched group), hypercholesterolemia (approximately 2.5 times as prevalent 
than the BMI + age-matched group) and kidney disease (approximately 3 times more prevalent than 
the BMI + age-matched group). The difference between women with PCOS and the age-matched 
only group was even more pronounced. 
When the total number of comorbidities, and only those linked to metabolic health were summed 
(Appendix 7.19), an ANOVA Kruskal-Wallis test revealed differences for both total comorbidities 
(χ² = 109; P <.001) and metabolic morbidity (χ² = 116; P <.001). DSCF analyses revealed that women 
with PCOS had significantly more comorbidities (PCOS vs age-matched: W = -14.26; P <.001; 
PCOS vs age + BMI-matched: W = -11.12; P <.001) and metabolic complications (PCOS vs age-
matched: W = -14.83; P <.001; PCOS vs age + BMI-matched: W = -10.45; P <.001) than those 
without. The age- and BMI + age-matched groups were more similar although there all comparisons 
were statistically significant. 
 
5.4.4. Cluster Analysis 
As described in the methods section, outliers 1.5*IQR above the third quartile or below the first 
quartile were replaced with the 95th or 5th centile, respectively, for each outcome in each group. The 
vast majority of outliers were transformed from above the third quartile with only seven cases 
trimmed below the first quartile. A description of the cut-off points and replacement outlier values 
(i.e., 5th and 95th centile) are presented in Appendix 7.13. 
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Many outcomes demonstrated highly significant correlations (Table 5.21), but the magnitude of the 
test was low in many instances (i.e., r ± < 0.30). Assessment of magnitude allows removal of 
outcomes where they are essentially reporting the same phenomenon. For example, LDL-C and total 
cholesterol (r = .946), SBP and DBP (r = .742), BMI with waist circumference (r = .917), and BMI 
with body fat (r = .888) are all unsurprisingly highly positively correlated. Because the strength of 
correlation is so great between these pairs, one from each pair can be removed. Although BMI is a 
measure of body weight widely used to define obesity status, it was felt that waist circumference and 
body fat reveal more about the metabolic status of the participant regarding central obesity and 
adiposity, respectively, and thus BMI was removed from additional analyses. 
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Table 5.6. Pearson correlation coefficients using complete pairs between any two variables. 
 HDL-C SHBG IGF-1 Test CRP WC BF% HbA1c DBP TG SBP BMI LDL-C TC 
HDL-C               
SHBG .400***              
IGF-1 .063 -.101***             
Test -.100** -.108*** .036            
CRP -.247*** -.142*** -.328*** .139***           
WC -.486*** -.421*** -.300*** .145*** .519***          
BF% -.413*** -.396*** -.260*** .132*** .461*** .861***         
HbA1c -.174*** -.256*** -.176*** .071* .247*** .344*** .257***        
DBP -.163*** -.247*** -.085** .100*** .262*** .439*** .465*** .138***       
TG -.408*** -.263*** -.169*** .016 .198*** .432*** .364*** .255*** .245***      
SBP -.058* -.191*** -.110*** .077** .191*** .320*** .336*** .213*** .742*** .200***     
BMI -.476*** -.422*** -.303*** .142*** .595*** .917*** .888*** .361*** .467*** .414*** .330***    
LDL-C -.006 -.151*** -.040 .018 .062* .181*** .219*** .100*** .197*** .334*** .175*** .169***   
TC .266*** -.041 -.042 -.017 .009 .074* .119*** .076** .160*** .331*** .171*** .055* .946***  
Key: HDL-C: high-density lipoprotein cholesterol; SHBG: sex hormone binding globulin; IGF-1: insulin-like growth factor-1; Test: testosterone; CRP: C-
reactive protein; WC: waist circumference; BF%: body fat percentage; HbA1c: glycated haemoglobin; DBP: diastolic blood pressure; TG: triglycerides; SBP: 
systolic blood pressure; Group: cohort; LDL-C: low-density lipoprotein cholesterol; TC: total cholesterol. *: P ≤ .05; **: P ≤ .01; ***: P ≤ .001. 
 




When missing data was analysed, SHBG (17.5%) had the largest amount of data missing, followed 
by, Total testosterone (16.6%), and HDL-C (16.1%). All other outcomes had ≤ 8% of data missing 
(Appendices 7.14 and 7.15). In fact, of these data, no single variable had zero missing data, 36.1% 
(n = 575) cases had some missing data. This equates to ~9% of values missing. 
Missing variable analysis revealed 39 unique patterns of missing data (Appendix 7.16). The most 
common pattern (n = 1020 cases) is no missing data for the included variables (Appendices 7.4 and 
7.5). The next most common missing patterns are SHBG and HDL-C as a pair (n = 112 cases); 
testosterone only (n = 107 cases); cholesterol, CRP, triglycerides, LDL-C, IGF-1, HDL-C, 
testosterone and SHBG all missing (n = 64 cases); HbA1c only (n = 64); DBP and SBP are also 
frequently missing pattern together (n = 62 cases).   
Although cholesterol and LDL-C had a similar amount of missing data, they exhibit a near perfect 
correlation (r = .946) with each other; it is not necessary to include both outcomes on further analyses. 
Total cholesterol was removed as it was more positively correlated with HDL-C (r = .266). 
Similarly, waist circumference and body fat have a strong positive correlation (r = .861) and are 
similar measures. Because waist circumference has fewer missing data and better describes the 
distribution of adiposity in participants, body fat was removed from subsequent analyses. 
Removing these outcomes reduced missing data patterns to 31 and marginally increased the number 
of complete cases to 1043. Little’s MCAR test was re-run on the amended data set (χ² = 274.289, df 
= 227; P = .017) indicating data missing not at random. Accordingly, data imputation was carried 
out on the following outcomes: waist circumference, DBP, SBP, CRP, HbA1c, HDL-C, IGF-1, LDL-
C, SHBG, testosterone and triglycerides.  
Four participants had no data for any of the included outcomes so it was not possible to impute 
missing data. These participants were removed from subsequent analysis. The descriptive statistics 
(mean ± SD) for each outcome before and after multiple imputation are presented in Appendix 7.21. 
Once missing values had been imputed, data was standardised before K-means cluster analysis was 
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completed (Appendix 7.22). Change in cluster centres and between cluster ANOVAs are presented 
in Appendices 7.22 and 7.23, respectively.
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Table 5.7. Descriptive statistics of outcomes included in Cluster 1 and Cluster 2. 
 Mean ± SD 95% Confidence Interval Median (IQR) Skewness Kurtosis Shapiro-Wilk 
P 
Cluster 1        
Waist circumference (cm) 80.26 ± 10.38 79.61 to 80.9 79 (15) .624 .251 <.001 
Diastolic BP (mmHg) 76.85 ± 8.86 76.30 50 77.40 77 (12) .148 .105 .047 
Systolic BP (mmHg) 124.03 ± 14.09 123.16 to 124.90 123 (18) .590 .500 <.001 
C-reactive protein (mg/L) 1.58 ± 2.03 1.45 to 1.70 0.95 (1.51) 3.433 15.73 <.001 
HbA1c 32.77 ± 3.34 32.57 to 32.98 32.8 (4.3) .313 1.844 <.001 
HDL-C (mmol/L) 1.59 ± 0.32 1.57 to 1.61 1.57 (0.44) .288 -.377 <.001 
IGF-1 (nmol/L) 24.13 ± 5.56 23.79 to 24.27 23.87 (7.49) .253 -.113 <.001 
LDL-C (mmol/L) 3.21 ± 0.69 3.17 to 3.25 3.16 (0.91) .316 .285 <.001 
SHBG (nmol/L) 70.51 ± 29.92 68.66 to 72.36 66.40 (36.75) .856 .884 <.001 
Testosterone (nmol/L) 1.18 ± 0.47 1.15 to 1.21 1.13 (0.59) .718 .552 <.001 
Triglycerides (mmol/L) 1.11 ± 0.46 1.08 to 1.14 1.01 (0.58) 1.254 2.080 <.001 
Cluster 2        
Waist circumference (cm) 104.83 ± 13.44 103.73 to 105.92 103 (16) .473 .050 <.001 
Diastolic BP (mmHg) 88.07 ± 8.74 87.36 to 88.78 87 (11) .094 -.264 .003 
Systolic BP (mmHg) 138.56 ± 14.59 137.38 to 139.75 137 (21) .287 -.149 .001 
C-reactive protein (mg/L) 6.25 ± 5.07 5.83 to 6.66 4.75 (6.72) 1.252 1.369 <.001 
HbA1c 37.28 ± 5.17 36.86 to 37.70 36.4 (5.7) 1.168 2.051 <.001 
HDL-C (mmol/L) 1.23 ± 0.25 1.21 to 1.25 1.21 (0.31) .633 .638 <.001 
IGF-1 (nmol/L) 20.13 ± 5.96 19.65 to 20.62 19.98 (8.43) .214 -.265 .019 
LDL-C (mmol/L) 3.65 ± 0.75 3.58 to 3.71 3.60 (1.09) .018 -.240 .176 
SHBG (nmol/L) 39.15 ± 21.53 37.40 to 40.90 34.54 (23.46) 1.749 6.319 <.001 
Testosterone (nmol/L) 1.33 ± 0.55 1.28 to 1.37 1.27 (0.65) .767 .575 <.001 
Triglycerides (mmol/L) 2.07 ± 0.88 2.00 to 2.14 1.90 (1.08) .998 1.180 <.001 
Key: BP: blood pressure; HbA1c: glycated haemoglobin; HDL-C: high-density lipoprotein cholesterol; IGF-1: insulin-like growth factor-1; LDL-C: low-density 
lipoprotein cholesterol; SHBG: sex hormone binding globulin; SD: standard deviation; IQR: inter-quartile range; P: significance value.
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Table 5.7 shows the descriptive statistics of each outcome separated by cluster number. Without 
exception, the values of cluster one are more favourable (i.e., associated with healthier status) than 
those presented in cluster two. In addition, when cluster membership by cohort is analysed, there is 
a relatively even split for women with PCOS (Cluster one: 48.7% vs Cluster two: 51.3%). The 
difference is slightly increased when cluster membership of the Age + BMI cohort is considered; 
~56% have membership in Cluster One. There are a far larger proportion of Age-matched women 
(~78%) in Cluster One. Looking at Cluster Two membership, the data reveals that women with PCOS 
have the highest proportion of their cohort as members, this is followed by the Age + BMI-matched 
(7.4% less than PCOS) and Age-matched only (29.2% less than PCOS). Table 5.8 shows the 
proportion of study group that make up each cluster. Although, women with PCOS have half as many 
cases as the other group, they still make up nearly a third of Cluster two. 
 
 
Table 5.8. Overview of cluster membership based upon study comparator group. 
 PCOS Age-matched Age + BMI matched 
Cluster One, n (%) 155 (15) 496 (49) 357 (35) 
Cluster Two, n (%) 163 (28) 141 (24) 279 (48) 
Key: PCOS: polycystic ovary syndrome cohort; Age-matched: cohort that are age-matched only with 
the PCOS cohort; Age + BMI-matched: cohort that are matched with the PCOS cohort using both 
age and body mass index; n: number from study group in cluster; %: percentage of cluster from each 
study group. 
 
Figures 5.2 and 5.3 present the median and interquartile ranges for each outcome separated by cluster 
number. Within cluster, data are presented by cohort/group membership. Statistical analysis was not 





Figure 5.2. Data presented are median values of each study group separated by cluster membership. A. waist circumference scores; B. diastolic blood pressure 
(BP) scores; C. systolic blood pressure (BP) scores; D. C-reactive protein scores; E. HbA1c (mmol/mol) scores; F. HDL-C scores; Coloured box represents 




Figure 5.3. Data presented are median values of each study group separated by cluster membership. A. IGF-1 scores; B. LDL-C scores; C. SHBG scores; D. 
testosterone scores; E. triglycerides scores; coloured box represents interquartile range; the lower whisker is the 1st quartile and upper whisker is the 4th quartile. 
Coloured dots outside of whisker are outliers.
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Using the clusters as categorical groups, descriptive statistics and tests of difference (Table 5.9) were 
completed for key outcomes relating to PA behaviours, namely weekly PA (MET-mins/wk) and total 
sedentary time (hrs/day). These analyses show that cluster one has significantly more MET-mins/wk 
performed (d = 0.23; P <.001) and less sedentary behaviour per day (d = 0.43; P <.001).  
Using independent samples t-tests, there were no statistical differences for the number of 
comorbidities (mean difference: 0.08; P = .204) or metabolic morbidities (mean difference: 0.03; P 
= .237) between clusters. However, when data is split by cohort, within each cluster (Figure 5.4), it 
is clear that in cluster one, women with PCOS have a greater number of comorbidities. These data 
also do not account for their PCOS diagnosis. 
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Table 5.9.  Descriptive statistics for selected variables for Cluster One and Cluster Two and test of difference using Mann-Whitney U independent samples.  
 Cluster One Cluster Two Mean 
difference 
95% CIs of 
difference 
U Cohen’s d P 
MET-mins/wk 1792 (2644) 1182 (2134) 610 276 to 796 179608 0.226 <.001 
Sedentary time (hrs/day) 4.00 (2.00) 5.00 (3.00) -1.00 -1.29 to -0.80 218352 -0.434 <.001 
Key: MET-mins/wk: metabolic equivalent of task minutes per week as measured by the IPAQ; SD: standard deviation; IQR: interquartile range; mean diff: 
mean difference between cluster; 95% CI of diff: 95% Confidence interval of difference; U: test statistic; P: significance level 
 
Figure 5.4. Comparison of mean number of total comorbidities (A) and metabolic comorbidities (B) separated by study group for each cluster. Error bars 
represent 95% confidence intervals. 
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5.4.5. Risk profiles of Physical activity and sitting 
When the PA and sitting time data was split into 50th centiles and used to create a new categorical 
variable intended to reflect risk of ill health, 207 participants were excluded because data from one 
of the two variables was missing (i.e., PA or sitting time). The majority of missing cases (n = 199) 
came from missing data on MET-mins/week performed. Descriptive statistics for missing cases are 
presented in Appendix 7.24 whilst the descriptive statistics for the remaining participants are 
presented in Tables 5.10 and 5.11. 
Table 5.10. Descriptive statistics for physical activity and sitting outcomes in each risk profile. 
Risk Group N MET-mins/wk  
Mean ± SD 
Sitting time (hrs/day)  
Mean ± SD 
High PA, Low Sit 394 3901 ± 2418 3.15 ± 0.82 
High PA, High Sit 297 4001 ± 2391 6.20 ± 1.77 
Low PA, Low Sit 325 735 ± 433 3.20 ± 0.82 
Low PA, High Sit 366 632 ± 444 6.99 ± 2.76 
Key: PA: physical activity (MET-mins-wk); Sit: sitting time (hrs/day); SD: standard deviation 
 
Figure 5.5 presents the percentage of study group (i.e., women with PCOS, age-matched controls, or 
age- and BMI-matched controls) membership that makes up each risk group based on PA and sitting 
time. It should be noted that the age-matched and the age- + BMI-matched study groups have twice 
as many participants than the women with PCOS. However, it can be seen that women with PCOS 
have the largest contribution in the Low PA, High Sit group (23%), which is equivalent to ~26% of 
















Table 5.11. Descriptive statistics for each physical activity (PA) and sedentary behaviour (sitting time; Sit) risk group and Kruskal-Wallis test results. 
 High PA, Low Sit High PA, High Sit Low PA, Low Sit Low PA, High Sit W P 
Age (yrs) 44.00 (6.00) 45.00 (7.00) 45.17 (6.00) 45.00 (7.00) 3.188 .364 
Waist circumference (cm) 79.00 (19.00) 87.00 (21.00) 85.00 (22.50) 94.50 (26.00) 99.627 <.001 
BMI (kg/m2) 26.40 (8.85) 25.25 (7.21) 29.65 (12.00) 29.88 (10.71) 84.952 <.001 
Diastolic BP (mmHg) 78.41 (13.93) 82.00 (13.35) 79.00 (15.78) 83.00 (13.00) 27.887 <.001 
Systolic BP (mmHg) 126.00 (20.00) 128.00 (21.54) 128.00 (21.00) 129.00 (23.62) 14.250 .003 
C-reactive protein (mg/L) 1.24 (2.24) 1.67 (3.00) 1.56 (3.07) 2.41 (5.12) 46.804 <.001 
HbA1c (mmol/mol) 33.40 (4.30) 34.00 (5.25) 33.70 (5.16) 34.75 (5.93) 27.471 <.001 
HDL-C (mmol/L) 1.52 (0.45) 1.41 (0.44) 1.46 (0.48) 1.33 (0.45) 46.801 <.001 
IGF-1 (nmol/L) 22.66 (7.38) 23.66 (8.29) 22.99 (7.63) 21.74 (8.83) 14.128 .003 
LDL-C (mmol/L) 3.22 (0.99) 3.38 (1.00) 3.30 (0.97) 3.39 (1.04) 6.849 .077 
SHBG (nmol/L) 63.65 (39.71) 51.66 (36.45) 53.47 (37.65) 48.26 (39.17) 42.538 <.001 
Testosterone (nmol/L) 1.13 (0.64) 1.19 (0.59) 1.20 (0.60) 1.21 (0.67) 7.899 .048 
Triglycerides (mmol/L) 1.08 (0.80) 1.27 (0.90) 1.16 (0.78) 1.42 (1.04) 41.959 <.001 
MET-mins/wk 3165.00 (2626.00) 3230.00 (2816.00) 720.00 (676.75) 594.00 (773.25) 1038.250 <.001 
Sitting time (hrs/day) 3.00 (1.00) 5.90 (2.00) 3.00 (1.10) 6.00 (3.00) 1042.807 <.001 
Key: BMI: body mass index; BP: blood pressure; HbA1c: glycated haemoglobin; HDL-C: high-density lipoprotein cholesterol; IGF-1: insulin-like growth 
factor-1; LDL-C: low-density lipoprotein cholesterol; SHBG; sex-hormone binding globulin; MET-mins/wk: metabolic equivalent of task minutes PA 









 Figure 5.6. Pairwise comparison (Mann-Whitney U) of waist 
circumference between physical activity (PA) and sedentary time 
(siting time; Sit) risk groups/categories. ** = P <.01; *** = P 
<.001. 
Figure 5.7. Pairwise comparison (Mann-Whitney U) of body mass 
index (BMI) between physical activity (PA) and sedentary time (sitting 
time; Sit) risk groups/categories. * = P <.05; *** = P <.001. 
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Table 5.12. Pairwise comparisons of physical activity (PA) and sedentary time (siting time; Sit) risk 
groups/categories. Analysis completed using Mann-Whitney U. 
Outcome Group One Group Two U P 
Diastolic BP High PA, Low Sit High PA, High Sit -2.876 .024 
High PA, Low Sit Low PA, High Sit -5.005 <.001 
Low PA, Low Sit Low PA, High Sit -3.587 .002 
Systolic BP High PA, Low Sit Low PA, High Sit -3.705 .001 
CRP High PA, Low Sit High PA, High Sit -2.820 .029 
High PA, Low Sit Low PA, High Sit -6.767 <.001 
Low PA, Low Sit Low PA, High Sit -4.214 <.001 
High PA, High Sit Low PA, High Sit -3.516 .003 
HbA1c High PA, Low Sit Low PA, High Sit -5.012 <.001 
Low PA, Low Sit Low PA, High Sit -3.801 .001 
High PA, High Sit Low PA, High Sit -2.935 .020 
HDL-C High PA, High Sit Low PA, High Sit -3.407 .004 
Low PA, Low Sit Low PA, High Sit -4.328 <.001 
High PA, Low Sit Low PA, High Sit -6.742 <.001 
High PA, Low Sit High PA, High Sit -2.907 .022 
IGF-1 High PA, Low Sit Low PA, High Sit -2.760 .035 
Low PA, Low Sit Low PA, High Sit -2.799 .031 
High PA, High Sit Low PA, High Sit -3.381 .004 
Triglycerides High PA, Low Sit High PA, High Sit -3.354 .005 
 High PA, Low Sit Low PA, High Sit -6.214 <.001 
 Low PA, Low Sit Low PA, High Sit -4.359 <.001 
Key: CRP: C-reactive protein; HbA1c: glycated haemoglobin; HDL-C; high-density lipoprotein 
cholesterol; IGF-1: insulin-like growth factor-1; U: Mann-Whitney test statistic; P: statistical 
significance. 
 
Table 5.11 presents the descriptive statistics [median (IQR)] of participants classified in each PA and 
siting time risk group. Furthermore, Kruskal-Wallis test results are presented demonstrating that all 
outcomes, apart from age and LDL-C, contain statistically significant between groups differences. 
Pairwise comparisons were performed using Mann-Whitney U tests (Table 5.12, Figures 5.6 to 5.9), 
showing that the greatest number (n = 11), and magnitude of differences were between the High PA, 
Low Sit and the Low PA, High Sit group. In addition, when the High PA, Low Sit was compared 
with the High PA, High Sit group (n = 7), and when the Low PA, Low Sit was compared with the 
Low PA, High Sit group (n = 7), there was an identical number of statistical findings. This tends to 
support the notion that sedentary behaviours have an integral role to play in health maintenance. 
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When the High PA, High Sit was compared to the Low PA, High Sit group, a further five differences 
were observed, and a further three when the High PA, Low Sit compared with the Low PA, Low Sit 
group. There were no observed differences for any outcome between the High PA, High Sit and the 
Low PA, Low Sit group. Without exception, outcomes favoured the risk group with more PA and 
less sitting time.  
Finally, morbidity prevalence was reported for the lowest risk group (Figure 5.10), and comparisons 
made to the highest risk group. It was observed that there was a 63% greater chance of having PCOS 
if in the high-risk group. Furthermore, for all other measured morbidities, prevalence was greater and 












Figure 5.8. Pairwise comparison (Mann-Whitney U test) of 
sex hormone binding globulin (SHBG) between physical 
activity (PA) and sedentary time (sitting time; Sit) risk 
groups/categories. * = P <.05; ** = P <.01; *** = P <.001 
Figure 5.9. Pairwise comparison (Mann-Whitney U test) of 
testosterone between physical activity (PA) and sedentary time 




Figure 5.10. Prevalence of morbidity for those with low risk behaviours (high physical activity and low sedentary/sitting time) and relative risk of disease 












5.5.1. Key Findings 
The current chapter aimed to build upon the findings of the previous chapter by addressing some of 
the research gaps that were identified. The initial analyses looked for differences between the three 
study groups. For outcomes related to body weight/composition, there were statistical differences 
between women with PCOS and the age-matched group; women with PCOS were heavier, with 
higher BMI and larger waist circumferences. However, these findings were not unique to women 
with PCOS, since the same differences were evidenced between the age + BMI-matched cohort and 
the age-matched only group. Because the women in the age + BMI-matched group were BMI 
matched to the women with PCOS, these findings may not be particularly surprising. However, this 
suggests that there appear to be no significant differences in the degree, or indeed the distribution of 
adiposity in women with PCOS when compared to an age + BMI-matched group without PCOS. 
Similarly, no observed difference was identified for numerous additional outcomes between women 
with PCOS and the age + BMI group; including DBP, IGF-1, testosterone, and CRP. However, both 
the women with PCOS and the age + BMI-matched group had statistically less-favourable values 
than the age-matched only cohort. Furthermore, there were certain notable differences between the 
women with PCOS and the age + BMI-matched cohort, with the former exhibiting a less favourable 
profile regarding HDL-C, triglycerides, HbA1c and SHBG. The magnitude of these less favourable 
effects was greater when women with PCOS were compared to the age-matched group. Although of 
a smaller magnitude than those with PCOS, the age + BMI-matched women also had statistically 
lower HDL-C and SHBG, and greater levels of triglycerides than the age-matched only group. 
In agreement with the findings presented in Chapter 4, there were no statistically significant between 
group differences in PA performed per week (either MET-mins/week or summed mins/week). 
However, when PA intensity was assessed, statistical differences in MET-mins/week achieved 
through vigorous intensity activity was lower in women with PCOS than either comparator group. 
There was no corresponding difference for MET-mins/week achieved through moderate intensity 
activity. Differences were also observed for sedentary behaviours; screen time and summed 
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sedentary time was statistically higher in women with PCOS than the age-matched only group. To 
further support these findings, when the IPAQ categorisation data was assessed for each group, a 
greater proportion (~9% more) of women with PCOS were in the low activity category, and fewer in 
the high-activity category, than either comparator group. Women with PCOS also had the smallest 
proportion meeting PA guidelines (i.e., 150 mins/week moderate intensity, 75 mins/week vigorous 
intensity or a combination of both) regardless of whether walking was accounted for in the 
calculation. 
In addition to the outcomes noted above, all participants were also asked to rate their satisfaction on 
a number of psychosocial variables. Women with PCOS tended to view their own health less 
favourably (i.e., perceived health rating and health satisfaction) than either comparator group. 
Similarly, women with PCOS largely reported less favourable scores for happiness, familial 
satisfaction, and financial satisfaction. Some of these less favourable scores may be due to incidences 
of comorbidity in women with PCOS. Prevalence of diagnosed type 2 diabetes, hypertension, 
hypercholesterolemia, obesity, kidney disease, chronic lung conditions and non-invasive cancers 
were statistically higher in women with PCOS compared to the other two study groups. Indeed, when 
total morbidities and only those associated with metabolic health (type 2 diabetes, 
hypercholesterolaemia, hyperlipidaemia, and obesity) were compared, they were statistically higher 
than either of the other groups. 
When cluster analysis was completed, two distinct clusters were identified. Based on the outcomes 
used to cluster, the average values in Cluster One (n = 1,008) were without exception, more 
favourable. Cluster Two demonstrated inferior health in all of these key biological markers. The 
majority of the age-matched (77.9%) and the age + BMI-matched (56.1%) participants were included 
in Cluster One. Indeed, it was only the women with PCOS that had their majority in Cluster Two and 
although this was approximately half (51.3%). In fact, 28% of Cluster Two was comprised of women 
with PCOS, compared to only 15% in Cluster One. The derived clusters were then used as categorical 
variables in subsequent analyses where outcomes relating to PA levels were compared. The total 
MET-mins/week of PA performed were statistically higher (MD: 535.18 MET-mins/week; d = 
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0.226) in the cluster with a more favourable health profile (as measured by circulating factors). In 
addition, those with a better health profile also spent less time (MD: 1.04 hrs/day; d = -0.434) engaged 
in sedentary behaviours each day. The number of morbidities (total and metabolic) were compared 
between clusters; no statistical differences were observed but, when separated by study comparator 
group membership, women with PCOS had the highest number of morbidities even when their PCOS 
diagnosis was excluded from the analysis.  
The final analysis grouped all participants into categorical groups based upon their total level of 
weekly PA (MET-mins/wk) performed and their time spent in sedentary time each day. Women with 
PCOS had the largest proportion of their group in the high-risk group (Low PA, High Sit), although 
the age + BMI-matched group closely followed this. When membership of the low-risk group was 
analysed (High PA, Low Sit), women with PCOS had the smallest proportion of their cohort in this 
group. Conversely, the age + BMI-matched cohort had the highest proportion of their group in the 
low-risk group. It should be noted that the age + BMI-matched cohort had only 4.4% of their total 
participants excluded from this analysis due to incomplete data (compared to PCOS: 21.3%, and age-
matched: 17.7% missing). When biomarkers were compared between these risk groups, statistical 
effects were observed for all outcomes apart from LDL-C. When pairwise comparisons were made 
to identify where the differences lay, it became apparent that the highest number of differences were 
between the lowest risk group and the highest risk group. Furthermore, the magnitude of these 
differences, without exception, was larger than any other pairwise comparison; from a health 
perspective, the values observed in the low-risk group for each outcome were favourable. Similarly, 
if categorised as high-risk, there was a 63% greater chance of having PCOS when compared to the 
low-risk group and furthermore, risk factors for metabolic syndrome and CVD all carried a greater 






The implications of these findings mean that: 
The null hypothesis that women with PCOS will not have a less favourable physical and 
psychological health profile than their counterparts without PCOS can in all likelihood be rejected. 
Compared to the age-matched cohort, women with PCOS had worse indicators of health across the 
majority of explored variables. When compared with the age + BMI-matched cohort, there were 
more similarities (particularly those linked to anthropometry). However, even where statistical 
significance was not evident, recorded values tended to be less favourable.  
For the second hypothesis, the null hypothesis must be rejected. The variation in metabolic 
health markers between women with PCOS and the BMI + age-matched cohort is negligible. Whilst 
there are many differences between women with PCOS and the age-matched only cohort, it is hard 
to ascertain the cause of these differences. Indeed, excess weight appears to be a key indicator of 
worsened health. However, it should be noted that when cases were grouped into two clusters, women 
with PCOS had the highest proportion (>51%) of their cohort as members in the cluster that would 
be classified as having poorer health. The BMI + age-matched cohort (~44% membership) and age-
matched (~22% membership) were predominantly allocated into the cluster with more favourable 
health outcomes. 
The null hypothesis that there would be no statistical between group differences in PA 
performed and time spent in sedentary behaviours must also be rejected. Whilst there were no 
differences in total MET-mins/wk or total minutes, women with PCOS performed significantly less 
vigorous PA per week, and spent more time engaged in sedentary behaviours, than their age-matched 
counterparts. It can however be accepted that regardless of PCOS diagnosis, those who are the most 
active, and spend the least amount of time sitting have the lowest cardiometabolic risk. 
 
5.5.2. Between group differences 
When outcomes associated with anthropometry and body composition were analysed, it was 
observed that women with PCOS had a significantly higher body weight, BMI, waist circumference 
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and body fat percentage than the age-matched women without PCOS. Whilst these findings agree 
with those presented in Chapter 4, the findings in the present study offer increased confidence 
because, as opposed to the self-report data captured in the previous chapter, data here were 
objectively measured in the UK Biobank testing centres. Whilst it has been widely reported that 
women with PCOS tend to be more overweight than their non-PCOS counterparts (Kiddy et al., 
1990; Balen et al., 1995; Yildiz et al., 2008), it is a reasonably novel approach to compare the body 
compositional outcomes of these women to (age and) BMI-matched women without PCOS. The 
women in the age + BMI-matched cohort within the current study were selected based upon their 
lack of a PCOS diagnosis, but also because their BMI was closely matched to the women with PCOS. 
What was not factored into their inclusion were their waist circumference or their body fat 
percentage. Previous studies have cited that the distribution of adipose tissue in women with PCOS 
tends to be more central (Talbott et al., 1995; Taponen et al., 2003), resulting in greater metabolic 
disruption. However, this does not appear to be evident across the current sample; there are negligible 
differences for waist circumference (MD: 1 cm) and body fat (MD: 0.01%) between the two cohorts.  
These findings tend to agree with previous studies albeit in much smaller samples; Orio et al. (2004) 
compared 30 overweight women with PCOS to an age + BMI-matched group and reported no 
statistical differences in waist-hip ratio (WHR). Similarly, Dolfing et al. (2011), compared a small 
group (n=10) of women with PCOS with 10 matched controls and found no significant differences 
in WHR or fat mass in these groups. The findings of the present study add confidence to these 
previous studies by including a sample size that is approximately 10 times greater; although women 
with PCOS are more likely to be overweight or obese than women without PCOS, when BMI is 
matched, the differences in the volume and distribution of adipose tissue is negligible. 
It is common knowledge that engaging in regular PA can help to minimise weight and fat gain and 
that maintenance of a physically active lifestyle is an effective strategy to improve obesity-related 
health outcomes irrespective of any concomitant weight loss (McArdle et al., 2015). However, when 
the PA levels of these women are compared, there are no statistical differences between each study 
cohort for the MET-mins/wk performed or the weekly minutes spent engaged in PA of any duration. 
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These findings agree with those from Chapter 4 and a number of previous studies that included 
measures of self-reported PA (Moran et al., 2013; Douglas et al., 2006; Wright et al., 2004; Alvarez-
Blasco et al., 2011; Cutler, Pride and Cheung, 2018). Lin et al. (2019) further supported these 
findings by incorporating objective measures of PA and assessing PA intensity levels; they reported 
no statistical differences in duration, type or intensity of activity. Whilst the UK Biobank did not 
capture the type of PA (beyond walking) that participants were engaged in, the relative intensity was 
captured and this is where, in contrast to Lin et al. (2019), significant differences were identified. 
Women with PCOS achieved fewer MET-mins/week through vigorous PA than either the age-
matched (MD: 185.8 MET-mins/week; P <.001) or BMI + age-matched (MD: 104.8 MET-
mins/week; P = .005) comparator groups. No corresponding differences were observed between the 
age-matched and the BMI + age-matched despite the differences in BMI, body fat and waist 
circumference. Lower body fat percentage has previously been associated with higher levels of 
Vigorous PA, but not for moderate PA (Gutlin et al., 2005). The importance of Vigorous PA levels 
in the maintenance of healthy weight is unclear. 
Another contrasting factor, is time spent engaged in sedentary behaviours; compared to the age-
matched cohort, women with PCOS had more screen time (TV viewing and computer usage) and 
more total sedentary time (0.4 hrs/day). Sedentary time is a known risk factor, independent of PA 
(Biswas et al., 2015), for a multitude of undesirable health outcomes, and, although the sedentary 
behaviours may also be a contributing factor to less favourable body composition, similar differences 
were not evident between the BMI + age-matched and the age-matched cohort. This could suggest 
that sedentary time may not be a key factor in outcomes relating to body composition for this 
population, but the chronic effects of longer-term increased sedentary time may lead to future health 
complications.  
However, what is not reported in the current study is the opposing side to the energy balance 
equation, which is calories consumed. Food diaries and other measures of caloric consumption were 
not reported in the present study, but differences in dietary habits almost certainly play a role in body 
composition (Schröder et al., 2004), and metabolic health (Fung et al., 2009), as well as in health-
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related quality of life (Milte et al., 2015). Despite the lack of reporting dietary habits in the current 
study, numerous studies have previously reported no differences between the caloric intake of 
women with PCOS compared to their non-PCOS counterparts (Douglas et al., 2006; Wright et al., 
2004; Alvarez-Blasco et al., 2011; Cutler, Pride and Cheung, 2018, Lin et al., 2019). In fact, from 
searching the relevant literature, only three contradictory studies were located. Indeed, Moran et al., 
(2013) cited higher daily energy [+215 KJ/day (~50 kcal); P = .02] consumption in women with 
PCOS compared to controls, but the women with PCOS incidentally had higher body weight and 
BMI than the control group. This study also factored in PA levels, reporting no statistical differences 
in PA performed, yet women with PCOS were sedentary for 30 mins more per day. Zhang and 
colleagues (2015) noted a considerably greater daily energy consumption in women with PCOS 
(~3664.1 KJ/day; P = .01) compared to BMI-matched healthy controls. Finally, Ahmadi et al. (2013) 
report that women with PCOS consumed ~300 kcal more per day than a healthy BMI-matched group, 
although, despite this increased calorie consumption, there were no statistical differences in body 
weight or BMI between these groups.  
Collectively, the findings of this chapter (and Chapter 4), alongside the findings of previous studies, 
indicate that women with PCOS have increased body weight and BMI compared to age-matched 
women without PCOS, but it appears that PA levels are not mediators or predictors of this 
phenomenon. The relationship between PCOS, BMI and sedentary time may demonstrate a causal 
effect; women with PCOS are inactive for longer periods each day when compared to age-matched 
controls. However, the BMI + age-matched cohort showed no statistical variation from the age-
matched group despite much less-favourable body composition; they also did not differ from the 
PCOS cohort. Thus, it is likely that, the magnitude of differences in PA and sedentary time are not 
responsible for observed differences in BMI, but as in any population, they may be contributing 
factors. These findings highlight the need for a comprehensive study that incorporates (preferably 
objective) measures of PA and sedentary time alongside analysis of dietary composition in order to 
gain a fuller understanding of their impact. 
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If factors pertaining to lifestyle are not fully implicated in overweight and obesity in PCOS, the 
findings of this study may be able to implicate some additional mechanisms. Teede et al. (2013) state 
that PCOS is an independent risk factor for overweight and obesity and that a bi-directional 
interaction exists, where PCOS causes a physiological and/or psychological environment that 
promotes weight gain and weight that is gained leads to increased prevalence and severity of PCOS 
symptoms. It is clear from the study results that the less-favourable values observed for most 
outcomes are likely due to excess body weight and/or increased adiposity. Indeed, for women with 
PCOS and the BMI + age-matched cohort, the majority of circulating biomarkers and physical 
measurements are significantly worse than the age-matched (and lower weight) cohort. However, 
four outcomes are statistically less favourable in women with PCOS than the BMI + age-matched 
study group, namely differences in HbA1c, HDL-C, triglycerides and SHBG levels between these 
groups, which will be the focus of the following paragraphs. 
One potential mechanism that demonstrates the aforementioned bi-directional relationship is the 
elevated HbA1c observed in PCOS. The current study found that women with PCOS had 
significantly higher levels of HbA1c than their counterparts without PCOS, even where participants 
were age and BMI-matched. HbA1c develops during hyperglycaemia when glucose bonds with 
haemoglobin in the blood and is typically used as a diagnostic/monitoring biomarker for 
diabetes/glycaemic control, typically representing the of average plasma glucose over the previous 
8-12 weeks (Nathan, Turgeon and Regan, 2007). Considering that a normal value for HbA1c is < 42 
mmol/mol (WHO, 2011), the average HbA1c values for women within this study are normal, but 
those recorded for women with PCOS are closer to the threshold for pre-diabetes (42-47 mmol/mol). 
Despite statistical significance (P <.001), the small magnitude of these differences tends to agree 
with the findings of previous studies. Ollila and colleagues (2017) reported similar values to those in 
the current study and when statistically controlling for variation in BMI, reported a statistical (but 
likely not clinically relevant) difference in HbA1c (P = .029). Sadaria and Ravi (2015) reported small 
variation between groups, but no statistical effect for HbA1c levels between age and BMI-matched 
women with and without PCOS. 
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In fact, it appears that it is only when the PCOS and control groups are not BMI-matched (that is the 
women with PCOS have higher BMI) that statistical and clinically relevant variation is observed in 
HbA1c. In age-matched women, Bala et al. (2017) noted elevated HbA1c and a markedly higher 
prevalence of type 2 diabetes and prediabetes in women with PCOS compared to controls. Similarly, 
additional studies have made similar comparisons and found again that women with PCOS had 
higher HbA1c levels than their counterparts without. However, these women were either not age- or 
BMI-matched (Ansari et al., 2017; Fuad and Alobaidy, 2018), or matching was not specified 
(Sathisha et al., 2020). A further study investigated prevalence of prediabetes (using HbA1c ≥ 5.7% 
as a diagnostic cut-point) in obese and lean women with and without PCOS (Kim et al., 2012). Whole 
cohort analysis (unmatched groups) revealed HbA1c to be higher (~20.9 mmol/mol) in women with 
PCOS and this was further supported by diagnoses of prediabetes. Of the non-obese women with 
PCOS, 31% were prediabetic compared to ~6% of controls. Although women with obesity and PCOS 
had a higher prevalence of prediabetes, there was more parity in these groups (23.5% vs 20% 
respectively), albeit from a smaller sample (n = 32). 
It is also pertinent to note that elevated HbA1c may promote weight gain (Ridderstråle et al., 2016). 
Higher HbA1c is indicative of a chronic elevation of blood glucose, which in turn increases insulin 
production. Insulin mediates facilitated diffusion of glucose into cells and when the body has met its 
energy demand quota, and glycogen stores are full, excess carbohydrates are converted into 
triglyceride molecules where they are stored as fat in adipose tissue, leading to weight gain (McArdle, 
Katch and Katch, 2015). It seems that HbA1c is elevated in women with PCOS and that there is a 
positive correlation with several anthropometric, metabolic and androgenic factors (De Medeiros et 
al., 2014). Indeed, in the general female population, HbA1c level is associated with CVD risk (Singer 
et al., 1992), and this is further compounded in PCOS (Kim et al., 2012).  
Between group differences were identified for lipid related parameters (triglycerides and HDL-C). 
Given the known associations that elevated triglycerides (Hjellvik, Sakshaug and Strøm, 2012) and 
HDL-C (Williams et al., 1994) have with overweightness, obesity and cardiometabolic risk, it is 
unsurprising that both women with PCOS and the age + BMI-matched groups had significantly less 
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favourable values for these lipidaemic parameters than the age-matched only group. However, the 
observation that women with PCOS had less favourable values for circulating triglycerides and HDL-
C than their BMI + age-matched counterparts was less expected. In the diagnostic criteria for 
metabolic syndrome (MetS), the diagnostic cut off point for triglycerides is ≥ 150 mg/dL (WHO, 
1998; IDF, 2005; NCEP ATP III, 2005), and for HDL-C in women is < 50 mg/dL (IDF, 2005; NCEP 
ATP III, 2005) (Alberti and Zimmet, 1998, Alberti, Zimmet and Shaw, 2006). When using standard 
conversion factors (triglycerides: mmol/L * 88.57; HDL-C: mmol/L * 38.67), the mean values 
reported for both these factors in the PCOS study group indicate that mean circulating triglyceride 
levels are indeed > 150 mg/dL, and that, although just above the aforementioned cut-off point, the 
mean HDL-C levels (52.6 mg/dL) are also low. 
Indeed, certain abnormalities in lipidaemic profiles, including low circulating levels of HDL-C and 
elevated triglycerides, are associated with increased CVD risk (Wilson et al. 1988; Bass et al., 1993), 
and are strong independent predictors of CVD-related death in women. Another used method of 
assessing CVD risk utilises plasma triglyceride to HDL-C concentration ratio (TG/HDL-C), with 2.5 
mg/dL-1 used as a cut off point for being at risk (Salazar et al., 2012). It has been further reported 
that an elevated TG/HDL-C ratio is as effective as the MetS diagnostic criteria at predicting the 
development of CVD (Salazar et al., 2013). Results from the current study indicate that women with 
PCOS are the only group that cross this threshold (TG/HDL-C ratio: 2.94 mg/dL-1) indicating that 
they are at an increased risk of cardiometabolic illness. Moreover, dyslipidaemia in women with 
PCOS has been previously reported (Kousta and Franks, 2007), with previous findings in line with 
those of the current study. Indeed, women with PCOS have been found to have higher circulating 
triglycerides (Talbott et al., 1995; Talbott et al., 1998; Pirwany et al., 2001), and lower HDL-C 
concentrations (Wild et al., 1985; Talbott et al., 1995; Talbott et al., 1998) when compared to women 
without PCOS.  Other studies also reported higher total cholesterol, LDL-C and very low-density 
lipoprotein cholesterol levels, which persisted when controlling for overweightness and obesity 
(Mather et al., 2000; Vrbikova et al., 2003). 
263 
 
Finally, the current study identified that SHBG was significantly lower in women with PCOS 
compared to either control group. A key feature of PCOS is hyperandrogenism; ovarian androgens, 
androstendione and testosterone are frequently elevated (Carmina, 2002) resulting in the common 
features of hyperandrogenism in PCOS, such as acne and hirsutism, androgenic alopecia and even 
virilisation that patients often present with (Pasquali et al., 1997; Davison et al., 2005; Elmlinger et 
al., 2005). SHBG concentration plays an important role in the metabolic clearance of sex hormones, 
as well regulating their bioavailability to target tissues. SHBG levels can vary substantially between 
individuals since its hepatic production and circulating concentrations are influenced by nutritional, 
hormonal and metabolic factors (e.g., insulin levels) (Allen et al., 2002) as well as diseases such as 
PCOS. Accordingly, reduced SHBG concentrations are widely reported in women with PCOS 
compared to those without and is often associated with overweight or obesity and insulin resistance 
(Teede, Meyer and Norman, 2005). Thus, even when testosterone levels are within the normal range, 
decreases in SHBG levels result is an increase in the bioavailable (free) testosterone/androgens 
(Deswal, Yadav and Dang, 2018), consequently increasing the peripheral androgen activity and 
potentially leading to manifestation of symptoms of hyperandrogenism). Despite the lack of reported 
PCOS-specific symptoms in the current study, the differences in biomarkers between each group 
tend to support the above points. In the present study there are no statistical or clinical differences 
between groups for total testosterone, yet the women with higher BMI have decreased SHBG and 
this is further compounded by a diagnosis of PCOS.  
 
5.5.3. Physical activity and ill health 
The results from the current chapter also provide additional information about the contribution of PA 
to a range of health-related parameters in women with PCOS (and indeed the control groups). Whilst 
the previous chapter found that women with PCOS had poorer HRQoL compared to a control group, 
it also revealed that there was no significant relationship between PA and HRQoL. Although the 
measures in the current chapter are still based upon self-reported data, the presented results indicate 
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that the PA is indeed an important component in the reduction of CVD risk and the maintenance of 
health.  
The performed cluster analyses grouped cases together based upon their within cluster similarities, 
whilst making them as varied as possible from other clusters based upon the outcomes used for 
clustering. In the current study, this analysis revealed that the best solution separated cases into two 
clusters and each outcome included was statistically different to the comparable data in the other 
cluster. Further than that though, the analysis has essentially created a cluster (cluster one) with a 
profile of more favourable measurements across all outcomes compared to the second cluster; that is 
cluster one members generally have reduced central adiposity, lower BP, improved lipidaemic 
parameters and less free circulating androgens. In order to gain a better understanding of this, cluster 
membership was investigated based upon PCOS and other group membership. Women with PCOS 
have a higher proportion of their group as members of cluster two and make up a greater proportion 
of cluster two than cluster one. This is not surprising, considering the aforementioned results 
indicating that women with PCOS had less favourable levels of circulating biomarkers than either of 
the other study groups. The other factors that may have influenced cluster membership were of course 
those relating to PA and sedentary behaviour. 
Chapter 4 revealed no between group (PCOS versus control) statistical differences for either weekly 
PA performed or sitting time and this is partially supported in the current study. There were no 
between group differences for total weekly PA performed, but women with PCOS completed less 
vigorous PA than either of the other cohorts and, they also spent more time engaged in sedentary 
behaviours than the BMI + age-matched group. Given the relatively small magnitude of these 
differences, it is questionable whether this alone could explain variation in health markers. Total 
MET-mins/wk and daily sitting time were used as dependent variables in statistical analyses, and it 
was revealed that women in the cluster with the healthier profile (cluster one) engaged in ~550 MET-
mins/wk more PA, and ~1 hr/day less sitting time than those in cluster two.  
 Notably, current PA guidelines (CMO, 2019) recommend that activities equivalent to 600 MET-
min/wk are beneficial for good mental and physical health. In this study, the average values reported 
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by both clusters, far exceed this recommendation. The all-cause mortality benefits of PA are based 
upon an inverse linear dose-response relationship (Lee and Skerrett, 2001); that is, the more PA 
performed, then the longer life an individual will have. In fact, it has previously been revealed that, 
when compared to those engaging in no PA, individuals performing 3-5 times the PA 
recommendations (as is reported in the current study) have a 39% lower risk of premature all-cause 
mortality (Arem et al.,2015). Furthermore, an additional 4.5 years in life expectancy can be gained 
when weekly PA exceeds 1350 MET-mins/wk (Moore et al., 2012). When considering morbidity 
rather than mortality, it is those completing the greatest volume of PA that have the greatest risk 
reduction for chronic disease. For example, those achieving 5-6 times the PA guidelines have relative 
risk reductions of 28% for type 2 diabetes, 26% for ischaemic stroke, and 26% for coronary artery 
disease compared to those falling below the guidelines (Kyu et al., 2016). From the data reported in 
the current study, both clusters should benefit from the protective effects of being physically active, 
but there is a marked difference in health status. This variation may be explained in part by the 
difference in weekly PA, but the magnitude of beneficial effects becomes less marked when 
comparing relatively high volumes; for example, those performing 22.5-<40 MET-hrs/wk or 40-<75 
MET-hrs/wk have identical mortality risk (0.61) over time in a study by Arem et al. (2015). 
Another possible explanation for health variability may concern time spent in sitting behaviours. 
Sedentary behaviour is an independent risk factor for chronic disease and premature mortality (Owen 
et al., 2010). In fact, it has been demonstrated that individuals must complete high levels (> 35.5 
MET-hrs/wk) of PA to protect against prolonged bouts of sitting (Ekelund et al., 2016). In a 
longitudinal study (Saidj et al., 2013), prolonged daily sitting has been demonstrated to be a predictor 
of fasting insulin, VO2max and waist circumference, independent of PA.  
Some potential mechanisms to explain the independent association of sedentary behaviours with 
cardiometabolic health have been purported; lipid and glucose metabolism are severely impaired 
during sedentary activities and this is thought to be due to the inactivity of large skeletal muscles that 
are usually engaged when standing/moving (Hamilton, Hamilton and Zderic, 2004; Tremblay et al., 
2010). Another suggested mechanism relates to the dysregulation of haemodynamic vascular 
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signalling; that is an absence of exercise-induced vascular dilation which promotes inflammatory-
mediated atherogenesis (Raschke and Eckel, 2013; Young et al., 2016) leading to a narrowing of 
blood vessels. In addition to the physiological responses to sitting, Bowman (2006) suggests that 
when engaged in sedentary behaviour, particularly TV/computer usage, diet is substantially changed; 
total energy intake is increased, and macronutrients consumed are less desirable. These two factors 
(total calorie intake and poor diet quality) are also risk factors for premature mortality and 
determinants of type 2 diabetes (Kant et al., 2000). Finally, the timings of sedentary behaviour may 
also be key in determining the degree of harm; Almoosawi et al. (2012) suggest that prolonged screen 
time is more likely to occur in the evening, following most people’s main meal of the day. The 
implication is that postprandial glucose and lipids are elevated with a potentially harmful effect to 
cardiovascular health.  
What is clear from the current study is that, compared to the most active individuals, those who are 
the least physically active and spend the most amount of time in sedentary behaviours, have the least 
favourable markers of metabolic health regardless of their health status (i.e., PCOS or control). 
Unfortunately, it appears that women who have PCOS are more likely to be classified as high risk 
based on their activity levels than low risk; this categorisation means that they have an increased risk 
of developing other chronic health conditions. In this context, it is reasonable to assume that unless 
they become more physically active and spend less time sitting, their metabolic health could further 
deteriorate and the sequelae of PCOS could be further exacerbated.  
 
5.6. Limitations 
Whilst the obvious strengths of the current study are the large number of participants with PCOS that 
are included, and that large comparator groups of matched participants were also analysed, the lack 
of PCOS-specific data used to define participants is a potential limitation. The UK Biobank project 
reports participants’ health conditions, allowing for the women with PCOS to be identified, but it 
does not report any further diagnostic criteria and since, as previously described, there are different 
phenotypes within PCOS based on the applied diagnostic criteria which are not defined/reported 
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within the current study. Whilst Chapter 4 of this thesis reported negligible differences between 
phenotypic subgroups for a range of self-reported outcomes, including perceived quality of life, it 
was not possible to make similar comparisons with the outcomes included in the present study. It has 
previously been reported (Diamanti-Kandarakis and Panidis, 2007) that there are variations in the 
biochemical profiles of women with PCOS dependent upon the phenotype with which they have 
been diagnosed. One such variation is the degree of insulin resistance and/or metabolic syndrome 
(Legro, 2007), and its increased prevalence in those who are hyperandrogenic and anovulatory 
(Mehrabian et al., 2011). The identification of women with PCOS who are at increased risk of type 
2 diabetes and CVD could have been facilitated if phenotypic prevalence measures were completed 
in this study.  
Another limitation of the current study surrounds the omission of several outcomes that are specific 
to PCOS and its treatment. Circulating hormones such as luteinising hormone (Liu et al., 2012), 
follicle stimulating hormone (Elsheikh and Murphy, 2008), anti-Mullerian hormone (Piouka et al., 
2009) and progesterone (Li et al., 2014) are all implicated in the pathophysiology of PCOS and the 
severity of its symptoms. However, these hormones are not available in the current UK Biobank data 
set. Furthermore, had it been possible to include PCOS specific quality of life measures such as the 
PCOS-Q, alongside those circulating biomarkers that have been reported in the current study, an 
objective assessment of key metabolic risk factors could have been conducted.    
The age of included participants is another limitation of this study. UK Biobank participants are aged 
between 40 and 69 years; whilst PCOS symptoms are evident in reproductive-aged women and the 
characterisation of the related sequalae in post-menopausal women with PCOS remains understudied 
(Schmidt et al., 2011). PCOS is indeed a heterogeneous condition with a complex pathophysiology 
(Kovacs and Norman, 2007), but it is also a dynamic syndrome that manifests with different clinical 
and metabolic traits throughout the reproductive age (Tannus et al., 2018). Young women of 
reproductive age, tend to present with the full features of hyperandrogenism, anovulation and 
polycystic ovaries (depending upon diagnostic criteria). In contrast, women with PCOS over the age 
of 40 years tend to report reduced incidence of hyperandrogenaemia (Hsu, 2013).    
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There are also potential limitations in the sedentary behaviour data; because the UK Biobank data 
does not explicitly ask about total daily sitting time, there are some uncertainties in the data. Firstly, 
the data sums total minutes driving, using a computer and watching TV; this may miss other 
sedentary activities from participants’ day-to-day routines. There is some evidence however (Prince 
et al., 2020) that multi-item questionnaires may result in more accurate reporting of self-report 
sedentary time. In addition to questionnaire format, there is no evaluation of when these sedentary 
periods occurred making it difficult to establish the role of the aforementioned mechanisms in 
metabolic health. Finally, it is unclear whether the sedentary bouts were continuous or accumulated 
throughout the day; Healy et al. (2008) found that interrupting prolonged bouts of sedentary time 
with short activity breaks was beneficial for a range of CVD risk factors.   
Finally, another potential study limitation relates to the prevalence of PCOS within the UK Biobank 
sample. Conservative estimates report that 6-8% of reproductive-aged women are affected by PCOS 
(March et al., 2010), but some estimates report prevalence as high as 21% (Lizneva et al. 2016). 
Here, from a sample of ~250,000 women, only 319 were classified as having PCOS, which equates 
to 0.13% prevalence in this sample. The exact reasons for this reduced prevalence is unclear, but it 
may be partly explained by the age of the population that is included in the UK Biobank sample.  
 
5.7. Conclusion 
The findings of the current study build upon those of the previous chapter. Whereas the previous 
chapter identified that women with PCOS had less favourable self-reported anthropometric measures 
and perceived HRQoL, the current study benefitted from more objective measures. Similarly to 
previous findings, when compared to a random sample (age-matched cohort), more women with 
PCOS were classified as having overweight/obesity with poorer markers of metabolic health. The 
findings that women with PCOS are at a greater risk of poor cardiometabolic health are generally 
supported by the existing relevant research. Moreover, the current study also benefitted from a large 
comparator group that was matched both for BMI and age, thus removing a variable that potentially 
has a large mediating role in an individual’s health (Trent et al., 2005). 
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The current study did not include a specific HRQoL measurement (such as the SF-12), but it was 
revealed that a higher proportion of women with PCOS self-rated their health as “poor”(+10.4%), or 
that they were “extremely unhappy” with their health satisfaction (+6.5%) compared to their BMI + 
age-matched counterparts. This may be a fairly crude indicator that PCOS, as opposed to elevated 
BMI, is having a negative effect upon their own health perceptions. However, the objectively 
measured metabolic and hormonal biomarkers also indicate that women with PCOS have worse 
health profiles, or increased risk of worse health, than their counterparts without PCOS. It is true that 
the greatest observed differences were between women with PCOS and the age-matched cohort only, 
whilst it is also pertinent that statistical differences were lacking when women with PCOS were 
compared to the BMI-matched group. This is indicative that increased body weight and/or adiposity 
has a significant role in metabolic dysregulation and clearly, if women with PCOS are more 
susceptible to overweight and obesity (Lim, Davies and Moran, 2012), this should be a treatment 
priority. However, there are a number of outcomes (HDL-C, triglycerides, HbA1c and SHBG) that 
are less favourable for women with PCOS even when controlling for BMI. This suggests that PCOS 
further disrupts biological processes which has a two-fold effect; that is further exacerbation of PCOS 
symptoms and increased risk of CVD and or type 2 diabetes. 
The current study also agrees with previous studies (and the previous chapter) in that there are no 
differences in the amount of PA performed between women with PCOS and the control groups. 
However, in contrast to many previous studies, it was apparent that women with PCOS performed 
less vigorous PA each week and spent more time in sedentary behaviours; the cumulative effect of 
this may explain some of the variability, but it is unlikely to be responsible for the large differences 
observed in key outcomes when compared to the age-matched only cohort. Where this study builds 
upon previous findings is through the use of clustering; when the study clusters were created, it 
became apparent that they were diametrically opposed in terms of health status. Cluster One had 
more favourable values for all outcomes, whereas Cluster Two was opposing. It was also apparent 
that the majority of participants from the non-PCOS cohort were assigned to the cluster with the 
healthier profile, but women with PCOS were split almost evenly between the two, supporting the 
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notion that a PCOS diagnosis further disrupts the health profile of a large proportion of women with 
PCOS. 
Regardless of PCOS diagnosis, additional factors defined the two clusters. Cluster One were more 
physically active and spent less time engaged in sedentary behaviours than those in Cluster Two. 
Whilst it is feasible that some individuals may not engage in physical activity due to ill health 
(Macniven et al., 2014), there were no statistical differences in the number of morbidities (excluding 
PCOS) between the two clusters. This cluster pattern indicates that being physically active and 
spending less time sitting are important variables in the preservation of health in these women. When 
women with PCOS are considered individually, these findings support current treatment 
recommendations for lifestyle improvements, with the women with PCOS who have the most 
favourable health measures being also the ones who are more physically active. 
Overall, considering both the findings and the limitations of the current study, a need for further 
projects in women with PCOS is also highlighted. The UK Biobank is a valuable resource for 
population level enquiry, but it may not be the most suitable resource for disease specific enquiry, 
particularly for certain conditions such as PCOS. Indeed, studies such as this one, offer further insight 
which generate subsequent research ideas and generate informed hypotheses, but are also limited in 
their ability to make definitive statements/conclusions. As with previous chapters, this again 





































The work presented in this thesis focused on polycystic ovary syndrome (PCOS) because it 
represents the most common endocrinopathy in reproductive aged women which, depending upon 
the applied diagnostic criteria and the sampled population, affects between 2% (Chen et al., 2008) 
and 21% (Lizneva et al. 2016) of reproductive-aged women, and therefore, poses an increasing 
problem to healthcare systems globally. The PCOS diagnostic criteria include a combination of three 
principle features (hyperandrogenism, menstrual irregularity and polycystic ovary morphology) 
(Azziz et al. 2009), which frequently manifest in a range of symptoms, such as hirsutism, acne, 
alopecia and irregularity of periods. Adding to the complexity of PCOS, there is also a range of 
additional health problems that are widely associated with PCOS. These include obesity and insulin 
resistance (leading to increased prevalence of type 2 diabetes), psychological issues (namely anxiety 
and depression), which, in turn, have a further negative effect upon health-related quality of life 
(HRQoL) (Diamanti-Kandarakis and Panidis, 2007; Moran and Teede, 2009; Barry et al., 2014). 
Increasing physical activity (PA) has been demonstrated in numerous populations to be an effective 
strategy for lowering body weight (Look et al., 2013), restoring insulin sensitivity (Conn et al., 2014), 
lowering cardiovascular disease (CVD) risk (Pattyn, et al., 2013) and at reducing levels of 
psychological morbidity (Cooney et al., 2013). This evidence indicates that PA may be a suitable 
treatment strategy for improving the overall health of women with PCOS. Accordingly, the first line 
treatment recommendations for these women focus upon lifestyle changes, incorporating caloric 
restriction through dietary regulation alongside increases in the volume of PA/exercise performed 
(Legro et al., 2013). Although the high prevalence of PCOS is widely recognised, and there is a 
general consensus regarding the purported benefits of PA and the relevant recommendations for 
women with PCOS, there is still a degree of uncertainty based on the available evidence as to its 
effectiveness in this female patient population. Indeed, previous systematic reviews (Harrison et al., 
2011; Moran et al., 2011; Domecq et al., 2013; Haqq et al., 2015, Benham et al., 2018) have not 
been able to determine the beneficial effects of PA, in a range of outcomes, for women with PCOS. 
In addition, many reviews have overlooked the dietary components of lifestyle interventions and 
have included only a small number of studies that typically incorporate a low number of participants. 
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Alongside this, some previous reviews have included non-randomised, uncontrolled or cohort studies 
and the authors’ methods for evaluating the quality of included studies, and the degree of confidence 
that can be assumed from their findings, may not be deemed as robust (Higgins and Green, 2009).  
In this context, the systematic review and meta-analysis presented in Chapter 3 of this thesis aimed 
to address many of the issues in previous reviews and provide a current synthesis of all available 
evidence using the highest level of methodological rigour. It also went further than previous 
systematic reviews in that, where evidence was available, it included multiple permutations of 
‘lifestyle’ as comparators; that is exercise, diet, and exercise combined with diet. It is also currently 
the only systematic review on the topic to use the GRADE assessment tool (Guyatt et al., 2008) for 
evaluating the certainty of the evidence, something that is recommended by the Cochrane 
Collaboration (Schünemann et al., 2011).   
The work presented in Chapter 3 identified many statistically significant benefits of the effects of 
exercise interventions on individual outcomes which tend to agree with the findings of one (or more) 
of the preceding systematic reviews. As such, when exercise was compared to no intervention in the 
present systematic review, statistical effects favouring exercise were observed for only four outcomes 
(fasting insulin, total cholesterol, LDL-C, and VO2 max) when both change from baseline and post-
intervention comparisons were made. Similar findings were reported for fasting insulin (Moran et 
al., 2011; Domecq et al., 2013; Benham et al., 2018), total cholesterol (Benham et al., 2018), LDL-
C (Benham et al., 2018) and VO2 max (Haqq et al., 2015) in previous reviews, which collectively 
suggests that exercise may have a beneficial effect on women with PCOS. However, the magnitude 
of these improvements must be noted. For these four outcomes named above, the mean difference 
was relatively small, and when considering the width of the 95% confidence intervals (CIs), there 
was evidence of a lack of precision (i.e., wide CIs) and differences that were close to zero were 
included within their bounds. Alongside this, studies included in individual analyses typically had 
included results from a small number of participants and a high or unclear risk of bias across multiple 
domains. Thus, the quality of the related evidence was downgraded to either low, or very low, 
indicating that true effect estimates are likely to be substantially different from those reported 
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(Hultcrantz et al., 2017). Moreover, when comparisons including diet, or diet and exercise were 
made, the findings had even more uncertainty surrounding them. Of note, although exercise and 
dietary control are key constituents of current recommendations for the management of PCOS, very 
few studies have applied these as investigative interventions in randomised controlled trials (RCTs). 
Indeed, only six eligible trials incorporated any type of dietary intervention and the variability 
between the included outcomes was great, making a meta-analysis difficult. Where meta-analysis 
was completed, results were null or negligible and the certainty of the evidence was very low.  
Building on the findings from the presented systematic review and although it appears that exercise 
interventions may induce favourable changes for some outcomes in women with PCOS, the evidence 
presented in Chapter 3 suggests that the magnitude of these changes is relatively small. In fact, it is 
difficult to state whether changes reported are clinically meaningful because, for many included 
outcomes, there is ambiguity around what constitutes a clinically meaningful change in women with 
PCOS (and often in the general population). This poses the question about whether is it appropriate 
to recommend exercise as a treatment for these women even where there are statistical improvements 
reported, since there is uncertainty surrounding the degree of importance that this change represents, 
and the body of evidence upon which it is based is graded as low, or very low quality. 
In view of the question posed above, it was clearly apparent from completing the systematic review 
presented in Chapter 3 that there is a paucity of studies which have adequately investigated the impact 
of lifestyle interventions in women with PCOS. The latter requires having sufficient statistical power 
(i.e., larger sample sizes), well conducted and reported studies (i.e., evidence that risk of bias has 
been reduced) that utilise appropriate interventions (i.e., exercise, diet and behaviour change) with 
appropriate follow-up assessments that assess long-term patient benefits. Given that PCOS is so 
prevalent in a young patient population, conducting these studies should be a priority. It is in fact the 
quality of the existing evidence highlighted in Chapter 3, rather than the observed statistical 
improvements, which highlights the need for such studies to be completed. Accordingly, in response 
to the findings of the systematic review, the objective of this PhD project was to also design and 
implement a randomised feasibility study which would compare an intervention incorporating 
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exercise and diet, underpinned by behaviour change techniques (BCTs), to a diet and usual care 
control group.  
Unfortunately, it was not feasible to conduct this planned randomised controlled trial despite a 
comprehensive protocol design. In fact, the National Health Service (NHS) Health Research 
Authority and Health and Care Research Wales (HCRW) ethics committee (18/WM/0123) granted 
approval for this planned study in 2018. Despite ethical approval and extensive preparation, it was 
subsequently not possible to progress to the recruitment phase within the time and budget constraints 
of a PhD project due to logistical and administrative complications. Sufficiently sized RCTs are the 
main staple of determining the safety and efficacy of treatments and are principle in global health 
improvements (Collins and MacMahon, 2001). Whilst there is a need to ensure the safety of 
participants, increasingly stringent regulation and bureaucracy make the commencement and conduct 
of trials more complicated (Califf, 2006) and whilst such policy may be well-intentioned, it can cause 
unprecedented and irreversible delays to important patient-centred research (Reith et al., 2013). One 
such example surrounds the requirement to obtain approval from multiple organisations before such 
a study can commence. Even when study regulation and ethics are centralised, permission is required 
from each study site (e.g., universities, hospitals, etc.) which in many instances, leads to duplicated 
efforts and unnecessary administration (Duley et al., 2008). Indeed, the presence of such hurdles in 
the current project were unassailable given the time constraints of a typical PhD, and this may be 
also viewed as a finding confirmed by the work conducted in the context of this PhD. Nevertheless, 
and despite setbacks in conducting such well-designed RCTs, the research recommendations should 
remain unchanged and objective, and unbiased investigations into the effectiveness of lifestyle 
interventions in this under-studied female patient population should be a research priority.  
Although not deemed the gold standard of scientific investigation (Abel and Koch, 1999), well-
designed case-control studies and observational studies utilising concurrent selection of control 
subjects can produce useful results and help to support/shape patient care, clinical practice guidelines 
and the education of healthcare professionals (Concato et al., 2000). Therefore, without the 
incorporation of an exercise intervention, the remainder of this PhD thesis addressed some key 
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questions surrounding the effects of PA (as opposed to structured exercise) as a desirable health 
behaviour in women with PCOS and looked to seek comparisons with women without PCOS.  
Accordingly, the case-control study presented in Chapter 4 recruited women with PCOS and healthy 
controls and found that those with PCOS had substantially worse body weight, greater waist 
circumference, poorer self-esteem and reduced HRQoL than the comparison group. Furthermore, it 
revealed that there were no statistical differences in the volume of self-reported weekly PA, or indeed 
time spent in sedentary behaviours. Somewhat surprisingly, when mediation analysis was completed, 
PA appeared to have no influence upon HRQoL in either study group, which contradicts commonly 
held beliefs. This suggests that the PA behaviours of these women are not responsible for these 
undesirable differences, and that other mechanisms, most likely a diagnosis of PCOS, are implicated. 
In fact, both a positive PCOS diagnosis and higher self-reported BMI were associated with poorer 
self-esteem and lower HRQoL. However, it would be problematic to conclude that PCOS is solely 
responsible for poorer health in these women, because self-reported BMI explains a similar 
proportion of the variance. Thus, it is more likely is that the diagnostic symptoms/manifestations of 
PCOS result in considerable physical and psychological burden, whilst the metabolic dysregulation 
also promotes weight gain leading to decreased self-esteem. This triple-threat effect is then 
responsible, at least in part, for the impaired HRQoL observed in the study participants. 
To some extent, this is supported by the results of the study presented in Chapter 5 where, as 
expected, more women with PCOS had overweightness/obesity than an age-matched control group. 
Again, it is likely that the consequences of increased adiposity (i.e., systemic inflammation and 
insulin resistance), alongside the PCOS diagnosis, is responsible for the less-favourable health 
measures that were found in this study. In addition, although the UK Biobank do not use a previously 
validated measure of HRQoL (such as the SF-12), a greater proportion of women without PCOS 
rated their health as “excellent” or “good” compared to women with PCOS (76% versus 52%, 
respectively). Chapter 5 also utilised a BMI- and age-matched control group with almost two thirds 
of this group (66%) self-rating their health as “excellent” or “good”. This is a reasonable indicator 
suggesting that increased BMI may impair health, but that health may be further negatively affected 
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when these women have PCOS. Further evidence for this can be gained when circulating biomarkers 
and physiological characteristics are also considered since, without exception, women with PCOS in 
this study had less favourable values than the age-matched group. Moreover, the former also had less 
favourable values for four key CVD risk factors (HDL-C, triglycerides, HbA1c and SHBG) when 
compared to the BMI-matched cohort. The culmination of these less favourable outcomes for women 
with PCOS in this study may be associated with the increased number of comorbidities (total and 
metabolic-related, namely type 2 diabetes, hypertension and hypercholesterolemia) when compared 
to either comparator group.  
It is also noteworthy that, whilst higher PA has been shown to independently improve 
cardiometabolic risk factors and to reduce CVD mortality (Warburton, Nicol and Bredin, 2006; 
Leitzmann et al., 2007), the evidence from the current PhD, albeit using CVD risk factors as surrogate 
measures of mortality, suggests PA does not have an equally protective role in women with PCOS. 
Indeed, many previous studies report no statistical differences between women with PCOS and 
healthy comparators for PA (Moran et al., 2013; Lin et al., 2019; Douglas et al., 2006; Wright et al., 
2004; Alvarez-Blasco et al., 2011; Cutler, Pride and Cheung, 2018). Regarding this point, where the 
work presented in Chapter 4 agreed with these findings, the study detailed in Chapter 5 did uncover 
some statistical variation. As such, in the latter, women with PCOS performed less vigorous PA than 
both comparator groups and spent more time engaged in sedentary behaviours than the age-matched 
group. It is unlikely that the magnitude of difference for vigorous PA can explain the poorer health 
in women with PCOS. Indeed, in a female population, it has previously been reported, that where 
energy expenditure was matched, regardless of intensity (walking compared to vigorous PA), the 
magnitude of type 2 diabetes risk reduction was comparable (Hu et al., 1999). 
What the results presented in Chapter 5 allowed, was a classification of participants based upon their 
objectively measured health (clustering) and between group PA and sedentary behaviour 
comparison. This cluster analysis revealed two clusters, one where the values of the measures 
indicated a healthier profile (Cluster one) and one with less favourable values indicating a less 
healthy profile (Cluster two). A defining feature of these clusters was the PA behaviours, with 
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participants in cluster one reporting higher PA levels and less sitting time than those in cluster two. 
When classified on PA and sedentary time centiles, women who were in the upper centile for PA and 
the lower centile for sedentary time (low risk group/category) had more favourable values in all 
outcomes, and lower instances of morbidity compared to those in the lower PA and higher sedentary 
centiles (high risk group/category). Importantly, women with PCOS made up a greater proportion of 
Cluster two than Cluster one, and despite being represented by half as many study participants, also 
had greater membership to Cluster two than the age-matched study group. Women with PCOS in 
cluster one completed more PA and spent less time sitting than those in cluster two, suggesting that 
there is a health protective effect in these women. This is strongly supported by the centile analysis 
where the health of these women gradually decreases as they move from low, to moderate, to high 
risk based upon their PA behaviours.     
Overall, the implications of these findings are that higher PA and reduced sedentary time appear to 
be associated with a more favourable health profile in the general female population, but also 
specifically in women with PCOS. The effectiveness of structured exercise interventions at 
improving health in PCOS is uncertain and there remains very limited information about the long-
term impact of such interventions. However, there is evidence, as also indicated by the present work, 
that those women with PCOS who are more physically active and spend less time sitting have better 
health which reinforces its suitability as a treatment recommendation by healthcare professionals. 
However, it is possible that the healthier women with PCOS are more active because they have better 
health; eliminating reverse causation such as this is difficult to do using observational study designs 
and further reinforces the need for robust interventional trials. 
In this context, an additional problem lies in how to support lifestyle changes in women with PCOS, 
who are often sedentary, in order to engage in more PA and maintain favourable PA behaviours long-
term. This represents an additional area that needs well-designed large-scale research studies in this 
understudied female patient population. These should focus upon delivering effective lifestyle 
interventions, which incorporate diet and exercise, but should also place increased emphasis on the 
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Appendix 7.1. Review of author’s judgements about each risk of bias item for each included study. Support for judgement based upon evidence 
presented within each paper. 
Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Almenning et al. 
2015 
Selection Bias Random sequence 
generation 
Low Risk Women were stratified by BMI and allocated in a 1:1:1 
manner to study arms. Computer number random 
generator developed and administered to randomise 
subjects. 
Allocation concealment Low Risk Baseline testing was done before randomisation 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions) 
Detection Bias Blinding of outcome 
assessment  
High Risk Follow-up testing was performed, and these 
measurements were done non-blinded to group 
assignment. An observer blinded for group allocation 
analysed the FMD. 
Attrition Bias Incomplete outcome 
data 
Low Risk 89 participants assessed for eligibility; 58 excluded and 
reasons provided. 31 randomised and allocated 10:11:10. 
6 (19%) lost to follow up (reasons provided) and data 
analysis completed on those remaining. Consort flow 
diagram used. 
Reporting Bias Selective reporting  Low Risk Trial preregistered on ClinicalTrials.gov (NCT01919281) 
and all proposed outcomes reported in paper. 
Other bias Group similarity at 
baseline 
Low Risk FMD% significantly lower in HIT group. No other 
significant differences at baseline. 
Adherence Low Risk 87% for RT arm and 90% for HIT arm.  
Contamination Unclear Risk Physical activity in control group not reported 
Brown et al. 2009 Selection Bias Random sequence 
generation 
Low Risk Randomisation was accomplished by generating a random 
sequence of two variables (representing the two treatment 
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
groups) using the online program at 
http://graphpadcom/quickcalcs/randomize 2.cfm 
Allocation concealment  Low Risk Each group assignment was placed in its own sequentially 
numbered envelope by an individual not involved in the 
study. Participants were assigned to a group based on 
these envelopes, and each participant had an equal chance 
of being randomised to either group. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions) 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported 
Attrition Bias Incomplete outcome 
data  
High Risk Attrition is reported in study but considerably greater in 
exercise group. Acknowledged as a limitation in study and 
reasons for attrition not clearly stated. Overall attrition 
reported as 43%. 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol 
Other bias Group similarity at 
baseline 
High Risk Significant differences in age and lipid profiles. Also, 
although not statistically significant, exercisers tended to 
be heavier, less hyperandrogenic, less fit and more insulin 
resistant.  
Adherence Low Risk 89.8% adherence to exercise reported 
Contamination Unclear Risk Physical activity in control group not reported 
Bruner et al. 2006 Selection Bias Random sequence 
generation 
Unclear Risk Not reported 
Allocation concealment  Low Risk Researcher chose a sealed envelope for each participant 
indicating which treatment they would receive. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported 
Attrition Bias Incomplete outcome 
data  
High Risk Attrition not reported. There are data missing from 
results; LH:FSH - 2 women in EN group (lab error & 
pregnancy); FI - 1 from EN & 1 from N (lab error).  
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Low Risk No significant difference between groups for all 
outcomes. 
Adherence Unclear Risk Not reported 
Contamination Unclear Risk Physical activity in control group not reported 
Guzick et al. 1994 Selection Bias Random sequence 
generation 
Unclear Risk Subjects were randomised method used, not reported 
Allocation concealment  Unclear Risk Not reported 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported 
Attrition Bias Incomplete outcome 
data  
Low Risk Reports those who were excluded during screening. 12 
participants randomised; results for 12 presented in 
findings. No missing data. 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Low Risk No significant difference between treatment and control 
subjects for key outcomes of interest. 
Adherence Unclear Risk Not reported 
Contamination Unclear Risk Physical activity in control group not reported 
Hoeger et al. 
2004 
Selection Bias Random sequence 
generation 
Low Risk Randomisation schedule was computer generated in 
blocks by an independent pharmacy representative.  
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Allocation concealment  Unclear Risk The block schedule was blinded to the investigators. 
Methods not reported. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
However, participants and investigators double blinded to 
placebo or metformin by independent pharmacist. 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported 
Attrition Bias Incomplete outcome 
data  
High Risk Detailed analysis of attrition and adherence throughout. 
Balanced attrition across groups and explanations given 
for drop out. However, attrition is high in trial (39%). 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Low Risk No significant differences between groups for all 
outcomes. 
Adherence Unclear Risk Not reported 
Contamination Unclear Risk Physical activity in control group not reported 
Konopka et al. 
2015 
Selection Bias Random sequence 
generation 
Unclear Risk Women were randomised but unclear what method was 
used to do this. 
Allocation concealment  Unclear Risk Women were assessed before and after the intervention. 
Unclear when randomisation took place and whether 
investigators were blinded. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported 
Attrition Bias Incomplete outcome 
data  
High Risk No attrition reported. However, hyperinsulinemic-




Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Reporting Bias Selective reporting Low Risk Trial preregistered on ClinicalTrials.gov (NCT02105428 
and NCT01477164). 
Other bias Group similarity at 
baseline 
Low Risk No significant differences between groups for all 
outcomes. 
Adherence Unclear Risk Not reported. 
Contamination Unclear Risk Physical activity in control group not reported. 
Nasrekani et al. 
2016 
Selection Bias Random sequence 
generation 
Unclear Risk Following eligibility screening and informed consent 
participants were randomised. Method of randomisation 
is not reported. 
Allocation concealment  Unclear Risk Not reported whether assessors were blinded to allocation. 
Randomisation occurred before baseline measurements. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported. 
Attrition Bias Incomplete outcome 
data  
Low Risk 20 participants randomised and all data reported. No use 
of Consort flow diagram. 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Low Risk No significant differences between groups for all 
outcomes. 
Adherence Unclear Risk Not reported. 
Contamination Unclear Risk Physical activity in control group not reported 
Nybacka et al. 
2011 
Selection Bias Random sequence 
generation 
Low Risk The randomisation was carried out with the permuted-
block randomization method with ten blocks and a block 
size of 6. 
Allocation concealment  Unclear Risk Not reported. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Detection Bias Blinding of outcome 
assessment  
High Risk Same investigators completed outcome assessments but 
unclear whether they were blinded to allocation. Blinding 
unlikely. 
Attrition Bias Incomplete outcome 
data  
High Risk Attrition is reported for each arm. Higher in 2 groups. But 
overall 25%. Reasons stated as personal or medical 
grounds. 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Low Risk Baseline characteristics were comparable regarding age, 
BMI, body composition, and endocrine, metabolic and 
gynaecological outcomes. 
Adherence Unclear Risk Not reported. 
Contamination Unclear Risk Physical activity in control group not reported 
Petranyi et al. 
2011 
Selection Bias Random sequence 
generation 
Unclear Risk Participants were age matched between groups. Method 
of sequence generation not reported. 
Allocation concealment  Unclear Risk Not reported. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported. 
Attrition Bias Incomplete outcome 
data  
Low Risk Attrition not reported. 56 participants randomised and 
data present for all. No use of Consort (or similar) flow 
diagram. 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Unclear Risk Significance of baseline differences not reported. There 
appears to be some variation across outcomes. 
Adherence Unclear Risk Not reported. 
Contamination Unclear Risk Physical activity in control group not reported 
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Roessler et al. 
2013 
Selection Bias Random sequence 
generation 
Unclear Risk Participants were randomised but the method used to 
generate sequence is not reported. 
Allocation concealment  Unclear Risk Not reported. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported. 
Attrition Bias Incomplete outcome 
data  
Low Risk Three participants did not complete – injury (not study 
related) and time concerns stated. Baseline data presented 
for all participants and separately for completers. 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Low Risk No significant difference between groups for all outcomes 
reported. 
Adherence High Risk Aerobic exercise adherence was 67% 
Contamination High Risk This was a crossover design. Control group received 
group counselling sessions that explored motivation for, 
and barriers to PA. Exercise not stated but likely that 
behaviour may have been influenced. 
Sa et al. 2015 Selection Bias Random sequence 
generation 
High Risk Randomisation sequence computer generated but 
allocation to exercise group was partially based on ability 
to attend the 16 weeks of training, which was limited for 
some participants (n = 5) due to their remote geographical 
location. 
Allocation concealment  High Risk Five participants allocated to control group as they were 
unable to attend all sessions. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported. 
Attrition Bias Incomplete outcome 
data  
Low Risk Consort flow diagram used; 30 randomised and baseline 
data presented for all in initial study. Post-intervention 
data presented for completers  
Reporting Bias Selective reporting High Risk Unable to locate prospectively published trial protocol. A 
range of baseline outcomes reported, but no post-
intervention analysis completed.  
Other bias Group similarity at 
baseline 
Low Risk No significant differences between groups at baseline. 
Adherence Unclear Risk Not reported. 
Contamination High Risk Five participants in the control group did not receive the 
allocated intervention due to living in a remote 
geographical location 
Saremi et al. 2013 Selection Bias Random sequence 
generation 
Unclear Risk Quasi-randomisation. Methods used for sequence 
generation not reported. 
Allocation concealment  Unclear Risk Not reported. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported. 
Attrition Bias Incomplete outcome 
data  
Low Risk 22 randomised and all post-intervention data present. No 
evidence of Consort flow diagram. 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Unclear Risk Significant differences not reported between groups. 
Some variability in data (HOMA-IR and lipid profile). 
Adherence Unclear Risk Not reported. 
Contamination Unclear Risk Physical activity in control group not reported 
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Saremi et al. 2016 Selection Bias Random sequence 
generation 
Unclear Risk Method of randomisation and sequence generation not 
reported. 




Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
However, allocation of placebo and calcium supplement 
was blinded to participant. 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported. 
Attrition Bias Incomplete outcome 
data  
Unclear Risk Attrition not reported. Consort flow diagram not 
presented. Number of participants randomised unclear. 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Unclear Risk Significant differences not reported between groups. 
Some variability in data (fasting insulin, blood glucose 
and lipid profile). 
Adherence Unclear Risk Not reported. 
Contamination Unclear Risk Physical activity in control group not reported 
Stener-Victorin et 
al. 2009 
Selection Bias Random sequence 
generation 
Low Risk Randomly allocated in a 2:2:1 ratio to low-frequency EA, 
physical exercise, or no active intervention. To ensure 
equal proportions of age and BMI in each study arm, 
randomisation was stratified by those variables. 
Computer-generated randomisation within each stratum 
was conducted using permuted blocks of five. 
Allocation concealment  Unclear Risk Allocation was concealed until interventions were 
assigned. Methods used, not reported. 
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions and 
EA). 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported 
Attrition Bias Incomplete outcome 
data  
High Risk Attrition data reported throughout each stage of the study. 
Comparable dropout in each arm of study and appropriate 
reasons provided. However, 29% attrition from 
randomisation to post-intervention and 40% to follow-up. 
Reporting Bias Selective reporting Low Risk Trial preregistered on ClinicalTrials.gov 
(NCT00484705). 23 participants were recruited for 
microneurography; no criteria given for inclusion or detail 
on method of selection. 
Other bias Group similarity at 
baseline 
Low Risk No significant differences between groups for all 
outcomes. 
Adherence Low Risk Mean number of weekly sessions reported; ~3 per week 
in PA group.  
Contamination High Risk There were no differences between the groups (PA, EA 
and control) in self-reports of PA frequency.  
Thomson et al. 
2008 
Selection Bias Random sequence 
generation 
Low Risk A parallel study design where subjects were randomly 
assigned by computer generation into three 20-wk 
lifestyle interventions. 
Allocation concealment  Unclear Risk Not reported 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported. 
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Attrition Bias Incomplete outcome 
data  
High Risk Overview of reasons for dropout provided in study flow 
diagram but high rates reported – 49% 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Low Risk No significant differences between groups at baseline. 
Adherence Unclear Risk Not reported. 
Contamination Unclear Risk Physical activity in control group not reported 
Turan et al. 2015 Selection Bias Random sequence 
generation 
Low Risk A computer generated random number table was used to 
generate sequence for allocation. 
Allocation concealment  Low Risk Randomised following baseline testing. Allocation 
concealed using pre-labelled, sealed envelopes. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
Detection Bias Blinding of outcome 
assessment  
High Risk Not reported. 
Attrition Bias Incomplete outcome 
data  
Low Risk Small attrition (n = 2) from exercise group due to non-
attendance of exercise sessions. 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Low Risk There were no significant differences between groups at 
baseline. 
Adherence Low Risk Two participants’ data removed from analysis as 
adherence was < 75%  
Contamination Unclear Risk Physical activity in control group not reported 
Vigorito et al. 
2007 
Selection Bias Random sequence 
generation 
Unclear Risk Women were randomly subdivided into groups. Methods 
not reported. 
Allocation concealment  Unclear Risk Not reported. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Detection Bias Blinding of outcome 
assessment  
Low Risk All clinical assessments were performed by the same 
physician who was blinded to the patient allocation into 
the study protocol. 
Attrition Bias Incomplete outcome 
data  
Low Risk All subjects completed the study protocol. 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
Unclear Risk Significant differences at baseline not reported. Patients 
share similar characteristics across groups. 
Adherence Low Risk All participants completed the study protocol. Attendance 
was 100% in exercise group. 
Contamination Low Risk Small decrease (-0.1 MET hr/wk) in LTPA for control 
group.  
Vizza et al. 2016 Selection Bias Random sequence 
generation 
Low Risk Randomisation assignments were generated via an online 
randomisation programme. 
Allocation concealment  Low Risk Randomisation done by an investigator not involved in the 
data collection and given to participants in sealed 
envelopes upon completion of baseline testing. 
Performance 
Bias 
Blinding of participants 
and personnel 
High Risk Impossible to blind participants and personnel due to 
nature of the trial (i.e. supervised exercise sessions). 
Detection Bias Blinding of outcome 
assessment  
High Risk Clinical assessment completed by lead investigator - lead 
investigator also completed weekly status check with 
participants to monitor adverse events. Suggests no 
blinding. 
Attrition Bias Incomplete outcome 
data  
High Risk 15 participants randomised, 13% attrition across trial. 
Attrition detailed in results section and baseline data from 
non-completers used in results. Baseline data carried 
forward for two participants in the PRT and three in the 
control group that did not complete follow-up testing.  
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Trial Bias Domain Source of Bias Author’s 
judgement 
Support for judgement 
Reporting Bias Selective reporting Unclear Risk Unable to locate prospectively published trial protocol. 
Other bias Group similarity at 
baseline 
High Risk Paper reports no significant difference between baseline 
characteristics of groups but does note trends in waist and 
hip circumference being higher in exercise group. 
Looking at the descriptive characteristics, mean body 
weight and BMI are considerably greater in the exercise 
group albeit with large standard deviations. 
Adherence High Risk Supervised training sessions have very good attendance 
(95%) but home-based component was only 51%. 












Appendix 7.2. Overview of previous systematic reviews assessing the effectiveness of exercise, or lifestyle in the management of polycystic ovary 
syndrome. 





1. EX vs. control 5 RCT and 3 cohort 
studies (n = 421) 
Databases: MEDLINE, PsycINFO EMB Reviews, 
EMBASE, CINAHL 
Quality assessment: Standard forms adapted from the 
Cochrane Handbook of Systematic Reviews1 and Quality 
of Reporting of Meta-Analyses checklist3 
Analysis: Qualitative synthesis only 




1. LSM (EX, diet or EX 
and diet combined) vs. 
control 
6 RCT (n = 164) Databases: CENTRAL, MEDLINE, CINAHL, EMBASE, 
PsycINFO, AMED 
Quality assessment: Cochrane risk of bias tool, sensitivity 
analyses, I2 statistic 
Analysis: Qualitative synthesis, meta-analysis (RE) 
assessment of MD post-intervention values. 
LB, pregnancy, miscarriage, 
OC, OR, T*, SHBG, FT, FG*, 
BW*, BMI, WC*, WHR, 
OGTT, FBG, TC, HDL-C, 
LDL-C, TG, FI*, QOL 
Domecq 
(2013) 
1. LSM (EX, diet or EX 
and diet combined) vs. 
control 
2. LSM vs. metformin 
9 RCT (n = 610) Databases: MEDLINE, EMBASE, CENTRAL, Web of 
Science, Scopus, PsycINFO, CINAHL 
Quality assessment: Cochrane risk of bias tool, sensitivity 
analyses, I2 statistic 
Analysis: Qualitative synthesis, meta-analysis (FE and RE) 
MD of change from baseline to post-intervention. 
FBG*, FI*, FG*, fertility, 
amenorrhea, acne  
Haqq 
(2015) 
1. EX vs. control 
2. LSM vs. control 
12 RCT (n = 668) Databases: PubMed, CINAHL, CENTRAL BMI*, BW*, WC*, WHR*, 
BF%*, FI, FBG, HOMA, TG, 
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Study Comparisons Included studies 
(participants) 
Methods Outcomes 
Quality assessment: Modified PEDro4, sensitivity analyses, 
Cochrane Q, Egger plots 
Analysis: Qualitative synthesis, meta-analysis (FE and RE) 
MD of change from baseline to post-intervention 
TC, LDL-C, HDL-C, CRP*, 
RHR*, VO2 peak*   
Benham 
(2018) 
1. LSM (EX, diet or EX 
and diet combined) vs. 
control  
7 RCT, 1 non-RCT 
and 6 UCT (n = 
617) 
Databases: MEDLINE, EMBASE 
Quality assessment: Newcastle-Ottawa Scale (NRCT), 
Cochrane risk of bias tool (RCT), I2 statistic 
Analysis: Qualitative synthesis, semi-quantitative analysis 
of reproductive outcomes, meta-analysis (FE and RE) MD 
of change from baseline to post-intervention 
LB, Pregnancy, OR, OC, MF, 
MCL, BMI, WC*, BF%, VO2 
max, SBP*, DBP, FBG, FI*, 
TC*, LDL-C*, HDL-C, TG*, 
HbA1c, HRQoL 
Key: LSM: lifestyle modification; EX: exercise; RCT: randomised controlled trial; UCT: uncontrolled trial; CINAHL: Cumulative Index to Nursing and Allied 
Health Literature; EMBASE: Excerpta Medica dataBASE; CENTRAL: Cochrane Central Register of Controlled Trials; AMED: Allied and Complementary 
Medicine Database; FBG: fasting blood glucose; FI: fasting insulin; BMI: body mass index; BW: body weight; WC: waist circumference; WHR: waist-to-hip 
ratio; BF%: body fat percentage; HOMA: homeostatic model assessment; TG: triglycerides; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; 
HDL-C: high-density lipoprotein cholesterol; CRP: C-reactive protein; RHR: resting heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure;  
LB: live births; OR: ovulation rate; OC: ovulatory cycle; MF: menstrual frequency; MCL: menstrual cycle length; FG: Ferriman-Gallwey score; T: testosterone; 
SHBG: sex hormone binding globulin; FT: free testosterone; OGTT: oral glucose tolerance test; QOL: quality of life; HRQoL: health-related quality of life; 
IR: insulin resistance; HbA1c: glycated haemoglobin; MD: mean difference; FE: fixed effects; RE: random effects; ▲: qualitative improvements consistently 
reported within the review; *: statistically significant (P <0.05) improvements in exercise groups compared to control. 1Higgins and Green (2009); 






Appendix 7.3. Details of excluded studies and reasons for exclusion. 
Study Reason for Exclusion 
Almenning et al. 2015 Conference abstract; full study included in analysis 
Asante et al. 2014 Conference abstract; full study included in analysis 
Bachani et al. 2012 Comparison ineligible. Compares lifestyle modification with pharmacological intervention. 
Barr et al. 2011 Ineligible study design. No intervention applied 
Bongaard 2010 Comparison ineligible. Compares a low-GI diet with a moderate- to high-GI diet 
Brown et al. 2005 Conference abstract; full study included in analysis 
Chizen et al. 2014 Comparison ineligible. Compares a pulse diet with National Cholesterol Education Program Therapeutic Lifestyle 
Changes (TLC) Diet. 
Christiansen et al. 2014 Ineligible patient population. Pregnant women. 
Crosignani et al. 2003 Ineligible study design. Not a randomised controlled trial. 
Curi et al. 2012 Comparison ineligible. Compares lifestyle modification with pharmacological intervention. 
Fux Otta et al. 2010 Comparison ineligible. Compared lifestyle and pharmacological intervention with lifestyle and placebo. 
Galletly et al. 2007 Comparison ineligible. Compares a low-protein high-carbohydrate diet with a high-protein low-carbohydrate diet.  
Gambineri et al. 2006 Comparison ineligible. Compares a hypocaloric diet with placebo to a hypocaloric diet with pharmacological 
interventions. 
Giallauria et al. 2008 Ineligible study design. Patients not randomised. 
Harris-Glocker et al. 2010 Ineligible comparison. Compares lifestyle modification and placebo with lifestyle modification and pharmacological 
intervention.  
Hoeger et al. 2008 Ineligible patient population. Adolescent patients were used in the trial. 
Jaffe et al. 2006 Comparison ineligible. Compares high-carbohydrate low-fat diet and placebo with high-carbohydrate low-fat diet and 
pharmacological intervention. 
Jedel et al. 2010 Conference abstract; full study included in analysis 
Johansson et al. 2013 Ineligible comparison. Compares acupuncture to physical therapy.  
Karimzadeh et al. 2010 Comparison ineligible. Compares lifestyle to pharmacological interventions. 
Kumar et al. 2010 Comparison ineligible. Compares lifestyle to lifestyle and pharmacological interventions. 
Ladson et al. 2011 Comparison ineligible. Compares lifestyle to lifestyle and pharmacological interventions. 
Ladson et al. 2011 Comparison ineligible. Compares lifestyle and placebo to lifestyle and pharmacological interventions. 
Le Donne et al. 2012 Comparison ineligible. Compares diet with diet and pharmacological interventions. 
Legro et al. 2014 Comparison ineligible. Compares lifestyle with lifestyle and pharmacological interventions. 
Legro et al. 2015 Comparison ineligible. Compares lifestyle with lifestyle and pharmacological interventions. 
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Study Reason for Exclusion 
Liao et al. 2008 Ineligible study design. Observational design. 
Lindholm et al. 2008   Comparison ineligible. Compares lifestyle and placebo to lifestyle and pharmacological interventions. 
Ma et al. 2007 Ineligible comparison. Compares weight loss treatment to weight loss treatment and pharmacological intervention. 
Machlitt et al. 2007 Ineligible comparison. Compares lifestyle and placebo with lifestyle and pharmacological intervention. 
Marzouk et al. 2015 Ineligible intervention. Intervention use dietary advice and caloric restriction. 
McBreairty et al. 2015 Ineligible comparison. Compares pulse based diet and exercise with National Cholesterol Education Program therapeutic 
lifestyle changes (TLC) diet and exercise. 
Mehrabani et al. 2012 Ineligible intervention. Two hypocaloric diets are used for the intervention. 
Moran et al. 2002 Ineligible intervention. Low-protein and a high-protein hypocaloric diets are used as the intervention. 
Moran et al. 2003 Ineligible intervention. Meal replacement programme utilised; no comparison made. 
Moran et al. 2006 Ineligible intervention. Two diets are utilised in the intervention. 
Nidhi et al. 2012 Ineligible patient population. Adolescent patients were used in the trial. Also compares two exercise modalities. 
Nidhi et al. 2013 Ineligible patient population. Adolescent patients were used in the trial. Also compares two exercise modalities. 
Nidhi et al. 2013 Ineligible patient population. Adolescent patients were used in the trial.  
Nybacka et al. 2014 Conference abstract; full study included in analysis 
Nybacka et al. 2012 Conference abstract; full study included in analysis 
Omar et al. 2013 Ineligible patient population. Compares women with PCOS to healthy controls. 
Orio et al. 2016 Ineligible comparison. Compares lifestyle to pharmacological interventions.  
Ornstein et al. 2011 Ineligible patient population. Adolescent patients were used in the trial. 
Palomba et al. 2007 Ineligible comparison. Compares lifestyle to lifestyle and pharmacological interventions. 
Palomba et al. 2010 Ineligible study design. Non-randomised controlled trial. 
Papakonstantinou et al. 2016 Ineligible intervention. Compares two dietary interventions in a cross-over design.  
Pasquali et al. 1986 Ineligible comparison. Compares hypocaloric diet with diet and pharmacological intervention. 
Pasquali et al. 2000 Ineligible patient population. Compares hypocaloric diet with diet and pharmacological intervention. 
Popova et al. 2010 Ineligible comparison. Compares lifestyle with lifestyle and pharmacological interventions. 
Randeva et al. 2002 Ineligible study design. Non-randomised controlled trial. 
Redman et al. 2011 Ineligible patient population. Women with PCOS are compared to healthy controls. 
Roessler et al. 2011 Conference abstract; full study included in analysis 
Silva Dantas et al. 2015 Ineligible patient population. Compares women with PCOS to healthy controls. 
Sorensen et al. 2011 Ineligible intervention. Either a high- or standard-protein diet are used for the intervention. 
Tang et al. 2005 Ineligible comparison. Compares lifestyle and placebo with lifestyle and pharmacological intervention.  
Thomson et al. 2009 Conference abstract; full study included in analysis 
Thomson et al. 2011 Ineligible study design. No control group or comparison made. 
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Study Reason for Exclusion 
Turner-McGrievy et al. 2014  Ineligible study design. No lifestyle intervention  
Turner-McGrievy et al. 2015 Ineligible comparison. Compares vegan diet to low-calorie diet. 
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Appendix 7.4. STROBE Statement—Checklist of items that should be included in reports 
of case-control studies  
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Appendix 7.8. Demographic questionnaire 
 
Understanding physical activity behaviours in women with polycystic ovary 
syndrome (PCOS) 
 
Thank you for agreeing to participate in this study. The first thing we need 
from you is some information about you and your background. Please try to 
be as accurate as possible when providing your answers and please answer all 
questions. We remind you at this point that all information provided will be 
held in strictest confidence and at no point will your identity be revealed to 
anyone beyond the research team. 
 
Name of Student Researcher:  Mr. Chris Kite 
Principal Investigator: Dr. James Brown  
Aston University Study Number: 1442 
Participant Identification Number for this study: 
 





2. Have you ever been diagnosed with PCOS?  Yes  No       
 






3. For those who answered YES to Question 2. How long has it been since 
you were diagnosed with PCOS? 
 
________ Years ________ 
Months 
 
4. There are different varieties (phenotypes) of PCOS. Has your 
GP/consultant advised you, or are you aware which phenotype you 
have? 
 
Polycystic ovaries, menstrual disruption and excess androgens   
Polycystic ovaries and menstrual disruption     
Polycystic ovaries and excess androgens     
Menstrual disruption and excess androgens     
Not sure          
 
*Note: polycystic ovaries will usually be identified by ultrasound. Menstrual 
disruption refers to irregular or absent periods. Excess androgens mean you 
have elevated sex hormones (typically testosterone) causing symptoms like 
acne or excess hair growth. 
 
5. What is your height? 
 
______ Feet ______ inches or ______metres ______ cm 
 
 
6. What is your weight? 
 
______ stone ______ lbs   or  ______ kg 
 










8. How would you define your ethnicity? 
 
White       Other Asian Background  
  
Gypsy or Traveller         Mixed: White & Black Caribbean   
Black or Black British: Caribbean   Mixed: White & Black African
  
Black or Black British: African    Mixed: White & Asian 
  
Other Black background    Other Mixed background 
  
Asian or Asian British: Indian    Arab    
  
Asian or Asian British: Pakistani   Other Ethnic background 
  
Asian or Asian British: Bangladeshi  Not known   
  




9. Please indicate your marital status: 
 
Married      Single     
Divorced      Widowed  
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10. Please tell us your occupational status: 
 
Student      Full-time employed    
Part-time employed     Unemployed   
Retired     House person   






11. Please tell us your highest level of education: 
 
Secondary (O-level, GCSE, etc.)    College (A-level, BTEC, etc.)  
  
Undergraduate (BSc, BA, etc.)  Postgraduate (MA, MSc, PG-Cert, etc)
  
Doctorate (PhD, MD, etc.)  Other (please specify)  
  
 
12. Do you have children? 
 
Yes      No   
 
If yes, how many children do you have: Under 5 years _______ 
       6-11 years   _________ 
       11-16 years _________ 
 




Adults____________   Children_____________ 
 
 
14. Please tell us your current annual household income: 
 
Less than £39,999    £40,000 to £79,999  
More than £80,000  
 
 
Please ensure that you have answered all questions as accurately as possible. 
Should you have any queries about any item(s) on this form, please do not 
hesitate to contact a member of the research team (Chris Kite:  
).  
 



























Appendix 7.9. Rosenberg Self-esteem (RSE) Scale 
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Appendix 7.10. Self-efficacy for Exercise Scale 
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Appendix 7.12. Original project application to UK Biobank for access to database 
Project Title (200 characters): 
Clustering of cardiometabolic risk factors and their association with physical activity and 
sedentary time in women with and without polycystic ovary syndrome: a principal component 
analysis.  
 
Research Question and aims (up to 5000 characters or 200 words): 
 
• Do cardiometabolic risk factors cluster together in women with polycystic ovary 
syndrome (PCOS), and is the clustering pattern different compared to healthy controls? 
• Are low physical activity (PA) levels and high sedentary time risk factors in the 
development of cardiometabolic conditions, do differences exist between women with 
PCOS and a healthy control group? 
 
Our aims are: 
 
• To describe the characteristics of female participants with and without PCOS according 
to their PA levels and sitting profiles: high PA-low sit (low cardiometabolic risk, reference 
group), high PA-high sit and low PA-low sit (intermediate risk), or low PA-high sit (high 
cardiometabolic risk) and the associations between groups and prevalence of 
cardiovascular disease (CVD), type 2 diabetes and metabolic syndrome.  
• To compare age- and BMI-matched women with and without PCOS to identify whether 
CVD and metabolic risk factors are unique to women with PCOS, and to see if clustering 
of risk factors is different for women with PCOS to those who are obese only. 
• To investigate whether other factors (such as socioeconomic status and mental health) 
cluster within subjects at increased risk of cardiometabolic conditions. 
 
 
Does your project require biological samples? 
No 
 
Does your project require UK Biobank to re-contact participants? 
No 
 
Please provide information on each of the following: 
A3. The background and scientific rationale of the proposed research project in general 
(up to 5000 characters or 300 words): 
 
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, affecting up to 21% of 
reproductive-aged women. PCOS is characterised by hyperandrogenism and ovulatory disruption, 
and typically manifests in a range of undesirable symptoms such as acne, hirsutism and infertility. 
Women with PCOS are also at an increased risk of cardiometabolic disturbances, such as obesity, 
increased waist circumference, and elevated cholesterol. Typically, management of PCOS focuses 
on lifestyle changes, incorporating increased physical activity (PA), aiming to alleviate symptoms, 
and lower the associated risk of type 2 diabetes and cardiovascular disease (CVD).  
 
Although increasing PA is a well-established method for improving CVD risk factors, the effect 
of reducing sedentary behaviours has become a more recent focus. The proportion of sedentary 
time an individual engages in has been strongly linked to cardiometabolic risk, independent of PA. 
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If a diagnosis of PCOS increases cardiometabolic risk, then those who are not physically active 
and also spend more time sitting are further increasing the risk of disease.  
 
If health professionals are able to better understand the characteristics of women with PCOS (and 
their counterparts without PCOS), and risk factors that are modifiable (e.g., PA levels), they may 
be able to more effectively target interventions for these risk factors, improving health-related 
outcomes in these women. Furthermore, this may allow earlier identification of individuals at risk 
of metabolic syndrome as a co-morbidity, and thus enable intervention that may reduce risk, 
decrease morbidity, improve patient quality of life, and lower subsequent health care cost. 
 
A4. A brief description of the method(s) to be used (up to 5000 characters or 300 words): 
 
Data from participants with PCOS plus age and age- and BMI-matched control groups of women 
without PCOS will be analysed. Outcomes selected according to diagnostic features of metabolic 
syndrome (waist circumference, blood pressure, blood glucose, and lipid profile). The physical 
(weight, BMI, cardiorespiratory fitness, inflammatory and androgenic biomarkers) and 
psychosocial (anxiety, depression, mood, self-esteem, and quality of life) characteristics 
associated with PCOS are also included. Incorporation of self-reported PA and sedentary 
behaviours, in addition to accelerometer measures where available.  
 
Shapiro-Wilk tests of normality will be performed. Appropriate descriptive statistics (mean ± SD 
or median and IQR) of data will be presented. Depending upon distribution either independent 
samples T-tests or Mann-Whitney U will be performed to assess between population differences. 
Outliers (>3 standard deviations from the mean) will be identified and removed. 
 
We will use principal component analysis (PCA) to assess whether one component can explain 
the variation within the data of each population. PCA is a statistical technique for identifying 
patterns within groups of correlated variables. For each population, we will assess associations 
between outcomes using Pearson’s correlation coefficients; variables that are weakly correlated to 
others, will be excluded from this analysis.  
 
PCA groups together linear combinations of the correlated variables into principle components. 
To allow interpretation, the identified principle components will be modified using orthogonal 
varimax rotation. This transforms the identified components so that each one is distinct 
(uncorrelated) from the others. The variables within each component are then more highly 
correlated than they are with variables in other components. The total variance explained by each 
component (eigenvalues) will be calculated by summing the squared correlation coefficients (r2) 
between independent variables and calculated components. The cumulative sum of eigenvalues 
will then be calculated allowing an explanation of observed variance and a direct comparison of 
women with and without PCOS. 
 
 
A5. The type and size of dataset required (e.g., case-control subset, men only, imaging data 
only, whole cohort, etc.) (up to 5000 characters or 100 words): 
 
All women with PCOS (defined as ICD10 E28.2) from the Biobank (n = 331) and both an age- 
and age- and BMI-matched control group of women without PCOS. 
 
A6. The expected value of the research (taking into account the public interest 
requirement) (up to 5000 characters or 100 words): 
 
PCOS affects up to 20% of reproductive-aged women; typically, these women report undesirable 
symptoms including lower quality of life and increased risk of cardiometabolic conditions. Whilst 
studies have shown that exercise interventions may have beneficial effects on health outcomes in 
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PCOS, there is limited information about the health-effect of PA, or of excessive sitting/sedentary 
behaviours as part of daily living. Therefore principle component analysis will be used to identify 
whether risk factors for cardiometabolic conditions (including activity levels) cluster within 
women with PCOS, and if there is any variation when compared to healthy controls.  
 
A7. Please provide up to 6 keywords which best summarise your proposed research 
project: 
 
Polycystic ovary syndrome, physical activity, sitting time, cardiometabolic risk, principal 
component analysis, clustering 
 
A8. Please provide a lay summary of your research project in plain English, stating the 
aims, scientific rationale, project duration and public health impact (up to 5000 characters 
or 400 words): 
Polycystic ovary syndrome (PCOS) affects many women worldwide and causes a range of 
symptoms such as acne, excess hair, irregular periods, and sometimes, infertility. Women with 
PCOS are also more likely to be obese, have high blood pressure and high cholesterol which can 
lead to diabetes and heart disease.  
 
Exercise is often recommended to manage the symptoms of PCOS. However, less is known about 
the effects of day-to-day activities. Day-to-day activities are the things you do for work, walking 
from place to place, household chores or sports you play for fun. We are also interested in the time 
you spend sitting. Those who sit for long periods of time have a higher risk of disease, and when 
activity levels are low, the risk is even greater. To our knowledge, this has not been investigated 
in women with PCOS. 
 
Participants in the UK Biobank have reported their physical activity and sitting behaviours. We 
will assess these reported values to find out whether being more physically active, and sitting less 
reduces the risk of developing further conditions in PCOS. We will also compare this data to a 
group of women without PCOS to find out whether it is more (or less) important if you have been 
diagnosed with PCOS.  
 
Gaining a better understanding about the role of being active, and high sitting time in PCOS will 
help to develop treatment guidelines and shape the information provided by health professionals. 
It will also help to educate women with PCOS about the physical and mental benefits of becoming 
more active. 
 
A9. Will the research project result in the generation of any new data fields derived from 
existing complex datasets, such as imaging, accelerometry, electrocardiographic, linked 




A10. What is the estimated duration of your project, in months? If you consider (because 
for example the project is one involving the generation of hypotheses) that it would be 
difficult to set a fixed end point, we are prepared to consider a rolling 3-year period 









Appendix 7.13. Descriptive statistics for outcomes included in cluster analysis; includes interquartile range (IQR), calculation of outlier cut 
points and trimmed values.  
Outcome PCOS Age-matched Age + BMI 
 IQR IQR*1.5 5th 95th IQR IQR*1.5 5th 95th IQR IQR*1.5 5th 95th 
SHBG (nmol/L) 39.42 59.13 16.59 135.63 40.77 61.16 20.45 139.85 38.55 57.83 21.47 128.13 
T (nmol/L) 0.73 1.10 0.49 2.72 0.68 1.01 0.45 2.15 0.72 1.09 0.51 2.34 
HDL-C (mmol/L) 0.46 0.68 0.92 2.06 0.52 0.79 1.00 2.23 0.50 0.75 0.94 2.09 
HbA1c 6.20 9.30 28.50 53.53 4.80 7.20 27.54 40.26 5.20 7.80 27.90 44.31 
IGF-1 (nmol/L) 9.40 14.10 11.44 33.52 7.49 11.24 13.78 34.78 8.56 12.85 11.96 32.78 
LDL-C  (mmol/L) 1.04 1.56 2.13 4.81 1.03 1.55 2.14 4.70 1.08 1.62 2.21 4.78 
TG (mmol/L) 1.19 1.78 0.65 4.47 0.83 1.24 0.58 3.16 0.88 1.32 0.60 3.11 
CRP (mg/L) 4.16 6.24 0.27 15.96 1.96 2.93 0.21 9.59 4.48 6.72 0.25 16.53 
TC (mmol/L) 1.36 2.04 3.85 7.37 1.29 1.93 3.97 7.20 1.42 2.14 3.90 7.14 
SBP (mmHg) 21.00 31.50 103.00 159.00 21.00 31.50 104.80 159.00 22.00 33.00 107.00 162.00 
DBP (mmHg) 15.25 22.88 66.00 102.00 14.00 21.00 64.00 98.00 15.00 22.50 65.00 101.00 
BF (%) 11.90 17.85 24.38 52.22 11.20 16.80 23.22 48.30 11.80 17.70 24.61 51.99 
BMI (kg/m2) 11.31 16.97 21.03 47.41 7.16 10.75 19.96 37.81 11.31 16.97 21.04 47.29 
WC (cm) 26.50 39.75 67.00 125.15 18.00 27.00 66.00 108.50 26.00 39.00 69.00 128.00 
Key: IQR: interquartile range; IQR*1.5: cut point for identification of outliers above 3rd quartile, or below 1st quartile; 5th: 5th centile; 95th: 95th centile; SHBG: 
sex hormone binding globulin; T: testosterone; HDL-C: high-density lipoprotein cholesterol; HbA1c: glycated haemoglobin; IGF-1: insulin-like growth factor-
1; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; CRP: C-reactive protein; TC: total cholesterol;   SBP: systolic blood pressure; DBP: diastolic 
blood pressure; BF%: body fat percentage; BMI: body mass index; WC: waist circumference.  
For the PCOS, age-, and BMI + age-matched groups, the following number of cases were transformed respectively: SHBG: 10, 17 and 15; testosterone: 7, 
7 and 9; HDL-C: 5, 7 and 7; HbA1c: 14, 11 and 19; IGF-1: 2, 8, 4; LDL-C: 2, 4 and 6; triglycerides: 10, 13 and 17; CRP: 9, 17 and 17; total cholesterol: 3, 





Appendix 7.14. Summary of missing data 
Outcome Missing Valid N Mean SD 
N Percent 
SHBG (nmol/L) 279 17.5 1316 60.18 36.15 
Testosterone (nmol/L) 264 16.6 1331 1.26 .67 
Glucose (mmol/L) 258 16.2 1337 5.02 1.24 
HDL-C (mmol/L) 256 16.1 1339 1.47 .38 
HbA1c (mmol/mol) 127 8.0 1468 34.97 7.41 
IGF-1 (nmol/L) 119 7.5 1476 22.75 6.36 
LDL-C (mmol/L) 116 7.3 1479 3.38 .80 
Triglycerides (mmol/L) 115 7.3 1480 1.50 .95 
CRP (mg/L) 115 7.3 1480 3.57 5.59 
Cholesterol (mmol/L) 113 7.1 1482 5.46 1.03 
Systolic BP (mmHg) 101 6.4 1494 129.55 17.22 
Diastolic BP (mmHg) 101 6.4 1494 81.03 10.83 
Body Fat (%) 48 3.0 1548 37.98 8.46 
WC (cm) 12 0.8 1583 89.37 16.87 
Key: SHBG: sex hormone binding globulin; HDL-C: high-density lipoprotein cholesterol; HbA1c: 
glycated haemoglobin; IGF-1: insulin-like growth factor-1; LDL-C: low-density lipoprotein 
cholesterol; BP: blood pressure; BMI: body mass index; WC: waist circumference; N: number of 
missing values; Percent: percentage of missing values from all cases.  
 
 













Appendix 7.17. Missing data, assumption checks (distribution, skewness and kurtosis) for each outcome by comparator group 
 
 











Skewness Kurtosis P 
Stature (cm) 3 (0.9) -0.0493 0.507 .207 3 (0.5) -0.0697 -0.0543 .207 6 (0.9) 0.0601 0.428 .030 
Body weight (kg) 3 (0.9) 0.836 0.623 <.001 4 (0.6) 1.24 2.56 <.001 6 (0.9) 0.903 0.813 .194 
BMI (kg/m2) 3 (0.9) 0.833 0.593 <.001 4 (0.6) 1.39 2.93 <.001 6 (0.9) 0.856 0.739 <.001 
Waist Circumference (cm) 3 (0.9) 0.508 0.00614 <.001 4 (0.6) 0.924 0.818 <.001 5 (0.8) 0.535 -0.0813 <.001 
Hip Circumference (cm) 3 (0.9) 0.855 0.535 <.001 4 (0.6) 0.956 1.33 <.001 5 (0.8) 0.849 0.674 .028 
WHR 3 (0.9) 0.614 0.345 <.001 4 (0.6) 0.526 0.543 <.001 5 (0.8) 0.118 -0.0656 <.001 
WSR 3 (0.9) 0.506 -0.187 <.001 3 (0.5) 0.562 2.50 <.001 6 (0.9) 0.553 0.0401 <.001 
Body Fat (%) 12 (3.8) -0.491 -0.143 <.001 17 (2.7) -0.0275 -0.259 .110 18 (2.8) -0.447 -0.0643 <.001 
Systolic BP (mmHg) 21 (6.6) 0.320 0.0518 .056 43 (6.7) 0.781 1.10 <.001 37 (5.8) 0.984 2.24 <.001 
Diastolic BP (mmHg) 21 (6.6) 0.226 0.0167 .174 43 (6.7) 0.330 0.260 .002 37 (5.8) 0.407 0.725 <.001 
Total Cholesterol (mmol/L) 21 (6.6) 0.352 0.490 .052 50 (7.8) 0.478 0.547 <.001 42 (6.6) 0.537 1.27 <.001 
HDL-C (mmol/L) 47 (14.7) 0.958 0.833 <.001 110 (17.2) 0.601 0.591 <.001 99 (15.5) 0.831 1.26 <.001 
LDL-C (mmol/L) 21 (6.6) 0.246 0.222 .289 52 (8.2) 0.439 0.542 <.001 43 (6.7) 0.619 1.08 <.001 
Triglycerides (mmol/L) 21 (6.6) 2.32 7.69 <.001 51 (8.0) 2.70 12.8 <.001 43 (6.7) 2.59 11.6 <.001 
HbA1c (mmol/mol) 31 (9.7) 3.43 15.9 <.001 55 (8.6) 5.86 63.5 <.001 41 (6.4) 3.89 23.3 <.001 
Glucose (mmol/L) 47 (14.7) 5.08 39.7 <.001 111 (17.4) 7.61 97.6 <.001 100 (15.7) 5.02 37.2 <.001 
IGF-1 (nmol/L) 22 (6.9) 0.204 -0.0701 .126 51 (8.0) 0.457 0.462 <.001 46 (7.2) 0.251 0.106 .025 
Testosterone (nmol/L) 56 (17.6) 2.79 15.9 <.001 112 (17.6) 1.39 4.03 <.001 96 (15.0) 4.58 45.2 <.001 
SHBG (nmol/L) 51 (16.0) 1.80 4.42 <.001 125 (19.6) 1.51 3.01 <.001 103 (16.1) 1.48 2.86 <.001 
Oestradiol (pmol/L) 131 (41.1) 4.21 25.5 <.001 314 (49.2) 2.31 6.60 <.001 304 (47.6) 2.98 12.6 <.001 
CRP (mg/L) 21 (6.6) 2.69 9.84 <.001 52 (8.2) 5.11 33.6 <.001 42 (6.6) 4.03 29.2 <.001 
MET-mins/wk 66 (20.6) 2.32 6.89 <.001 113 (17.7) 1.85 4.14 <.001 26 (4.1) 1.79 4.06 <.001 
Summed PA (mins/wk) 66 (20.6) 1.45 2.09 <.001 113 (17.7) 1.32 1.90 <.001 26 (4.1) 1.45 2.49 <.001 
MET-mins/wk VPA 66 (20.6) 4.18 22.3 <.001 113 (17.7) 2.91 13.1 <.001 26 (4.1) 3.25 16.9 <.001 
MET-mins/wk MPA 66 (20.6) 2.13 4.06 <.001 113 (17.7) 2.32 5.70 <.001 26 (4.1) 2.38 5.85 <.001 
Screen time (hrs/day) - 1.83 6.68 <.001 - 1.23 2.26 <.001 - 2.37 9.70 <.001 
Sedentary time (hrs/day) - 1.64 5.53 <.001 - 1.05 1.84 <.001 - 2.18 8.38 <.001 
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Appendix 7.18. Frequencies of whether PA recommendations are being achieved with and 
without walking included and χ² Tests of frequencies for both scenarios. 
 




n = 253 
Age-matched 
n = 525 
BMI + Age -matched 
n = 612 
No walking 
included 
Yes 112 (44.3) 278 (53.0) 291 (47.5) 
No 141 (55.7) 247 (47.0) 321 (52.5) 
Includes walking Yes 186 (73.5) 412 (78.5) 476 (77.8) 
No 67 (26.5) 113 (21.5) 136 (22.2) 
 Value df P 
No walking 
included 
χ² 6.06 2 .048 
n 1390   
Includes walking χ² 2.55 2 .279 
n 1390   
Key: IPAQ: International Physical Activity Questionnaire; PCOS: polycystic ovary syndrome; age-matched: 
control group age-matched only to case; BMI: body mass index; BMI + age-matched: control group both BMI 
+ age-matched to case; χ²: chi-square statistic; n: total participants in analysis; data are presented as number of 
participants in each IPAQ activity group (percentage of study group); χ²: chi-squared statistic; df: degrees of 





Appendix 7.19. Descriptive statistics for number of comorbidities, and only those related to metabolic health split by study cohort 
PA Outcome Group Mean ± SD Median (IQR) Maximum Skewness Kurtosis Shapiro-Wilk P 
Total Comorbidities PCOS 1.33 ± 1.72 1 (2) 9 1.82 3.91 <.001 
Age 0.47 ± 1.06 0 (1) 10 3.59 17.9 <.001 
BMI + Age 0.63 ± 1.28 0 (1) 10 3.44 15.7 <.001 
Metabolic Comorbidities PCOS 0.88 ± 1.36 0 (1) 10 2.05 5.03 <.001 
Age 0.25 ± 0.80 0 (0) 10 4.82 29.2 <.001 
BMI + Age 0.39 ± 1.01 0 (0) 10 4.02 20.3 <.001 
Key: PA: Physical activity; Group: study group; Mean: average number of morbidities; SD: standard deviation; Median: median number of morbidities; IQR: 
interquartile range; Maximum: maximum number of morbidities reported within study group; P: significance from Shapiro-Wilk test; PCOS: women with 





Appendix 7.20. Cluster plot of missing data and summary of missing data 
 
Often when DBP is missing, so too is SBP. In addition, HDL-C and SHBG tend to be missing together and so to do LDL-C and triglycerides.  
Although missing less frequently, three additional pairs also tend to be missing together. They are waist circumference and body fat, HbA1c 
and testosterone, and also CRP and IGF-1. 
377 
 
Appendix 7.21. Overview of imputed values and complete data set following imputation 
aggregation. 
Outcomes Pre-imputed Values                
(mean ± SD) 
Complete data after 
imputation 
(mean ± SD) 
Waist circumference (cm) 91.55 ± 15.52 89.26 ± 16.57 
Diastolic BP (mmHg) 81.89 ± 11.26 80.96 ± 10.34 
Systolic BP (mmHg) 131.13 ± 17.04 129.36 ± 15.89 
C-reactive protein (mg/L) 3.97 ± 4.36 3.29 ± 4.13 
HbA1c (mmol/mol) 34.49 ± 4.84 34.42 ± 4.64 
HDL-C (mmol/L) 1.44 ± 0.37 1.46 ± 0.34 
IGF-1 (nmol/L) 22.37 ± 6.56 22.66 ± 6.03 
LDL-C (mmol/L) 3.36 ± 0.78 3.37 ± 0.75 
SHBG (nmol/L) 59.36 ± 34.31 59.02 ± 31.07 
Testosterone (nmol/L) 1.22 ± 0.54 1.23 ± 0.50 
Triglycerides (mmol/L) 1.49 ± 0.85 1.46 ± 0.79 
Key: SD: standard deviation; BP: blood pressure; HbA1c: glycated haemoglobin; HDL-C: high-
density lipoprotein cholesterol; IGF-1: insulin-like growth factor-1; LDL-C: low-density lipoprotein 
































Appendix 7.22. Change in cluster centres following 12 iterations - convergence achieved 
due to no change in cluster centres  
 Initial Cluster Centres Final Cluster Centres 
 Cluster One Cluster Two Cluster 
One 
Cluster Two 
Z score: WC -1.22260 2.03621 -.54332 .93939 
Z score: DBP -2.02728 2.71140 -.39755 .68735 
Z score: SBP -2.22446 1.42455 -.33502 .57925 
Z score: CRP -.75960 3.00911 -.41367 .71524 
Z score: HbA1c -.67252 .03798 -.35559 .61481 
Z score: HDL-C .67177 -.97177 .38815 -.67110 
Z score: IGF-1 1.23418 -.64303 .24309 -.42030 
Z score: LDL-C -.38437 1.31129 -.21520 .37208 
Z score: SHBG -.84106 .12650 .36989 -.63954 
Z score: Testosterone 2.16762 -1.44133 -.10998 .19015 
Z score: Triglycerides -.94356 5.42349 -.44312 .76614 
Key: WC: waist circumference; BP: blood pressure; CRP: C-reactive protein; HbA1c: glycated 
haemoglobin; HDL-C: high-density lipoprotein cholesterol; IGF-1: insulin-like growth factor-1; 















Appendix 7.23. ANOVA between cluster one and cluster two for standardised final cluster 
centres.  
 Cluster Error  
F 
 





Z score: WC 812.025 1 .490 1589 1658.545 <.001 
Z score: Diastolic BP 434.749 1 .727 1589 597.980  <.001 
Z score: Systolic BP 308.747 1 .806 1589 382.906 <.001 
Z score: CRP 470.734 1 .704 1589 668.292 <.001 
Z score: HbA1c 347.828 1 .782 1589 444.946 <.001 
Z score: HDL-C 414.437 1 .740 1589 560.191 <.001 
Z score: IGF-1 162.552 1 .898 1589 180.949 <.001 
Z score: LDL-C 127.393 1 .920 1589 138.401 <.001 
Z score: SHBG 376.371 1 .764 1589 492.782 <.001 
Z score: Testosterone 33.270 1 .980 1589 33.960 <.001 
Z score: Triglycerides 540.128 1 .661 1589 817.493 <.001 
Key: WC: waist circumference; BP: blood pressure; CRP: C-reactive protein; HbA1c: glycated 
haemoglobin; HDL-C: high-density lipoprotein cholesterol; IGF-1: insulin-like growth factor-1; 
LDL-C: low-density lipoprotein cholesterol; SHBG: sex hormone-binding globulin; P: significance 
















Appendix 7.24. Descriptive statistics for missing cases based upon physical activity and 
sedentary behaviour risk. 
 Mean ± SD Median (IQR) Shapiro-Wilk P 
Waist Circumference 
(cm) 
91.1 ± 17.4 88.0 (27.0) <.001 
Diastolic BP (mmHg) 82.3 ± 10.7 81.9 (14.0) .040 
Systolic BP (mmHg) 131.6 ± 15.1 130.0 (21.0) .003 
C-reactive protein 
(mg/L) 
3.8 ± 4.5 1.8 (4.63) <.001 
HbA1c (mmol/mol) 35.7 ± 6.0 34.3 (5.9) <.001 
HDL-C (mmol/L) 1.4 ± 0.3 1.3 (0.5) <.001 
IGF-1 (nmol/L) 21.7 ± 6.5 21.6 (8.8) .696 
LDL-C (mmol/L) 3.4 ± 0.8 3.4 (1.0) .084 
SHBG (nmol/L) 56.3 ± 32.5 51.2 (43.0) <.001 
Testosterone (nmol/L) 1.2 ± 0.5 1.2 (0.6) <.001 
Triglycerides (mmol/L) 1.7 ± 0.9 1.45 (1.2) <.001 
MET-mins/wk⚫ 518.7 ± 595.3 297.0 ( - ) .373 
Sitting time (hrs/day)▲ 4.7 ± 2.3 4.0 (3.0) <.001 
Key: ⚫: 204 cases missing; ▲: 8 cases missing; BP: blood pressure; HbA1c: glycated haemoglobin; 
HDL-C: high-density lipoprotein cholesterol; IGF-1: insulin-like growth factor-1; LDL-C: low-
density lipoprotein cholesterol; SHBG: sex hormone binding globulin; MET-mins/wk: Metabolic 
equivalent of task-minutes per week; SD: standard deviation; IQR: interquartile range; P: statistical 
significance. 
 
